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Abstract 
Cardiovascular disease is a leading cause of mortality and morbidity worldwide. 
One of the key factors mediating cardiovascular disease risk, and the underlying 
atherogenic disease process, is disturbances to metabolism in the postprandial 
state, particularly with respect to lipoprotein metabolism. 
A number of studies have demonstrated that prior exercise can reduce 
postprandial triglyceride (TG) concentrations, with recent evidence indicating 
that increased clearance from the circulation of large very low density 
lipoproteins (VLDL1) plays an important role. However, it was unclear how exercise 
facilitated this potentially beneficial effect and this was the focus of the present 
work.  
 
The first experimental study in this thesis demonstrated, in 10 overweight/obese 
men, that 90 minutes of prior moderate exercise increased the affinity of VLDL1 
for TG hydrolysis by lipoprotein lipase by 2.2-fold in the fasted state (p = 0.02) 
and 2.6-fold in the postprandial state (p = 0.001), but did not significantly alter 
the affinity of chylomicrons, a novel observation that adds to understanding of the 
mechanism by which exercise lowers TG concentrations.  
 
Postprandial responses to meal ingestion depend on the macronutrient 
composition of the food ingested. In the second experimental chapter, 
postprandial responses to ingestion of a test meal containing 75g glucose, or 75g 
fat, or a combination of 75g glucose and 75g fat were compared in 10 
overweight/obese men. The main finding was that co-ingestion of fat with the 
glucose load reduced the postprandial glucose response, but not insulin response, 
compared with glucose ingestion alone. Co-ingestion of fat with the glucose load 
also substantially reduced the postprandial suppression of non-esterified fatty 
acids (NEFA) compared to glucose only ingestion. Postprandial TG responses were 
similar when only fat was consumed compared with co-ingestion of fat and 
glucose, but postprandial VLDL1 concentrations were lower in the latter condition.  
 
It is well established that ethnic differences exist in the prevalence of cardio-
metabolic diseases. In particular, diabetes prevalence is high in Middle-Eastern 
 
 
 
II 
 
populations. It is not known whether ethnic differences in postprandial 
metabolism contribute to these differences in risk. In the third experimental 
study, eight white European men and eight men of Middle-Eastern origin consumed 
a mixed-meal and postprandial responses were assessed. Postprandial insulin 
responses were higher in the Middle-Eastern men and postprandial TG 
concentrations were higher in the European men. This suggests that ethnic 
differences may exist in the inter-relationship between insulin resistance and 
lipoprotein metabolism.  
 
Thus, overall this thesis has provided insights into how postprandial metabolism is 
modulated by exercise, macronutrient intake and ethnicity. 
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1 Introduction and literature review  
1.1 Introduction  
Cardiovascular disease (CVD) is a family of common multifactorial diseases, including 
coronary heart disease (CHD), cerebrovascular disease, hypertension, and heart 
failure, which develop as a consequence of interactions between the innate factors, 
encoded in a person's genotype interacting with environmental factors (e.g. nutrition, 
smoking, inactive lifestyle) (Sing et al., 2003). Atherosclerosis, which develops over 
decades, is the underlying pathology of these conditions (Griffin, 1999). 
Cardiovascular disease, together with related metabolic diseases, such as diabetes - 
often termed cardio-metabolic diseases – are leading causes of disability and 
premature death around the world, and make a substantial contribution to total 
health care costs (WHO, 2014a). According to the World Health Organization (WHO) 
an estimated 16.7 million - or 29.2% of deaths - result from the various forms of CVD 
(WHO, 2014a). In the UK, CVD was a major cause of death, accounting for almost 
155,000 deaths in 2014 (Townsend et al., 2015). Thus, this disease places an 
extensive economic burden on healthcare systems (Deaton et al., 2011, WHO, 2014a). 
More than £6.8 billion was spent on treating CVD within the NHS in England in 
2012/2013 (British Heart Foundation, 2012). The highest expenditure was on 
secondary care with £4373 million spent on secondary care for CVD in England. Within 
secondary care, emergency admissions had the greatest expenditure. Within primary 
care, the second highest setting for expenditure, the majority of costs were due to 
prescribing (£1387.5 million). In 2012/2013 in Wales, a total of £442.3 million was 
spent on CVD, in Northern Ireland, £393 million was spent and in Scotland it is 
estimated that >£750 million was spent on treatment of CVD (Bhatnagar et al., 2015). 
Environmental factors influencing CVD can be classified as non-modifiable risk 
factors, such as age, sex, family history and ethnicity, and modifiable risk factors 
(see Figure 1.1). Much of our knowledge about the latter comes from the pioneering 
Framingham study (D'Agostino Sr et al., 2001). This longitudinal cohort study 
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identified a number of potentially modifiable risk factors including high levels of 
cholesterol and triglycerides, hypertension, diabetes, high adiposity, obesity, 
smoking, unhealthy diet, and lack of physical activity (WHO, 2014b, Bitton and 
Gaziano, 2010). Although many cases of CVD are potentially preventable by action on 
risk factors such as unhealthy diet, physical inactivity and smoking, the public health 
and economic importance of CVD means the need to fully understand all the root 
causes of CVD prevalence remains. 
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Figure 1.1. Cardiovascular diseases risk factors. 
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1.2  Non-modifiable risk factors  
Age, sex, family history and ethnicity are factors that cannot be modified. Age plays 
an important role in the development of cardiovascular disease. The risk of CVD 
increases approximately by 3 fold with each decade of life (Finegold et al., 2013). 
Similarly, the risk of having a stroke doubles every decade after the age of 55 
(American Heart Association, 2011, Brown et al., 1996, Wolf et al., 1992). Even in 
developed countries, despite a decrease in mortality due to CVD, mortality from CVD 
still increases with age (Finegold et al., 2013). Approximately 82% of CVD deaths 
occur after 55 years of age (Mackay and Mensah, 2004). The reasons for the increase 
in incidence of CVD with age are not completely clear, however, with advancing age 
the serum total cholesterol concentration increases which is likely to contribute to 
the effect (Jousilahti et al., 1999). Loss of compliance and functions of blood vessels 
due to mechanical and structural changes in vessel wall with advancing age, may also 
contribute to CVD development and progression (Jani and Rajkumar, 2006). 
Sex contributes to 40% of the variation in coronary heart disease mortality (Jousilahti 
et al., 1999, Hu and Group, 2003). Epidemiologically, the sex difference in prognosis 
of CVD suggests an intrinsic sexual difference in susceptibility to CVD (Finegold et 
al., 2013, Kannel et al., 1976, WHO, 2014a). In developed countries, CHD is being 
two to five times more common in men than in women in the younger age groups. 
(Möller-Leimkühler, 2007). CHD risk increases with age in both men and women, but 
shows a more prominent increase in women older than 50. Despite better medical 
treatment of CHD, It remains the leading killer of women (Mosca et al., 2007). In 
Europe, about 55% of all female deaths are caused by cardiovascular disease (CVD), 
especially CHD and stroke, compared with 44% of all male deaths (Petersen et al., 
2005). Age-adjusted mortality for CVD has continuously declined in the last four 
decades, but to a lesser extent in women than in men. In fact, the temporal trend of 
the incidence of CVD even shows a rise in women (Tunstall-Pedoe et al., 1999, Thom 
et al., 2006). This has been mainly attributed to a decrease in myocardial infarction 
incidence in younger men, with a concomitant increase in older women (Tunstall-
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Pedoe et al., 1999). Although, the mechanism behind these differences is unclear, 
some explanations such as hormonal difference in premenopausal stages were 
suggested. Oestrogen, for example may provide protective effects through glucose 
metabolism and haemostatic system indirectly and may improve endothelial cell 
function directly (Jousilahti et al., 1999).  
Family history of CVD is another unmodifiable risk factor that is an independent 
predictor of future disease incidence (Hunt et al., 1986). The risk of developing CVD 
doubles if a first degree male relative develops coronary heart disease or stroke 
before the age of 60 or if a first degree female relative does so before 65 years 
(British Heart Foundation, 2012, Sesso et al., 2001). The risk increase by 50%, if both 
parents have suffered from heart disease before the age of 55 (British Heart 
Foundation, 2012). 
Finally, ethnic origin can play a role in the incidence of CVD. There is ample evidence 
for substantial and persistent disparities between racial/ethnic groups in 
cardiovascular disease and associated risk factors, such as obesity, hypertension and 
diabetes (Mensah and Brown, 2007, Halder et al., 2012). Research into ethnic 
differences in general health has mainly focused on factors that are related to the 
ethnic minorities directly, such as genetic, socioeconomic, and sociocultural factors 
(Venema et al., 1995). Another possible determinant of ethnic health differences is 
health care itself, more specifically the accessibility and the quality of health care 
(Venema et al., 1995, Lanting et al., 2005). However, it has been reported that South 
Asian men and women in the UK experience approximately 50% higher age-
standardised CHD mortality than European Whites (Wild et al., 2006). Also, compared 
to Caucasians, African–Caribbeans and people of African descent have high incidence 
of stroke (Balarajan, 1991, Cappuccio, 1997), end-stage renal failure but lower CHD 
(Roderick et al., 1994, Raleigh, 1997). This may be due to higher rates of high blood 
pressure: in those of African ancestry, hypertension is three- to four- fold more 
prevalent than in Caucasians (McKeigue et al., 1991, Cruickshank et al., 1991, 
Cappuccio et al., 1997, Joffe et al., 1992, Chaturvedi et al., 1994), as is diabetes 
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(Shai et al., 2006, McKeigue et al., 1991, Simmons et al., 1991). Risk factors in South 
Asians are hyperinsulinaemia, raised TG and low HDL cholesterol levels, central 
adiposity with a high waist to hip ratio (McKeigue, 1991, McKeigue et al., 1992, 
Cruickshank et al., 1991). Whereas in Africans with glucose intolerance there is a low 
triglyceride and high HDL cholesterol levels, due to lower visceral adiposity when 
compare to whites at the same BMI (Chaturvedi, 1993, Chaturvedi, 1994, Cooper et 
al., 1997, Cappuccio, 1997). 
1.3 Modifiable risk factors 
The international heart study over 52 countries (INTERHEART) assessed the 
importance of risk factors for coronary artery disease worldwide (Yusuf et al., 2004a, 
Yusuf et al., 2004b). Nine measured and potentially modifiable risk factors, 
accounted for more than 90% of the proportion of the risk for acute myocardial 
infarction. These can be classified into two categories, modifiable biomarkers and 
modifiable behavioural factors. The modifiable markers are linked to metabolic 
syndrome (MetS).Metabolic syndrome had been identified by Dr. Gerald Reaven 
almost three decades ago. Originally known as “syndrome X”, the cluster has also 
been termed pluri-metabolic syndrome (MS), or Reaven's syndrome. These 
characteristics, when found in the same person, are so ominous that they have also 
been called “the deadly quartet” or “the awesome foursome”(Reaven, 1988). Reaven 
and subsequently others postulated that insulin resistance underlies Syndrome X 
(hence the commonly used term insulin resistance syndrome) (Haffner et al., 1992). 
According to the National Cholesterol Education Program Adult Treatment Panel III 
(NCEP-ATP III) panel, MetS include an increased waist circumference, blood pressure 
elevation, low HDL cholesterol, high triglycerides, and hyperglycaemia (NCEP, 2002). 
Although the risk associated with the MetS is well-documented, the definition of the 
syndrome is still in flux. In addition, there are behavioural risk factors include, 
physical activity, diet pattern, smoking, psychosocial factors and alcohol 
consumption. The effect of these risk factors was consistent in men and women across 
different geographic regions and by ethnic group. The British Regional Heart Study 
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also found that smoking, blood pressure and cholesterol accounted for 90% of 
attributable risk of CVD (Emberson et al., 2003). CVD can be prevented through 
modification of behavioural risk factors and /or through pharmacological therapy for 
medical conditions (e.g., using blood pressure-lowering agents and lipid-modifying 
agents). Modifiable and non-modifiable risk factors can interact with each other’s, 
thus, through a combination of treatments and healthy lifestyle choices, the risk of 
heart disease and stroke can be significantly decreased (See Figure 1.2). 
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1.3.1 Behavioural factors  
Socioeconomic status and psychosocial factors  
Socioeconomic status (SES) refers to an individual's social position relative to other 
members of a society. A number of studies suggest that poor living conditions in 
childhood and adolescence contribute to increased risk of developing CVD in both 
genders (Clark et al., 2009, Kaplan and Keil, 1993). The social status is linked also to 
alcohol consumption. The Marmot Review (2010) mentioned an association between 
alcohol-related hospital admissions and high levels of deprivation for both men and 
women, with particularly high rates of admission for those areas among the most 
deprived quintile of England and Wales. Binge drinking was also reported to be most 
common among those living in deprived areas (Marmot, 2010). Cigarette smoking 
follows a social class gradient in the USA and most developed countries. Starting in 
youth, smoking initiation is positively correlated with being from a low income 
household and performing poorly in school (Barbeau et al., 2004b, Elders, 1997, 
Steptoe et al., 2002). The prevalence of smoking is linked to low educational 
attainment (Pierce et al., 1989, Cavelaars et al., 2000, Barbeau et al., 2004a), 
working class occupations (Bang and Kim, 2001, Barbeau et al., 2004a), and lower 
income levels (Barbeau et al., 2004a, Control and Prevention, 2002, H., 2005). Thus, 
cigarette smoking is clearly associated with social disadvantage as defined by 
educational attainment, income, and occupational class. Cigarette smoking is the 
social behaviour that has the single largest impact on health inequalities. All these 
risk factors increase the incidence of developing CVD. Moreover, depression and 
depressive symptoms are common in patients with CVD (Timberlake et al., 1997) or 
heart failure (Rutledge et al., 2006) and are associated with adverse outcomes (Van 
Melle et al., 2004) showing strong and consistent evidence that depression and social 
isolation or lack of quality social support are independent risk factors for the 
development of and prognosis with CHD (Carney and Freedland, 2016, Valtorta et al., 
2016). 
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Alcohol consumption  
Alcohol is one of the behavioural risk factors. It is known to have both beneficial and 
harmful effects on the biochemical basis for CHD and the psychological consequences 
of the disease (Foppa et al., 2002). Systematic reviews and meta-analyses have 
addressed the association of alcohol consumption with cardiovascular disease 
outcomes (Cleophas, 1999, Corrao et al., 2000, Corrao et al., 2004, Di Castelnuovo 
et al., 2002, Fillmore et al., 2007, Maclure, 1993, Reynolds et al., 2003). In Scotland, 
32% of men and 4% of women drink above weekly recommended limits. Patterns of 
drinking vary and 44% of men who had drunk in the last week consumed eight units 
or more on their heaviest drinking day (where one unit is defined as approximately 8 
g /10 ml of alcohol), indicating that binge drinking may be a particular problem 
(Wilson et al., 2015). Drinking is harmful and associated with a poorer lipid profile, 
and adverse effect on systolic blood pressure and increased risk of thrombosis (McKee 
and Britton, 1998, Britton and McKee, 2000). Clearly, ethanol consumed with a meal 
elevates plasma and VLDL-TG (Lee et al., 2005). It has been observed that, the 
addition of 47·5 g alcohol to a high-fat meal (54 % of energy) was associated with an 
approximately 60 % increase in the peak plasma TG concentration compared with a 
meal consumed without alcohol (Fielding et al., 2000). Ethanol has also been shown 
to increase fatty acid synthesis (Siler et al., 1998) and also to reduce TG clearance 
from the plasma (Pownall et al., 1999). The relationship between alcohol 
consumption and stroke is believed to involve various mechanisms including alcohol-
induced hypertension, cardiomyopathy, coagulation disorders, atrial fibrillation, and 
reductions in cerebral blood flow (Malarcher et al., 2001, Hillborn, 1998, Gorelick et 
al., 1999, Zakhari, 1997). A possible explanation of a reduced risk of ischemic stroke 
with moderate alcohol consumption is that alcohol increases high-density lipoprotein 
cholesterol levels and decreases platelet aggregation and fibrinolytic activity 
(Gorelick et al., 1999, Zakhari, 1997, Stampfer et al., 1988). There does not appear 
to be any differential effect associated with type of alcohol consumed (Whelan et 
al., 2004, Di Castelnuovo et al., 2002). 
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Smoking  
Smoking is a strong independent risk factor of cardiovascular events and mortality 
even at older age, advancing cardiovascular mortality by more than five years (Mons 
et al., 2015, Gellert et al., 2013, Kenfield et al., 2010). Smoking is linked to a two- 
to four-fold increased risk of CHD (Go et al., 2014, Kondo et al., 2011). Smoking 
independently contributes to the risk of myocardial infarction (Ferrie et al., 2009, 
Teo et al., 2006), stroke (Kelly‐Hayes, 2010). A dose–response relationship between 
the number of cigarettes smoked per day and both myocardial infarction and stroke 
has been established in large cohort studies (Kenfield et al., 2010, Kondo et al., 
2011). It also, influences the risk factor of developing CVD. Cigarette smoking also 
increases postprandial triglyceride levels by 50% (Pourmand et al., 2004, Axelsen et 
al., 1995, Chiolero et al., 2008), and studies of young adults have identified early use 
of alcohol and tobacco as key determinants of subsequent levels of serum triglyceride 
(Croft et al., 1987), lower HDL-C (Ellison et al., 2004). Data obtained in a large sample 
of men and women support the interpretation of Axelson et al. that smoking affects 
postprandial TG metabolism primarily by raising lipoproteins of intestinal origin 
because cigarette smokers had substantially greater postprandial retinyl palmitate 
and apo B-48 (by 114 – 259 %) responses than did non-smokers, when adjusted for 
fasting TG. In addition, smoking may increase insulin resistance directly (Benowitz, 
2003, Houston et al., 2006, Janzon et al., 1983). The response of insulin in smokers 
to an oral glucose test was more pronounced compared to non-smokers (Facchini et 
al., 1992), insulin resistance was dose dependently related to smoking (Eliasson et 
al., 1994). Most of the excess risk and risk advancement disappeared within 5 years 
after smoking cessation. Smoking cessation is highly and rapidly beneficial also at 
advanced age (Gellert et al., 2013, Iso et al., 2005). A Japanese cohort study found 
that quitting smoking more than 4 years ago was found to reduce the risk for major 
cardiovascular events by 70% compared to continuing smoking (Kondo et al., 2011). 
A systematic review of 20 studies concluded that quitting smoking is associated with 
a 36% reduction in the relative risk of mortality for patients with CHD who quit 
compared with those who continued smoking (RR 0.64; 95% CI 0.58 to 0.71). This risk 
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reduction appears to be consistent regardless of age, sex, index cardiac event, 
country, and year of study commencement (Critchley and Capewell, 2003). 
 
1.3.2  Biomarker Risk factors  
Blood pressure 
High blood pressure or hypertension refers to a chronic condition characterised by 
increase of blood pressure in the arteries. This increase could either be in systolic 
blood pressure (SBP) which represents the peak pressure due to ventricular 
contraction during systole, or a diastolic blood pressure (DBP) which represents the 
pressure during ventricular relaxation in diastole, or both. A reading of ≥ 140 mm Hg 
of SBP or ≥ 90 mm Hg of DBP indicates the presence of hypertension (Tajeu et al., 
2017, Schiffrin et al., 2016).  
The Department of Health survey of 2010 for England showed 31.5% prevalence of 
hypertension in male adults over 16 years and above and 29.0% in women. This puts 
a huge burden of approximately £2 billion on NHS annually (Public Health England, 
2014, British Hypertension Soceity, 2015). Hypertension is considered as a major risk 
factor for stroke, myocardial infarction, heart failure, chronic kidney disease, 
peripheral vascular disease, cognitive decline and premature death (Freis, 1969, 
Baudouin-Legros and Meyer, 1990, Rapsomaniki et al., 2014). Hypertension affects 
blood vessels by altering their functionality. It can lead to atherosclerosis and 
narrowing of the blood vessels making them more likely to block from blood clots or 
bits of fatty material breaking off from the lining of the blood vessel wall. Both SBP 
and DBP can be used as predictors of cardiovascular risk (Stamler et al., 1993a), atrial 
fibrillation (Kannel et al., 1982), coronary heart disease, stroke, transient ischemic 
attack, and congestive heart failure (Hubert et al., 1983). Untreated hypertension is 
associated with a progressive rise in blood pressure and shows a strong positive 
correlation with the risk of CVD onset and mortality (Cutler, 1996). The risk of 
cardiovascular events doubles for every 20/10 mmHg rise in blood pressure beyond 
the normal range (Rapsomaniki et al., 2014, Bauchner et al., 2014).  
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Figure 1.2. Interaction between modifiable risk factors in aged population. Ageing increases negative behaviours like smoking 
and drinking alcohol. It also, reduces the physical activity for the individuals all these factors contribute to increase body weight 
and develop some CVD risk factors such as diabetes, dyslipidemia and hypertension.   
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Lipid and CHD risk  
Lipid metabolism disturbance can lead to CVD. These diseases could be a result of 
inherited defects in lipoprotein metabolism, such as hyper- or hypo-lipoproteinemias, 
or of a metabolic disorder; abnormal lipoprotein metabolism is often observed as a 
secondary effect of diabetes, hypothyroidism and kidney disease, or it could be due 
to life style. 
 
1.4 Lipid metabolism  
1.4.1 Lipoproteins  
Lipids are hydrophobic and mostly insoluble in blood, so they require transport within 
hydrophilic, spherical structures called lipoproteins. Circulating lipoproteins are 
originally produced either from the intestine (exogenous) or from the liver 
(endogenous). They can be broadly divided in order of increasing density into: 
chylomicrons (CM), very-low-density lipoprotein (VLDL), intermediate-density 
lipoprotein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). 
The density of lipoprotein depends on cholesterol, TG and protein content as the 
more cholesterol and TG and less protein the less dense it is. LDL are the major 
carriers of cholesterol in blood and contain one molecule of apolipoprotein B100 
which is recognized by the LDL receptors (Gurr et al., 2002). VLDL and CM are the 
major carriers for TG. Lipoproteins can classified according to their lipid contents 
into TG-Rich Lipoprotein (TRL; includes CM and VLDL) and Cholesterol Rich 
Lipoprotein (CRL; includes LDL and HDL (Sparks JD, 1994)) (See Table 1.1).  
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Table 1.1; Lipoprotein composition (Sparks JD, 1994). 
 
CM VLDL LDL HDL 
Density (g.mL-1) 
<0.96 0.96-1.006 1.006-1.063 <1.063-1.21 
Diameter (nm) 
100-1000 30-90 20-25 10-20 
Apolipoprotein 
A,C,E,B48 A,C,E,B100 B100 A,C,D,E 
Composition (%) 
    
Proteins 
2 10 20 40 
Lipids 
98 90 80 60 
Lipid composition (%) 
    
Triglyceride 
88 55 12 12 
Cholesterol Ester + cholesterol 
4 24 59 40 
Phospholipid 
8 20 28 47 
Free fatty acid 
- 1 1 1 
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1.4.2 Apolipoproteins  
Apolipoproteins are specific proteins associated with lipoprotein particles, and they 
are either an integral part of the lipoprotein or are located peripherally. They can 
emulsify and transport lipids in the blood. They appear on the surface of the 
lipoproteins and a number are synthesized in the liver and intestine. They are apoB, 
(B-48 and B-100) apoA-I, apo A-II. apo A-IV, apo A-V, apoC-II, apoC-III and apoE. 
Apoproteins have important structural and metabolic functions. For example, 
apolipoproteins A are predominantly found in the high HDL and are important for 
reverse cholesterol transport (Zhao et al., 2012). Moreover, they are responsible for 
recognition of particles by receptors and act as coenzymes (enzyme activator) 
(Ginsberg, 2002, Gurr et al., 2002). Table 1.2 illustrates sources and functions of 
apolipoproteins.  
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Table 1.2; Sources and functions of some lipoproteins (Jackson et al., 1976, Schaefer et al., 1978).  
Apolipoprotein Molecular wt. Source Function 
apo A-I 28.300 Liver, Intestine Structural component of HDL; activates LCAT 
apo A-II 17.000 Liver, Intestine May inhibit HL activity; inhibits AI/LCAT 
apo A-IV 44.500 Intestine Activates LCAT; possibly facilitates transfer of apos between HDL 
and CM 
apo A-V 39.000 Intestine Associated with lower TG levels; facilitates LPL 
apoB-48 241.000 Intestine 
Necessary for secretion of chylomicron from intestine, activates 
LPL uptake of remnants by the liver 
apo B-100 55.000 Liver 
Necessary for secretion of VLDL from liver; structural protein of 
VLDL, IDL and LDL; ligand for the LDL receptor 
apo C-I 6.331 Liver 
Activates LCAT; may inhibit hepatic uptake of CM and VLDL 
remnants; may inhibit CETP 
apo C-II 8.837 Liver, Activates LPL (essential cofactor) 
apo C-III 8.764 Liver, intestine 
Inhibits LPL and hepatic uptake of CM and VLDL remnants Ligand 
for LDL receptor, LDL receptor-related protein and proteoglycans 
apo E 33.000 
Liver (60-80%), and 
other tissues including 
adipose tissue 
May inhibit HL activity; inhibits AI/LCAT 
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As each apolipoproteins has a specific function the proportions of them differ 
between lipoprotein particles (Schaefer et al., 1978) as shown in Table 1.3. 
Table1.3; Distribution of Apolipoproteins in different lipoprotein particles (Schaefer et al., 
1978). 
Apoprotein (%) CM VLDL LDL HDL 
apo A-I 7.4 Trace  67 
apo A-II 4.2 Trace  22 
apo B-48 
apo B-100 
22.5 
 
36.9 
 
98 
 
Trace 
apo C-I 15 3.3 Trace 1-3 
apo C-II 15 6.7  3-5 
apo C-III 36 39.9  + 
apo E  13.0 Trace  
 
Two pathways are involved in lipoprotein metabolism; exogenous and endogenous. 
Exogenous pathway delivers cholesterol, TG and phospholipids from the small 
intestine to the liver and peripheral tissues, while the endogenous pathway transfers 
lipids from liver to peripheral tissue.  
1.4.3 De‐novo lipogenesis (DNL) pathway 
In the DNL carbohydrates transformed into FA in the liver and adipose tissues 
(Hellerstein, 1999, Ameer et al., 2014). This pathway is activated in the feeding state 
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in which it is controlled by many hormonal factors such as insulin (Ameer et al., 
2014). These factors include sterol response elements (SRE) binding protein isoform 
one (SREBP1-c) (Horton et al., 2002) and the liver X receptor-α (LXRα) (Liu et al., 
2007b). It has been demonstrated that SREB1-c upregulates all enzymes in the FA 
synthesis pathway and enzymes that regulate the availability of acetyl-CoA units in 
the pathway (Horton et al., 2002). Also, LXRα regulates lipogenesis via inducing the 
expression of SREBP-1c (Liu et al., 2007b). The Insulin increases the activity of LXRα, 
which hence induces SREBP-1c expression (Hellerstein, 1999, Ameer et al., 2014, Liu 
et al., 2007a). DNL contributes in FFA syntheses in endogenous pathway by 4% in 
fasted state and this rise to 8% postprandially. (Hellerstein, 1999, Ameer et al., 2014, 
Barrows and Parks, 2006). 
1.4.4  Exogenous lipoprotein metabolism   
The exogenous lipoprotein pathway starts in the intestine. Dietary triglycerides 
(approximately 100 grams per day) are hydrolysed to free fatty acids and 
monoacylglycerol by intestinal lipases and emulsified with bile acids, cholesterol, 
plant sterols, and fat soluble vitamins to form micelles. While the fatty acids in the 
intestine are overwhelmingly accounted for by dietary intake the cholesterol in the 
intestinal lumen is primarily derived from bile (approximately 800-1200 mg of 
cholesterol from bile vs. 300-500mg from diet) (Feingold and Grunfeld, 2015). 
In the postprandial state, endothelial cells of the gut produce digested fat from food 
as CM, which contains varies components as seen in Table 1.3. These particles travel 
to plasma through lymph, and acquire the apoC-I,C-II, C-III and E from VLDL and HDL 
(Patsch, 1987). By acquiring apoC-II the action of LPL starts on CM hydrolysing TG to 
fatty acid and 2-monoacylglycerols. The hydrolysis continues until CM have lost 70-
90% of their TG (Chen and Reaven, 1991). LPL cannot hydrolysis the TRL remnant 
particles and they are taken up by liver through specific receptors (Martins et al., 
1997) (see Figure 1.3). It appears that apo B-48 containing particles are continuously 
secreted from the enterocyte and at times of excessive triglyceride availability, lipid 
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droplets fuse with nascent lipoprotein particles resulting in secretion of very large 
chylomicrons (Hayashi et al., 1990, Martins et al., 1994).  
A balance between apoC-III, apoE which inhibit LPL and apoC-II which activates LPL 
is required for effective hydrolysis (Corrao et al., 1990). The CM remnant is generated 
by the lipolysis process. By definition, a TRL-remnant is an apo B-containing 
lipoprotein that has delivered some, or the major part, of its original triglyceride 
content to tissues by means of LPL-mediated lipolysis (Karpe, 1999). Certain other 
modifications also often take place, such as apoE enrichment, possibly apoC-III 
enrichment and apoC-II depletion. This new particle has more apoE and apoB and less 
apoA-I and apoCs with an abundant amount of CE. CE is transferred to other 
lipoproteins in exchange for TG, mediated by cholesteryl ester transfer protein 
(CETP) (Roche and Gibney, 2000). The CM-remnant is responsible for delivering 
cholesterol and TG to the liver (Redgrave, 2004). The liver uses lipid from this 
remnant to assemble VLDL (Jung et al., 1999). It has been shown that endogenous 
VLDL accumulate in the plasma postprandially due to delayed competitive lipolysis 
of apoB-100 TRL particles with CM for the sites of LPL action (Bjorkegren et al., 1996) 
( see Table 1.4).  
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Figure 1.3; Chylomicron metabolism. Chylomicron metabolism begins when it emerges from the lymph carrying triglyceride into the circulation. Lipoprotein 
lipase from adipose tissue and skeletal muscles starts hydrolysing the triglyceride into fatty acids and glycerol. After it goes through the hydrolysis it loses 
most of its triglyceride, resulting in the formation of chylomicron remnants. These remnants enter to the liver through apoE receptors. 
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1.4.5 Endogenous lipoprotein metabolism 
Metabolism in the post-absorptive state 
Post-absorptive state refers to a state in which most of the previous meal has been 
fully absorbed e.g. after an overnight fast prior to any further food being 
consumed (Frayn 2009). The studies in subsequent chapters were implemented in 
the post absorptive state and therefore the following section will consider the 
metabolic processes involved in lipid metabolism during this state. 
Lipoproteins synthesized by the liver transport endogenous TG and cholesterol. 
Lipoproteins circulate through the blood continuously until taken by peripheral 
cells or cleared by the liver. Factors that stimulate hepatic lipoprotein synthesis 
generally lead to elevated plasma cholesterol and TG levels. 
VLDL metabolism parallels that of CM in many aspects. Like all lipoproteins, VLDL 
contains CE, phospholipids, free cholesterol and TG, and apolipoproteins as 
mentioned in Table 1.3. They are secreted continuously from liver and they are 
responsible for delivering TG to the peripheral tissues during fasting (Figure 1.4).  
There are two subclasses of VLDL particles: large TG-rich VLDL1 and smaller, more 
dense VLDL2, which have more cholesterol and a lower ratio of apoCs and apoE to 
apoB (Packard and Shepherd, 1997, Packard et al., 1984). VLDL is continuously 
being excreted from the liver. A major proportion of the VLDL undergoes 
sequential delipidation to form LDL in the fasting state (Björkegren et al., 1997).  
The secretion of the large VLDL particles is regulated by insulin-sensitive 
mechanisms which regulate the availability of triglyceride for VLDL production. 
FA are generated by lipolysis in adipose tissue through the action of HSL and are 
a major source for liver TG (Mifflin et al., 1990). Insulin stimulates the endothelial 
expression of LPL, the key enzyme for TRL metabolism, in a post-absorptive state 
(Semb and Olivecrona, 1986, Ong and Kern, 1989). Hepatic uptake of partially 
lipolysed VLDL or chylomicrons remnant particles may also contribute to the 
hepatocellular TG availability. Likewise, a lower rate of FA uptake by adipose and 
muscle tissues after LPL-mediated lipolysis of chylomicrons and VLDL promotes 
FFA uptake by the liver (Frayn et al., 1994). In addition, the liver has the capacity 
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of de novo synthesis of triglycerides, which is most evident in carbohydrate 
overfeeding. Therefore, the balance between oxidation of FFA in liver and muscle 
and the relative contribution of all of these TG/FFA flux rates, all regulated to a 
greater or lesser extent by insulin, determine the availability of hepatic TG for 
VLDL secretion (Malmström et al., 1997). Also, insulin seems to have a direct 
inhibitory effect on the hepatic secretion of large VLDL (Malmström et al., 1997). 
However, the secretion of smaller and less triglyceride rich VLDL, doesn’t required 
any of the above stated mechanism. It needs cholesterol availability or a high 
cholesterol synthesis rate (Watts et al., 1995).  
VLDL represents most of the pool of TRL in the post absorptive state. Table 1.4 
shows the variations of TRL concentrations during the day. It has been estimated 
that the endogenous TRL constitutes 96-97% of all TRL particles in the fasting 
state, and this figure was reduced to 91-96% in the postprandial state (Karpe et 
al., 1999, Sharrett et al., 1995).  
 
Table 1.4; Percentage of TRL particles which are of endogenous origin (apo B-100) in the 
fasting and the postprandial state inhuman plasma (Karpe, 1999). 
 0 h 3 h 6 h 
Large TRL 
(Sf 60 - 400) 
96 ± 3 91 ± 3 93 ± 4 
Small TRL 
(Sf 20 - 60) 
97 ± 2 95 ± 4 96 ± 3 
  
It has been demonstrated that chylomicron and VLDL particles are competing for 
the same lipolytic pathway (Bjorkegren et al., 1996, Brunzell, 1973). After fat 
intake, an accumulation of endogenous TRL has been reported (Cohn et al., 1988a, 
Schneeman et al., 1993). This is might be due the delayed lipolysis of the apo B-
100 TRL particles due to competition for the sites of LPL action by the 
chylomicrons (Brunzell, 1973). In rat plasma, it has been shown that the 
accumulation of endogenous TRL due the competition of the chylomicron-like 
triglyceride emulsion for the hydrolysis by LPL (Karpe and Hultin, 1995). In 
postprandial state, the rise of the number of TRL apoB-100 particles is actually 
far greater than that of apoB-48 containing lipoproteins (Havel, 1994). Conversely, 
80% of the postprandial increase of triglycerides is accounted for by apoB-48 
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containing lipoproteins (Cohn et al., 1993). This apparent paradox is explained by 
the fact that the major triglyceride-carrier in the postprandial state is the 
chylomicron with each chylomicron particle carrying a very large number of 
triglyceride molecules. Therefore large quantities of triglycerides are transported 
by very few chylomicron particles (Karpe, 1999). 
Within the circulation, LPL hydrolyses the TG in the core of VLDL. This action turns 
VLDL1 into VLDL2 which is then hydrolysed by the action of hepatic lipase (HL) and 
LPL to IDL, and HL then hydrolyses IDL to LDL (Nakajima et al., 2011b, Cohn et 
al., 1993). This delipidation process is slowed by the presence of chylomicrons 
resulting in a prolonged residence for VLDL in the postprandial state (Björkegren 
et al., 1997, Bjorkegren et al., 1996). This leads to more opportunities for 
cholesterol ester exchange between lipoprotein particles, and a cholesterol-
enriched VLDL remnant is subsequently formed. This remnant lipoprotein is also 
enriched by apoE. Because of its increased cholesterol content, the remnant will 
probably not be further delipidated (Björkegren et al., 1997). 
Cholesterol is an essential steroid involved in the formation of steroid hormones 
and bile salts and is also an important structural component of cell membranes 
(Hardman et al. 2003). LDL contains relatively high cholesterol content (around 
40-50%) and transports the majority of cholesterol (Frayn, 2002). Binding of LDL 
to target tissue occurs through an interaction between the LDL receptor and 
apolipoprotein B-100 or E on the LDL particle. Uptake occurs through endocytosis, 
and the internalized LDL particles are hydrolysed within lysosomes, releasing 
lipids, mainly cholesterol (Packard and Shepherd, 1997). LDL is the supplier of 
body tissue with cholesterol; around 65% of total plasma cholesterol is carried in 
LDL (Wang and Briggs, 2004). Larger LDL particles exhibit the highest affinity 
(Packard and Shepherd, 1997). While 70% of the LDLRs are located on hepatic 
cells, 30% are located on the other cells of the body (Verges, 2005).
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HDL metabolism  
HDL particles are synthesized in the liver and the small intestine. They are a 
heterogeneous group of particles that differ in size, shape, density, cholesterol 
and phospholipid content, as well as in apolipoprotein such as, Apo A1, ApoE and 
Apo C-II (Miller, 1990). Apo A-1 activates LCAT, an enzyme associated to HDL (Von 
Eckardstein et al., 2001). They contain higher protein content, around 50 % of the 
particle total weight (Miller, 1990). The life cycle of HDL begins with 
apolipoprotein A-I being secreted by the liver (Miller, 1990). As ApoA-I bind 
circulating phospholipids and cholesterol, nascent discoid lipid-poor HDL particles 
are formed. These immature HDL particles trigger cholesterol efflux in sub-
endothelial macrophages and fibroblasts and, via interactions with ATP-binding 
cassette transporter A1 (ABCA1) (Miller, 1990). This process is called Reverse 
Cholesterol Transport (RTC) which involves transport of cholesterol back to the 
liver for excretion or to other tissues that use cholesterol to synthesize hormones 
(Lewis and Rader, 2005). HDL particles assimilate cholesterol from cells into their 
cores, then the cholesterol is esterified by the action of LCAT. Finally, uptake of 
HDL cholesteryl esters by the liver, through the scavenger receptor B1 (SR-BI), 
hepatocytes and steroid-producing cells delivers cholesterol to sites where it can 
be metabolized or excreted in the bile (Lagrost and Gambert, 1991, Barter et al., 
2003, Alan, 1993).  
 
Mature HDL particles have a spherical shape. There are two main mature particles, 
HDL2 and HDL3 (Miller, 1990, Jaye et al., 1999). HDL particles acquire triglyceride 
via Cholesteryl Ester Transfer Protein (CETP) which promotes the transfer of 
cholesteryl esters and TG between HDL, LDL and VLDL (Lagrost and Gambert, 
1991, Barter et al., 2003, Alan, 1993). CE is carried from HDL to VLDL and LDL 
particles, and TG is carried in the opposite direction from VLDL and LDL to HDL 
particles, resulting in CE depletion and TG enrichment of HDL (Lagrost and 
Gambert, 1991, Barter et al., 2003, Alan, 1993). The subsequent HDL particle 
enriched with triglycerides may regenerate small HDL particles through hydrolysis 
from hepatic lipase (Kontush and Chapman, 2006, Von Eckardstein et al., 2001, 
Lewis and Rader, 2005). It has been, demonstrated that the lower HDL 
concentration in the plasma the higher the risk of developing CHD (Gordon et al., 
1989a) (see Table 1.5). 
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Table 1.5 Enzymes involved in lipoprotein metabolism (Gurr et al., 2002, Frayn, 2009). 
Enzyme Secretion place Function 
ABCA1 Within cells Contributes to intracellular cholesterol transport to membrane 
CETP Liver  Mediates transfer of cholesteryl esters from HDL to VLDL 
LPL Endothelium Hydrolyses triglycerides of chylomicrons and VLDL to release free fatty acids 
LCAT Liver  Esterifies free cholesterol for transport within HDL 
HL Endothelium Hydrolyses triglycerides of VLDL2, IDL, and LDL 
HSL Adipocyte cells Hydrolyses triglyceride in adipocytes facilitating fatty acid release 
ABCA1 = ATP-binding cassette transporter; CETP = cholesteryl ester transfer protein; LCAT = lecithin-cholesterol acyltransferase; LPL = lipoprotein lipase; HL= Hepatic 
Lipase; HSL= hormone-sensitive lipase. 
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Figure 1.4. VLDL metabolism. VLDL is secreted from the liver with one apo B on the surface and triglyceride and cholesteryl ester in the core. Core triglyceride 
is hydrolyzed by lipoprotein lipase and becomes a remnant lipoprotein that is recognized by the liver in part, by apo E. The remnant lipoprotein is further 
processed to form LDL, which has a cholesterol-rich core and an intact apo B on its surface. The LDL particle can be removed by peripheral or hepatic LDL 
receptors. As the VLDL core is hydrolyzed, the unesterified cholesterol and phospholipid are transferred to HDL by phospholipid transfer protein to become the 
cholesteryl ester of HDL. 
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Function of Lipoprotein Lipase  
Lipoprotein lipase (LPL) is a central enzyme in lipid metabolism. It is mainly produced 
by parenchymal cells of adipose tissue, heart and skeletal muscle (Merkel et al., 
2002, Merkel et al., 1998, Olivecrona and Olivecrona, 1999). LPL is also produced in 
kidney (Ruge, 2004), lung (Hamosh and Hamosh, 1975), placenta (Lindegaard et al., 
2005), brain (Vilaró, 1990) as well as in pancreatic islets (Cruz et al., 2001b) and in 
macrophages (Camps et al., 1990). LPL hydrolyses mainly TG, but also some 
phospholipids in TRL (Goldberg and Merkel, 2001, Olivecrona and Olivecrona, 1999). 
Moreover, LPL has the ability to bind simultaneously to lipoproteins and to specific 
cell surface receptors, such as the LDL receptor-related protein (LRP) (Beisiegel et 
al., 1991) and this allows it to carry out a non-catalytic, bridging function, which 
leads to the accumulation and cellular uptake of lipoproteins (Mead et al., 1999). 
These interactions lead to the increased accumulation and cellular uptake of 
lipoproteins. A number of studies have been provided evidence for this function of 
LPL. This bridging function has been reported in several tissue culture-based studies 
and in vivo (Mead and Ramji, 2002, Mead et al., 1999, Merkel et al., 1998).A variation 
of such bridging action involves cells rather than lipoproteins. For instance, LPL can 
act as a monocyte adhesion protein by forming a bridge between the monocyte 
surface HSPG and the arterial endothelial cells (Mamputu et al., 1997).  
LPL activity is modulated by apoC-I, C-II and C-III (Jong et al., 1999). All three 
apolipoproteins are produced in the liver and they are physically associated with CM, 
VLDL IDL and HDL. Studies have provided support for a plasma TG-lowering effect of 
apoC-II via stimulation of LPL activity (Jong et al., 1999). It is wildly known that apoC-
II is an activator or co factor for LPL (LaRosa J. C., 1970). However, studies in mice 
have shown that the overexpression of the human apoC-II gene leads to marked 
hypertriglyceridemia via impaired plasma TG clearance (Hoogewerf et al., 1991), 
suggesting that at higher concentrations apoC-II may inhibit LPL (Jong et al., 1999). 
Several factors were shown to impact plasma apoC-II levels, including obesity 
diabetes and several hypolipidemic drugs (Kolset and Salmivirta, 1999). However, 
these factors are primarily pathological or pharmacological in nature, suggesting that 
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based on current knowledge apoC-II does not appear to be a major mediator of 
regulation of LPL activity in response to physiological stimulates, such as 
feeding/fasting, exercise and cold exposure. As opposed to C-II, C-I and C-III inhibit 
LPL-dependent plasma TG clearance, as shown using transgenic mice overexpressing 
human and mouse apoC-I or C-III (Nadanaka and Kitagawa, 2008, Pillarisetti et al., 
1997, Wang et al., 2013) or mice lacking apoC-I (Stins et al., 1992)., It was proposed 
that apoC-I and C-III inhibit LPL activity by displacement of the enzyme from TG-rich 
particles (Chajek-Shaul et al., 1990). In addition, apoC-I and C-III may influence 
plasma lipoprotein metabolism via modulation of the activity of other enzymes 
involved in lipoprotein processing, as well as by altering the binding of apoC-
containing lipoproteins to their receptors (Jong et al., 1999).  
1.4.6 Plasma lipids as risk factors 
 Cholesterol and triglycerides, like many other essential components of the body, 
attract clinical attention when present in abnormal concentrations. Increased or 
decreased levels usually occur because of abnormalities in the synthesis, 
degradation, and transport of their associated lipoprotein particles. When 
hyperlipidaemia or hypolipidaemia are defined in terms of the class or classes of 
increased or decreased plasma lipoproteins, the names hyperlipoproteinaemia or 
hypolipoproteinaemia are preferentially employed (Stone, 2001, Havel, 1982). 
Increased concentration of plasma lipids is etiologically related mainly to genetic 
disorders, dietary factors (such as ingestion of excessive calories, trans and saturated 
fatty acids), or ingestion of some drugs, or it may occur as a secondary phenomenon 
in a large variety of diseases (Cox and Garcia-Palmieri, 1990, Stone, 2001). In any of 
these instances the elevation of the different plasma lipoproteins usually occurs in a 
number of combinations that have led to their classification into six different 
patterns or phenotypes (see Table 1.6). 
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Table 1.6.Lipoprotein Patterns Resulting from Elevation of Different Plasma Lipid Fractions 
(Cox and Garcia-Palmieri, 1990). 
Lipoprotein pattern Increased lipid fraction Predominant lipoprotein 
Type I Triglycerides Chylomicrons 
Type 2a Cholesterol LDL 
Type 2b Cholesterol and 
triglycerides 
LDL and VLDL 
Type 3 Triglycerides and 
cholesterol 
Remnants 
Type 4 Triglycerides VLDL 
Type 5 Triglycerides and 
cholesterol 
VLDL and chylomicrons 
 
LDL as risk factor  
 
Many studies have repeatedly shown that elevated levels of cholesterol play a key 
role in the development of atherosclerotic disease. In particular, LDL cholesterol has 
been strongly associated with CHD risk (Pyörälä et al., 1994, Expert Panel on 
Detection, 2001, Stamler et al., 1986, Castelli et al., 1992, Verschuren et al., 1995). 
LDL measurements are complicated by the fact that LDL is not a single-molecular 
species, but a multimolecular particle aggregate composed of protein and thousands 
of molecules of cholesterol and other lipids. Quantification can thus be accomplished 
in different ways, depending on which molecular constituent of LDL is measured. 
Because cholesterol is the most abundant lipid in LDL, and cholesterol assays have 
been available for many years, LDL concentrations in clinical practice are routinely 
expressed in terms of measured or estimated cholesterol content (LDL cholesterol 
[LDL-C]) (Friedewald et al., 1972). An elevated total serum low-density lipoprotein 
(LDL) cholesterol ≥ 4 mmol.l-1, is considered as risk factor. An excess number of LDL 
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particles undergo oxidation and at hemodynamically vulnerable parts of the arterial 
vessels get trapped in the sub intimal space where they are taken up by monocytes 
that are transformed into macrophages (Pedersen, 2011). Ultimately these cells end 
up as foam cells in plaques and attract inflammatory molecules that further intensify 
the pathological process (Pedersen, 2011). Glycation is another type of atherogenic 
modification of LDL that may contribute to atherosclerosis (Soran and Durrington, 
2011). Glycation is the result of bonding of a protein or lipid molecule with a sugar 
molecule, such as fructose or glucose, via a non-enzymatic process. Small, dense 
LDL is more susceptible to glycation than more buoyant LDL (Soran and Durrington, 
2011, Ravandi et al., 2000).  
A number of key studies provide the evidence base to understand the role of LDL in 
CHD. Total cholesterol was positively associated with IHD mortality in both middle 
and old age and at all blood pressure levels (Prospective Studies Collaboration, 1995, 
Prospective Studies Collaboration, 2007). Evidence that lowering LDL leads to 
reduced risk has come from landmark clinical trials. The Framingham study 
(considered the longest running study of cardiovascular disease in the world) which 
started in 1948 with an original cohort of 5,209 subjects aged 30-62 at baseline 
concluded that serum total cholesterol derived its atherogenic potential from its LDL 
component and showed also the importance of assessing the cardio-protective HDL 
fraction (Castelli et al., 1986). The total/HDL-cholesterol ratio was demonstrated to 
be the most efficient lipid profile for predicting coronary disease. LDL was shown to 
be correlated with hemostatic factors, suggesting that there would be additional 
benefits to lowering LDL (Castelli et al., 1986).  
Important intervention trials helped proved the causal association between LDL 
cholesterol and CVD risk. The Scandinavian Simvastatin Survival Study (4S) further 
boosted the status of statins in preventive cardiology. A total of 4,444 patients with 
CHD and total plasma cholesterol 5.5–8.0 mmol.l-1 on a lipid-lowering diet were 
randomly allocated on a double-blind basis to simvastatin 20–40 mg once daily or 
placebo for five years. There was an unequivocal 30% reduction in all-cause mortality 
(P = 0.0003), due to a 42% reduction in coronary deaths (Scandinavian Simvastatin 
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Survival Study Group, 1994). Even after 10 years of follow up, Simvastatin treatment 
for 5 years in a placebo-controlled trial, followed by open-label statin therapy, was 
associated with survival benefit over 10 years of follow-up compared with open-label 
statin therapy for the past 5 years only (Strandberg et al., 2004). The West of 
Scotland Coronary Prevention Study (WOSCOPS) was a landmark primary prevention 
trial that used pravastatin to reduce LDL cholesterol, (Packard and Shepherd, 1997). 
It showed again that statin use was associated with a reduction in CHD events. These 
studies and many other studies have shown the benefits of reduction in cholesterol 
on cardiovascular end points. The Heart Protection Study (HPS) was a landmark study 
in secondary prevention in which 20,536 people were divided into those given a statin 
and those on placebo. The active treated arm showed a substantial reduction in risk 
over the 5 years of the trial (Collins et al., 2002). For people with raised LDL who are 
at high CVD risk, drugs (statins) are considered essential. Dietary intervention leads 
to only a moderate lowering of cholesterol i.e. in the Whitehall Study in which 4469 
patients completed the study, the patients who improved diet and lifestyle lowered 
cholesterol by only about 0.9 mmol.l-1 over 9 years compared with 2.7 mmol.l-1 for 
lipid lowering drug treatment (Bouillon et al., 2011). It has been observed that a 
reduction in plasma LDL-C concentrations by 1.0 mmol.l-1 reduces CVD mortality and 
non-fatal myocardial infarction by around 20-25% (Flather, 2010). It has been 
recommended to achieve a concentrations of 1.8 mmol.l-1 of LDL-C among high risk 
patients (Flather, 2010). 
Small Dense LDL and CHD 
 
Fisher et al proposed that small dense LDL may be more prevalent among CHD cases 
with premature atherosclerosis compared with controls (Fisher, 1983). The amount 
of TG transfer from TRL to LDL plays a crucial role in the formation of sdLDL. Thus, 
repeated episodes of exaggerated postprandial lipaemia can result in disturbances of 
the lipoprotein profile, characterized by elevated TG levels, increased hepatic VLDL-
TG production, generation of sdLDL and a decrease in HDL concentrations. Small, 
dense LDL is thought to be particularly atherogenic because these particles have low 
affinity for LDL receptors and this will increase the residence time in the circulation 
and their opportunity for binding to the arterial wall (Chancharme et al., 1999). 
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Cross-sectional studies have reported that the odds of finding CHD among individuals 
with small, dense LDL particles was increased by 2-5 fold compared with individuals 
having larger, more buoyant LDL particles in Caucasian men (Campos et al., 1992, 
Tornvall et al., 1991, Coresh and Kwiterovich, 1996) and women (Austin et al., 1988, 
Coresh et al., 1993).  
Other studies have explored further the atherogenicity of these LDL variants. Smaller 
and denser LDL particles are more susceptible to in vitro oxidation and taken up by 
macrophages and smooth muscle cells, leading to the development and progression 
of atherosclerosis (Carmena et al., 2004, Twickler et al., 2005, Tribble et al., 1994, 
de Graaf et al., 1991, de Graaf et al., 1993, Tribble et al., 1992), a mechanism that 
may contribute to the formation of foam cells in vivo. Small, dense LDL particles 
have also been shown to be degraded less rapidly than particles of intermediate 
density (Lamarche et al., 2008). This process has been attributed, among other 
factors, to the reduced binding affinity of small, dense LDL particles to the LDL 
receptor (Lamarche et al., 2008, Galeano et al., 1994). Small LDL particles also 
display an increased potential for interaction with proteoglycans of the arterial wall 
(Superko and Krauss, 1992, La Belle and Krauss, 1990), and appear to penetrate the 
endothelial barrier 1.7-fold more than large LDL particles (Rosenson, 2005). These 
processes could contribute to accelerate the formation of the atherosclerotic plaque 
and could explain, at least partly, the relationship between LDL particle size and 
density and the risk of CHD risk. 
Role of HDL in the prevention of CHD 
 
HDL is thought to protect against atherosclerosis in a number of ways including; 
removing cholesterol from foam cells, inhibiting the oxidation of LDL, and limiting 
the inflammatory processes that underlay atherosclerosis (Stender et al., 2005). The 
reduced plasma HDL cholesterol of <0.9 mmol.l-1 concentration characterizing 
hypertriglyceridaemic individuals with small dense LDL particlescan be explained by 
an alteration of intravascular lipase activities. It has been shown that abdominal 
obesity was associated with a reduced plasma post-heparin lipoprotein lipase activity 
and with an increased hepatic lipase activity (Despres et al., 1990, Despres et al., 
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1989) and these metabolic alterations may contribute to the hypertriglyceridemic-
low HDL cholesterol dyslipidemia noted among subjects with small, dense LDL 
particles. The first study to show the negative relation between HDL and heart 
disease was the Framingham Heart Study in the 1980s (Brezina and Padmos, 1994). 
Supportively it has been demonstrated that independent negative association 
between HDL and ischaemic stroke mortality during a long-term (21-year) follow-up 
(Tanne et al., 1997). Another prospective study measured the survival in 535 elderly 
and they found that a significant negative association of serum HDL-C with mortality 
(Nikkla and Heikkinen, 1990). An estimated rise of 10 mg.dl-1 of HDL-C is associated 
with a 2% lower risk of CHD for men and a 3% lower risk for women (Gordon et al., 
1989b). A recent meta-analysis, including 302.430 subjects from 68 long-term 
prospective studies, supported the importance of HDL-C measurement in the risk 
assessment for CAD (Di Angelantonio E et al., 2009).  
VLDL as a risk factor  
 
Although LDL is the lipoprotein most commonly associated with atherosclerosis, other 
lipoproteins, such as chylomicrons and VLDL are also considered to be atherogenic 
(Khetarpal and Rader, 2015). A link between fasting plasma TG and CHD was first 
proposed in the 1950s (Gofman, 1953) and this was later confirmed in 1996 in a meta-
analysis that showed that fasting TG levels are a weak risk factor for CVD (Austin et 
al., 1996, Austin et al., 1998). However, the association between fasting TG and CVD 
events is weakened or neglected in multivariate analysis which include HDL (Austin, 
1990, Austin et al., 1996). This reported weak link between fasting TG levels and CHD 
is somewhat surprising, given that HDL-C concentrations which are mainly 
determined by the efficiency of TRL metabolism have a strong relation with CHD 
(Griffin, 1999). The perceived weakness of the association might be due the 
significant biological variation observed in fasting TG concentrations (Durrington, 
1990, Tolfrey et al., 1999); this variations would lower its predictive power in 
multivariate analysis (Durrington, 1990). Moreover, fasting TG might not reflect the 
true state of the lipid’s metabolism over a 24 hour period; postprandial plasma TG 
may be a more accurate and sensitive indicator of TRL metabolic efficiency. This has 
been supported by the observation that individuals with similar fasting plasma TG 
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have different levels of postprandial plasma TG (Patsch et al., 1983, Alcala-Diaz et 
al., 2014, Schrezenmeir et al., 1992, Corella and Ordovas, 2005).  
Triglyceride concentrations in the postprandial period, are emerging as a 
significant independent risk factor for atherosclerosis, and may be a 
stronger predictor of cardiovascular disease and a contributor to insulin 
resistance compared with fasting TG levels (Langsted et al., 2011, Mora et 
al., 2008, Nordestgaard et al., 2007, Bansal et al., 2007, Schrezenmeir et 
al., 1997). Postprandial TG levels are well known to be a significant risk for 
CHD events (Mamputu et al., 2000, G Nordestgaard and J Freiberg, 2011, 
Patsch JR, 1992, Langsted et al., 2011). It has been reported also that 
postprandial TG has a stronger association to CHD than HDL-C 
concentrations (Patsch JR, 1992). Karpe (1999), found that a strong 
correlation between postprandial lipaemia and atherosclerosis.  
High concentrations of large VLDL (VLDL1, Sf 60-400) are the major 
determinants of plasma TG levels and believed to initiate a chain of 
reactions that generate the atherogenic lipoprotein phenotype associated 
with insulin resistance, obesity, T2D and MetS (Taskinen, 2003, Ginsberg et 
al., 2005, Bloomgarden, 2007). However, the elevation of CM and CM-
remnant concentrations might be as a result of the lipaemia that occurs 
due to impaired LPL function or any TRL and their remnants are the major 
lipoproteins which are increased in the postprandial hyperlipidaemia. 
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Chylomicrons as risk factors 
 
Zilversmit was first to suggest that postprandial lipaemia as an important 
risk factor of CVD (Zilversmit, 1979). The increase in postprandial TRL from 
fasting levels contributed to approximately 80% of the increase of 
postprandial total TG from total fasting TG (Nakajima et al., 2011a). 
Individuals with hypertriglyceridemia tend to have a prolonged postprandial 
hypertriglyceridemia after a fat-meal tolerance test (Patsch JR, 1992). 
Exaggerated postprandial TG can occur at any age, as it has been observed 
in young women aged 22.5 years with existence of other CHD risk factors 
(Kolovou et al., 2011). Higher postprandial TG has been measured among 
diabetic adolescents (Umpaichitra et al., 2004), children with familial 
hypercholesterolemia (Reiber et al., 2003), and central obesity (Moreno et 
al., 2001) compared to control healthy participants. Evidence suggests that 
high postprandial concentration of TG can promote generation of 
potentially atherogenic TRL remnants (Karpe, 1999, Nakajima et al., 2009). 
It is also has been observed postprandial TG correlates more strongly with 
Remnant Lipoprotein (RLP) than fasting TG (Nakajima et al., 2009). It also 
induces the structural abnormalities in LDL and HDL particles (Karpe et al., 
1993, Yang and Smith, 2007, Packard, 2003). 
High concentrations of TRL in the postprandial state affect endothelial 
function and contribute to atherosclerotic plaque formation (Zilversmit, 
1979, Groot 1991). An increased of CVD risk in men (32%) and women (76%) 
with elevated plasma concentrations of postprandial TG has been reported 
(Groot 1991, Patsch JR, 1992). Many other studies support Zilversmit’s 
hypothesis, and show that patients with CHD have increased postprandial 
levels of TG and intestinally-derived TRL in response to a fat load challenge 
compared to healthy controls (Patsch JR, 1992, Groot 1991, Simons et al., 
1987, Weintraub et al., 1996).  
Plasma TG concentration fluctuates throughout the day in response to the 
ingestion of meals. Even if measured after a 10 to 12 hours overnight fast 
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(as is normal clinical practice), TG levels vary considerably more than LDL 
and HDL cholesterol levels (Nakajima et al., 2011b, Varbo et al., 2011).  
Remnant lipoproteins and CHD risk  
 
RLP, include chylomicron remnants and VLDL remnants which are subject 
to clearance by the liver (Mahley and Ji, 1999). They can enter the arterial 
wall, where they are preferentially retained and then taken up by 
macrophages. In macrophage-based studies, lipoprotein particles that 
increase sterol delivery or reduce sterol efflux or that promote an 
inflammatory response are considered atherogenic (Moore and Tabas, 
2011). Compared with the nascent TG-rich lipoproteins, TRL remnants are 
depleted of TG, phospholipid, and apoC, but enriched in EC and apoE with 
a reduced size. Thus they are more likely to diffuse into the blood vessel 
wall, and retained by heparin sulphate proteoglycans (HSPG) within the 
arterial intima and can be taken up by macrophages (Nordestgaard and 
Nielsen, 1994, Tetali et al., 2010, Tomono et al., 1993). Therefore, they 
are more potentially atherogenic. Indeed, TRLP cholesterol level has 
recently considered as an independent risk factor for atherosclerosis and 
cardiovascular disease (Twickler et al., 2005, Nakajima et al., 2008). 
Postprandial RLP has also been shown to increase the expression of pro-
inflammatory genes such as, interleukin-6, intercellular adhesion molecule-
1, vascular cell adhesion molecule-1, and monocyte chemotactic protein-1 
(Norata et al., 2007), induce apoptosis (Shin et al., 2004) and accentuate 
the inflammatory response of cultured endothelial cells to tumour necrosis 
factor-α (Ting et al., 2007). It has been suggested that the atherogenic 
potential of these lipoproteins is mainly due to their cholesterol content 
(Varbo et al., 2013). A non-fasting remnant cholesterol increase of 1 
mmol.l-1 is associated with a 2.8-fold causal risk for ischemic heart disease, 
independent of reduced HDL cholesterol (Varbo et al., 2013). 
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1.4.7 Obesity insulin resistance, diabetes and CVD risk  
Prevalence and importance of obesity in CVD 
Obesity and overweight are considered as one of the leading health issues and obesity 
is becoming a global epidemic (Kelly et al., 2008). The increase in the prevalence of 
obesity has occurred across every age, sex, and race (Hill and Melanson, 1999). 
Overweight and obesity are defined as abnormal or excessive fat accumulation of the 
adipose tissue that may impair physical and psychosocial health (Haslam and James, 
2006, Naser et al., 2006). Overweight and obesity depend on the imbalance between 
energy intake and expenditure (Koopmans, 2003). To asses obesity Body Mass Index 
(BMI) is a widely used tool (see Table 1.7). 
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Table 1.7; Body Mass Index categories (WHO, 2012). 
Category BMI (kg.m-2) 
Under weight 16-18.5 
Normal 18.5-24.99 
Overweight 25.00 - 29.99 
Moderately obese 30-35 
Severely obese >35 
 
These BMI cut points in adults are the same for men and women, regardless of their 
age. For clinical and research purpose, obesity is classified into three categories: 
class I (30–34.9), class II (35–39.9), and class III (>40) (James et al., 2004). With the 
growth of extreme obesity, researchers and clinicians have further divided class III 
into super obesity (BMI 50–59) and super-super obesity (BMI > 60). 
The current used BMI cut-off values are based on morbidity and mortality studies in 
Caucasian population (De Lorenzo et al., 2016). Several studies observed that some 
obese patients do not show expected metabolic abnormalities despite their 
substantial excess of body fat, demonstrating that while obesity increases the 
possibility of having complications, not every obese patient will develop them 
(Tchernof and Després, 2013). Although BMI is the accepted method to classify 
obesity and it can be used to predict and evaluate disease risk in epidemiological 
studies, it does not differentiate the composition of lean versus fat tissue and 
therefore may lead to erroneous interpretations (Sharma and Kushner, 2009). In 
addition to BMI and WC, there are other markers for excess body fat evaluation used 
for clinical practice, as the skinfold thickness and the waist-to-hip ratio (De Lorenzo 
et al., 2016). 
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Finally, direct measure of body mass fat, through magnetic resonance imaging (MRI), 
computed tomography (CT), dual-energy X-ray absorptiometry (DXA), bioimpedance 
analysis, and total body water, is gaining interest to assess the obese phenotype, but 
more studies are needed before either can be routinely recommended for office use. 
 Many large scale studies have shown a positive relationship between h CVD mortality 
and body mass index, a widely used measure of human obesity (McGee and 
Collaboration, 2005, Wilson et al., 2002, Stevens et al., 1998, Raben et al., 2003, 
Flint and Rimm, 2006, Calle et al., 2000, Larsson et al., 1984, Lapidus et al., 1984). 
Although cohort studies from Gothenburg, Sweden, in 1984 found that fat distribution 
was potentially stronger risk factor for morbidity and mortality (Lapidus et al., 1984, 
Larsson et al., 1984). Intra-abdominal fat has been associated with adverse clinical 
effects, characterized by hyperinsulinemia, dyslipidemia, glucose intolerance, and 
hypertension, increased risk of diseases such as type 2 diabetes, cardiovascular 
disease, and some cancers (Han et al., 1995, Bosello and Zamboni, 2000). Waist 
circumference for a given BMI was found to be a strong risk indicator of all-cause 
mortality in both men and women, and the combination of waist circumference and 
BMI may be very relevant in clinical practice (Bigaard et al., 2003). (see Table 1.8). 
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Table 1.8. Sex-specific cut-offs for waist circumference in different ethnic population (WHO, 
2012). 
Country / Ethnic group Waist circumference 
Europids 
In the USA, the ATP III values ( 102 cm male; 88 cm 
female) are likely to continue to be used for clinical 
purposes 
Male 
Female 
94 cm 
80 cm 
South Asians 
Based on a Chinese , Malay and Asian-Indian 
population 
Male 
Female 
90 cm 
80 cm 
Chinese Male 
Female 
90 cm 
80 cm 
Japanese Male 
Female 
90 cm 
80 cm 
Ethnic South and Central Americans  Same recommendations for South 
Asian until more specific data are 
available 
Sub-Saharan Africans   Same recommendations for 
European data until more specific 
data are available 
EMME ( Arab) populations  Same recommendations for South 
Asian until more specific data are 
available 
 
WHO statistics estimate the prevalence of overweight adults in 2014 was more than 
1.9 billion and of these over 600 million were obese which is 13% of the world’s adult 
population in 2014 (WHO, 2014b). Obesity is the sixth most important risk factor 
contributing to the overall burden of disease worldwide (Ezzati et al., 2002). In 
England in 2013, the percentage of adults aged 16 years and over measured as 
overweight or obese (BMI > 25) was 67 per cent in men and 57 per cent in women; 
the percentage measured as obese was 26% in men and 24% in women (Health and 
Social Care Information Centre, 2014). In Scotland in 2014, 69% of men and 61% of 
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women aged 16 years and over were overweight or obese; 26% of men and 29% of 
women were defined as obese (The Scottish Health Survey, 2014).  
According to a recent health survey in the UK, the average prevalence of overweight 
and obesity (BMI > 25) is 66.1% in men and 57.5% in women, while the prevalence of 
obesity (BMI > 30) alone is 24.8% in men and 25.3% in women (NCD Risk Factor 
Collaboration, 2016). In the Middle East obesity has become a growing problem in the 
past two decades. The WHO indicates that the Gulf States have the highest rate of 
obesity and are in the list of top ten countries worldwide in term of obesity. In all 
WHO regions women were more likely to be obese than men. In the WHO regions for 
Africa, Eastern Mediterranean and South-East Asia, women had roughly double the 
obesity prevalence of men (WHO, 2014b, Alwan, 2011). Among different countries in 
the Middle East region there is significant heterogeneity in obesity prevalence (Sliem 
et al., 2012). Kuwait is the worst affected with a 42.8% obese population, placing 
Kuwait in the top 10 most obese countries in the world. Countries such as Saudi Arabia 
and Qatar are not far behind, with 35.2% and 33.1% obesity rates respectively (Arab 
Human Development Report, 2009). Obesity is assessed using body-mass index 
globally. Individuals are considered overweight with a BMI of 25 kg.m-2 or higher and 
obese with BMI of 30 kg.m-2 or more (WHO, 2014b). Obese individuals differ not only 
in respect to the excess fat mass but also in its regional distribution in different body 
sites. Indeed, central or visceral abdominal obesity is associated with substantially 
different metabolic profiles and cardiovascular risk factors than gluteal-femoral 
obesity. To assess these differences, it is useful to measure waist circumference 
(WC). Population studies have shown that people with larger WC have impaired health 
and increased cardiovascular risk compared with those with normal WC within the 
healthful, overweight, and class I obesity BMI categories. Abdominal fat is clinically 
defined as a WC of 102 cm or more in men and 88 cm or more in women (Sharma and 
Kushner, 2009). 
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Aetiology of obesity 
Obesity is a multifaceted problem that can occur due to physiological, psychological 
and cultural factors. The aetiology of obesity is highly complex and includes genetic 
predisposition, physiologic, environmental, psychological, social, economic, and 
even political factors that interact in varying degrees to promote the development 
of obesity (Haslam, 2007, Haslam and James, 2006, Hill and Melanson, 1999). Obesity 
is most commonly caused by excess energy consumption (dietary intake) relative to 
energy expenditure (energy loss via metabolic and physical activity) (Jequier et al., 
1987). Nutritional changes towards westernized diet, high in sugar and fats, and the 
sedentary lifestyle have led to increased obesity and CVD prevalence even in the 
developing countries (Sodjinou et al., 2008, Boutayeb, 2006, Popkin, 2002). Chronic 
positive shift of the energy equation resulting from increases in energy input, 
decreases in energy output, or both led to excess fat deposition in body (Bray, 1987). 
The imbalance in energy intake and expenditure does not need to be large to induce 
changes in body weight and an energy intake of just 5% higher than energy 
expenditure can result in 5 kg weight gain each year (Hill and Melanson, 1999). If 
repeated every year this has obvious implications for the development of obesity.  
 
Energy balance is determined by macronutrient intake, energy expenditure and 
partitioning in nutrient storage (Bray, 1997). Thus, protein and carbohydrate intakes 
spontaneously elicit powerful autoregulatory adjustments in protein and 
carbohydrate oxidation, while the fat balance is less acutely regulated and more 
easily disrupted (Flatt, 1995, Schutz, 1995, Schrauwen et al., 1997). However, at the 
same time consumption of carbohydrates in excess of what is required may decrease 
internal fat oxidation which will contribute to a positive fat balance (Frayn, 2009). 
Although interventions on a person's nutrition can reduce BMI, it has been shown that 
efforts towards BMI reduction can be affected by a person's genetic profile 
(Arkadianos et al., 2007, Ordovas and Mooser, 2004). The synergy of genes and 
nutrition is studied within the new fields of nutrigenetics and nutrigenomics (Ordovas 
and Mooser, 2004). These new disciplines establish new strategies for CVD control 
which traditionally has been limited to nutrition interventions (e.g. fruits, 
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vegetables, fish) and supplementation, the latter being more popular in American 
population (Pearson et al., 2000). In addition, physical inactivity has dramatically 
increased in the past several decades and more time is spent on sedentary behaviours 
such as television watching, surfing the internet, and playing video games (Andersen 
et al., 1998). 
 
Metabolic consequences of obesity 
Obesity contributes to many metabolic abnormalities such as hypertension, IR, T2D 
and dyslipidaemia (Haffner, 2006) and organ damage such as fatty-inflammatory 
degeneration of the liver and peripheral vascular disease (Abate et al., 2001, Visscher 
and Seidell, 2001, Skilton et al., 2011). It is also a significant risk for the development 
of CHD and increased arterial stiffness (Zebekakis et al., 2005).  
It is important to distinguish between android obesity and gynoid fat distribution, in 
which fat is allocated peripherally around the body (De Lorenzo et al., 2016). The 
type of obesity (android vs gynoid) and the amount of adipose tissue in the body could 
influence risk of developing CVD. Gynoid obesity, refer to preferential adipose tissue 
accumulation in the hips and thighs, with poor muscle-blood development, typically 
described as female obesity, a form much less associated with complications. Gynoid 
obesity is menaced only by direct mechanical complications of excessive adiposity: 
locomotor difficulty, abdominal pressure, limitation of respiratory motion, slowing 
of the venous and lymphatic circulation, cellulitis, lowering of energy, and reduction 
of the elasticity of the fat-infiltrated myocardium—complications which are all 
proportional to the degree of excess fat (Vague, 1956). Whereas, android obesity, 
refer to adipose tissue accumulated preferentially in the trunk/upper body area and 
pronounced muscle-blood development and suggested that this was a form of obesity 
closely associated with metabolic disturbances. It not only is associated with 
premature atherosclerosis and diabetes, but it is also the usual cause of diabetes in 
the adult in 80 to 90% of the cases. Gout and uric calculous disease generally appear 
in this form of obesity (Vague, 1956). Android obesity is associated with greater 
health risks such as increased TG and lower HDL concentrations in the plasma (Frayn 
2002) and the progression of atherosclerosis (Kortelainen and Särkioja, 1999). 
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Accumulation of visceral fat contributes to a higher risk of hypertriglyceridaemia 
(Couillard et al., 1998), glucose intolerance and IR (Yang and Smith, 2007), all of 
which increase an individual’s risk of developing CHD.  
Interestingly the risks of diabetes, hypertension and dyslipidaemia increase from a 
BMI of about 21 kg.m-2 , thereby reducing life expectancy and greatly increasing socio 
economic burden (James et al., 2004). Evidence suggests that a 1 kg.m-2 increase in 
BMI increases the risk of developing new-onset T2D by 8.4%. The risk of impaired 
fasting glucose rises by 9.5%. An increase in waist circumference by 1 cm increases 
the risk of type 2 diabetes and impaired fasting glucose by 3.5% and 3.2% respectively 
(Bombelli et al., 2011). Moreover, it has been observed in the Asian Pacific study 
that, for each unit increase in BMI there is a 9% increase in ischaemic cardiac events 
and 7% of hypertensive death and strokes (Collaboration, 2004). Many mechanisms 
driven by obesity are thought to be responsible for this increased health risk and 
almost all are based on the unifying principle of generalized inflammation (Wellen 
and Hotamisligil, 2005, Wellen and Hotamisligil, 2003, Visscher and Seidell, 2001). 
Other mechanisms include impairment of glucose and insulin function.  
 
Diabetes and insulin resistance  
Insulin is a hormone produced by the β cells of the islets of Langerhans (Greenfield 
and Campbell, 2004, Kriketos et al., 2004, Dimitriadis et al., 2011). These cells are 
are embedded in the exocrine portion of the pancreas (Greenfield and Campbell, 
2004, Kriketos et al., 2004, Dimitriadis et al., 2011). Insulin is carefully coordinated 
with the release of glucagon from pancreatic α cells. The relative amounts of both 
hormones released by the pancreas are regulated so that the rate of hepatic glucose 
production is kept equal to the use of glucose by peripheral tissues (Greenfield and 
Campbell, 2004, Kriketos et al., 2004, Dimitriadis et al., 2011). The synthesis and 
release of insulin are decreased during the scarcity of dietary fuels and during stress. 
These latter effects are mediated by adrenaline which is a hormone secreted by the 
adrenal medulla in response to stress, trauma, or extreme exercise. On the other 
hand, insulin secretion and synthesis are increased by glucose, amino acids, FA and 
gut hormones (Greenfield and Campbell, 2004, Kriketos et al., 2004, Dimitriadis et 
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al., 2011). Insulin exerts important actions on metabolism as shown in Table 1.9. For 
instance, in the liver and muscle tissues, insulin increases glycogen synthesis, and 
glucose breakdown by increasing glycogenesis and glycolysis respectively. In muscle 
and adipose tissue, insulin increases glucose uptake by increasing the number of 
glucose transporters (GLUT-4) in the cell membrane. Also, in the liver, insulin 
decreases the production of glucose through the inhibition of glycogenolysis and 
gluconeogenesis (Greenfield and Campbell, 2004, Kriketos et al., 2004, Dimitriadis et 
al., 2011). Insulin also decreases TG degradation by inhibiting lipolysis in adipose 
tissue. This is accomplished by inhibition of hormone-sensitive lipase (HSL) activity 
which reduces the concentration of circulating FFA. Insulin also increases TG 
synthesis in adipocytes by increasing the rate of transport and metabolism of glucose 
into adipocytes, providing the substrate glycerol 3-phosphate for TG synthesis. Insulin 
also increases LPL activity in adipose tissue by increasing its synthesis, which 
increases TG hydrolysis releasing FAs needed for TG synthesis. Also, insulin in the 
liver promotes de novo lipogenesis, amino acid cellular uptake and protein synthesis 
(Greenfield and Campbell, 2004, Kriketos et al., 2004, Dimitriadis et al., 2011).  
Table 1.9; Insulin’s effects on metabolism.  
Inhibit Stimulates 
 Gluconeogenesis  Glucose uptake 
Glycogenosis Glycolysis 
Lipolysis Glycogenesis 
Ketogenesis Protein synthesis 
 
An altered cellular biological response to insulin action is known as IR, and it is 
associated with T2D, obesity and metabolic syndrome (Greenfield and Campbell, 
2004, Kriketos et al., 2004). Therefore, IR is a strong sign of the risk of developing 
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T2D especially in obese individuals who are present with central or visceral obesity 
(Greenfield and Campbell, 2004, Kriketos et al., 2004). 
Insulin resistance, defined as inhibition of insulin stimulation of several metabolic 
pathways including glucose transport, glycogen synthesis and anti-lipolysis, is of 
considerable clinical relevance because it is pathophysiologically linked to several 
serious medical problems including type 2 diabetes (Boden, 2011). Type two diabetes 
is a metabolic disorder of the haemostasis of body fuel characterized by a decreased 
rate of insulin-mediated glucose uptake due to peripheral insulin resistance (Kasuga, 
2006). The pathology of diabetes is a complex process and it is accompanied by a 
variety of metabolic abnormalities attributed to IR (Atkinson and Maclaren, 1994, 
Baekkeskov et al., 1982, Catalano et al., 2014). Insulin sensitivity fluctuation occurs 
across through life cycle for example, during puberty, in pregnancy, and during the 
aging process (Karpe et al., 2011). Generalized insulin resistance occurs primarily as 
a result of obesity. Insulin resistance is associated with many serious medical 
conditions, such as type 2 diabetes, hypertension, atherosclerosis, and metabolic 
syndrome (Boden, 2011, Reaven, 1988).  
 
Adipose tissue affects metabolism by secreting hormones, glycerol, and other 
substances including leptin, cytokines, adiponectin, and pro-inflammatory 
substances, and by releasing NEFA. In obese individuals, the secretion of these 
substances will be increased (Karpe et al., 2011). Insulin sensitivity is inversely 
proportional to adiposity (Yki-Järvinen and Koivisto, 1983). Body fat distribution also 
has an influence on insulin sensitivity. Insulin resistance is associated with body mass 
index at any degree of weight gain. Insulin sensitivity also differs completely in lean 
individuals because of differences in body fat distribution. Individuals whose fat 
distribution is more peripheral have more insulin sensitivity than do individuals whose 
fat distribution is more central (Karpe et al., 2011). Abdominal fat is considered more 
lipolytic than subcutaneous fat, and it also does not respond easily to the antilipolytic 
action of insulin, which makes intra-abdominal fat more important in causing insulin 
resistance, and thus diabetes (Roden et al., 1996, Fain et al., 2004). 
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NEFA levels are strong predictors of muscle insulin resistance (Kelley et al., 2001). 
Increased release of NEFAs is observed in T2D and in obesity, and it is associated with 
insulin resistance in both conditions (Jelic et al., 2007). Muscle fat content is 
increased in obesity and more so in type 2 diabetes (Kelley et al., 2001). Shortly after 
an acute increase of plasma NEFA levels in humans, insulin resistance starts to 
develop. Conversely, when the level of plasma NEFA decreases, as in the case with 
antilipolytic agent use, peripheral insulin uptake and glucose monitoring will be 
improved (Roden et al., 1996). Circulating concentrations of plasma NFFA are 
determined to a large extent by the release by lipolysis of adipocyte triglyceride 
stores by adipose lipase (AL) (Lass et al., 2011) and HSL. Hormone-sensitive lipase 
stimulated release of FFA from TG stores in adipose tissue, is tightly controlled by 
hormones that are regulated by the metabolic status. During conditions such as 
fasting, when blood glucose is low or when energy demands are increased, glucagon, 
glucocorticoids and catecholamines lead to activation of HSL to promote hydrolysis 
of stored triglycerides to FFA (Stanley et al., 2005). By contrast, in the fed state 
insulin inactivates HSL and inhibits lipolysis (Stanley et al., 2005). In vivo, the 
majority of FFA that are delivered to tissues arise from hydrolysis of a triglycerides, 
which are transported in plasma in chylomicrons or VLDL particles and the remainder 
exist in the non-esterified form bound to albumin. Plasma FFAs can increase in 
healthy individuals due to adrenergic stimulation brought on by exercise, stress, 
fasting, ischemia, or diabetes. The release of FFA from chylomicrons or VLDL by 
lipoprotein lipase in these situations also increases plasma FFA (Stanley et al., 2005). 
When tissues up take FA, they have three major fates in the cell. They can be 
esterified into TG, diglycerides, or phospholipids; converted to sphingolipids; or 
oxidized for energy (Chavez and Summers, 2010). FFAs are transported to 
cardiomyocytes by either passive diffusion or transport proteins (Stanley et al., 
2005). Since the majority of FFA that enter the heart are to provide 70-90% of the 
energy (Lopaschuk et al., 1994), they must enter the mitochondrial matrix for β-
oxidation. FFA are transported across the outer and inner mitochondrial membrane 
by carnitine palmitoyl transferase 1 (CPT1), which is the rate-limiting step of fatty 
acid oxidation, and CPT2. The acetyl-CoA enters the tricarboxylic acid cycle, yielding 
NADH and FADH2, which enter the electron transport chain to produce ATP (Stanley 
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et al., 2005). Persistent exposure of tissues to increased concentrations of fatty 
acids, and associated changes in the metabolic fate of fatty acids are an important 
cause of insulin resistance. 
The resistance to insulin action in diabetes is due to reduced insulin action on target 
tissues such as skeletal muscle and adipose tissues (Atkinson and Maclaren, 1994, 
Baekkeskov et al., 1982). The normal effect of insulin on carbohydrate metabolism is 
reducing glucose levels on the plasma, on lipids it favours its synthesis (lipogenesis) 
and decreases its breakdown by favouring cholesterol biosynthesis by using glucose 
as substrate and also favours protein synthesis by decreasing protein catabolism. The 
dysregulation of insulin action on carbohydrate, protein and lipid metabolism causes 
the clinical condition ‘hyperglycaemia’ (Falciglia, 2007, Triplitt et al., 2015). Still it 
is highly debatable about the events that are causing T2D. It is associated with 
adverse changes in cardiovascular risk factors such as high TG levels, low levels of 
HDL-C and raised blood pressure. It usually results from impairment of ß cells to 
secrete adequate insulin in response to overeating, inactivity, obesity and IR (Weyer 
et al., 1999, Schrauwen-Hinderling et al., 2011). It has been observed that patients 
with diabetes are more likely to have high plasma TG concentration (Shen, 2007). In 
the San Antonio Heart Study patients with insulin resistance were at high risk for CVD 
development and presented with elevated TG, blood pressure and lower HDL 
compared with healthy non-diabetic individuals (Haffner et al., 2000). IR may be the 
underlying cause of impaired glucose tolerance (Weyer et al., 2001, Garvey and 
Hermayer, 1998). The exact mechanisms that cause IR are not fully understood and 
both environmental and genetic factors are involved. IR has been linked with one or 
more genes with varying frequencies among different ethnic groups (Mercado et al., 
2002, Stern and Mitchell, 1999). 
 
Diabetes and CVD risk 
According to IDF (International Diabetes Federation, 2014), there are currently 382 
million people with diabetes, which is projected to rise to 592 million by 2035. Over 
three-quarters of these cases are in low middle-income countries (International 
Diabetes Federation, 2014, Shaw et al., 2010, Whiting et al., 2011). Diabetes caused 
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around 4.9 million deaths in 2014 (International Diabetes Federation, 2014, Shaw et 
al., 2010, Whiting et al., 2011). Diabetes and IR are prime risk factors for CVD. 
Diabetes leads to metabolic, structural and functional changes in the heart and 
vasculature leading to diabetic cardiomyopathy, coronary artery disease and 
myocardial ischemia, and ultimately heart failure (Gray and Kim, 2011, Donnelly et 
al., 2000). Along with complications like retinopathy and nephropathy, peripheral 
vascular disease (PVD), it is also one of the leading risk factors for stroke and coronary 
artery disease (CAD). As people progress from impaired glucose tolerance (IGT) to 
diabetes mellitus, their risk of coronary heart disease (CHD) and stroke increases 2 
to 3 fold (Wilson et al., 1991, Stamler et al., 1993b, Zimmet et al., 2001), while the 
risk of peripheral vascular disease increases by four-fold (Haffner et al., 1998). The 
risk of all cause and CVD mortality is almost double in people with glucose levels ≥ 
11.1 mmol.l-1 in the fasted state, measured in response to an oral glucose load (Shaw 
et al., 2010). Diabetes also affects the heart muscle causing heart failure (Dokken, 
2008, Muhlestein et al., 2003, Thrainsdottir et al., 2005). A possible explanation is 
the impact of insulin resistance to induce impaired vascular function, which leads to 
impaired nitric oxide mediated vasorelaxation, which may contribute to hypertension 
and to increased risk of atherosclerosis (Zhang et al., 2012, Symons et al., 2009, 
Muniyappa et al., 2008). Moreover, genetic manipulation of insulin action in the 
vasculature will increase atherosclerosis (Rask-Madsen et al., 2012, Rask-Madsen et 
al., 2010, Qiang et al., 2012). Insulin resistance via multiple mechanisms may 
contribute to macrophage accumulation in the vessel wall to increase atherosclerosis 
and instability of vulnerable plaques (Bornfeldt and Tabas, 2011, Aurigemma et al., 
2013). Lastly, insulin resistance has been shown in many human and animal studies 
to increase the extent of myocardial injury in the context of myocardial ischemia, 
which may contribute to the increased risk of heart failure in affected individuals 
(Aurigemma et al., 2013, Abel et al., 2008). 
Causes of diabetic dyslipidemia 
Diabetic dyslipidaemia is caused by several factors, including hyperglycaemia, insulin 
resistance, hyperinsulinaemia, visceral adiposity, hepatic steatosis, and dysregulated 
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fatty acid metabolism (Taskinen, 2003, Chan and Watts, 2011). Insulin is involved in 
the regulation of lipid metabolism particularly in the release of FFA, as patients with 
IR or diabetes have higher TRL level and abnormalities in their lipid profile (Taskinen, 
2003). Any impairment of insulin sensitivity appears in the liver, skeletal muscles and 
adipose tissue (Turner and Clapham, 1998) and causes impairment in glucose uptake 
and storage (Turner and Clapham, 1998). Insulin resistance leads to an increase in 
the burden of fatty acid which builds up in the liver as triglyceride. The liver has 
three options for handling excess TG: store them, enhance β-oxidation in 
mitochondria (Gavrilova et al., 2000, Turner and Clapham, 1998, Meena et al., 2014, 
Shen, 2007, Björntorp, 1991, Wood, 2006) or stimulate the synthesis VLDL resulting 
in hypertriglyceridemia (Steinberger et al., 2001, Björntorp, 1991, Reaven, 1988, 
Reaven and Chen, 1996, Wood, 2006).  
In patients with T2D have high concentrations of both fasted and postprandial TG and 
apoB-48 (Lewis et al., 1991, Meng et al., 1983, Schaefer et al., 2002, Taniguchi et 
al., 2000, Curtin et al., 1996). Elevated concentrations of postprandial CM and CMRs 
in insulin resistance have been mainly attributed to impaired TRL clearance from the 
circulation (Shojaee-Moradie et al., 2013). In patients with T2D, increased plasma 
apoB-48 is related to reduce the rate of CMRs catabolism (Dane-Stewart et al., 2003, 
Hogue et al., 2007). Therefore, clearance of CMRs could be impaired as a result of 
increased hepatic-VLDL secretion in insulin resistance (Lewis, 1995). That is because 
increased availability of TG and cholesterol in T2D increases VLDL-hepatic synthesis 
which might affect the LPL activity in clearing CMR (Lewis, 1995).  
The overproduction of VLDL is a key mechanism leading to the development of 
dyslipidaemia in the metabolic syndrome and a frequent co-morbidity of peripheral 
IR and type 2 diabetes mellitus (Bamba and Rader, 2007). This resulting 
overproduction of VLDL1 causes an increase in small density LDL and decreases HDL 
transport to liver (Duell et al., 1991, Zimmet et al., 2001).  
Insulin resistance also contributes to elevated TG levels in plasma by reducing the 
activity of LPL which inhibit the clearance of both VLDL and TRL (Mead et al., 2002). 
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The slow removal of CM and CMRs by reduced LPL activity has been addressed in 
insulin resistance (Kobayashi et al., 2007) due to the diminished regulation of LPL by 
insulin (Patsch, 1998). Moreover, diabetic patients in general and diabetic women in 
particular have slow clearance of CM which expose the arterial wall to high 
concentrations of accumulated VLDL and CM (Goldberg and Merkel, 2001, De Man et 
al., 1996, Howard, 1999).  
Formation of small dense LDL in diabetics 
 
CETP promotes exchange of HDL cholesteryl ester for triglycerides of TRL. In the 
presence of high concentrations of chylomicrons and VLDLs, HDL cholesteryl esters 
are preferentially transferred by CETP to larger VLDL particles that become 
cholesterol rich and thus, potentially more atherogenic (Guérin et al., 
2001). Transfers of cholesteryl esters to TRLs, particularly chylomicrons, are 
enhanced in the postprandial state (Guerin et al., 2002, Contacos et al., 1998). The 
rate of cholesteryl ester transfer to TRLs and LDLs and the mass of CETP are increased 
in patients with a range of atherogenic dyslipidaemias (McPherson et al., 1991). Thus, 
reducing VLDL1 concentration is likely to induce clinically important changes to the 
atherosclerotic risk profile. 
Other studies show that insulin directly increased degradation of newly synthesized 
apoB (Sparks and Sparks, 1990). Therefore, insulin deficiency or hepatic insulin 
resistance may increase the secretion of apoB. Insulin may modulate the production 
of a number of other proteins that affect circulating levels of lipoproteins. These 
include apoC-III (Chen et al., 1994), a small apoprotein that may increase VLDL by 
preventing the actions of LPL and inhibiting lipoprotein uptake via the LDL receptor-
related protein (LRP). This leads to decrease in the clearance of postprandial remnant 
lipoproteins. LDL particles in diabetic patients can also become glycated, in a process 
similar to the glycation of the haemoglobin. Glycation of LDL lengthens its half-life 
(Napoli et al., 1997) and therefore increases the ability of the LDL to promote 
atherogenesis (Bucala et al., 1993).  
HDL acquires cholesterol and PL by the actions of phospholipid transfer protein (PLTP) 
or by the efflux of cellular FC by the esterification of this cholesterol by the enzyme 
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lecithin cholesterol acyl transferase (LCAT) (Hayek et al., 1993, Jiang et al., 1999, 
Young and Fielding, 1999). This metabolism is often defective in diabetes, reducing 
the production of HDL-C from this source (Taskinen, 1987). Also, high concentrations 
of TRL, stimulate CETP exchange of VLDL triglyceride for cholesteryl ester in the core 
of LDL and HDL. This triglyceride can then be converted to free fatty acids by the 
actions of plasma lipases, primarily hepatic lipase. The net effect is a decrease in 
size and an increase in density of both LDL and HDL (Chahil and Ginsberg, 2006). (see 
Figure 1.5). 
Dyslipidaemia is only one mechanism by which diabetes promotes atherosclerosis. IR 
is also believed to be a key factor mediating the progression of endothelial 
dysfunction (Lteif et al., 2005). Moreover, diabetes might also influence CVD by 
leukocyte adhesion, thrombogenesis and inflammation (Celermajer, 1997, Pickup and 
Mattock, 2003). The latter also has a paracrine suppressive effect on the secretion of 
adiponectin, a powerful insulin sensitizer which is secreted less as the adipocyte mass 
expands (Ryo et al., 2004, Kojima et al., 2005, Friedman and Halaas, 1998). The fat 
accumulation into islet cells might cause a reduction in the capacity of islets 
ultimately causing glucose intolerance and premature T2D (Ouchi et al., 1999, Kojima 
et al., 2005).  
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Figure 1.5. Dyslipidaemia of insulin resistance. Panel [A], shows the normal lipedmic response, Panel [B] shows insulin resistance/diabetes dyslipidaemia. 
Hypertriglyceridaemia reflects accumulation in plasma of TRL, the pivotal defect in lipoprotein metabolism. Over secretion of VLDL and chylomicrons by the 
liver and intestine, coupled with decreased catabolism, increases the plasma pool of TRLs, including remnant lipoproteins; increased hetero exchange of 
neutral lipids between TRL and LDL and HDLs via CETP results in remodelling of LDL and HDL to form correspondingly smaller, denser particles. LPL activity 
is decreased in skeletal muscle and adipose tissue owing to the inhibitory effects of insulin resistance and apoC-III. 
[A] 
[B] 
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1.5 Intervention to modify CVD through 
behavioural changes  
Most patients often undergo pharmacological treatments for lipoprotein disorders, 
obesity and IR. Long-term pharmacological therapies are often expensive, and 
probably undesirable to large sections of the population, whereas life style, diet 
and exercise can be an alternative solutions that are more acceptable and carry 
less risk of side effects.  
1.5.1 Controlling plasma lipids by exercise  
Moderate exercise is one potential non-pharmacological treatment to reduce 
elevated postprandial TG concentrations. In the last decade studies have shown 
that exercise can lower TG concentrations in both fasting and postprandial state 
by 20-25%, mostly the VLDL1 particles among highly risk CVD population (Gill et 
al., 2004a) such as centrally obese middle-aged men (Gill et al., 2004a) and 
postmenopausal women (Gill and Hardman, 2000). This effect is seen following a 
single exercise session and is not due to weight loss (Gill et al., 2004b, Gill et al., 
2004a). The TG-lowering effect cannot be replicated by a dietary-induced energy 
deficit of the same magnitude (Gill and Hardman, 2000) although it contributes as 
replacing the energy expended by exercise attenuates the TG-lowering effect 
(Burton et al., 2007). However, exercise induces lower postprandial TG 
concentrations when food is consumed ad libitum (Farah and Gill, 2012). 
Various studies indicated that exercise reduces postprandial lipaemia in various 
age groups and usually the effect of exercise appears after some hours of after 
exercise (Peterson et al., 1990). 
Borghouts et al., indicated that insulin sensitivity is improved by exercise training 
(Borghouts and Keizer, 2000). Mestek et al., (2009) reported that, in men with 
MetS, postprandial lipaemia tends to be lower after continuous aerobic exercise 
with 500 kcal of energy expenditure before a meal (Mestek, 2009). Ziogas et al., 
(1997) demonstrated that endurance exercise individuals exhibit a significantly 
lower postprandial hyperinsulinaemia response to a fat-rich meal compared with 
sedentary individuals (Ziogas et al., 1997). Ten hypertriglyceridaemic men with 
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insulin resistance were studied by Zhang et al., (2007), and they suggested that 
in individuals with metabolic syndrome, exercising at moderate intensity for 45 
min effectively resulted in a reduction of postprandial hypertriglyceridemia, while 
exercise for 30 min is sufficient to improve insulin action (Zhang et al., 2007). 
Similarly, Schrauwen-Hinderling et al., (2011) studied the effect of exercise on 11 
diabetic patients for 12 weeks of progressive endurance/strength training and 
found that although the cardiac lipid content remained unchanged, the aerobic 
capacity and insulin sensitivity were increased (Schrauwen-Hinderling et al., 
2011). Lee et al., (2011), investigated the effect of exercise on diabetic mice and 
implied that adiponectin (APN) suppresses inflammation and oxidative stress in 
the aorta (Lee et al., 2011). Supervised aerobic training exercise for 16 week in 
dyslipidemic patients without MetS was associated with weight loss, increased APN 
and a decline in LDL, IDL and VLDL-cholesterol (Yoshida et al., 2010). Endurance 
exercise training is known to generally increase HDL cholesterol concentrations 
and to decrease plasma triglyceride and LDL cholesterol levels (Després and 
Lamarche, 1993, Després and Lamarche, 1994).  
Studies show that trained individuals have lower postprandial lipaemia than 
untrained (Ziogas et al., 1997) and 50% lower TG concentration after exercise 
(Merrill et al., 1989). The period of endurance has been studied in different groups 
of individuals: overweight men and women with dyslipidaemia (Kraus et al., 2002) 
and older men and women (Halverstadt et al., 2007), and these indicate that the 
period of training reduces either fasting and/or postprandial TG. However, the 
effect on TG is due to short term metabolic response as shown by Herd et al., 
(2000) who found no difference in postprandial TG concentrations between 
endurance trained and untrained young adults. The basic role of exercise depends 
on how much energy is expended, according to a study conducted in 2008 by 
Burton et al., on 13 overweight/ obese men who enrolled for a three arms namely 
control, energy defect and energy replacement (Burton et al., 2007). The authors 
found that the greater reduction in postprandial TG was with energy defect by 
14%, compared to with 10% observed control and energy replacement arms 
respectively. 
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Comparing regular exercise with a single bout of exercise 
Regular exercise is beneficial for health by maintaining the healthy weight and it 
reduces TG concentration in the plasma (Jakicic, 2002). It also helps to reduce 
the acute changes in TG metabolism (Peterson et al., 1990). It has been found 
that there is no difference on level of TG on plasma between 30 min of moderate 
cycling (0.87 MJ per 30 min) accumulated in short bouts and one continuous 30 
min bout of cycling in obese men (Miyashita, 2008). Exercising at moderate 
activity over the course of 6 months, was shown to significantly increase HDL-C in 
young adult women (Duncan et al., 1991). In a population of men and women 
ranging from 50 to 65 years of age, however, an increased frequency of exercise 
resulted in the highest HDL-C levels (Kraus et al., 2002). Over the course of only 
3 weeks of exercise, although HDL-C levels did not increase, HDL preferentially 
converted to an anti-inflammatory state (Roberts et al., 2006). A beneficial effect 
on LDL particle size and density has been observed in long -distance runners 
(Williams et al., 1986).  
On the other hand, many studies show that a single session of exercise is more 
effective on TG reduction than continuous exercise. A session of aerobic exercise 
tends to reduce postprandial hyperinsulinaemia in healthy adult (Tsetsonis and 
Hardman, 1996, Zhang et al., 2007, Graham, 2004). Moreover, Mestek et al., 
(2009), stated that accumulating moderate-intensity exercise does not appear to 
effectively modulate postprandial lipaemia in men with MetS (Mestek, 2009). 
Similarly, different kinds of exercise either in its intensity or duration have the 
same influence in decreasing plasma TG (Tsetsonis and Hardman, 1996). The 
greatest effect of exercise appears 12-18 h after exercise (Peterson et al., 1990). 
Similarly exercise is considered to have short lived effect on insulin because insulin 
sensitivity can decline significantly after as little as 38 h after the final exercise 
training (Mikines et al., 1989). One single 90 minute session of moderate intensity 
exercise completely reversed FFA induced insulin resistance in healthy volunteers 
one day later (Schenk and Horowitz, 2007). 
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Energy Expenditure and Energy Deficit 
Accumulating evidence suggests that the TG lowering effect of exercise depends 
on the energy expended during the exercise sessions (Gill et al., 2003). It is widely 
accepted that the higher the energy expenditure, the larger amount of TG 
reduction (Petitt and Cureton, 2003). Maraki et al., (2009) studied the influence 
of low energy expenditure exercise (30% of maximal oxygen uptake(VO2max) along 
with mild energy intake restriction by 2.44 MJ on fasting and postprandial TG in 
young women (Maraki et al., 2009). They demonstrated that, fasting plasma TG, 
TG in TRL and serum insulin concentrations reduced by 18, 34 and 30% respectively 
after intervention compared with the control trial. Postprandial concentrations of 
plasma TG and TRL-TG also reduced significantly but there was no difference in 
serum insulin concentrations. Although energy intake restriction can reduce 
fasting TG, postprandial lipaemia and insulin concentrations, exercise was more 
effective in reducing fasting and postprandial TG and insulin in postmenopausal 
women (Gill and Hardman, 2000). Another study by Burton et al., indicated an 
approximately doubling of the reduction in postprandial lipaemia and rise in fat 
oxidation through exercise alone when compared to exercise plus energy 
replacement (Burton et al., 2007). 
Another way to manipulate the energy expenditure is to increase the duration of 
exercise. For instance significant reductions of both postprandial TG and 
postprandial insulin response was showed in premenopausal women who exercised 
for 2 h vs. 1 h at 50% VO2max another (Gill et al., 2002). They found that the 
reduction of postprandial TG concentrations was more after 90 min exercise at 60 
% of VO2max compared to the same period at 30% VO2max (Tsetsonis and Hardman, 
1996). Magkos et al., in different study found that a 2 h cycling at 60% decreased 
VLDL-TG –but not VLDL-apoB at the same intensity (Magkos et al., 2007, Magkos 
et al., 2006). As the exercise intensity and duration reduce postprandial TG, it 
also increases insulin sensitivity. It has been suggested that the effect of exercise 
on insulin sensitivity can last for 15 days on middle age overweight men which 
depends on intensity and weekly amount of exercise during each session 
(Breckenridge et al., 1982). Babraj and his team reported that low volume, high 
intensity exercise is effective in reducing plasma glucose and insulin in sedentary 
young adults (Babraj et al., 2009).  
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Possible Mechanisms for the effect of exercise on TRL 
The TG lowering effect of exercise does not appear to be due to a reduction in 
the rate of appearance of CM in the circulation (Gill et al., 2006, Gill et al., 
2001a). There is also no impact of exercise on CM number (James et al., 2007).  
Evidence supports the hypothesis that endurance trained individuals have high 
clearance rates of CM-like lipid emulsions compared with untrained peers 
(Carmena et al., 2004, Podl et al., 1994). LPL activity in muscles has been reported 
to increase over 200% in response to intense exercise sessions (Sady et al., 1986), 
which can be used as indicator of increased post-heparin plasma LPL activity (Podl 
et al., 1994). The level of LPL post exercise has been investigated in many studies. 
For instance; Miyashita and Tokuyama demonstrated that 30 min of moderate-
intensity cycling performed the day before a meal of moderate fat content reduce 
postprandial serum TG concentrations but did not affect serum pre-heparin 
lipoprotein lipase concentrations in young men (Miyashita, 2008). Similarly there 
was no difference observed in post-heparin plasma LPL activity, although it was 
correlated significantly with exercise-induced changes in fasting and postprandial 
TG (Gill et al., 2003).  
VLDL is the lipoprotein most influenced by exercise (Peterson et al., 1990, Gill et 
al., 2001b, Gill et al., 2006). The rise of postprandial lipaemia occurs due to a rise 
in VLDL remnant apoB-100 particles, not CM or CM remnants or apoB-48 particles 
(Havel, 2000). Recently it has been demonstrated that the major RLP associated 
with postprandial hyperlipidaemia is in fact VLDL and not CM remnants (Nakajima 
et al., 2011a). 
Despite the fact that CM is the preferred substrate for LPL (Fisher et al., 1995, 
Bjorkegren et al., 1997), it seems that VLDL concentration reductions after a 
session of exercise are mediated by increased peripheral clearance, rather than 
reduced hepatic production (Al-Shayji et al., 2012). It was hypothesised that this 
may be due to exercise altering the composition of VLDL1 to make it a more 
favourable substrate for LPL (Al-Shayji et al., 2012). The first objective of this 
PhD thesis is to explore and understand why LPL clears VLDL1 more rapidly 
after exercise by testing the hypothesis that the affinity of VLDL to LPL 
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increases after exercise. This work in described in Chapter 3. This may help to 
improve the understanding of the nature of these exercise-induced changes. 
For health care professionals this will help to emphasize the reason behind high 
level of TG and might recommend exercise as part of the treatment for people 
with high TG level.  
1.5.2 Controlling plasma lipids by diet modification  
A balanced dietary intake is necessary for optimal health benefits. Despite the 
essential role of diet in the treatment of many metabolic syndromes, the role of 
diet in the treatment of hypercholesterolemia has been largely neglected with the 
advent and use of medications (statins) (Kreisberg and Oberman, 2003). The 
relationship between plasma lipid and dietary intake has been studied in 
populations and individuals. Older studies examined total cholesterol and 
triglyceride levels; more recent studies have looked at specific lipoproteins and 
apolipoproteins.  
Studies relating the effect of diet to serum lipid levels and to rates of 
atherosclerosis in free-living populations have consisted mostly of cross-sectional 
surveys. Some studies found correlations between dietary fat and serum lipids 
when different groups were compared, e.g. Japanese living in urban and rural 
areas (Ueshima et al., 1982) and Polynesian groups consuming different levels of 
dietary saturated fat (Prior et al., 1981). Surveys of single populations such as that 
of the Western Electric Study showed that a high ratio of polyunsaturated to 
saturated fat was correlated positively with plasma lipid levels and positively with 
a decreased incidence of coronary heart disease (Shekelle et al., 1981), but the 
correlation coefficients were small. The Tecumseh Study, on the other hand, 
failed to show a correlation between fat, cholesterol, and other macronutrient 
intake and serum cholesterol and triglyceride levels (Nichols et al., 1976). The 
North American diet pattern of consuming higher quantities of red meat, high-fat 
dairy products, and refined grains and low amount of fiber was positively 
correlated with higher CRP (Fung et al., 2001). The Northern Manhattan Study 
(Gardener et al., 2011), European Prospective Investigation into Cancer and 
Nutrition (EPIC) cohort reported (Dilis et al., 2012) that a dietary pattern 
resembling the Mediterranean Diet was inversely associated with a composite 
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outcome of CVD (ischemic stroke, myocardial infarction or vascular death). 
Worldwide cross-sectional surveys, both prospective and retrospective, generally 
support the concept that low-fat diets correlate with lower lipid levels and lower 
incidence of atherosclerotic heart disease; and they are used to support position 
papers advocating the adoption of such diets (Gotto Jr et al., 1984). Nevertheless, 
there are problems in interpreting such studies. It is difficult to assess the part 
played by other factors such as the type of consumed fat, percentage of fat and 
carbohydrate, exercise, total caloric intake, obesity, and stress (Gordon et al., 
1984). More information concerning the relationships of diets and lipoproteins has 
come from individual and group feeding studies.  
 
Effect of total fat ingestion on lipid metabolism  
There is growing evidence about how major shifts in the macronutrient content of 
the diet can affect plasma lipoprotein patterns, which can be used to form dietary 
recommendations to minimize the risk of developing CVD. Early work focused on 
assessing the effect of a high fat meal on plasma lipoprotein pattern and it was 
observed that plasma TG increased (Havel, 1957b). However, later in the 1960s, 
it was noted that diets very low in fat resulted in hypertriglyceridemia (Ahrens Jr 
et al., 1961, Frayn, 2009, Lichtenstein and Van Horn, 1998). Hudgins and co-
worker observed an increase in fatty acid and VLDL-TG induction by very-low-fat, 
high-sugar diets (Hudgins et al., 1998, Nestel et al., 1970). From the early 1950, 
the role of fatty acid on plasma cholesterol was studied (Hegsted et al., 1959, 
Keys et al., 1950) and it is accepted that dietary saturated fatty acids (SFAs) are 
detrimental to health (Hunter et al., 2010). It was observed that not all saturated 
fatty acid (SFA) had similar effect on plasma cholesterol. The shorter the chain of 
saturated fatty acids (6:0–10:0) the lower effect on plasma cholesterol, whereas 
those with intermediate chain lengths (12:0–16:0) increased concentrations of 
cholesterol (Keys et al., 1950, Mcgandy et al., 1970). This increase in cholesterol 
level has been attributed to a decrease in low-density lipoprotein receptor activity 
(Matthan et al., 2004). Saturated fatty acid increases plasma LDL-cholesterol 
concentrations and lowers levels of cholesteryl esters in the liver (Spady and 
Dietschy, 1985). Myristic and palmitic acids increased LDL-C and HDL-C levels to 
a similar extent without significantly altering TC/HDL-C ratio, whereas lauric acid 
had the largest LDL-C- and HDL-C-raising effect leading to a decrease in the 
1 Introduction and Literature Review  
 
60 
Khloud Jamil Ghafouri ® 2017 
TC/HDL-C ratio (Mensink et al., 2003). Epidemiological studies have found an 
association between higher saturated fat intake and higher rates of cardiovascular 
disease (Howard et al., 2006, Dayton et al., 1969). Randomized clinical trials have 
documented that lowering saturated fat reduces coronary events and reduces 
cholesterol, and that Mediterranean diet (high in fibre, olive oil, fish, and a 30% 
fat) improves survival (De Lorgeril et al., 1999, Mauger et al., 2003, Roth and 
Brown, 2005).  
 
Effect of quality of diet fatty acids on lipid metabolism 
Trans-fatty acids 
 
The frequent ingestion of high fat content foods such as margarine, cookies, cake 
and white bread which contain partially hydrogenated vegetable oils provide the 
body with trans-fatty acid (TFA) which are significantly associated with higher 
risks of CHD. A diet with the same energy density from saturated or cis unsaturated 
fats showed that the consumption of trans fatty acids raises levels of LDL-C, 
reduces levels of HDL-C, and increases the ratio of total cholesterol to HDL 
cholesterol (Stampfer et al., 1991). For every 1% increase in total calories from 
TFA, the amount of LDL-C increases by 2% (Cleeman et al., 2001). Trans fatty acid 
also increases the plasma concentration of TG (Mensink et al., 2003), and Lp(a) 
lipoprotein (Zaloga et al., 2006) and reduces the particle size of LDL-C more than 
other fats (Mauger et al., 2003). Five weeks consumption of TFA derived partially 
hydrogenated fats was associated higher total and LDL cholesterol, and lower HDL 
cholesterol concentrations in post-menopausal women (Matthan et al., 2004). 
These changes were attributed to impaired LDL apoB-100 and enhanced HDL apoA-
I fractional catabolism. Consumption of TFA did not alter TRL apoB-100 or apoB-
48 metabolism (Matthan et al., 2004). The combined effect of dietary saturated 
and trans fatty acids on plasma lipids is amplified by the lack of n-3 long-chain 
fatty acids, which have complex competitive effects on prostanoid synthesis, 
cellular function, and thrombosis (Amine et al., 2002). Epidemiological studies 
have demonstrated that diets low in saturated fat are associated with lower rates 
of CVD (Vessby, 2003, Trial, 2006). For instance the inverse relationship of dietary 
ω-3 fatty acids and CVD events (Dyerberg et al., 1975). However, The effects of 
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dietary fats on plasma TG is less clear than the effects of dietary fats on 
cholesterol and tend to be determined by specific fatty acids (Howell et al., 1997).  
Monounsaturated fatty acid 
 
Zheng et al. reported that replacing 17% of total energy intake from complex 
carbohydrate with MUFA selectively stimulated the secretion of VLDL and IDL 
particles containing apoE and apoC-III, while suppressing the secretion of particles 
that did not (Zheng et al., 2008). Consequently, the concentration of apoB-
containing lipoproteins with apoE and apoC-III was higher with the MUFA diet 
compared with the carbohydrate diet (Zheng et al., 2008). The MUFA diet was also 
associated with increased VLDL and IDL apoB catabolism, although LDL apoB 
metabolism was not altered (Zheng et al., 2008). This study lends support to the 
potential benefits of increased MUFA and reduced complex carbohydrate in 
modulating lipoprotein metabolism. The study, however, was non-randomized and 
short-term, with an intervention period of only three weeks. Notably, this study 
compared two relatively healthy diets, both low in SFA, high in fiber and utilized 
primarily low glycaemic foods. High-MUFA diets have gained significant attention 
as an alternative dietary pattern to the commonly recommended low-fat and high-
carbohydrate (CHO) pattern. Several meta-analyses of randomized controlled 
trials (RCTs) suggested potential benefits of a high-MUFA diet compared with a 
high-CHO diet in improving metabolic factors, such as glycemic control, serum 
lipids, and blood pressure, among both healthy individuals and T2D patients 
(Schwingshackl et al., 2011, Shah et al., 2007, Garg et al., 1994). A recent meta-
analysis illustrated that, When comparing high-MUFA to high-CHO diets, there 
were significant reductions in fasting plasma glucose, TG, body weight, and 
systolic blood pressure along with significant increases in HDL cholesterol (Qian et 
al., 2016). Also a diet rich in MUFA has been linked to a reduction in LDL oxidation. 
Studies found that the particles rich in MUFA have been shown to be less 
susceptible to oxidative modification compared to LDL particles enriched with n-
6 fatty acids (Parthasarathy et al., 1990, Abbey et al., 1993, Bonanome et al., 
1991). 
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Polyunsaturated fatty acids  
 
An aspect of CVD research focuses on the cardio-protective effects of fish oils and 
of individual omega 3 polyunsaturated fatty acids (n-3 PUFA), or more specifically, 
eicosapentaenoic acid (EPA; 20:5 n-3), docosahexaenoic acid (DHA; 22:6 n-3) and 
α linolenic acid (ALA; 18:3 n-3). Many large-scale studies, including primary and 
secondary prevention clinical trials and meta-analysis of cohorts, have concluded 
that consumption of fatty fish, fish oils or individual n-3 PUFA is an effective 
dietary strategy to lower CVD morbidity, mortality, as well as classic and emerging 
risk factors (Bucher et al., 2002, von Schacky, 2003, Calder, 2004, Von Schacky 
and Harris, 2007, Yaktine and Nesheim, 2007, Hu et al., 2002). Clinical and 
epidemiological trials have shown that an elevated intake of long-chain was also 
associated with a reduced cardiovascular risk, reduced inflammatory processes 
and reduced all-cause mortality (Simopoulos, 2008, Tapiero et al., 2002). A high 
intake of n-3 PUFA has been associated with antiarrhythmic, anti-thrombotic and 
vasodilatory effects (De Caterina, 2011, Leaf et al., 2003). Replacement of energy 
from saturated fat with PUFA has been shown to decrease TC and LDL-C, with a 
concomitant decrease in HDL-C (Hodson et al., 2001). In addition, n-3 PUFA have 
been shown to improve a number of cardiac hemodynamic factors such as blood 
pressure (Mozaffarian et al., 2006, Geleijnse et al., 2002) and endothelial function 
(Hirafuji et al., 2003, Goodfellow et al., 2000) plasma TG reduction (Harris, 1997) 
anti-inflammatory responses (Calder, 2006) and anti-atherosclerotic effects (von 
Schacky, 2003). 
 
 
Effect of carbohydrate ingestion on lipid metabolism  
On the other hand, it has been observed that the ingestion of CHO alone (as in an 
oral glucose tolerance test (OGTT) has no influence on lipoprotein particles 
(Havel, 1957a). In free living, the majority of ingested food contains CHO, fat and 
protein. Most human interventions are carried out by holding the protein content 
of the diet relatively constant and varying the amount of fat and CHO. Therefore, 
many studies have been examining the effect of different ratios of fat/CHO diets 
on metabolism. Increases in the relative proportion of CHO result in reductions in 
HDL-C and an increase in TG concentration (Stampfer et al., 1996, Lichtenstein et 
al., 1994, Grundy et al., 1986, Mensink et al., 2003). 
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Diets high in carbohydrate (60-80% of calories) and low in fats (0-25% of calories) 
have marked effects on plasma levels of lipoproteins and on lipoprotein 
metabolism. The substitution of SFA by CHO decreases HDL-C and increases TG 
(Knopp et al., 2000, Howard and Wylie-Rosett, 2002). Plasma TG and VLDL–TG rise 
in both normal and hypertriglyceridaemic subjects (Blum et al., 1977, Falko et al., 
1980b, Falko et al., 1980a, Ginsberg et al., 1981, Huff and Nestel, 1982, Kashyap 
et al., 1982, Liu et al., 1984, Schonfeld et al., 1976). Hepatic secretion of VLDL 
increases (Schonfeld and Pfleger, 1971), and the VLDL becomes more TG enriched 
(Falko et al., 1980b, Ginsberg et al., 1981, Kashyap et al., 1982). The elevations 
in plasma TG reach a peak after one week and decrease after three weeks, 
although they do not return to baseline levels in that time (Kashyap et al., 1982). 
Interventional studies comparing the effects of low and high carbohydrate diets 
on LDL found that high-carbohydrate diets affect LDL particle size, generating 
smaller, potentially more atherogenic LDL particles as compared to low 
carbohydrate diets. During 3 days. After the low-fat and high-carbohydrate diet, 
LDL particle size distribution shifted towards smaller particle size. These changes 
in LDL particle size were thought to be the consequence of an observed increase 
in large triglyceride-rich VLDL particles and serum triglycerides, which both are 
of importance in the generation of small, dense LDL as mentioned above (Guay et 
al., 2012). However, changes such as those observed in the above-mentioned study 
have not been observed in another study after just a single meal with different 
fat content (Callow et al., 2002). One study of 4 weeks duration demonstrated a 
smaller LDL peak size in individuals after a low-fat and high-carbohydrate diet 
compared to a high-fat and low-carbohydrate diet (Faghihnia et al., 2010). A long-
term diet intervention over 9 months has been performed in overweight or obese 
middle-aged adults. Most importantly, LDL size increased in this population during 
a low-carbohydrate diet, whereas no differences were observed during a low-fat 
diet. The change in body weight did not differ between these two groups 
(LeCheminant et al., 2010). HDL-C also decreases after a few days on a high -
carbohydrate diet (Kashyap et al., 1982, Gonen et al., 1981, Blum et al., 1977, 
Schonfeld et al., 1976), with the HDL2 fraction falling to a greater extent than 
HDL3 (Gonen et al., 1981). Thus, in some respects diets high in carbohydrate and 
those with high P/S ratios both produce similar effects on LDL and HDL, but not 
on VLDL. There are significant changes in apolipoprotein concentrations in 
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response to these short-term increases in dietary carbohydrate. Proteins of the C 
family increase in response to high-carbohydrate diets. Plasma levels of apoC-II 
increase both in normal subjects fed a high-carbohydrate formula diet and in 
patients with high plasma TG (Falko et al., 1980b). Kashyap et al, found increases 
in both apoC-II and C-III but the ratio of apoC-III to apoC-II was lower in VLDL and 
HDL2 after three weeks of a high-carbohydrate diet; this indicates a relative 
enrichment of VLDL and HDL2 with apoC-II. Kashyap et al suggest that the 
difference in amounts of apoC-III and C-II in HDL2 subfractions may be due to 
differences in binding affinities of the different apoC's for HDL subfractions 
(Kashyap et al., 1982). 
The type of carbohydrate used in the diet significantly affects TG and VLDL 
responses. On a diet with 70% carbohydrate and with sucrose contributing 55% of 
calories, VLDL increased in six of seven subjects (Nestel et al., 1979). VLDL-apoB 
also increased. In two subjects there were increases in removal rates of apoB VLDL 
from the circulation, whereas in four subjects there was decreased removal of 
apoB VLDL. In most of the studies involving high carbohydrate diets, sucrose 
comprised a large part of the additional carbohydrate calories. In a recent study 
of hypertriglyceridaemic subjects, when the sucrose content of the diet was 
increased from 9 to 15% while total carbohydrate content was increased from 40 
to 60%, the degree of fasting hypertriglyceridemia and increase in VLDL 
triglyceride were greater than if sucrose was kept at a constant percentage of 
total carbohydrate (Liu et al., 1984). VLDL triglyceride, VLDL cholesterol, and 
VLDL protein rise by factors of 2.4, 1.67, and 1.88 respectively; LDL cholesterol 
decreases while LDL triglyceride remains the same. However, this response is 
attenuated when complex CHO primarily consisting of whole grains are given. Fifty 
percent CHO intake worsens lipid and non-lipid risk factors in patients with the 
metabolic syndrome. However, some CHO commonly referred to as complex has a 
higher glycaemic index (GI) and consequently increase insulin responses more than 
simple sugars (Ludwig, 2002). GI is a term used to classify food according their 
effects on glycaemic responses (Wolever et al., 1991). High GI Foods are digested 
and transformed into glucose rapidly for a given amount of CHO than foods with a 
low GI (Axen and Axen, 2010, Rossetti et al., 1987). A high glycaemic load (product 
of GI and CHO content) is associated with higher fasting TG and lower HDL-C levels 
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(Ludwig, 2002). Increased dietary carbohydrates, particularly simple sugars and 
starches with high glycemic index, can increase levels of small, dense LDL (Siri 
and Krauss, 2005). Ingesting high glycaemic meals can lead to various metabolic 
changes that promote excessive food intake (Ludwig et al., 1999). On the other 
hand, a meta-analysis of observational studies reported an association between 
the consumption of lower GI foods and lower TG, LDL-C and total cholesterol and 
higher HDL-C concentrations (Barclay et al., 2008, Goff et al., 2013). It was 
estimated that replacement of high GI foods for low GI foods can result 15% to 
25% reductions in TG concentrations (Pelkman, 2001). 
However, most studies have examined the long-term effect of high CHO diet or 
high fat diet or specific fatty acid ingestion on total plasma TG, HDL and LDL. 
There is limited data on the acute effect of fat, CHO or combination of both on 
the lipoprotein particles metabolism.  
Effects of dietary fibre on lipid metabolism 
 
Dietary fibre and whole grains contain a unique blend of bioactive components 
including resistant starches, vitamins, minerals, phytochemicals and antioxidants. 
As a result, research regarding their potential health benefits has received 
considerable attention in the last several decades. Epidemiological and clinical 
studies demonstrate that consumption of dietary fiber and whole grain intake is 
inversely related to obesity (Liu et al., 2002), type two diabetes (Meyer et al., 
2000), cancer (Forman and Hernandez, 2010) and CVD (Streppel et al., 2008).  
Dietary fibre, by its impact on the glycaemic response and other aspects of 
metabolism, may also have important effects on cardio metabolic pathways 
(Pereira and Liu, 2003). An increasing number of studies have reported that for 
every 10 g of additional fiber added to a diet the mortality risk of CHD decreased 
by 17–35% (Pereira et al., 2004, Streppel et al., 2008). Based on findings from 
epidemiologic studies regarding the protective effects of fiber intakes, the Dietary 
Reference Intakes (DRI) recommended consumption of dietary fiber is 14 g/1000 
kcal, or 25 and 38 g/day for adult women and men, respectively (Slavin, 2008).  
It has been proposed that dietary fibre could modify underlying CVD risk factors 
including lipid and lipoprotein metabolism, insulin homeostasis, inflammatory 
markers and coagulation, and improves insulin sensitivity, thereby reducing the 
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risk of CVD mortality (Erkkilä and Lichtenstein, 2006, Kokubo et al., 2011, Eshak 
et al., 2010). Although studies showed beneficial effects of soluble, gel-forming 
fiber on cardio metabolic risk factors, food sources of mainly insoluble fibers, 
primarily contributed by cereal products, have been the fiber most consistently 
associated with lower risk of CVD (Erkkilä and Lichtenstein, 2006). Findings of 
some investigations also suggest that the role of dietary fibre is more dependent 
on its types and sources, rather than the amount of intake (McKeown et al., 2004, 
Hosseinpour-Niazi et al., 2011). Different types or sources of dietary fibre may 
induce different physiological effects; soluble fibre is responsible for the 
cholesterol-lowering effect of dietary fibre whereas insoluble fiber interacts with 
intestinal absorption of foods and contributes to reduction in clotting factors 
(Brown et al., 1999). 
It has been demonstrated that inflammation may be an important mediator in the 
association between consumption of dietary fibre and CVD. A research has 
demonstrated an association between dietary fibre and levels of C-reactive 
protein (CRP), a clinical indicator of inflammation (King et al., 2003). After 
adjustment for age, gender, race, education, smoking, physical activity, BMI, total 
energy consumed, and fat intake. Dietary fiber intake from a variety of sources 
has been associated with a significantly decreased risk of coronary heart disease. 
In the Nurses’ Health Study, women in the highest quintile of fibre intake (median 
22.9 g/day) had an age- adjusted relative risk for major coronary events that was 
47% lower than women in the lowest quintile (11.5 g/day) (Stampfer et al., 2000).  
 
Several studies have evaluated dietary fibre in relation to intermediate vascular 
markers such as cholesterol. Studies suggest that 3 g soluble fiber from oats (three 
servings of oatmeal, 28 g each) can decrease total cholesterol and LDL by 0.13 
mmol.l-1 (Gulati et al., 2017, Katz, 2001). The mechanism can be explained by the 
reduction in the absorption of ileal bile acid (Morgan et al., 1993). These soluble 
forms of dietary fibre appear to have a negligible effect on triglyceride or HDL 
levels. Insoluble dietary fibre subgroups are derived largely from cereal sources 
and have little or no effect on lipids and lipoproteins (Jenkins et al., 2000). 
Effect of high fat vs. high carbohydrate diets 
 
In a meta-analysis of randomized controlled trials comparing high fat diets with 
high carbohydrate diets, it has been found that, both diets reduced participants' 
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blood pressures, total to HDL cholesterol ratios, and total cholesterol, LDL 
cholesterol, triglycerides, blood glucose, and serum insulin levels and raised HDL 
cholesterol; however, participants on high fat diets had greater increases in HDL 
cholesterol and greater decreases in triglycerides but experienced less reduction 
in total and LDL cholesterol compared with persons on high carbohydrate diets 
(Hu et al., 2012, Mansoor et al., 2016b, Sackner-Bernstein et al., 2015). However, 
it should be noted that the associations between diets and lipid profiles may be 
stronger in shorter-term studies due to greater control over the participants’ diets 
and higher compliance rates, and might provide insight to how these effects might 
be long-term. The acute effect of high carbohydrate diet on lipid metabolism 
would explain the mechanism behind the long term ingestion. It has been shown 
that ingesting high carbohydrate diet by patients with non-insulin-dependent 
diabetes mellitus led to little or no decrease in postprandial plasma or lipoprotein 
TG or cholesterol concentrations and an actual increase in concentration of 
potentially atherogenic small chylomicron and/or chylomicron remnants (Chen et 
al., 1992). Also, in nondiabetic population, it reduces total, LDL and HDL 
cholesterol. In contrast, the acute ingestion of fat has been related to increase in 
the postprandial concentrations of TG, phospholipid and remnant lipoprotein 
(Wilson et al., 1985, Nestel, 1964, Jeppesen et al., 1995, Cohen et al., 1988, 
Havel, 1957b). In addition, the acute fat ingestion increases plasma NEFA 
concentrations (Katan et al., 1994); also, the acute ingestion of fat led to stepwise 
increases in the postprandial rise of chylomicron and serum TG and induced 
marked changes in serum lipoproteins postprandially (Dubois et al., 1998). 
However, there is a limited knowledge in the effect of the acute ingesting equal 
amount of carbohydrate with fat or ingesting them separately on both TRL and 
CRL (Austin, 1990).  
In real life, fat and carbohydrate are consumed together, thus it is important to 
understand how this co-ingestion influences postprandial metabolic responses. 
Manipulating dietary macronutrient content has been shown to improve blood lipid 
profiles even in the absence of weight loss. For example, high fat diet increased 
HDL concentrations and decrease TG concentrations (Shai et al., 2008). Another 
study that compared the effects of dietary macronutrient content, found that the 
high fat/low carbohydrate diet resulted in greater improvements in blood lipids 
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and systemic inflammation when compared to the low fat/high carbohydrate, 
even though there were no detectable differences in body weight between the 
two diets (Ruth et al., 2013). On the other hand, high carbohydrate diets are 
linked to the elevation of fasting plasma TG concentrations (Parks et al., 1999, 
Roche, 1999), small but significant increases in total, LDL and HDL cholesterol 
(Wood et al., 2016, Mansoor et al., 2016a, Bueno et al., 2013, Hu et al., 2012), 
and higher postprandial glucose and insulin concentrations (Mohammed and 
Wolever, 2004). Ultimately, this may decrease insulin sensitivity (Wolever and 
Mehling, 2003), raising fasting triacylglycerol concentrations but also induced a 
shift toward smaller, denser LDL particles (Krauss, 2001).  
Therefore, the aim of the second experimental Chapter 4) is to determine the 
influence of the ingestion of CHO with fat on lipoprotein metabolism which will 
provide the information about acute ingestion of fat and carbohydrate on 
lipoprotein metabolism. 
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1.6  Ethnicity, plasma lipids and postprandial 
response  
Environmental, genetic and lifestyle factors are thought to affect the distribution, 
incidence and mortality of CVD and diabetes among racial and ethnic populations 
(Haga and Venter, 2003, Cooper, 1997a, McBean et al., 2004). Ethnicity play 
important roles in understanding disparities in health and health care (Karter, 
2003a, Karter, 2003b). Ethnicity has been defined as “a complex multidimensional 
construct reflecting the confluence of biological factors and geographical origins, 
culture, economic, political and legal factors, as well as racism” (Williams, 1997).  
 
1.6.1 Ethnicity and plasma lipids 
As mentioned above there are ethnic differences in the incidence of CVD. This can 
be as a result of differences in lipid profile and/ or differences on CVD risk factors. 
Differences in the lipid and lipoprotein concentrations between African American 
(AA) and Caucasian (CA) populations have been reported to occur in children 
(Crawford et al., 2001, Williams et al., 1992, Berenson et al., 1981, Morrison et 
al., 1979, Donahue et al., 1989) and this continues till adulthood (Tyroler et al., 
1975, Srinivasan et al., 1986, Tyroler et al., 1980). These differences include 
lower plasma TG and VLDL-cholesterol, as well as higher levels of HDL cholesterol 
in AA compared with CA women (Tyroler et al., 1975, Srinivasan et al., 1986, 
Tyroler et al., 1980). These differences in the plasma lipids and lipoprotein 
concentrations persist after adjustment for age, degree of obesity and adiposity, 
and the use of tobacco and alcohol (Tyroler et al., 1980, Glueck et al., 1984). This 
is also had been reported in black men when compared to White Europeans, Blacks 
generally have a favourable lipoprotein-lipid profile including low fasting TG and 
apoB levels and higher HDL-C concentration (Després et al., 2000, Lovejoy et al., 
1996, Albu et al., 1997, Howard et al., 2003, Kuller, 2004, Chaturvedi et al., 
1994). Similarly, Japanese have higher HDL-C and TG levels than Whites (Wolfe et 
al., 2002). Afro- Caribbean men have lower levels of LDL-C, total cholesterol, TG, 
large and small VLDL, sdLDL, as well as lower VLDL particle size, than either 
African American or White men (Miljkovic-Gacic, 2006). On the other hand, South 
Asians have high incidence of CHD and more than double risk of developing T2D 
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than Whites, Hispanics and Blacks. This might be related to increased frequency 
of IR and diabetes, elevated TG and low HDL-C in Asians (Anand et al., 2003, 
McKeigue et al., 1991, Chandalia et al., 2007). Middle Eastern (ME) adults seem 
to have mean plasma cholesterol levels of ~5.2 mmol.l-1 (Al-Nozha et al., 2008, 
Al-Lawati et al., 2003, Zindah et al., 2008), which is near to the average European 
level 5.0 mmol.l-1 (WHO, 2014a). 
 
A possible explanation of these variations is low birth weight, In a retrospective 
study of adult men and women living in South India, the prevalence of CHD was 
related to their size at birth, low birthweight, short birth length and small head 
circumference at birth and these were all associated with a raised prevalence of 
CHD later in life (Stein et al., 1996)=. In Jamaican schoolchildren age between 6-
12 years, indices of small size at birth were associated with higher systolic BP, 
glycated haemoglobin and serum cholesterol levels (Forrester et al., 1996).  
 
Another possible explanation for differences are alterations in the metabolic 
factors that regulate lipoprotein levels. For example, the activity of LPL in 
subcutaneous adipose tissue of lean black African males residing in the Quebec 
City area no more than 3 years is higher than lean Caucasian males (Ama et al., 
1985). Also it has been found that the rate of clearance of TG from circulation 
was higher in the AA men. Accompanying this increased clearance was an elevation 
in post-heparin plasma LPL activity (Friday et al., 1999). Other alterations in 
metabolism are seen in hyperinsulinaemic South Asians where there is, raised TG 
and lower HDL cholesterol levels, central adiposity with a high waist to hip ratio 
(McKeigue, 1991, McKeigue et al., 1992, Cruickshank et al., 1991). Moreover, 
Black subjects both men and women, have significantly higher post heparin 
hepatic lipase activity but lower hepatic lipase activity than White subjects (Albu 
et al., 1997). The low hepatic lipase activities in Blacks may have a genetic basis 
and contribute to their higher plasma HDL-C concentrations when compared to 
Whites (Vega et al., 1998).  
1.6.2 Ethnicity, obesity and adipose tissue 
The distribution of overweight and obesity in this population is known to vary 
considerably by ethnic group (Saxena et al., 2004). For the same BMI as 
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Caucasians, the body fat percentage in Asians would be 5–7% higher in Indian men 
(Forouhi et al., 1999, Nair et al., 2008, Chandalia et al., 2007) 8% in Indian 
women(Rush et al., 2009, Rush et al., 2007, Kamath et al., 1999)1–4% in Japanese 
women (Gallagher et al., 2000), 5% and 7% for Indonesian men and women from 
Malay ancestry respectively (Gurrici et al., 1999), and 1.3% and 1.7% for 
Indonesian Chinese men and women respectively (Gurrici et al., 1999). 
Interestingly, there was a tendency that the difference in body fat percentage 
became smaller with increasing BMI and age (Gallagher et al., 2000). In Asians, it 
was predicted that with increasing age, the body fat percentage increased to a 
lesser degree than in Caucasians (Chung et al., 2005, Rush et al., 2009). Among 
Asians, Indians have the highest body fat percentage followed by Malays and 
Chinese. The suggested BMI cut-off points for obesity are 26 kg.m-2 for Indians, 
27 kg.m-2 for Malays and 27.5 kg.m-2 for Chinese, as compared to 30 kg.m-2 for 
Caucasians (Deurenberg-Yap et al., 2001). It can be concluded that the difference 
in body fat percentage between Asians and Caucasians is dependent on the 
region/ethnicity. It is most pronounced in South (Indians), than Southeast (Malay) 
and than East Asian (Chinese/Japanese). Ethnic differences in the relationship 
between BMI and body fat percentage may be explained by the difference in body 
build and frame size (Deurenberg et al., 1999), in part by differences in 
muscularity and bone mineral content (Rush et al., 2007) as well as fat distribution 
and relative leg length (Rush et al., 2009). 
Ethnicity also influences adipose tissue distribution. For a similar level of total 
body fat, white subjects have been shown to have more intra-abdominal adipose 
tissue than Blacks (Despres, 2000, Hoffman et al., 2005). It has been suggested 
that Asian, Hispanic and Caucasian are particularly prone to intra-abdominal fat 
and associated health risks. Interestingly, besides having less intra-abdominal 
adipose tissue accumulation, Black women are more likely to develop IR. This 
finding holds up even after matching them with White women for age, degree of 
obesity, and waist-to-hip ratio (Lovejoy et al., 1996). However, it was suggested 
that Black individuals are less likely to have intra-abdominal fat deposition and 
therefore have a more favourable metabolic profile than White individuals 
(Despres, 2000, Albu, 1999). Similarly, in Nurses’ Health Study, the increases in 
weight over 20 years were more harmful in Asians than other ethnic groups. For 
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every 11 pounds weight gained during adulthood, Asians had 84% increased risk of 
T2D. The risk for diabetes with weight gain also increased for Hispanics and Blacks 
but to a much lesser degree than Asians (Deurenberg-Yap et al., 2000, Wen et al., 
2009, Pan et al., 2004). The possible explanation for this could be amount of body 
fat.  
Interestingly, Far-East Asians and South Asian are different from Caucasians and 
each other in BMI and body fat percent relationship (Pan et al., 2004, Deurenberg-
Yap et al., 2000). Despite lower BMI indices, Asian populations have an increased 
tendency to accumulate Intra-abdominal Fat (IAF) and are more likely to develop 
T2D and CVD (Abate et al., 2001, Ramachandran et al., 2006, Chandalia et al., 
2007). South Asians, in particular, have high levels of body fat and are more prone 
to develop abdominal obesity, which may account for very high risk of T2D and 
CVD (Misra and Khurana, 2009, Misra and Vikram, 2004). Additionally, several 
studies have shown that Japanese Americans have a greater amount of intra-
abdominal adipose tissue and higher prevalence of T2D (Boyko et al., 1995, 
Fujimoto et al., 1999). A 32% of adults in the Middle East are having a BMI ≥ 30 
kg.m-2 (WHO, 2014b). Unfortunately, there is no available data of fat distribution 
among the Middle Eastern. 
Obesity, particularly visceral adiposity, is associated with IR and often assumed to 
be causative. According to the “lipid supply” hypothesis, higher concentrations of 
FA resulting from higher fat intake or higher visceral or intramuscular fat, inhibit 
carbohydrate oxidation and thereby produce IR (Kraegen and Cooney, 1999). 
However, the Arabic Caucasian subjects had the highest measure of abdominal fat 
(using WHR) but were among the most insulin sensitive (Dickinson et al., 2002). 
Furthermore, the Arabic Caucasian group reported the greatest fat intake (36% of 
energy vs. only 28% in the European Caucasian group), but the two groups were 
indistinguishable on the basis of HOMA-IR or postprandial responses to the bread 
meal. Hence differences in “lipid supply” do not account for differences in insulin 
sensitivity among these young adults (Dickinson et al., 2002).  
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1.6.3 Ethnicity and diabetes 
The West Pacific region had the highest number of individuals (131.9 million) 
diagnosed with diabetes with a comparative prevalence rate of 8.3% The two 
countries in this region that had the highest prevalence rates were the Kiribati 
and Marshall Islands, with rates of 25.7% and 22.2%, respectively. Middle East and 
North Africa regions had the highest comparative prevalence rates of diabetes at 
11.3%. Six countries in this region are among the world's top ten countries for 
highest diabetes prevalence rates, Kuwait (21.1%), Lebanon (20.2%), Qatar 
(20.2%), Saudi Arabia (20.0%), Bahrain (19.9%) and United Arabian Emirates 
(19.2%). The North America/Caribbean region had the second highest comparative 
prevalence rate of diabetes at 10.7%. South-Central America and South East Asia 
had similar diabetes prevalence rates of 9.2%, whereas Europe had a 6.7% 
comparative prevalence rate. Africa had the lowest comparative prevalence rate 
of diabetes (4.5%); however the Africa region has the highest proportion of 
undiagnosed diabetes, with at least 78% of affected individuals being undiagnosed 
(Cho et al., 2013, International Obesity Task Force 2012). Pima Indians and Asian 
Indians are more insulin resistant than European Caucasians of similar age and BMI 
(Chandalia et al., 1999, Lillioja et al., 1991). In most studies, however, the 
subjects have been middle-aged and/or overweight, with IR already well 
developed. Studies in young lean subjects are required to determine whether 
reduced insulin sensitivity and postprandial hyperglycemia/hyperinsulinemia can 
be present without overt signs of the metabolic syndrome. 
Although the different explanations mentioned above there is a different in the 
metabolic response in different ethnic groups. The glycaemic response seems to 
favour White Europeans compared with South Asians (Mohan et al., 1986, Raji et 
al., 2001). Also, it has observed that higher insulin concentrations after glucose 
load were reported in both normal and diabetic Navajo Indians compared with 
Pennsylvania Amish of similar weight (Rimoin, 1969). It has been observed that 
stimulated plasma insulin concentrations in the Pima Indians were 2-3 times higher 
than in the White population (Aronoff et al., 1977). The Pima Indians of the Gila 
River Indian Community in Arizona, a population in whom insulin-dependent 
diabetes is unknown, have the world's highest reported incidence of NIDDM, which 
often occurs in early adulthood (Savage et al., 1979, Knowler et al., 1978). Afro-
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Caribbean also, have a higher insulin response compared with Whites (Chaturvedi 
et al., 1994). It has been reported, in lean, young adults of Thai, Vietnamese and 
Chinese origin displayed marked postprandial hyperglycemia and hyperinsulinemia 
compared with matched Caucasian subjects. This corresponded to reduced insulin 
sensitivity as determined by HOMA, although the level of insulin sensitivity was 
still within the normal range for healthy individuals. The differences among ethnic 
groups were evident despite similarities in age (mean 20–22 y), BMI (20–23 kg.m-
2), waist circumference (72–82 cm), birth weight (3.2–3.5 kg) and diet (Liew et al., 
2003). After a high fat meal consist of (52% of energy as fat, 40% as carbohydrate 
and 8% as protein), the postprandial lipaemia is not affected in young South Asians 
compared to Northern Europeans although glucose intolerance is detectable (Cruz 
et al., 2001a). Consuming a carbohydrate meal that's provides 75 g of available 
carbohydrate, it has been found that SE Asians had the highest postprandial 
glycaemia and lowest insulin sensitivity, whereas European and Arabic Caucasian 
subjects were the most insulin sensitive and carbohydrate tolerant (Dickinson et 
al., 2002). Also, the lipaemic response after a high liquid fatty meal (86.5% of 
calories from fat), The increase in TG levels at 2 and 4 hours postprandially, 
tended to be lower in the AA than the CA (Bower et al., 2002). 
1.6.4 Ethnicity and other CVD risk factors  
Another possible cause of the variability of CVD among different ethnic groups 
could be due to the prevalence of risk factors such as hypertension. It has been 
observed that in both genders in Black population tend to have higher prevalence 
of hypertension than Whites (Greenlund et al., 1998). In addition, family history 
of hypertension was also greater among Blacks than Whites within sites. Alvis et 
al reported significantly higher age adjusted CVD mortality rates among Black men 
with hypertension (65.1 per 10,000 person/years) compared to Whites (55.8 per 
10,000 person/years) (Thomas et al., 2005). Other factors can influence ethnic 
differences such as environmental factors with respect to access to healthy food 
sources, places to exercise or crime related safety (Golden et al., 2012). Lack of 
healthy food stores, lack of places to exercise and increased psychosocial stressors 
related to crime or limited social cohesion have been linked to poor health 
outcomes (Casagrande et al., 2009). Evidence from the Multi-Ethnic Study of 
Atherosclerosis found that better neighbourhoods were associated with improved 
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insulin sensitivity and decreased risk of type 2 diabetes (Auchincloss et al., 2009). 
Neighbourhoods have also been associated with increased smoking, physical 
inactivity and poorer control of blood pressure, which can contribute to 
development of diabetes and its complications (Gary et al., 2008). For instance, 
Mexican American women had the highest prevalence of no leisure-time physical 
activity compared to Black and White women (Winkleby et al., 1998). American 
Indian an Alaska Natives (AIANs) (Denny et al., 2005) and Blacks (Appel et al., 
2002) also had higher prevalence of no leisure-time physical activity compared to 
Whites. Management of chronic diseases can also be more difficult in low 
socioeconomic areas (Brown et al., 2007). A study conducted in the GCC countries 
revealed that only 40% of men and 27% of women reported that they were 
physically active for at least 150 min per week (Mabry et al., 2010). 
 
Smoking also vary between ethnic groups, non-Hispanic Black (NHB) and non-
Hispanic White (NHW) have been reported to have similar smoking rates whereas 
Native Americans and Alaska Natives have higher smoking rates compared to NHB 
and NHW. Mexican Americans have the lowest smoking rates (Kurian and 
Cardarelli, 2007). In the Asian population there is great variability in the rates of 
smoking with the highest rates among Korean men and the lowest among the Asian 
Indian men (Venkat Narayan et al., 2010). Higher smoking rates among Native 
Americans may explain the higher prevalence of diabetes and peripheral arterial 
disease in this population. The rates of cigarette smoking in the GCC ranged from 
13.4% to 37.4% in males and from 0.5% to 20.7% in females. Furthermore, the 
prevalence of smoking fluctuated from age group to age group. It was more 
common in males at younger ages (18–25 years); however some studies reported a 
high prevalence in the older age group (40–59 years). In females, the highest rates 
of smoking were in the older age group (40–49 years) (Bassiony, 2009, Hajat et al., 
2012, Memon et al., 2000, Hamadeh and Musaiger, 2000). 
 
1.6.5 Middle East and North Africa 
The most frequent comparisons of ethnic groups have been between Caucasian vs. 
Asian and Caucasian vs. African American. This is because most of the studies were 
carried out in the UK and US where these are the dominant ethnic groups. Other 
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countries are now undertaking similar investigations therefore other populations 
are increasingly subject to study. 
For example, in the last 10 years, there have been reports of high prevalence of 
haemoglobin disorders, neurogenetic disorders, birth defects and inherited 
metabolic diseases in Middle Eastern and North African populations (Teebi, 2010, 
Al-Gazali et al., 2006, Christianson et al., 2006). For example, as mentioned in 
previous sections there has been an increase in the prevalence of non-
communicable diseases such as, heart disease by around 44%, stroke 35%, and 
diabetes 87% (International Diabetes Federation, 2014, WHO, 2014a). 
The populations of The Middle East and North Africa (MENA) belong to a unique 
genetic pool because of the high historical rates of horizontal mixing between 
ethnicities, the high rate of consanguineous marriages within subpopulations, and 
the broad geography of the states making up the region. Nevertheless, wide 
prospective population studies on the effects of polymorphisms on such disorders 
of metabolism in the MENA are still lacking (Farhud and Yeganeh, 2010). It will be 
helpful to understand the metabolic response for this population. Therefore, it is 
timely to investigate the impact of ethnicity on the postprandial metabolism on 
lipoproteins, glucose and insulin.  
Therefore, the aim of the third experimental chapter (Chapter 5) is to 
illustrate the differences in lipid metabolism, glucose and insulin after 
ingesting a combined meal, between European and Middle Eastern men.
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1.7 Aim of the thesis  
The aims of this thesis are: 
1) Determine the effect of moderate exercise on the affinity of triglyceride rich 
lipoproteins to lipoprotein lipase  
2) Examine the effect of the co-ingestion of fat with carbohydrate on lipoprotein 
metabolism.  
3) Compare the postprandial response of middle-aged European men and Middle 
Eastern men.  
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2 General methods  
2.1 Subject Recruitment and Screening   
Subjects were recruited from the population in the Glasgow area via local 
advertising. All subjects were required to attend a screening visit at the university 
prior to participation to ensure they met with the inclusion criteria of each study. 
They were provided with an information sheet describing the aim of the study, the 
experimental procedures involved and any potential risk or discomfort associated 
with these procedures. Written, informed consent was recorded for each subject 
(Appendix A1 for the study in Chapter 4 and A2 for study in Chapter 5). 
Questionnaires detailing the subject’s past and present health status and family 
history of disease were completed (Appendix B). Resting blood pressure was 
measured at screening using an automated sphygmomanometer (Omron Healthcare, 
Inc., Illinois, USA) and fasting finger-prick blood samples were taken to determine 
glucose using Accu-Chek Aviva Blood Glucose® instrument and Accu-Chek Aviva® Test 
reagent strips. Once the analysis finished, each participants received a feedback 
sheet (appendix D).  
Exclusion criteria common to all studies were: 
 A history of known CVD (e.g myocardial infarction, stroke, coronary artery 
bypass graft surgery), acute illness, or active, chronic systemic disease.  
 Anaemia (Hb<12g.dl-1).  
 Diabetes (fasting blood glucose ≥7 mmol.l-1).  
 Abnormal renal, liver or thyroid function tests.  
 Participation in a recent research study within last three months. 
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2.1.1 Anthropometric Measurements    
Standing Height  
Stretch stature method was used to measure the height using a stadiometer (Seca, 
Hamburg, Germany). Stature is the maximum distance from the floor to the highest 
point of the skull when the head is held in the Frankfort plane position (Ross and 
Marfell-Jones, 1991).  
Height was recorded to the nearest 0.1 cm.  
Body Mass 
Subjects were asked to wear light and minimal clothing and to remove their shoes. 
Weight was measured using a balanced beam scale to the nearest 0.01 kg. BMI was 
then calculated as body mass in kilograms divided by the square of height in metres. 
Waist and hip circumference Measurement  
Waist and hip circumference were measured using a flexible, steel tape measure 
(Supralip®160, West Germany) in direct contact with the skin. Waist circumference 
was taken with subjects standing with feet shoulder-width apart and arms on the side 
and landmarked as the narrowest part of the torso, mid-way between the inferior 
margin of lowest rib and the iliac crest with the abdominal muscles relaxed. Hip 
circumference was taken with the subjects standing with feet together and arms at 
the side and landmarked as the maximum circumference over the trochanters 
(buttocks) (Lean et al., 1995). The tape was placed horizontally directly on the skin 
with respect to both landmarks. All measurements were taken at the end of a normal 
expiration, with repeat measurements. Two measurements were made and the 
average was taken. If the measurements differed by more than 0.5 cm, a third 
measurement was made.  
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2.1.2 Skinfold Measurement  
A skinfold thickness is defined as the measure of the double thickness of the 
epidermis, underlying fascia and subcutaneous adipose tissue on different standard 
anatomical sites around the body. The following four sites were used according to 
Durnin and Womersley (1974) who validated the sum of four skinfold thickness against 
densitometry and devised sex- and age-dependent population-based linear regression 
equations to estimate total body density (Durnin and Womersley, 1974):   
1) Biceps: vertical skinfold raised on the anterior aspect of the biceps;  
2) Triceps: vertical skinfold raised on the posterior aspect of the triceps, mid-way 
between the olecranon process and the acromion process (shoulder) when the hand 
is supinated; 
 3) Subscapular: oblique skinfold raised 1 cm below the under most tip of the inferior 
angle of the scapula at approximately 45° to the horizontal plane following the 
natural cleavage lines of the skin;  
4) Suprailiac: diagonal fold raised immediately superior the crest of the ilium on a 
vertical line from the mid-axillary line.  
Skinfold sites were landmarked on the body prior to measurement so that repeat 
measures could be taken at the same place. The skin at each respective site was 
pinched up firmly between thumb and forefinger to raise a double layer of skin and 
the underlying adipose tissue, excluding the muscle tissue. The calipers were then 
applied to the fold with 1 cm between the edge of fingers and the nearest edge of 
the calliper and a reading in millimetres (mm) was recorded. All skinfold measures 
were taken on the right side of the body with skinfold calliper (Holtain Ltd., Crymych, 
UK). Measurements were recorded in duplicate for each site, not taken consecutively 
but by running through all sites once and back again as to allow the skin to regroup 
between measurements. If the readings for each site were more than 5% apart, a 
third measurement would then be taken, and the two closest measurements were 
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taken for calculation. The sum of the four skinfolds (Σ4SF = biceps + triceps + 
subscapular + suprailliac) was calculated. Relative fat mass was derived from the 
formula of Durnin and Womersley (1974) of linear regression equations for the 
estimation of body density x 103 (kg.m-3) (Durnin and Womersley, 1974) in 
combination with Siri's equation for estimating body fat percentage (Siri, 1961):  
Body density (BD) (g.cm3) = c – [m x (Σ4 SF (mm))] 
Where:  
C and M = standard age and sex-specific coefficients (Table2.1). 
Table 2.1; standard age and sex-specific coefficients (Durnin and Womersley, 1974). 
 Age (yrs) 17-19 20-29 30-39 40-49 50 + 
Male 
c 1.1620 1.1631 1.1422 1.1620 1.1715 
m 0.0630 0.0632 0.0544 0.0700 0.0779 
Female 
c 1.1549 1.1599 1.1423 1.1333 1.1339 
m 0.0678 0.0717 0.0632 0.0612 0.0645 
 
Σ4SF = sum of all four-site skinfolds (mm)  
Once the density was calculated, the Siri equation was used to estimate body fat  
Percentage:  
Body fat percentage (%) = [(4.95/d) – 4.5] x 100  
Where:  
d= density, 4.95 and 4.5 = constants.   
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2.2 Expired air measurements 
Oxygen uptake (VO2) and carbon dioxide (CO2) production was determined at rest, 
before and during exercise. Samples of expired air were collected into 100 or 150 L 
Douglas bags. While wearing a nose clip, subjects breathed through a mouthpiece 
fitted to a lightweight, large 2-way respiratory valve (2700 series, Hans Rudolph Inc. 
USA), which in turn was connected to a lightweight tube. The tubing was terminated 
at a two-way valve which opened and closed the Douglas bag. (All equipment was 
supplied by Cranlea & Co. Birmingham, England). 
An aliquot of expired air (measured using a flow meter) was removed from each 
Douglas bag to determine the fraction of O2 and CO2 using a gas analyser (Servomex 
4100, Servomex Group Ltd., East Sussex, England). The analyser was calibrated 
before each use with certified reference gases (BOC Ltd, Surrey, UK) and the 
reference gases were calibrated against a ‘gold standard’ reference gas to ensure 
consistency of results. 
The remaining volume of expired air in each Douglas bag was measured by evacuation 
through a dry gas meter (Harvard apparatus, supplied by Cranlea & Co. Birmingham, 
England). The temperature of air in the Douglas bag was measured during evacuation 
using the same dry gas meter. 
Barometric pressure was measured using a barometer and the measured expired gas 
volumes were corrected to standard temperature and pressure (STPD) for a dry gas 
using the universal gas equation. Inspired gas volumes were derived using the Haldane 
transformation (Consolazio et al., 1963) and O2 uptake, CO2 production, minute 
ventilation, respiratory exchange ratio and the ventilatory equivalent for oxygen 
were calculated. Rates of substrate utilization were calculated via indirect 
calorimetry using the equations described by Frayn (Frayn, 1983) and energy 
expenditure was determined by multiplying the mass of substrates used by their 
respective energy densities. 
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2.3 Monitoring of Heart Rate  
The subject’s heart rate was monitored continuously during exercise and the recovery 
period by short range telemetry (Polar S610i, Polar Electro, Finland).  
2.4 Submaximal Exercise Test  
Submaximal exercise test was performed to predict maximum oxygen consumption 
(VO2max) for each subject prior to commencing main trials. The test was designed to 
exercise subjects through a range of intensities from moderate to vigorous but not 
maximum. The test consisted of four, continuous 5-min stages of walking on a 
treadmill to determine the relationship between gradient and oxygen consumption 
at self-selected walking speed of about 5 – 6 km.h-1 (see Figure 2.1). The first stage 
of the test was performed on a level treadmill and gradient was increased by 2.5- 
3.0% at the end of every stage depending on subject’s heart rate response in the 
previous stage: if heart rate exceeded 100 beats per minute in the first stage, a 2.5% 
increment was used for subsequent stages. Each stage lasted five minutes with 
expired air being collected into Douglas bags during the last two minutes for the 
determination of VO2 and VCO2 by using the Douglas bag method. Five-minute stages 
were performed to ensure subjects were in steady state during expired air collection 
periods. Heart rate was recorded continuously during the test and the Borg scale was 
used to assess subject’s perceived exertion simultaneously with the expired air 
collections at the end of every stage. The test was terminated if subject’s heart rate 
reached 85% of his predicted maximum heart rate. At the end of the test, the oxygen 
uptake at each stage was plotted against the heart rate and gradient to estimate the 
gradient and speed necessary to elicit an intensity corresponding to 50% VO2max during 
the main trials.   
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2.5 Test meals  
Subjects were provided test meals as described in each of the three experimental 
chapters on completion of all fasting measurements. These were consumed within 10 
minutes. The compositions of the meals were as follows: 
2.5.1 Fat Loading Test (FLT)using high fat mixed meal 
(HFM) 
The composition of the meal provided in Chapter 4 and to a subset of participants in 
Chapter 6 is shown in Table 2.2. The meal provided 1278 kcal of energy, of which 
27% was carbohydrate, 65% was fat and the remaining 8% as protein. The ComplanTM 
formula was mixed thoroughly with whole milk and double cream to form a milkshake 
type drink. The croissant was lightly toasted, and spread with Lurpack™ spreadable 
butter.  
 
Figure 2.1. A schematic diagram of a 4-stage submaximal incremental test (black boxes 
represent expired air collection and heart rate measurements). 
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Table 2.2; Composition of the high fat mixed meal. 
     Total carbohydrate 
 
Portion 
Size 
Energy (Kcal) Protein (g) Total fat (g) Starch (g) Sugar (g) Total  CHO (g) 
Croissant (g) 100 430.0 9.2 25.3 34.8 5.8 40.6 
Lurpack spreadable butter 
(g) 20 
144.8 0.1 16.0 0.0 0.1 0.1 
Complan (powder in g) 57 250.2 8.7 8.4 8.3 26.7 35.0 
Whole milk (mls) 180 118.8 5.8 7.0 0.0 8.6 8.6 
Double cream (mls) 75 333.8 1.3 35.6 0.0 2.0 2.0 
Total - 1277.6 25.1 92.4 43.1 43.2 86.3 
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2.5.2 Oral glucose Tolerance Test (OGTT)  
This was provided to subjects in chapter 5. The drink prepared by dissolving 75 g of 
glucose in 275 ml of water and adding 25 ml of concentrated lemon juice. This 
provided 75 g of carbohydrate 0 g fat, 0 g protein and 300 kcal energy. 
2.5.3 Oral fat Tolerance Test (OFTT)  
This was provided to subjects in Chapter 5. This comprised 150 ml double cream, 
with 0.5 ml of sugar-free raspberry flavouring. This provided 2.4 g of carbohydrate 
75 g fat, 2.3 g protein and 700 kcal energy (see Table 2.3). 
Table 2.3; Composition of the OFTT.  
TescoTM double cream portions 
Portion Size (ml) 150 
Energy (Kcal) 700 
Protein (g) 2.3 
Carbohydrate (g) 2.4 
Fat (g) 75 
 
2.5.4  Combined test (COMB) 
This comprised the OGTT drink and the OFTT drinks described above and provided 
77.4 g of carbohydrate 75 g fat, 2.3 g protein and 1000 kcal energy. This was provided 
to subjects in Chapter 5 and a subset of participants in Chapter 6. 
2.6 Blood sampling and processing 
Venous blood was obtained via a cannula (Biovalve, 18G/1.2 mm, Vygon, France) 
placed in an antecubital vein. The cannula was kept patent by flushing with saline 
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solution (0.9% NaCl). Blood samples were collected directly in 10 ml tubes 
containing EDTA as an anticoagulant (Chapter 4) (BD Vacutainer Systems, 
Plymouth, UK) or in 6 ml SST™ serum tubes (Chapters 5 and 6) (BD Vacutainer 
Systems, Plymouth, UK). When EDTA tubes were used, they were placed 
immediately in ice, the cold temperatures (4°C) inhibit glycolysis. The samples 
were centrifuged (GS-6KR, Beckman Instruments, Inc, California, US) within 15-30 
min of collection for 15 minutes at 3000 rpm and 4°C (WHO, 2006, Gambino et al., 
2009). When serum tubes were used, samples were left in room temperature for 60 
minutes and then centrifuged (GS-6KR, Beckman Instruments, Inc, California, US) 
for 15 minutes at 3000 rpm and 4°C. EDTA plasma was pipetted into aliquots of 500 
μl in 0.5 ml Apex tubes (0.5 ml, Alpha Laboratory Ltd, UK) and 2 x 350 μl in Apex 
tubes and frozen immediately at -70 ºC, for subsequent analysis of insulin. Another 
350 μl was placed in the fridge at 4 ºC, for NEFA, glucose and lipid profile analysis 
within 24 hours. The remaining EDTA plasma (Chapter 4) or serum plasma 
(Chapters 5 and 6) was used for lipoprotein separation. This was started on the 
same day of blood collection.  
 
Justification of using EDTA tube to measure glucose 
The commonly used glycolysis inhibitors are unable to prevent short-term glycolysis. 
Glycolysis can be attenuated by inhibiting enolase with sodium fluoride (2.5 mg/mL 
of blood) or, less commonly, lithium iodoacetate (0.5 mg/mL of blood). These 
reagents can be used alone or, more commonly, with such anticoagulants as 
potassium oxalate, EDTA, citrate, or lithium heparin. Unfortunately, although 
fluoride helps to maintain long-term glucose stability, the rates of decline in the 
glucose concentration in the first hour after sample collection are virtually identical 
for tubes with and without fluoride, and glycolysis continues for up to 4 h in samples 
containing fluoride (Chan et al., 1989). After 4 h, the concentration of glucose in 
whole blood in the presence of fluoride remains stable for 72 h at room temperature 
(Chan et al., 1989) (leukocytosis will increase glycolysis even in the presence of 
fluoride if the leukocyte count is very high). 
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Few effective and practical methods are available for prompt stabilization of glucose 
in whole-blood samples. Loss of glucose can be minimized in two classic ways: 1) 
immediate separation of plasma from blood cells after blood collection [the glucose 
concentration is stable for 8 h at 25°C and 72 h at 4°C in separated, nonhemolyzed, 
sterile serum without fluoride (Burtis et al., 2012); and 2) placing the blood tube in 
an ice–water slurry immediately after blood collection and separating the plasma 
from the cells within 30 min (WHO, 2006, Gambino et al., 2009). 
2.6.1 Plasma Analysis  
Plasma glucose, insulin, TG, NEFA, total and HDL cholesterol and small dense LDL 
(Chapter 4, 5 and 6) and 3-hydroxybutyrate (Chapter 4) concentrations were 
analysed in the fasted state. In postprandial state TG, NEFA, glucose, insulin, sdLDL 
(Chapter 4, 5 and 6) and 3-hydroxybutyrate (Chapter 4) concentrations were 
analysed at all-time points. LDL cholesterol was calculated in the fasted state using 
the Friedewald equation (Friedewald et al., 1972),(Appendix C). All tests listed 
above were carried out by Mrs. Josephine Cooney, in the Vascular Biochemistry 
Department of McGregor building, University of Glasgow (Appendix C). 
2.6.2  Lipoprotein separation  
Principle  
Flotation of lipoprotein particles through a gradient formed by layering solutions of 
decreasing density (generated using specific concentrations of NaCl, NaBr or KBr) 
above a sample of plasma adjusted to high density. (Lindgren et al., 1972). 
Sequential preparation of chylomicrons (Sf >400) by 
Ultracentrifugation 
To separate the chylomicron fraction (Sf >400), two ml of plasma were overlayered 
with 4 ml of 1.006 g.ml-1 density solution in Ultra-Clear centrifuge tubes and spun at 
10K rpm and 15°C for 30 min (Lindgren et al., 1972) using the Beckman L8-60M 
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Ultracentrifuge and Beckman 50.4 rotor (Beckman Instruments Inc., UK). The top 2 
ml containing chylomicron particles (d <1.006 g.ml-1) were removed (termed CM-1) 
and TG concentrations were measured using commercially available kits as described 
in Appendix C. This top fraction was used in the experiment mentioned in chapter 
3. TG concentrations were also measured in the middle 1.5 ml fraction (CM-2) to 
verify complete collection of the CM fraction. The final chylomicron-TG 
concentration was calculated as the addition of these two fractions [CM-1 + (CM-2 × 
1.5/2)] (chapter 4 and chapter 5). The final 0.5 ml of the density solution overlay 
was discarded and the remaining 2 ml of chylomicron-free plasma was used for 
separation of VLDL1 and VLDL2. The CV for the chylomicron-TG separation using 
triplicate samples from the same participant was 4.9%.  
 
Isolation of VLDL1 (Sf 60–400), VLDL2 (Sf 20–60), IDL (Sf 12-
20) and LDL (Sf 0-12) Fraction by Swing-Out 
Ultracentrifugation 
Two ml of the chylomicron-free plasma from the previous step was adjusted a density 
of d 1.118 g.ml-1 by the addition of 0.341 g NaCl. This was gently layered over a 
cushion of 0.5 ml d 1.182 g.ml-1 solution in an Ultra-Clear Beckman SW 50 
ultracentrifugation tube (Beckman Instruments Inc., UK) which had been coated with 
polyvinyl alcohol (Holmquist, 1982); this allowed the solutions to be introduced down 
the side of the tubes smoothly without disturbing the formation of the gradient. A 
discontinuous gradient was formed by over-layering sequentially d 1.0988 g.ml-1 (1 
ml), d 1.0860 g.ml-1 (1 ml), d 1.0790 g.ml-1 (2 ml), d 1.0722 g.ml-1 (2 ml), d 1.0641 
g.ml-1 (2 ml) and finally d 1.0588 g.ml-1 (2 ml) (see Table 2.4 below). 
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Table 2.4; Layers of density solutions 
 Density g.ml-1 
Volume in ml 
- 1.182 0.5 
Plasma 1.118 2 
1 1.0988 1 
2 1.0860 1 
3 1.0790 2 
4 1.0722 2 
5 1.0641 2 
6 1.0588 2 
 
Centrifugation was carried out using a Beckman SW 40 rotor (Beckman Instruments 
Inc., UK) in Beckman L8-60M ultracentrifuge for 1.38 h at 39K rpm and 23 ºC for 
separation of the VLDL1 fraction. The rotor was decelerated without braking and by 
using a finely drawn glass Pasteur pipette the VLDL1 fraction was removed in the top 
1 ml. This volume was replaced by 1 ml of d 1.0588 g.ml-1 and tubes were recapped 
and place back in the centrifuge overnight for separation of VLDL2, for practical 
reasons, the times and speeds were calculated using g X minutes by applying a 
formula for conversion. The relationship between RPM and RCF is as follows: 
  RCF= 1.118 X R X (RPM X 1000)2 
Where RPM is rotational speed (revolution per minute), RCF is relative centrifugal 
force, r is the radius of rotation measured in millimetres. R is constant here. Different 
speeds used for VLDL2 separation are shown in Table 2.5. 
 
At the end of the run, 0.5 ml of VLDL2 fraction was removed using a finely drawn 
glass Pasteur pipette.  
top 
bottom 
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Tubes were recapped and place back in the centrifuge for 2.35 h at 39K for separation 
of IDL. IDL was removed from the top of the tube as a 0.5 ml aliquot was withdrawn 
into Apex tubes and placed in the fridge for composition analysis. The tubes were 
recapped and placed into the rotor again and centrifuged overnight for separation of 
LDL, different speed and time could be applied (See Table 2.5). All lipoprotein 
subfractions have been stored in fridge at 4 ºC to be analysed next day for 
composition. 
 
Lipoprotein composition analysis  
Lipoprotein fraction TG, phospholipid (PL), total cholesterol, free cholesterol (FC), 
cholesteryl ester (CE), (Chapter 4 and 5) were analysed by Mrs. Josephine 
Cooney, in the Vascular Biochemistry Department of McGregor building, University 
of Glasgow (Appendix C).
  
 
 
Table 2.5; Centrifugation conditions used for the separation of lipoprotein fractions. 
chylomicron 
VLDL1 VLDL2 IDL LDL 
Time (h) RPM Time (h) RPM Time (h) RPM Time (h) RPM Time (h) RPM 
00.30 10K 1.31 39K 14.41 18.5K 2.35 39K 21.10 30K 
Alternative conditions 
  12.03 21.1K 3.12 35K 17.30 33K 
  17.31 17.5K 3.24 34K 16.29 34K 
  18.08 17.2K 3.50 32K 18.36 32K 
  14.52 19K   18.02 32.5K 
  
 
 
2.6.3 Insulin Analysis  
Principle  
Mercodia Insulin ELISA is a solid phase two-site enzyme immunoassay. It is based 
on the direct sandwich technique in which two monoclonal antibodies are directed 
against separate antigenic determinants on the insulin molecule. During 
incubation insulin in the sample reacts with peroxidase-conjugated anti-insulin 
antibodies and anti-insulin antibodies bound to wells on microtitration plates. A 
washing step removes unbound enzyme labelled antibody. The bound conjugate is 
detected by reaction with 3,3’,5,5’-tetramethylbenzidine (TMB). The reaction is 
stopped by adding acid to give a colorimetric endpoint that is read 
spectrophotometrically (Lequin, 2005). 
 
Procedure 
Plasma samples (25 µl) were pipetted into the assay wells. 100 µl of freshly 
prepared enzyme conjugate solution was then added to each well. Plates were 
incubated on a plate shaker for 1 hour at room temperature. During this incubation 
period, insulin in the samples reacted with peroxidase-conjugated anti-insulin 
antibodies and anti-insulin antibodies bound to plate wells. After incubation, the 
plates were washed and dried 5 times by an automatic washer to remove any 
unbound enzyme labelled antibody using the provided wash buffer solution. Bound 
conjugates which remained in the wells were detected by adding 200 µl of 
3,3’,5,5’-tetramethylbenzidine (TMB). The plates were then incubated for 15 
minutes at room temperature to allow reaction between substrate TMB and bound 
conjugates. After incubation, 50 µl of the Stop solution containing 0.5 M sulphuric 
acid were added to each well to stop the reaction. A yellowish-tint colour 
developed according to the concentration of conjugate-substrate complex. The 
optical density of each well was read at 450 nm using a spectrophotometer. All 
samples were run in duplicate together with the standards ranging from 0 to 200 
mU.l-1. A standard curve was obtained using cubic spine regression. The 
concentration of insulin in the samples was then determined by comparing the 
optical density of the samples to that of the standard curve for each respective 
plate. All reagents and samples were brought to room temperature before use. 
Coefficients of variation between assays were <5%. 
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2.6.4 Insulin resistance estimated the homeostasis 
model  
The homeostasis model assessment-estimated insulin resistance (HOMA-IR), 
developed by Matthews et al. (Matthews et al., 1985) has been widely used for 
the estimation of insulin resistance. Due to the simplicity of its determination and 
calculation, HOMA-IR has been the most frequently employed technique both in 
clinical practice and in epidemiological studies. HOMA-IR was calculated in 
Chapter 6 using this formula (fasting plasma insulin in mU.l-1 X fasting plasma 
glucose in mmol.l-1)/22.5 (Wallace et al., 2004). Low HOMA-IR values indicate high 
insulin sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity 
(insulin resistance)(Matthews et al., 1985).  
2.7 Lowry assay  
Principle  
Protein is measured by the addition of Biuret Reagent and Folin-Ciocalteu reagent, 
which produces a colour change to blue. The colour intensity, which is 
proportional to the concentration of the protein present, is measured by optical 
density (OD) at 750 nm using a spectrophotometer. The protein concentration is 
calculated using a standard curve of known concentrations. The following method 
is a modification from the original. All volumes have been halved (Lowry et al., 
1951). 
Procedure 
Total protein was measured by adding 1 ml of Biuret Reagent and Folin-Ciocalteu 
reagent, [100 ml of 2% Na2CO3 in 0.1 M NaOH (w/v), 1 ml of 2% NaK Tartrate (w/v), 
1 ml of 1% CuSO4 (w/v), and 1 ml of 10% (w/v) sodium dodecyl sulphate (SDS)] to 
a total volume of 200 μl of sample (100 μl VLDL1 + 100 μl of distilled water or 50 
μl VLDL2 + 150 μl distilled water). One hundred microlitre of 1:1 Folin-Ciocalteu 
reagent (Sigma-Aldrich Company Ltd., Irvine, Scotland) was then added and mixed 
immediately. After incubation at room temperature for 30-60 min, the developed 
colour intensity was measured at an optical density of 750 nm using a Beckman 
DU 70 Spectrophotometer. The protein concentration was calculated using a 
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standard curve of known concentrations. Inter-assay precision was checked using 
2 levels (100 μl and 200 μl) of human and bovine quality control (QC) materials 
(Lowry et al., 1951). The coefficients of variation (CVs) for the low QC were 
(human: 1.8%, bovine: 1.3%) and high QC were (human: 1.0%, bovine: 1.4%). 
 
2.8 LPL assay 
Principle 
Triglycerides are hydrolysed by lipoproteinlipase to produce glycerol and free 
fatty acids. In order to apply this reaction a medium should be prepared to run 
the experiment.  
Procedure  
Tris-HCL buffer Preparation  
Tris-HCl buffer was prepared by mixing; 24.22 g.l-1 Tris-HCl (200 mmol.l-1) (Sigma-
Co NO. T3253), 366.24 mg.l-1 of CaCl2 (3.3 mmol.l-1) (Sigma-Co NO. C4901), 
7597.59 mg.l-1 of NaCl (130 mmol.l-1) (VWR C-S9888) and 66.7 mg.l-1 of sodium-
heparin (0.010 mmol.l-1) (Sigma-Co NO. H3393) to stabilized LPL and this inhibit 
the release of the attached LPL from VLDL, in a pH level of 8.2. To reach the 
required pH level HCl, or NaOH were used (Zambon et al., 1996, Saheki et al., 
1991). Different concentrations of LPL were prepared by diluting the stock 
solution in Tris-HCl buffer. 
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2.9 Statistical analysis  
2.9.1 Power calculations 
An a priori power calculation, on the basis of our data for intra-subject 
reproducibility of postprandial TG responses in men (between-day coefficient of 
variation 10.1%) indicated that 10 participants would enable detection exercise-
induced changes of ~10 % in the TG response with 80 % power (Gill et al., 2005). 
Significance was accepted at the p < 0.05 level. Data are presented as means ± 
SEM unless otherwise stated.  
 
2.9.2 Calculation of summary postprandial responses 
Time-averaged postprandial concentrations, calculated as the trapezium rule-
derived areas under concentration versus time curve, divided by the duration of 
the postprandial observation period, were used as summary measures of the 
postprandial responses. 
 
2.9.3 Normality of data 
The normality tests are supplementary to the graphical assessment of normality 
(Elliott and Woodward, 2007). There are many tests to assist normality (Elhan and 
Tuccar, 2006, Peat and Barton, 2008). In chapter 4,5 and 6 normality of data was 
tested using Anderson-Darling test (Elhan and Tuccar, 2006). 
If a variable did not fit a normal distribution or had greatly different standard 
deviations in different groups, data transformation was applied (Tu and Xia, 2008, 
Chou et al., 1998). Where data did not approximate a normal distribution, these 
were log-transformed prior to analysis and data are expressed as geometric means 
with 95% confidence intervals (95% CI).   
 
2.9.4 Significant testing  
Data was analysed using Statistica (version 10, StatSoft Inc.) and Minitab (version 
17, Minitab Ltd).  
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Comparisons between interventions were made using paired t-tests, where a 
single pair of means was compared. The validity the test based on normality of 
the data, the sample is a simple random sample from its population and data is 
continuous of the data. 
When comparisons were made between groups or across multiple time-points as 
in Chapter 4 or in different trials as in chapter 5 and 6 a two-way repeated 
measures ANOVA, with post hoc Fisher tests, were used. The validity of the test 
based on, homogeneity of variance, independency of the sample and normality 
of the data.  
2.9.5  Cohen’s d, effect size  
In comparing different intervals, it is useful to express the size of the effect in 
standardized way. One common way is to report Cohen’s d effect size, which is 
relating the effect size to the variance. Statistical significance depends on the 
sample size and the precision of the data. When a large set of data analysed, very 
small effects may reach statistical significance. Therefore, it is useful to 
determine effect size to describe, if effects have a relevant magnitude and to 
describe the strength of a phenomenon. The most popular effect size measure is 
Cohen's d (Cohen, 2013). Effect size is a standard measure that can be calculated 
from any number of statistical outputs (Cohen, 2013). 
Cohen’s ‘d’, expresses the mean difference between two groups in standard 
deviation units. Typically, this is reported as Cohen’s d, or simply referred to 
as “d.” Though the values calculated for effect size are generally low, they share 
the same range as standard deviation (-3.0 to 3.0), so can be quite large. 
Interpretation depends on the research question. The meaning of effect size varies 
by context, but the standard interpretation offered by Cohen (1988) is: 
0.8 = large (8/10 of a standard deviation unit) 
0.5 = moderate (1/2 of a standard deviation) 
0.2 = small (1/5 of a standard deviation) 
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Reporting effect size helps to: understand the importance of an effect (Kirk, 
1996), comparing the effect size within or between studies, and secondary 
analysis such as power calculations or meta-analysis (Reiser and Faraggi, 1999). 
The effect size of the interventions was calculated in Chapter 4 and 5. The effect 
size was calculated differently in chapter 6. The mean difference was calculated 
for each individual then divided by the SD of both groups (Cohen, 2013). 
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3 Development of a Method to 
Determine the Susceptibility of 
Triglyceride-Rich Lipoproteins for 
Hydrolysis  
 
Lipoprotein lipase is the major enzyme which hydrolyses triglycerides (TG) present 
in the circulation to release free fatty acids (FFA). It is the rate-limiting enzyme 
controlling plasma TG clearance. Hydrolysis of TG is essential for energy storage 
and utilization (Goldberg and Merkel, 2001, Wang and Eckel, 2009). Elevated 
postprandial TG concentrations are independently associated with risk of 
cardiovascular events and atherosclerotic disease process (Chapman et al., 2011, 
Goldberg IJ, 2011, Bansal et al., 2007). Considerable attention over the last 
decades has been focused on the effect of exercise on postprandial metabolism 
and its potential role in the reduction of fasted and postprandial TG. Exercise is 
considered an effective method to lower postprandial TG concentrations by about 
20-25% (Farah and Gill, 2012, Gill et al., 2004a). The mechanism(s) by which 
exercise induces triglyceride lowering is currently not clear. It has been 
hypothesised that exercise may cause compositional changes to the VLDL1 
particles, which are the major determinants of plasma TG concentrations (Austin, 
1990, Patsch et al., 1992, Deckelbaum et al., 1984), thereby increasing their 
clearance by LPL (Al-Shayji et al., 2012). Therefore, in order to test this 
hypothesis, it was essential to develop a method to test the susceptibility of 
chylomicron and VLDL1 to TG hydrolysis in standardised assay (described in 
Chapter 4 as “affinity of TRL for LPL”). In this chapter, the development and 
optimisation of this assay, based a method previously described by (van Barlingen 
et al., 1996).  
 
3.1 Elements of standardised lipolysis assay 
The ultimate aim of this study is to develop a method to determine how exercise 
influences the susceptibility of TRL to lipolysis. This requires development of a 
standardised assay to determine the rate of TG hydrolysis when the concentrations 
of substrate TRL and enzyme are fixed. 
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To generate an appropriate working method, a number of factors need to be 
considered (see Figure 3.1). These include:  
1) Determining of optimal indicator of lipolysis (i.e., TG decrease or NEFA / 
glycerol rise).  
2) Standardizing the concentration of lipoprotein particles.  
3) Determining optimal concentration of LPL. 
4) Determining the optimal assay conditions including:  
a) Duration of the assay.  
b) Optimizing the inhibitor of the reaction.  
c) Albumin interference.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LPL 
affinity 
assay 
lipoprotein 
concentrations 
concentration 
of LPL and 
source 
precision of 
the 
measuremnts 
inhbition of the 
reaction 
duration of 
incubation 
Figure 3.1. Conditions that been addressed in lipolysis assay include, standardizing TRL, LPL 
concentration and optimal assay conditions.  
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3.1.1 Choice of indicator of rate of lipolysis 
 
The principle based on the hydrolysis of TG by the action of LPL producing three 
NEFA and glycerol (Fahy et al., 2009): 
 
 
 
 
 
 
 
There is no gold standard or universal method for LPL measurement. To measure 
LPL activity in a closed system, any of the following products can be assessed in 
principle: 
(a) the rate of degradation of the TG  
(b) the rate of production of fatty acids or glycerol (Smeltzer et al., 1992) (See 
Figure 3.2). 
 
 
 
 
 
 
 
Figure 3.2. The products of TRL hydrolysis, panel [A] shows the rise in NEFA, panel [B] shows the 
degradation of TG; both can be used as a parameter of the reaction. NEFA concentration will rise as 
triple as TG will fall. The higher TG will breakdown the higher NEFA will be released. The rate of the 
reaction will increase when a higher activity enzyme is used.  
 
[A] [B] 
TG 
3 NEFA + 
glycerol  
LPL 
3 Development of a Method to Determine the susceptibility of Triglyceride-Rich Lipoproteins 
for hydrolysis  
 
102 
       Khloud Jamil Ghafouri ® 2017 
Thus, by incubating TRL with LPL for over a range of time intervals, it is possible 
to calculate the rate of LPL activity. 
The assay was initiated in a medium contains Tris-HCl with a pH of 8.2. The initial 
volume of the reaction was; 250 µl lipoprotein incubated with 125 µl of albumin 
and 125 µl of Tris-HCl buffer at 37 ºC for 10 min to climate the tube. A 125 µl of 
LPL were added in each tube except the control, and incubated for different time 
points 0, 5, 10, 15, 20, 30, 60, and 90 mins. Each tube was quenched by 500 µl of 
pre-cooled NaCl (1 Ml) (Table 3.1). Then assay the products of the reaction (TG, 
glycerol and NEFA) to assess TG hydrolysis rate. 
 
Table 3.1; initial assay mixture.  
 Time (min) 
All in µl Control        
0 0 0 5 10 15 20 30 60 90 
Tris-HCl 125 125 125 125 125 125 125 125 125 125 
1.006 g.ml-1 250 0 0 0 0 0 0 0 0 0 
LPL 0- 250 0 125 125 125 125 125 125 125 
Albumin 125 125 125 125 125 125 125 125 125 125 
lipoprotein 0 0 250 250 250 250 250 250 250 250 
NaCl 500 500 500 500 500 500 500 500 500 500 
Total volume 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 
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3.1.2 Triglyceride measurements  
Method  
Initially, two hydrolysis assays were carried out using constant concentration of 
VLDL1 (0.10 mmol.l-1) as substrate 100 units of LPL during 30 minutes interval. 
Followed by another assay, using higher doses of VLDL 0.25 mmol.l-1 of and 400 
units of LPL during 30 minutes interval.  
Result  
As shown in Figure 3.3, Panel [A] and [B], the rate of NEFA was increasing with 
time. Figure 3.3, Panel [B], shows that with increasing the TRL and LPL 
concentrations, more NEFA were released. However, TG concentration remained 
constant in both trials.  
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Figure 3.3. Release of NEFA and degradation of TG from VLDL1 during 30-minutes observation, 
Panel [A] shows the release of NEFA and degradation of TG from (0.10 mmol.l-1) of VLDL1 and 100 
units of LPL, Panel [B] shows release of NEFA and degradation of TG from (0.25 mmol.l-1) VLDL1 
and 400 units of LPL.  
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TG concentration was constant because the assay that was used to detect TG in 
ILab-600 based on hydrolysing TG into glycerol and this result in measuring all the 
glycerol in the mixture. The principle of the reaction is as the following:  
 
Principle: 
The principle for this reaction is based on lipase hydrolysis of TG to glycerol 
followed by oxidation to dihydroxyacetone phosphate and hydrogen peroxide. The 
hydrogen peroxide produced then reacts with 4-aminophenazone and 4-
chlorophenol under the catalytic action of peroxidase to form a red dyestuff which 
was measured spectrophotometrically using the IL600 analyser at 550 nm. The 
equation is shown below: 
 
(GK: Glycerol kinase; GPO: Glycerol phosphate oxidase; POD: Peroxidase; DHAP: 
dihydroxyacetote phosphate). The CV for the assay was 3.8%. 
 
Moreover, it has been reported that a single action of LPL would not release 
glycerol, it would release monoglyceride and diglycerides (Gilham and Lehner, 
2005). Therefore, glycerol was measured later on and the TG concentrations were 
corrected by subtracting glycerol.  
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3.1.3 Glycerol measurements  
Method 
Hydrolysis assay was carried out using different concentrations of VLDL1 and 
constant amount of LPL. VLDL1 at a concentration of 0.5 mmol.l-1 was incubated 
with 0.1 unit of LPL.  
Result 
As shown in Figure 3.4, TG concentrations did not decrease during the 30 minutes 
interval; however, the glycerol and NEFA concentrations were not increasing as 
desired. Moreover, it has been observed that, glycerol measurement appeared not 
to be reproducible. Therefore, we measured the inter-assay CV of free glycerol 
kit used on the ILab-600.  
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Figure 3.4. Release of NEFA and glycerol and degradation of TG from 0.5 mmol.l-1 VLDL1 and 0.1 
units of LPL concentrations during 30-minutes observation. 
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3.1.4 I‐Lab reproducibility 
The glycerol measurement was fluctuating, thus we tested the reproducibility of 
ILab-600 by running 10 times repeated measure using aliquots of same 
participants. The Initial results from the measurement of glycerol concentrations 
using the automated ILab-600 analyser in whole plasma, chylomicrons, VLDL1, and 
VLDL2, revealed are shown in Table 3.2. It was clear that the CV for glycerol at 
the required concentrations was very high, an order of magnitude higher than that 
for TG or NEFA, but CVs for TG and NEFA were also higher than expected. This 
prompted servicing of the analyser, where a new lamp and pump were fitted, with 
a system wide clean of the analyser. Additionally, measurements for NEFA, TG, 
and glycerol were being taken simultaneously within each sample, however 
further examination found that the reagents for ensuring TG and glycerol were 
having a carryover of NEFA. Therefore, NEFA, glycerol, and TG were measured 
separately and in that order thereafter. However, based on these data, it was felt 
that the rise in NEFA concentration provided the best signal for LPL hydrolysis. 
Table 3.2 ; reducibility of glycerol measurements in ILab-600. 
 Glycerol CV% TG CV% NEFA CV% 
Plasma 0.06 ± 0.01 1.6 % 1.42 ± 0.01 0.81% 0.39 ± 0.09 1.2% 
1:5 diluted 
plasma 
0.02 ± 0.001 75% 0.33 ± <0.01 1.2% 0.14 ± 0.07 5% 
1:10 diluted 
Plasma 
0.009 ± 0.008 85% 0.20 ± <0.01 5% 0.09 ± 0.02 10% 
Chylomicrons 0.02 ± 0.004 17% 0.14 ± 0.01 3.5% 0.16 ± <0.01  16% 
 
3.1.5 Albumin Interference  
As it has been reported above, the NEFA values were at the lower borderline of 
ILab detection limit. This has been reported previously. A number of studies have 
shown that serum albumin caused a decrease in NEFA detection when using the 
same reaction (Duncombe, 1963, Duncombe, 1964, Matsubara et al., 1983). The 
albumin complexes with NEFA preventing it from binding to the active site of ACS, 
thus preventing it from joining with CoA to form Acyl-CoA, and hindering the 
detection reaction (Matsubara et al., 1983). 
3 Development of a Method to Determine the susceptibility of Triglyceride-Rich Lipoproteins 
for hydrolysis  
 
108 
       Khloud Jamil Ghafouri ® 2017 
The enzymatic reaction used to quantify the concentration of NEFA by the Waco 
kit is based on the Dole method (Dole, 1956), which involves the covalent binding 
of NEFA with Coenzyme A (CoA) to form Acyl-CoA. This reaction is catalysed by 
the enzyme Acyl-CoA synthetize (ACS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ATP = adenosine triphosphate; ACS = acyl-CoA synthetase; AMP = adenosine 
monophosphate; PPi = pyrophosphate; ACOD = acyl-CoA oxidase; MEHA = 
3¬methyl¬N¬ethyl¬N¬(β-hydroxyethyl)¬aniline; POD = peroxida  
 
Therefore, we ran an assay using different concentrations of albumin to 
investigate previous assays 5% of albumin was added to each sample to sequester 
excess-background NEFA, which in high concentrations has been shown to inhibit 
LPL activity (Bengtsson and Olivecrona, 1980). Therefore, we opted to compare 
the concentration of NEFA detected in an assay without, and with 2%, and 5% 
albumin. 
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Result  
Figure 3.5, Panel [A], shows that after a 30 minute of incubation of chylomicron 
with 0.1 unit of LPL and without albumin, there was 14% more NEFA released than 
with albumin. For VLDL1 when incubated without albumin, there was an over 2-
fold increase in detected NEFA concentration over its albumin containing 
counterpart (Figure 3.5, panel [B]). Without albumin, there was a steady increase 
in NEFA concentration over the 20 minute period, however, with albumin the NEFA 
concentration appeared to be levelling off after 10 minutes, but more data points 
are needed for both conditions to tell conclusively. Based on these data, albumin 
was removed from the LPL assay and the volume deficit has been replaced with 
Tris-HCl buffer. A final step of a sonication of each sample for 2 minutes before 
analysis to remove interference from bubbles was also included. 
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Figure 3.5. The effect of adding albumin to the hydrolysis assay during 30m interval. Panel [A] shows the release of NEFA from chylomicron when 
different albumin concentrations were added to the assay mixture, panel [B], shows the degradation of TG in chylomicron when different albumin 
concentrations were added to the assay mixture, panel [C], shows the release of NEFA from VLDL1 when different albumin concentrations were added to 
the assay mixture, panel [D], shows the degradation of TG in VLDL1 when different albumin concentrations were added to the assay mixture. 
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3.1.6 Conclusion  
The increase in NEFA concentration, rather than the degradation of TG and rise 
of glycerol as final products of the reaction was used an indicator of TRL 
hydrolysis. In addition, it was decided TG and NEFA were measured separately in 
the ILab-600 to avoid any interference might affect the readings. The removal of 
albumin helped in better detection of NEFA. These modifications allowed us to 
reach a CV% of <1% for NEFA at concentration of 0.18 mmol.l-1 and 2.1% at 
concentration of 0.15 mmol.l-1 for TG when measured in ILab-600.  
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3.2 Standardisation of TRL concentration 
3.2.1 Aim  
To accurately and precisely determine TRL susceptibility to TG hydrolysis it is 
necessary to ensure that TRL concentration in the assay is standardised. The aim 
here was to optimise a process to concentrate TRL particles to enable easy dilution 
to a single standardised concentration for all TRL (chylomicrons, VLDL1 and VLDL2) 
in all individuals under all conditions (fasted and postprandial, control and 
exercise). This would also enable the use of a concentration high enough to be 
read accurately and precisely by the ILab-600. 
 
3.2.2 Method  
Subjects were fasted for >12 h before a high fat meal was given (see Section 
2.5.1). Fifty ml of fasting and postprandial (4 hours after meal ingestion) blood 
was collected from rested subjects in EDTA tubes and was placed immediately on 
ice. Plasma was separated within 15 minutes of collections as previously 
mentioned in Section 2.6. 
 
Concentration of chylomicrons 
Chylomicron particles were separated from postprandial plasma samples a 
described in section 2.6.2. Chylomicrons were then concentrated in this sample 
using washed 10000 MWCO Centrifugal Filter Units (Fisher scientific, UK). The 
Centrifugal Filter Units were washed with distilled water 4-5 times at 2400 rpm 
for 13-23 minutes to remove any traces of glycerol. 
Each subfraction was then centrifuged at 3000 rpm for 90 minutes until a constant 
volume was produced, giving a 2-10X concentrated sample. Concentrated 
chylomicron was stored at 4 °C (Figure 3.6). 
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Figure 3.6. Chylomicron were concentrated using filtered tubes at 3000 rpm at 4ºC for 90 minutes. 
 
VLDL particles  
It was thought that VLDL1 and VLDL2 particles may not be stable once they were 
separated from plasma; therefore, we assessed the stability for both particles, 
by, measuring concentrations of TG in samples stored for 0, 24 and 48 hours. Both 
subfractions were stable for 48 h in the fridge at 4 °C.  
 
After the removal of chylomicron particles as detailed in Section 2.6.2, plasma 
was adjusted to a density of 1.25 g.ml-1 by the addition of 0.3517 g.ml-1 potassium 
bromide (KBr; BDH: 101954F), 15 ml of 1.25 g.ml-1 density solution (1.006 g.ml-1 
density Solution + 0.3517 g.ml-1 of KBr) was overlaid on 10 ml 1.25 g.ml-1 plasma 
in Ultra-Clear centrifuge tubes (Figure 3.7), which was then ultracentrifuged at 
39 k rpm for 46 hours at 15℃ using the Beckman L8-60M Ultracentrifuge and Ti 70 
fixed angle rotor (Beckman Instruments Inc., 337922, UK). The samples were left 
for 5-10 minutes after centrifugation to settle, before the top 2 ml was aspirated 
and reserved for VLDL separation as it mentioned in section 2.6.2. This resulted 
in a 5-fold concentration of TRL. The ultracentrifugation process to separate 
VLDL leads to a further doubling of the VLDL1 concentration (as 2 ml of the 
initial solution is collected in 1 ml) and 4-fold increase in VLDL2 concentration 
(as the fraction is collected in 0.5 ml). Thus this process leads to a 10-fold 
increase in concentration of VLDL1 and 20-fold increase in concentration of 
VLDL2.  
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Figure 3.7. 70 Ti rotor and tubes, used to concentrate VLDL particles.  
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3.2.3 Result  
After concentration of TRL, typical concentrations achieved were 1.0 mmol.l-1 for 
chylomicrons, 5.0 mmol.l-1 for VLDL1 and 3.0 mmol.l-1 for VLDL2. Thus, to ensure 
that a reproducible concentration of TRL could be achieved in all participants in 
all conditions (including following exercise, where concentrations could be 
reduced by up to 40%), it was decided to standardise TRL concentrations in the 
assay at 0.6 mmol.l-1.  
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3.3 Optimising lipase amount  
3.3.1 Aim  
To determine suitable concentration of LPL to hydrolyse TRL to release NEFA. This 
includes testing the concentration of LPL and the volume of TRL in the assay. 
Further questions were addressed included whether the enzyme needed an 
activator and the incubation period. A previously described assay was used as the 
starting point (van Barlingen et al., 1996). 
 
3.3.2 Methods 
Serial assays wereconducted using different LPL concentrations from Burkholderia 
sp. The above separated VLDL1 particles were incubated with LPL in Tris-HCl 
buffer and then quenched with different NaCl concentrations.A number of 
adjustments were applied to reach the optimal assay conditions as following;  
 
LPL concentrations and reaction duration  
A range of LPL concentrations were used (100, 200, 400 and 800 units) for a range 
of incubation periods with TRL up to 90 minutes.  
As shown in Figure 3.8 the release of NEFA increased by increasing LPL 
concentrations. Also, it observed that most of the reaction occurred in the first 5-
10 minutes and saturation was generally seen within the first 10 minutes.  
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The reactions were fast and reached the saturation point quickly. In addition, 
concentrations of NEFA were low, which providing challenges for accurate and 
precise measurement using the iLab 600 analyser. This was not optimal; to 
measure the affinity of LPL after exercise a slower reaction was needed to be able 
to observe the change. Thus much lower concentrations of LPL were used in a 
second set of assays as described below. In addition, the volume of the reaction 
mixture was reduced by reducing the volume of buffer to increase final NEFA 
concentrations. 
3.3.3 Final enzyme concentrations  
In order to achieve a slower action of the reaction, a decision was made to reduce 
the concentrations of LPL substantially and to try LPL from different sources. 
Thus, experiments using 0.1 unit of LPL from Pseudomonas sp. and Burkholderia 
sp. were performed. In addition, the volume of the mixture was adjusted from 
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Figure 3.8. Values for NEFA release over 90-minutes in LPL-affinity assay in VLDL1 using different 
LPL concentrations; 100, 200, 400 and 800 units. 
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500 µlto 140 µl as seen in Table 3.3, to increase the final concentration of NEFA 
in the reaction mixture VLDL1 was incubated with 0.1 units of LPL from both 
sources (Figure 3.9).  
With 0.1 units of LPL from Pseudomonas sp. and a reaction mixture volume of 140 
µl, the rate of NEFA released over the incubation period was linear until 20 
minutes with NEFA concentrations within a range which enabled accurate and 
precise detection by the ILab-600 analyser. In contrast NEFA release using LPL 
from Burkholderia sp. was negligible over the incubation period (Figure 3.9). 
 
 
Figure 3.9. Release of NEFA over 30-minutes in LPL-affinity assay in VLDL1 using 0.1 unit of LPL 
from different sources, Burkholderia sp. and Pseudomonas sp. 
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3.3.4 Conclusion  
The combination of using 0.1 units of LPL from Pseudomonas sp. and reducing the 
final volume of the reaction mixture to 140 µl led to an acceptable rate of NEFA 
release in the TG-hydrolysis assay. It was decided to use these conditions for the 
assay going forward.  
 
3.4 Assay conditions  
3.4.1 Stopping the reaction  
There are many enzyme inhibitors had been used to inhibit LPL action in different 
studies. Use of L- paraxon has been reported (Saheki et al., 1991), however its 
high toxicity meant that it was not considered for use here. Tetrahydrolipstatin 
(THL) has been used as an inhibitor of mammalian lipases, including pancreatic 
lipase, LPL, and HL (Hadvary et al., 1991, Lookene et al., 1994, Zambon et al., 
1996). However, the THL solution is not completely clear, small particles may 
remain floating, which make it impractical to be used in the current assay. In 
addition, ethanol:chloroform:heptane (1.00.90.7, v/v) was used in a study by 
Shirai and Jackson to inhibit LPL activity (Shirai and Jackson, 1982, Gómez-
Coronado et al., 1993). Again, chloroform is poisonous liquid. Sodium chloride has 
also been used as an inhibitor of LPL previously (van Barlingen et al., 1996, 
Fielding and Fielding, 1976). In current study NaCl was used as the inhibitor, 
because it is practical and not poisonous. Based on the original paper by (van 
Barlingen et al., 1996) an initial concentration of NaCl of 2 M was chosen. To test 
whether this concentration was sufficient, a higher concentration of 5 M was also 
tested.  
 
Results  
Figure 3.10, Panel [A] shows NEFA concentrations when the reaction was 
quenched with 2 M and 5 M NaCl, with NEFA concentrations measured immediately 
after the assay was completed (i.e. at 30 minutes). Figure 3.10, Panel [B] shows 
the same data when NEFA concentrations were re-measured an hour later. There 
are two clear observations here. First, NEFA concentrations were higher at the 
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early time-points of the reaction when quenched with 2 M NaCl than with 5 M 
NaCl, suggesting that 2 M NaCl was not sufficient to quench the reaction and TG-
hydrolysis was continuing until the NEFA measurement. Secondly, when the NEFA 
was re-measured one hour later, concentrations were higher compared with 
immediate NEFA measurement when the reaction was quenched with 2M NaCl, but 
not 5 M NaCl, which reinforces the initial observation that 2 M NaCl was not 
sufficient to fully quench the reaction, and demonstrates that 5 M NaCl was 
sufficient. Thus, a decision was made to use 5 M NaCl to quench the reaction. 
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Figure 3.10. Stopping the reaction by using two concentrations of NaCl. Panle [A] shows the 
effect of adding 2 and 5 M of NaCl to stop the reaction, Panel [B] shows the repeated measurement 
for the same reaction after one hour. 
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3.5 Discussion  
The purpose of the present study was to develop a method to measure lipolytic 
capacity of TRL, based on a previously published approach by (van Barlingen et 
al., 1996). Although, there are many methods to measure the lipolytic capacity 
for LPL, this assay is relatively easy to perform and meaningful in that it provides 
a good measure for the lipolytic rate in a given sample. There was some 
modification needed to reach to the optimal assay. Concentrating TRL helped to 
overcome any error from low concentrations measurements of NEFA. The 
modification of assay mixture and volume to avoid any dilutions related low 
concentrations. The LPL assay has been improved after the changes that had been 
made. The beginning was with ILab-600, but after exploring alternatives, and ILab-
600 maintenance, automatic sample analysis using the ILab-600 presented the 
best option. Albumin removal enhanced the action of LPL to hydrolyse TG, with a 
more than 2 fold increase in detected NEFA, which is in line with a number of 
observations showing reduced NEFA recovery when albumin is present, using the 
same detection method (Duncombe, 1963, Duncombe, 1964, Matsubara et al., 
1983). Moreover, the detection of TG concentration without albumin was better 
than with albumin, but these results were based on data from only one 
experiment. Repeats confirmed this observation. The final concentration of LPL 
was 0.1 units as it gives a linear increase of NEFA release during 30 minutes of 
interval. Before making all these modifications in the assay, a quality control was 
carried out thought out all the equipment that involved in the assay.  
The final assay mixture ended up by using the following; 70 µl lipoprotein (0.6 
mmol.l-1) incubated with 35 µl of Tris-HCl buffer at 37 ºC for 10 min to climate 
the tube. A 35 µl of LPL were added in each tube except the control, and incubated 
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for different time points 0, 5, 10, 15, 20 and 30 mins. Each tube was quenched by 
35 µl of pre-cooled NaCl (5 Ml). NEFA was measured, in triplicate, at different 
time point using enzymatic colorimetric methods. The final reaction conditions 
are shown in Table 3.3. The protocol of the assay is illustrated in Figure3.11. 
One limitation of this assay is that bacterial, rather than human, LPL was used, 
thus the absolute rates of TRL TG-hydrolysis are likely to differ from values 
obtained if human LPL was used. However, the purpose of the assay was to 
compare relative differences between susceptibility of TRL species to TG-
hydrolysis under different experimental conditions and as the same type of LPL 
will be used under all conditions, the outcomes should be largely independent of 
the LPL species used. In conclusion, by concentrating TRL, removing albumin from 
the assay and lowering the assay volume, the measurements of both TG and NEFA 
become consistent and enabled this assay to be used in the study described in 
experimental Chapter 4. 
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Table 3.3;Final assay mixture.  
 Time (min) 
 Control      
All in µl 0 0 0 5 10 15 20 30 
Buffer 35 70 35 35 35 35 35 35 
Albumin 0 0 0 0 0 0 0 0 
LPL 0 35 0 35 35 35 35 35 
lipoprotein 0 0 70 70 70 70 70 70 
Density sol. 70 0 0 0 0 0 0 0 
Total Vol. 140 140 140 140 140 140 140 140 
NaCl 93 93 93 93 93 93 93 93 
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Blood sampling at;  
0, 120, 240 min 
Plasma analysis; 
TG,NEFA. 
Plasma samples;  
2 ml for analysis and lipid 
separation  
Blood samples;  
30 ml for concentrated lipid 
separations  
Spin for 48 h to concentrate.  
Spin for  
VLDL1 and VLDL2 
Spin at 3000 rpm for 30 min at 4 °C 
Spin for 
VLDL1 and VLDL2 
Concentrate 
chylomicron  
Standardize lipoproteins 
concentrations at 0.6 
mmol.l
-1
 
Spin for chylomicrons at 10k 
rpm  
Lipoprotein analysis; 
TG, FC, EC, PL, apos 
and Lowry assay  
Chylomicron analysis; 
TG. 
Spin for chylomicrons at 10k 
rpm  
Chylomicron‐free plasma  
Incubate with LPL in Tris-HCL 
at different time points, then 
stop the reaction by NaCl.  
Reaction result 
analysis; TG and NEFA.  
Figure 3.11. Schematic diagram of LPL assay protocol.  
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4 Effect of Exercise on the Affinity of 
Lipoproteins for Lipoprotein Lipase 
4.1  Introduction 
Postprandial triglyceride concentrations are independently associated with risk of 
cardiovascular events (Bansal et al., 2007, Mora et al., 2008, Nordestgaard et al., 
2007) and chylomicrons and their remnants are implicated in the atherosclerotic 
disease process (Goldberg IJ, 2011, Chapman et al., 2011). Recent Mendelian 
randomisation studies reasserted the likely causal role of TG-mediated pathways in 
CVD (Jørgensen et al., 2012, Consortium and Collaboration, 2010, Cohorts, 2014, 
Jørgensen et al., 2014). Moderate intensity exercise lowers postprandial TG 
concentrations by about 15-25% in a range of population groups at increased risk of 
cardiovascular disease (Farah and Gill, 2012, Gill et al., 2004a, Gill and Hardman, 
2000) and is recommended as a TG-lowering intervention for patients at high CVD risk 
(Chapman et al., 2011). However, the mechanism(s) by which exercise lowers TG 
have not been fully elucidated. The exercise-induced reduction in postprandial TG 
concentration is quantitatively greater in VLDL than in chylomicrons (Gill et al., 2006, 
Gill et al., 2001b),with large VLDL particles (VLDL1, Sf 60- 400) being the lipoprotein 
subclass most affected (Gill et al., 2006). Kinetic studies have shown that exercise-
induced VLDL-TG reductions are due to increased clearance from the circulation, 
rather than reduced hepatic production (Al-Shayji et al., 2012). While exercise has 
also been shown to increase clearance of chylomicron-like particles (Al-Shayji et al., 
2012, Sady et al., 1986, Annuzzi et al., 1987), the magnitude of this change is smaller 
than the increase in clearance of VLDL1-TG (Al-Shayji et al., 2012), and the effect 
has not been consistently observed (Gill et al., 2001a). Furthermore, although 
exercise-induced reductions in postprandial TG concentrations are sometimes 
accompanied by an increase in post-heparin plasma or skeletal muscle lipoprotein 
lipase (LPL) activity, post-exercise TG reductions are also commonly observed in the 
absence of increased LPL activity (Harrison et al., 2012, Herd et al., 2001). The 
affinity of chylomicrons/chylomicron-like particles for LPL clearance is many fold 
greater than that of VLDL particles (Bjorkegren et al., 1996); thus the observation 
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that exercise increases VLDL1-TG clearance to a greater extent than chylomicron-like 
particles (Al-Shayji et al., 2012), taken together with the inconsistent changes to LPL 
activity in response to exercise (Malkova et al., 2000), suggest that mechanisms other 
than increased LPL activity are likely to contribute to the exercise-induced increase 
in VLDL1-TG removal. There is evidence that circulating VLDL1 particles are larger 
and more TG enriched following exercise (Al-Shayji et al., 2012, Gill et al., 2006) 
changes that might be expected to increase the susceptibility (affinity) of these 
particles for LPL-mediated hydrolysis (Fisher et al., 1995) and we have recently 
demonstrated that these exercise-induced changes to the size and TG enrichment of 
circulating VLDL1 particles explain about half of the variance in the exercise-induced 
increase in VLDL1 particle clearance in correlational analyses (Al-Shayji et al., 2012). 
This observation is consistent with exercise-induced changes to VLDL1 particles 
increasing their affinity for LPL-mediated clearance (Magkos, 2009, Al-Shayji et al., 
2012): this data interpretation would also explain how exercise could increase 
clearance of VLDL1-TG without necessarily increasing LPL activity, and why the 
exercise-induced increase in VLDL1-TG clearance is quantitatively larger than that 
observed in chylomicron-like particles. However, the hypothesis that exercise 
increases the affinity of VLDL1 as a substrate for LPL has not been directly tested. 
The purpose of this study was therefore to determine the effects of exercise on the 
affinity of TG-rich lipoprotein species (chylomicrons, VLDL1, and VLDL2 (Sf 20-60)) for 
LPL- mediated TG hydrolysis. 
 
4.2  Participants and Methods  
4.2.1 Participants 
Fifteen overweight/obese men were initially recruited to this study. Three were 
excluded at the outset for not being normoglycaemic. A further two withdrew without 
completing the experimental period for undisclosed personal reasons. 
Characterizations of the remaining 10 are listed in Table 4.1. All subjects were 
apparently healthy, normotensive, normoglycaemic and nonsmokers. None was 
taking any drugs known to affect lipid or carbohydrate metabolism. The study was 
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conducted with the approval of University of Glasgow Ethics Committee, and subjects 
gave written informed consent prior to participation 
  
Table 4.1; Physical characteristics 
  
Age (years) 36.44 ± 0.77 
Weight (kg) 95.85 ± 24.39 
Height (m) 1.76 ± 0.09 
BMI (kg.m-2) 30.46 ± 6.27 
Waist (cm) 101.85 ± 15.40 
Percentage fat (%) 26.66 ± 5.84 
Sum of skinfolds* (mm) 56.27 ± 42.61 
Systolic blood pressure (mm Hg) 127.09 ± 17.03 
Diastolic blood pressure (mm Hg) 81.27 ± 10.62 
N=10 Values are means ± SD  
*triceps, biceps, subscapular and superiliac 
 
4.2.2 Study design 
Participants attended the laboratory for two oral fat loading test (FLTin a random 
order, with an interval of 7-14 days. On the day before one of the OFTTs, participants 
walked on a treadmill for 90-min at an intensity of 50% V ̊O2max (Exercise trial). For 
the other FLT, subjects performed no exercise on the day preceding the oral fat 
tolerance test (Control trial). Subjects were asked to weigh and record their dietary 
intake and refrain from alcohol for the 2 days prior to the first FLT and replicated 
this prior to the second fat tolerance test. During the 3 days prior each FLT subjects 
were instructed to perform no exercise, other than the treadmill walk in the exercise 
trial (see Figure 4.1). 
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Fat Loading Test  
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Figure 4.1. Study Design. A day prior the OFTT participants performed either exercise for 90 minutes or rest. A base line blood sample was acquired, 
then a test meal was provided, further blood samples were obtained at 30, 60, 90, 120 and 240 minutes after meal consumption. 
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Exercise tests 
One week prior the first FLT a preliminary sub-maximal incremental treadmill test 
was performed to estimate V̊O2max (Armstrong, 2006) and determine the walking 
speed and gradient required to elicit 50% V̊O2max as mentioned in section 2.4. In 
the exercise trial, the treadmill walk was performed on the afternoon preceding 
the oral fat tolerance test about 16–18 h before the FLT. During the walk, O2 
uptake and CO2 production were measured as mentioned in section 2.2, heart 
rate was measured by short range telemetry (Polar Electroky, Kempele, Finland) 
as mention in section 2.3 and ratings of perceived exertion (Borg, 1973) were 
obtained at 15-minute intervals. 
 
Fat loading test  
Subjects reported to the lab in the morning after an overnight fast for ≥ 12h. A 
cannula was placed in an antecubital vein and, after a 10-min interval, a fasted 
state blood sample was withdrawn. A high fat mixed meal (HFM) as mentioned 
above in section 2.5.1 was provided. Further blood samples were obtained at 30, 
60, 90, 120 and 240 minutes after meal consumption. Subjects rested and 
consumed only water during this time.  
 
4.2.3 Lipoprotein separation 
Plasma samples (2 ml) at 0, 2 and 4 h were centrifuged to isolate lipoprotein 
subfractions as previously described in section 2.6.2 VLDL1 and VLDL2 fractions 
were assayed to determine concentrations and composition for TG, free 
cholesterol (FC) and phospholipids (PL), apoB, apoE and apoC as mention in 
Appendix C. Cholesteryl ester (CE) was determined by using the equation 
mentioned in Appendix C. Chylomicron fractions were assayed for TG 
concentration. In the VLDL1 and VLDL2 fractions, total protein was measured using 
a modified Lowry assay (see section 2.7).  
 
At the 4 h time point, chylomicrons were separated from 30 ml plasma by 
centrifugation. The chylomicron fraction was then concentrated 8-10 fold by 
centrifugation as mentioned in section 3.2. The chylomicron-free plasma at the 
4 h time-point, and 10 ml of plasma collected at 0 hours was then concentrated 
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~10-fold by centrifugation (see section 3.2) before lipoprotein separation to 
obtain concentrated VLDL1 and VLDL2 fractions. Chylomicron concentrations were 
adjusted to 0.6 mmol.l-1 of triglyceride, and VLDL1 and VLDL2 concentrations were 
adjusted to 0.6 and 2.0 mmol.l-1, by the addition of a d 1.006 g.ml-1 density 
solution.  
 
4.2.4 LPL affinity assay 
Affinity of lipoproteins for LPL was determined using a modified version a method 
described previously as mention in Chapter 3. 
 
4.2.5 Plasma assays 
Plasma glucose, TG, NEFA, and 3-hydroxybutyrate concentrations were analysed 
at all time points as previously mentioned in Appendix C. Total, HDL cholesterol 
concentrations were measured in the fasted state as mentioned in Appendix C. 
Small dense LDL was measured in the fasted state and 4 h postprandially as 
mention in Appendix C, LDL cholesterol was calculated in the fasted state using 
the Friedewald equation (Friedewald et al., 1972). Insulin was measured in EDTA 
plasma as described in section 2.6.4.  
 
4.2.6 Data analysis  
Statistical analyses were performed using Statistica (version 10, StatSoft Inc.) and 
Minitab (version 17, Minitab Ltd). All data were tested for normality using the 
Anderson-Darling test. Where data did not approximate a normal distribution, 
these were log-transformed prior to analysis and data are expressed as geometric 
means with 95% confidence intervals (95% CI)(Bland and Altman, 1996a, Bland and 
Altman, 1996b). Time-averaged postprandial concentrations, calculated as the 
trapezium rule-derived areas under concentration versus time curve, divided by 
the duration of the postprandial observation period (240 minutes), were used as 
summary measures of the postprandial responses. Comparisons between trials 
were made using paired t-tests where a single pair of means was compared, or by 
two-way repeated measures ANOVA, with post hoc Fisher tests, when comparisons 
were made across multiple time-points. Differences in lipoprotein affinity for LPL 
were expressed in terms of absolute changes and in terms of relative (fold) 
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changes. Relationships between variables were assessed using Pearson product-
moment correlations. Cohen’s effect size was calculated to measure the 
magnitude of the exercise effect (Cohen, 2013) see section 2.9.5. Statistical 
significance was accepted at p < 0.05. Please see Appendix E for Dr.Farag Al-
Shuweihdi statistical report. 
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4.3 Results 
4.3.1 Plasma concentrations in the fasted and 
postprandial states 
Plasma TG concentrations in the fasted and postprandial states for the group are 
shown in Figure 4.2 and Tables 4.2 and 4.3. Individual values are shown in Figure 
4.3. Exercise reduced fasting TG concentrations in 8, and postprandial TG in 7, of 
the 10 participants (Figure 4.3, panels A and B). TG concentrations were not 
normally distributed in either the fasted or postprandial states, largely due to one 
participant having substantially raised TG concentrations (> twice the mean) (see 
Figure 4.3, panels A and B) and thus statistical analysis was performed on log 
transformed data. Log transformed values approximated a normal distribution 
(Figure 4.3, panels C and D). Fasting TG concentrations were reduced by 18% (-
0.18 (-0.20 to -0.04) mmol.l-1 (mean difference (95% confidence interval)); p=0.04) 
by exercise, to give a Cohen’s d effect size for the exercise effect of 0.77. Time-
averaged postprandial TG concentrations were reduced by 13% (-0.33 (-0.63 to -
0.04) mmol.l-1; p=0.04), to give a Cohen’s d effect size of 0.70. Exercise had a 
statistically significant, moderate-sized effect on TG concentrations in both the 
fasted and postprandial states (Cohen, 2013).   
 
Group data for insulin are shown in Figure 4.4, panel B and Tables 4.2 and 4.3. 
Like TG, fasting and postprandial insulin concentrations were not normally 
distributed due to one individual with substantially elevated concentrations (see 
Figure 4.5, panels B and D), so values were log transformed prior to analysis. 
Although exercise reduced mean fasting insulin concentrations by ~25% and 
postprandial insulin concentrations by almost 60%, there was substantial individual 
variability in the exercise response (6 out of 10 lower with exercise in both fasted 
and postprandial states), leading to non-significant effects of exercise on both 
fasting (mean (95%CI) difference: -0.29 (-0.34 to +0.26) mU.l-1) and postprandial 
(-0.15 (-0.19 to +0.24) mU.l-1) insulin concentrations. Also, 3-hydroxybutyrate 
values were not normally distributed due to one individual with substantially 
elevated concentrations (see Figure 4.7, panel C and panel D) therefore, values 
were log transformed prior to analysis. Fasted 3-hydroxybutyrate values were 
higher in the exercise trial by 77% +0.37 (+0.34 to +0.62) mmol.l-1; p=0.02) but 
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there was no significant different between the two trials in the postprandial state 
(-0.08 (-0.12 to +0.36) mmol.l-1; p=0.74). The Cohen’s d effect size was 0.89 and 
0.11 respectively.  
 
Figures 4.7, panels A and C, Figure 4.8, panels A and C and Tables 4.2 and 4.3 
show fasting and postprandial concentrations for glucose and NEFA control and 
exercise trials. NEFA did not significantly changed by exercise, although there was 
a trend for fasting values for NEFA (+0.07 (-0.01 to +0.15) mmol.l-1) to be higher 
in the exercise trial. 
 
Exercise did not significantly affect total, LDL or HDL cholesterol concentrations 
in the fasted state (Table 4.2), but fasted small dense LDL concentrations were 
significantly lower by 16% (-0.23(-0.31 to -0.16) mmol.l-1 (mean difference (95% 
confidence interval); p=0.0002) following exercise, to give a Cohen’s d effect size 
for the exercise effect of 1.89. Time-averaged postprandial sdLDL concentrations 
were reduced by 11% (+0.17 (-0.13 to +0.47)) mmol.l-1; p=0.0006), to give a 
Cohen’s d effect size of 0.35. (see Figure 4.8, panel A and panel B and Table 4.2 
and 4.3).  
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Table 4.2; Fasting plasma concentrations. 
 Fasting concentration 
 Control Exercise Mean difference and 95% CI 
Cohn’s d 
effect size 
p-value 
Plasma TG (mmol.l-1)* 0.45 ± 0.14 0.27 ± 0.15 -0.18 (-0.20 to -0.04) 0.77 0.04 
Glucose (mmol.l-1) 5.50 ± 0.22 5.47 ± 0.23 -0.04 (-0.31 to +0.24) 0.08 0.81 
Insulin (mU.l-1)* 2.50 ± 0.35 2.21 ± 0.20 -0.29 (-0.34 to +0.26) 0.33 0.33 
ΝΕFΑ (mmol.l-1) 0.66 ± 0.06 0.73 ± 0.05 +0.07 (-0.01  to +0.15) 0.57 0.11 
3-hydroxybutyrate (mmol.l-1)* 2.45 ± 0.25 2.82 ± 0.21 +0.37 (+0.34 to +0.62) 0.89 0.02 
Plasma Small dense LDL (mmol.l-1) 1.40 ± 0.20 1.17 ± 0.17 -0.23 (-0.31 to -0.16) 1.89 0.0002 
Total cholesterol (mmol.l-1) 5.44 ± 0.33 5.49 ± 0.36 +0.05 (-0.19 to +0.28) 0.13 0.69 
HDL cholesterol (mmol.l-1) 1.06 ± 0.09 1.09 ± 0.10 -0.03 (-0.09 to +0.03) 0.29 0.38 
LDL cholesterol (mmol.l-1) 3.68 ± 0.28 3.83 ± 0.33 +0.15 (-0.06 to +0.35) 0.45 0.19 
Values are mean ± SEM, n = 10. Statistical analysis performed using paired t-test. *log-transformed values.  
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Table 4.3; Time-averaged postprandial plasma concentrations. 
 Postprandial concentration 
 Control Exercise Mean difference and 95% CI  
Cohen’s d 
effect size 
p-value 
Plasma TG (mmol.l-1) 2.72 ± 0.40 2.36 ± 0.31 -0.33 (-0.63 to -0.04) 0.70 0.03 
Glucose (mmol.l-1) 6.39 ± 0.46 6.35 ± 0.36 -0.04 (-0.34 to +0.33) 0.08 0.81 
Insulin (mU.l-1)* 4.24 ± 0.27 4.09 ± 0.25  -0.15 (-0.19 to +0.24) 0.24 0.33 
ΝΕFΑ (mmol.l-1) 0.65 ± 0.06 0.64 ± 0.06 -0.01 (-0.09 tο +0.07) 0.005 0.11 
3- hydroxybutyrate (mmol.l-1) 0.08 ± 0.01 0.10 ± 0.03 -0.02 (-0.09 to +0.04) 0.24 0.74 
Plasma Small dense LDL (mmol.l-1) 1.31 ± 0.16 1.14 ± 0.14 +0.17 (-0.13 to +0.47) 0.35 0.0002 
 
 
Values are mean ± SEM, n = 10. Statistical analysis performed using paired t-test. *log-transformed values. Statistical analysis performed using paired t-test 
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Time 0 min 30 min 60 min 90 min 120 min 240 min 
Mean 
difference 
0.32*± 0.16 0.29*± 0.15 0.31*± 0.13 0.37*± 0.14 0.26* ±0.19 0.57* ± 0.19 
Figure 4.2. Time-averaged postprandial plasma TG concentrations in Control and Exercise trial. 
Values and statistical analysis of these data is shown in Table 4.1 and 4.2. N = 10, Values are mean ± 
SEM. The SEM shows the variability among the whole population.  
The table below, shows the mean ± SEM differences between the two trials at each time point.* 
significant difference between trials at this time-point within subject (p < 0.005). 
Note.Error bars are calculated on the between subjects data, but the test is of the within subjects 
data. 
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Figure 4.3. Individual values for TG in the Control and Exercise trials. Panel [A] shows raw values for fasting TG concentrations; panel [B] shows raw values for 
time-averaged postprandial TG concentrations; panel [C] shows log transformed values for fasting TG concentration; panel [D] shows log-transformed values for 
time-averaged postprandial TG concentrations. Black symbols show individual values; red symbols show the mean values. Values and statistical analysis of these 
data is shown in Table 4.2 and Table 4.3.  
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[C] Fasted oncentrations – log ransf rmed data [A] Fasted concentrations – raw data 
 
[B] Time-averaged postprandial concentrations – raw 
data 
[D] Time-averaged postprandial concentrations – log 
transformed data 
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Figure 4.4. Time-averaged postprandial concentrations in Control and Exercise trial, panel [A] shows time-averaged postprandial glucose concentrations 
and panel [B] shows time-averaged postprandial insulin concentrations. Values and statistical analysis of these data is shown in Table 4.2 and Table 4.3 
and 4.2 N = 10, Values are mean ± SEM. The SEM shows the variability among the whole population. * significant difference between trials at this time-
point within subject (p < 0.005). 
Note.Error bars are calculated on the between subjects data, but the test is of the within subjects data. 
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Figure 4.5. Individual values for glucose and insulin in the Control and Exercise trials. Panel [A] shows raw values for fasting glucose concentrations; panel [B] 
shows fasting insulin concentrations; panel [C] shows time-averaged glucose concentration; panel [D] shows time-averaged postprandial insulin concentrations. Black 
symbols show individual values, red symbols show the mean values. Values and statistical analysis of these data is shown in Table 4.2 and Table 4.3.  
[A] Fasted glucose concentrations [C] Time-averaged postprandial glucose concentrations 
 
[B] Fasted insulin concentrations [D] Time-averaged postprandial insulin concentrations 
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Figure 4.6. Time-averaged postprandial concentrations in Control and Exercise trial, panel [A] shows time-averaged postprandial NEFA concentrations and 
panel [B] shows time-averaged postprandial 3-Hydroxybutyrate concentrations. Values and statistical analysis of these data is shown in Table 4.2 and Table 
4.3 and 4.2 N = 10, Values are mean ± SEM. The SEM shows the variability among the whole population. * significant difference between trials at this time-
point within subject (p < 0.005). 
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[A] Fasted NEFA concentrations 
[B] Fasted 3-Hydroxybutyrate concentrations 
 
[D] Time-averaged postprandial 3-Hydroxybutyrate concentrations 
Figure 4.7. Individual values for NEFA and 3-Hydroxybutyratein the Control and Exercise trials. Panel [A] shows raw values for fasting NEFA concentrations; panel 
[B] shows fasting 3-Hydroxybutyrate concentrations; panel [C] shows time-averaged NEFA concentration; panel [D] shows time-averaged postprandial 3-
Hydroxybutyrateconcentrations. Black symbols show individual values, red symbols show the mean values. Values and statistical analysis of these data is shown in Table 
4.2 and Table 4.3.  
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[C] Time-averaged postprandial NEFA 
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Figure 4.8.Individual values for sdLDL the Control and Exercise trials. Panel [A] shows fasting sdLDL concentrations; panel [B] shows time-averaged sdLDL 
concentration. Black symbols show individual values, red symbols show the mean values. Values and statistical analysis of these data is shown in Table 4.2 
and Table 4.3.  
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4.3.2 Lipoprotein concentrations and composition in 
the fasted and postprandial states 
Fasting and postprandial chylomicron-TG, VLDL1-TG and VLDL2-TG concentrations in 
the fasted and postprandial states for the group are shown in Figure 4.9, panel A, 
Figure 4.10, panel A and Figure 4.11, panel A and Tables 4.4 and 4.5. Individual 
values are shown in Figure 4.9, panel B, Figure 4.10, panel B and panel C and 
Figure 4.11, panel B and panel C. Chylomicron-TG concentrations in the fasted state 
were negligible in both trials, (-0.01 (-0.02 to +0.01) mmol.l-1 (mean difference (95% 
confidence interval)); p=0.25) by exercise. Whereas, exercise reduced postprandial 
chylomicron-TG concentrations by 31% (-0.12 (-0.13 to +0.02); p=0.08). The reduction 
of chylomicron TG observed in 7 out of the 10 participants. The effect of exercise on 
chylomicron time averaged TG concentrations in postprandial state gave a Cohen’s d 
effect size of 0.73 (see Figure 4.9, panel B). Exercise reduced fasting and 
postprandial VLDL1-TG concentrations in 7 out of the 10 participants in both trials 
(Figure 4.10, panel B and C). Fasting VLDL1-TG concentrations were reduced by 25% 
(-10.63 (- 21.26 to +0.00) mg.dl-1 (mean difference (95% confidence interval); 
p=0.056)) by exercise, to give a Cohen’s d for the exercise effect of 0.69. Time-
averaged postprandial VLDL1 TG concentrations were reduced by 18% (-14.62 (-27.40 
to -1.84) mg.dl-1; p=0.01), to give a Cohen’s d effect size of 0.96. Thus, exercise had 
a statistically significant, moderate to large-sized effect on TG concentrations in both 
the fasted and postprandial. Exercise did not significantly affect fasted and time-
averaged postprandial VLDL2-TG concentration did not differ significantly between 
trials (-3.21(-8 .84 to +2.42); p=0.22) and (+0.44 (-3.98 to +4.86); p=0.10) mg.dl-1 
respectively. (see Figure 4.11, panel B and C and Table 4.6 and 4.7).  
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Table 4.4, Table 4.5, Table 4.6 and Table 4.7 show total lipoprotein particle 
concentration and concentration of constituent lipoprotein molecules for VLDL1 and 
VLDL2 in the fasted state and 240 minutes postprandially. Exercise reduced fasting 
and postprandial total VLDL1 mass concentrations in 8 out of the 10 participants in 
both fasted and postprandial state. Fasting total lipoprotein mass for VLDL1 was lower 
in the fasted state by 24% (-20.43 mg/dl (-39.34 to -1.51); p = 0.04) by exercise, to 
give a Cohen’s d for the exercise effect of 0.79 and lower at 240 minutes 
postprandially by 17% (-23.34mg/dl (-45.83 to -0.86); p = 0.049), by exercise, to give 
a Cohen’s d for the exercise effect of 0.69. 
 
 VLDL1 apoB concentrations were significantly lower in the exercise than the control 
trial in the fasted state, but not 240 minutes postprandially. Concentrations of VLDL1 
TG, cholesteryl ester and free cholesterol were lower in the exercise than the control 
trial in both the fasted state and 240 minutes postprandially (Table 4.4 and 4.5). In 
the fasted state the VLDL1 TG/apoB ratio tended to be 39% higher (6942 (-1097 to 
+14982); p=0.09) by exercise, to give a Cohen’s d for the exercise effect of 0.60. At 
the 240 minute postprandial time-point VLDL1 TG/apoB ratio was similar in the two 
trials. Similarly, in the fasted state, the CE/TG ratio tended to be 26% lower -0.06 (-
0.15 to +0.03) (p=0.16). At the 240 minute postprandial time-point VLDL1 CE/TG ratio 
was similar in the two trials. In contrast to the findings for VLDL1, no differences in 
VLDL2 concentration or composition were observed between the control and exercise. 
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Table 4.4; Concentration and composition of VLDL1 in the fasted states. 
Fasting (0 minutes) 
 Control Exercise Mean difference and 95 % CI Cohen’s d 
effect size 
p-value 
Total lipoprotein concentration (mg.dl-1) 84.1 ± 17.4 63.7 ± 13.0 -20.43 (-39.34 to -1.51) 0.75 0.04 
ApoB (mg.dl-1) 1.98 ± 0.36 1.05 ± 0.21 -0.93 (-0.33 to -1.52) 1.08 0.01 
Triglyceride (mg.dl-1) 51.7 ± 11.1 41.0 ± 8.9 -10.63 (- 21.26 to +0.00) 0.69 0.056 
Cholesteryl ester (mg.dl-1) 7.7 ± 1.2 4.8 ± 3.0 -2.89 (-5.30 to -0.47) 0.83 0.03 
Free cholesterol (mg.dl-1) 4.0 ± 0.9 2.6 ± 0.6 -1.45 (-2.51 to -0.39) 0.95 0.02 
Phospholipid (mg.dl-1) 12.8 ± 3.0 9.2 ± 1.9 -3.55 (-7.48 to -0.38) 0.63 0.08 
Protein (mg.dl-1) 8.0 ± 1.6 6.1 ± 1.1 -1.91 (-4.37 to -0.55 ) 0.54 0.12 
TG/apoB ratio (mol:mol) 17751 ± 2507 24693 ± 4238 6942 (-1097 to +14982) 0.60 0.09 
CE/TG ratio (mol:mol) 0.23 ±0.03 0.17 ± 0.02 -0.06 (-0.15 to +0.03) 0.48 0.16 
 
 
 
Values are mean ± SEM, n = 10.  
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Table 4.5; Concentration and composition of VLDL1 in the postprandial states (240 minutes). 
 Postprandial (240 minutes) 
 Control Exercise Different between trials 
and 95 % CI 
Cohen’s 
d effect 
size 
p-value 
Total lipoprotein concentration (mg.dl-1) 137.9 ± 22.1 114.6 ± 18.0  -23.34 (-45.83 to -0.86) 0.72 0.049 
ApoB (mg.dl-1) 2.22 ± 0.34 2.01 ± 0.31 -0.22 (-0.68 to -0.24) 0.33 0.33 
Triglyceride (mg.dl-1) 88.5 ± 14.0 73.9 ± 12.3 -14.62 (-27.40 to -1.84) 0.79 0.03 
Cholesteryl ester (mg.dl-1) 11.6 ± 2.0 8.3 ± 1.2 -1.33 (-2.59 to -0.07) 0.73 0.048 
Free cholesterol (mg.dl-1) 5.9 ± 1.1 4.6 ± 0.8 -0.04 (-0.07 to -0.01) 0.92 0.045 
Phospholipid (mg.dl-1) 21.1 ± 3.7 17.6 ± 8.7 +6.84 ( 0.28 to +9.77) 0.73 0.13 
Protein (mg.dl-1) 10.8 ± 2.2 10.2 ± 1.2 -0.57 (-4.01 to +2.88) 0.11 0.73 
TG/apoB ratio (mol:mol) 25103 ± 2304 23072 ± 2561 -2031 (-7969 to +3846 ) 0.24 0.47 
CE/TG ratio (mol:mol) 0.18 ± 0.02 0.16 ± 0.01 -0.02 (-0.07 to +0.03) 0.28 0.40 
 
 
 
Values are mean ± SEM, n = 10.  
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[A]Time-averaged postprandial mean for chylomicron- TG 
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[B] Time-averaged postprandial chylomicron-TG 
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Figure 4.9. Values for chylomicron-TG in the Control and Exercise trials, panel [A] shows mean values for time-averaged postprandial chylomicron-TG 
concentrations, panel [B] shows individual values for time-averaged postprandial chylomicron-TG concentrations. Statistical analysis of these data is shown 
in Table 4.4 and 4.5. N = 10, Values are mean ± SEM. Black symbols show individual values, red symbols show the mean values. Values and statistical analysis 
of these data is shown in Table 4.2 and Table 4.3. * significant values from the other group (p = 0.005). The table below, shows the mean ± SEM differences 
between the two trials at each time point.* significant difference between trials at this time-point within subject (p < 0.005). 
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Time 0 min 120 min 240 min 
Mean difference 0.12 ± 0.05 0.24* ± 0.08 0.17* ±0.07 
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[A] Time-averaged postprandial mean for VLDL1- TG concentrations 
[C] Time-averaged postprandial VLDL1-TG concentrations 
[B] Fasted VLDL1-TG concentrations 
 
Figure 4.10. Values for VLDL1-TG in the Control and Exercise trials, panel [A] shows mean values for 
time-averaged postprandial VLDL1-TG concentrations, panel [B] shows individual values for fasted VLDL1-
TG concentrations, [C] shows individual values for time-averaged postprandial VLDL1-TG concentrations. 
Statistical analysis of these data is shown in Table 4.4 and 4.5. N = 10, Values are mean ± SEM. The SEM 
shows the variability among the whole population. * significant difference between trials at this time-point 
within subject (p < 0.005).Black symbols show individual values, red symbols show the mean values. Values 
and statistical analysis of these data is shown in Table 4.2 and Table 4.3. * significant values from the other 
group (p = 0.005). The table below, shows the mean ± SEM differences between the two trials at each time 
point.* significant difference between trials at this time-point within subject (p < 0.005). 
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Table 4.6; Concentration and composition of VLDL2 in the fasted state. 
Fasting ( 0 minutes) 
 
 
Control Exercise Mean difference and 95% 
CI 
Cohen’s d effect 
size 
p-value 
Total lipoprotein concentration (mg.dl-1) 49.5 ± 3.6 39.4 ± 2.2 -10.08 (-24.20 to +4.04 ) 0.49 0.15 
ApoB (mg.dl-1) 4.00 ± 0.57 3.39 ± 0.17 -0.61 (- 2.52 to +1.30) 0.22 0.50 
Triglyceride (mg.dl-1) 18.2 ± 3.2 15.0 ± 2.5 -3.21 (-8 .84 to +2.42) 0.35 0.29 
Cholesteryl ester (mg.dl-1) 11.3 ± 3.0 9.1 ± 1.5 -2.16 (-7.43 to +3.12) 0.28 0.39 
Free cholesterol (mg.dl-1) 4.0 ± 0.8 3.3 ± 0.5 0.38 (-1.18 to +1.93) 0.17 0.22 
Phospholipid (mg.dl-1) 9.8 ± 0.9 8.3 ± 0.5 1.55 (-5.06 to +1.96 ) 0.31 0.36 
Protein (mg.dl-1) 6.1 ± 0.4 3.7 ± 0.3 -2.43 (-5.11 to +0.26) 0.63 0.08 
TG/apoB ratio (mol:mol) 3679 ± 567 3051 ± 400 -628 (-1600 to +343) 0.45 0.19 
CE/TG ratio (mol:mol) 0.59 ± 0.10 0.62 ± 0.06 0.03 (-0.24 to +0.30) 0.09 0.79 
 
 
Values are mean ± SEM, n = 10. *Statistical analysis performed on log-transformed data, and values are geometric mean (95% confidence interval). 
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Table 4.7; Concentration and composition of VLDL2 in the postprandial state.  
 Postprandial (240 minutes) 
 Control Exercise Different between trials and 
95 % CI 
Cohen’s d 
effect size 
p-value 
Total lipoprotein concentration (mg.dl-1) 38.2 ± 1.6 40.0 ± 2.8 +1.80 (-5.35 to +8.93) 0.38 0.59 
ΑpοΒ (mg.dl-1) 2.43 ± 0.17 2.53 ± 0.15 +0.10 (-0.32 to +0.53) 0.37 0.60 
Triglyceride (mg.dl-1) 15.8 ± 2.2 16.2 ± 2.3 +0.44 (-3.98 to +4.86) 0.07 0.83 
Cholesteryl ester (mg.dl-1) 7.2 ± 1.5 6.7 ± 1.2 -0.44 (-1.63 to +0.76) 0.43 0.44 
Free cholesterol (mg.dl-1) 3.0 ± 0.5 2.9 ± 0.4 -0.12 (-0.54 to 0.30) 0.57 0.56 
Phospholipid (mg.dl-1) 7.3 ± 0.5 7.6 ± 0.6 +0.33 (-1.48 to +2.14) 0.13 0.70 
Protein (mg.dl-1) 5.0 ± 0.2 6.6 ± 0.7 +1.59 ( -1.07 to +4.24) 0.17 0.22 
TG/apoB ratio (mol:mol) 5416 ± 993 4169 ± 540 900592 (-609330 to +790513) 0.09 0.20 
CE/TG ratio (mol:mol) 0.45 ± 0.08 0.43 ± 0.04 -28.34 (-89.91 to +33.22) 0.32 0.78 
 
 
Values are mean ± SEM, n = 10. *Statistical analysis performed on log-transformed data, and values are geometric mean (95% confidence interval). 
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Figure 4.11. Values for VLDL2-TG in the Control and Exercise trials, panel [A] shows mean values for time-
averaged postprandial VLDL2-TG concentrations, panel [B] shows individual values for fasted VLDL2-TG 
concentrations [C] shows individual values for time-averaged postprandial VLDL1-TG concentrations. Statistical 
analysis of these data is shown in Table 4.4 and 4.5. N = 10, Values are mean ± SEM. Black symbols show individual 
values, red symbols show the mean values. Values and statistical analysis of these data is shown in Table 4.2 and 
Table 4.3. * significant values from the other group (p = 0.005). 
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4.3.3 Lipoprotein affinity for LPL 
 Figure 4.12, panel A, Figure 4.13, panel A, and Figure 4.14, panel A show mean 
(± SEM) NEFA release over the 30 minute incubation period in the LPL-affinity assay 
for VLDL1 and VLDL2 in the fasted state and 240 minutes postprandially, and for 
chylomicrons 240 minutes postprandially in the control and exercise trials. Affinity of 
chylomicrons, VLDL1 and VLDL2 for LPL was calculated from the gradient of the linear 
portion (before a plateau was achieved) of the individual NEFA release versus time 
plots. Table 4.8 shows VLDL1 and VLDL2 affinity for LPL in the fasted state and 240 
minutes postprandially and for chylomicrons 240 minutes postprandially, expressed 
as mmol of NEFA release, per mmol lipoprotein-TG, per unit LPL activity, per minute. 
Exercise did not affect the affinity of postprandial chylomicron, there was substantial 
individual variability in the exercise effect (6 out of 10 increased with exercise in 
postprandial state), leading to non-significant effects of exercise on both fasting 
(mean (95%CI) difference: (0.20 (-0.39 to 0.78) mmol of NEFA release, per mmol 
lipoprotein TG, per unit LPL activity, per minute (Figure 4.12, panel B). The Cohen’s 
d effect sizes at 0.21, for the change in chylomicron affinity with exercise were 
smaller than the effect of exercise on VLDL1 affinity. The exercise significantly 
increased the affinity of VLDL1 for LPL in 8 out of 10 and 9 out of 10 (Figure 4.13, 
panel C and D) in both fasted and postprandial states, (0.98 (0.55 to1.41); p=0.01) 
and (1.16 (0.63 to 1.70); p0.001), respectively, with a large Cohen’s d effect size of 
1.58 and 1.35 respectively. Exercise did not affect neither fasted nor postprandial 
VLDL2 affinity for LPL, with mean difference of (0.01 (-0.17 to 1.64); p=0.60) and 
(0.25 (0.12 to 1.45); p=0.34) (Figure 4.14 panel C and D). The Cohen effect size was 
small in both fasted and postprandial states 0.13 and 0.34 respectively.   
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Exercise increased affinity of VLDL1 for LPL by 2.2 (1.3 to 3.7) fold 
(geometric mean (95% CI)) in the fasted state (p= 0.02 for fold increase; p 
value for absolute increase shown in Table 4.8) and by 2.6 (1.8 to 3.8) fold 
in the postprandial state (p=0.001 for fold increase; p value for absolute 
increase shown in Table 4.8). However, there was no significant change in 
affinity of chylomicrons for LPL in either fold (1.2 (0.6 to 2.3) fold; p=0.59) 
or absolute units (see Table 4.8). Affinity of VLDL2 for LPL was negligible, 
~50-100-fold lower than chylomicrons and zero in many instances, and did 
not change in response to exercise. In the control trial, the affinity of 
chylomicrons for LPL was 11.3 (6.0 to 21.6) fold greater (p=0.0001) than 
the affinity of VLDL1 in the postprandial state, whereas in the exercise trial 
affinity of chylomicrons for LPL was 6.0 (3.0 to 12.0) greater (p=0.0007) 
than the affinity of VLDL1 in the postprandial state. Thus, the affinity of 
postprandial VLDL1 for LPL-mediated TG-hydrolysis relative to the affinity 
of chylomicrons was 2.6 (1.3 to 5.4) fold greater in the exercise compared 
to the control trial (p=0.03). There was no significant difference in affinity 
of VLDL1 for LPL between the fasted and postprandial states in either the 
control (postprandial VLDL1 LPL affinity 0.7 (0.4 to 1.1) fold compared with 
fasting VLDL1 LPL affinity, p=0.18) or the exercise (postprandial VLDL1 LPL 
affinity 0.8 (0.6 to 1.1) fold compared with fasting VLDL1 LPL affinity, p= 
0.28) trials.  
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Table 4.8;Lipoprotein Affinity for LPL. 
 
 
  
NEFA release (mmol.min-1 per mmol lipoprotein-TG per unit LPL activity) 
  Control Exercise Cohen d effect size p-value 
Fasting (0 minutes) 
VLDL1 
0.16 
(0.09 to 0.29) 
0.35 
(0.24 to 0.52) 
1.58 0.018* 
VLDL2 
0.013 
(0.004 to 0.044) 
0.018 
(0.007 to 0.049) 
0.13 0.60 
Postprandial (240 minutes) 
CM** 
1.25 
(0.94 to 1.66) 
1.52 
(0.98 to 2.34) 
0.21 0.53* 
VLDL1 
0.08 
(0.03 to 0.19) 
0.25 
(0.15 to 0.42) 
1.35 0.002* 
VLDL2 
0.021 
(0.006 to 0.070) 
0.013 
(0.004 to 0.048) 
0.34 0.34 
Values are geometric mean (95% confidence interval), n = 10. *Statistical analysis and mean differences performed on log-transformed data.**(CM) 
chylomicron.  
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Figure 4.12. Values for NEFA release over 30-minutes in LPL-affinity assay in chylomicron in postprandial state Control and Exercise trials, 
panel [A] shows mean value of NEFA release over 30-minutes from chylomicron, panel [B] shows the individual value of NEFA release over 30-
minutes from chylomicron. N = 10,Values are mean ± SEM. The SEM shows the variability among the whole population. Affinity of lipoproteins for 
LPL was determined by the rate of NEFA release over the linear portion of the 30-minute incubation period before a plateau was achieved for 
each individual participant. Values for lipoprotein affinity for LPL and statistical analyses are shown in Table 4.8. Significant values from the other 
group * (p = 0.005) and ** (p< 0.05). 
 
[A] Mean values for NEFA release from chylomicron in 
postprandial state 
[B] Individual values for NEFA release from chylomicron 
in postprandial state 
4  Effect of Exercise on the Affinity of Lipoproteins for Lipoprotein Lipase 
 
157 
Khloud Jamil Ghafouri ® 2017  
 
 
 
 
 
 
0
5
10
15
20
25
0 5 10 15 20 25 30
N
E
F
A
 r
e
le
a
se
 (
m
m
o
l 
p
e
r 
m
m
o
l 
V
L
D
L
1
 p
e
r 
u
n
it
 L
P
L
 
a
c
ti
v
it
y
)
Time (min)
*
*
*
**
[A] Mean values for NEFA release from VLDL1 in fasted state 
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[C] Individual values for NEFA release from VLDL1 in 
fasted state 
 
[B] Mean values for NEFA release from VLDL1 in postprandial state 
 
 
[D] Individual values for NEFA release from VLDL1 in 
postprandial state 
 
 
Figure 4.13.Values for NEFA release over 30-minutes in LPL-affinity assay in VLDL1 in fasted and postprandial state in Control and Exercise trials, panel [A] 
shows mean value of NEFA release over 30-minutes from VLDL1 in fasted state, panel [B] shows mean value of NEFA release over 30-minutes from VLDL1 in postprandial 
state, panel [C] shows the Individual value of NEFA release over 30-minutes from VLDL1 in fasted state, panel, panel [D] shows the Individual value of NEFA release 
over 30-minutes from VLDL1 in fasted state. N = 10, Values are mean ± SEM. The SEM shows the variability among the whole population. Affinity of lipoproteins for 
LPL was determined by the rate of NEFA release over the linear portion of the 30-minute incubation period before a plateau was achieved for each individual 
participant. Values for lipoprotein affinity for LPL and statistical analyses are shown in Table 4.8 Significant values from the other group * (p = 0.005) and ** (p< 
0.05). 
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Figure 4.14. Values for NEFA release over 30-minutes in LPL-affinity assay in VLDL2 in fasted and postprandial state in Control and Exercise trials, panel [A] shows mean value of 
NEFA release over 30-minutes from VLDL2 in fasted state, panel [B] shows mean value of NEFA release over 30-minutes from VLDL2 in postprandial state, panel [C] shows the individual 
value of NEFA release over 30-minutes from VLDL2 in fasted state, panel, panel [D] shows the individual value of NEFA release over 30-minutes from VLDL2 in fasted state. N = 10, Values 
are mean ± SEM . The SEM shows the variability among the whole population.  Affinity of lipoproteins for LPL was determined by the rate of NEFA release over the linear portion of the 
30-minute incubation period before a plateau was achieved for each individual participant. Values for lipoprotein affinity for LPL and statistical analyses are shown in Table 4.8. Significant 
values from the other group * (p = 0.005) and ** (p< 0.05). 
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[A] Mean values for NEFA release from VLDL2 in fasted 
state 
 
[C] Individual values for NEFA release from VLDL2 in fasted state 
 
[B] Mean values for NEFA release from VLDL2 in postprandial state 
 
[D] Individual values for NEFA release from VLDL2 in postprandial 
state 
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4.4  Discussion 
Elevated postprandial TG concentrations are associated with increased risk of 
cardiovascular events (Bansal et al., 2007, Nordestgaard and Nielsen, 1994, Mora 
et al., 2008), and there is evidence that this relationship is likely to be causal 
(Goldberg IJ, 2011, Chapman et al., 2011, Jørgensen et al., 2012, Consortium and 
Collaboration, 2010, Cohorts, 2014, Jørgensen et al., 2014). Prior exercise has 
consistently been shown to lower postprandial TG concentrations, but the 
mechanisms responsible have been unclear (Gill and Hardman, 2000, Gill et al., 
2004a, Farah and Gill, 2012). Previous studies have shown that TG reductions in 
large VLDL1 make the largest quantitative contribution to the overall TG-lowering 
effect of exercise (Gill et al., 2006); that exercise lowers VLDL1-TG concentrations 
by increasing clearance of these lipoproteins from the circulation, rather than 
reducing their production (Al-Shayji et al., 2012); but that exercise-induced TG-
lowering is often observed in the absence of an elevation in post-heparin plasma 
or skeletal muscle LPL activity (Malkova and Gill, 2006, Harrison et al., 2012). The 
main novel finding of the present study is that prior exercise increased the affinity 
of large VLDL1 – but not of chylomicrons or VLDL2 – for clearance by LPL. This 
provides an important advance in our understanding of the mechanism by exercise 
lowers TG concentrations; an effect which is likely to contribute to exercise’s 
overall cardioprotective benefit. 
 
The present findings put previous observations about the effects of exercise TG-
rich lipoprotein metabolism into context. Earlier work demonstrated that exercise 
often lowered TG concentrations without a substantial increase in post-heparin 
plasma or skeletal muscle LPL activity (Harrison et al., 2012, Malkova and Gill, 
2006, Gill et al., 2006, Herd et al., 2001); that the TG reductions induced by 
exercise are typically larger in VLDL than chylomicrons (Malkova and Gill, 2006, 
Gill and Hardman, 2000, Gill et al., 2006); and that exercise increased clearance 
of VLDL from the circulation but did not reduce hepatic VLDL production 
(Tsekouras et al., 2007, Magkos et al., 2006).  
 
However, these observations could not explain how this increased VLDL clearance 
could occur without a concomitant increase in LPL activity. More recently, we 
demonstrated that the exercise-induced increase in clearance of VLDL1-TG was 
twice as large as the exercise-induced increase in clearance of TG from 
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chylomicron-like particles (Al-Shayji et al., 2012). This suggested that exercise 
upregulated clearance of VLDL1 to a greater extent than chylomicrons, which led 
to the hypothesis that exercise increased the affinity of VLDL1 for TG-hydrolysis 
by LPL. This hypothesis was confirmed by the findings of the present study. 
Exercise increased the affinity of VLDL1 for LPL clearance by 2.2-fold in the fasted 
state (p = 0.02) and 2.6-fold in the postprandial state (p = 0.001), but did not 
significantly alter the affinity of chylomicrons for LPL-mediated TG-hydrolysis 
Accordingly the affinity of VLDL1 relative to chylomicrons for LPL-mediated 
clearance in the postprandial state was 2.6-fold greater in the exercise compared 
with the control trial (p = 0.03). Data shown there was a numerical increase in 
chylomicron affinity for LPL of 1.2 fold. However there was a large amount of 
individual variability in this effect – six of the 10 had an increase in chylomicron 
affinity for LPL in response to exercise, the other four subjects experienced a 
decrease, which meant that the 95% confidence interval around this point was 
large (0.6-2.3 fold) and the p-value for the fold change was 0.59 (p=0.53 for 
absolute change in affinity). The Cohen’s d for the effect of exercise on 
chylomicron affinity for LPL was 0.21, which is considered a small effect size, 
whereas the effect size for the effect of exercise on VLDL1 affinity for LPL was 
1.58 in the fasted state and 1.35 in the postprandial state, which are both 
considered to be large effect sizes (Cohen, 2013). This magnitude of this change 
in relative VLDL1 affinity for LPL-mediated TG-hydrolysis is consistent our earlier 
observation that the exercise-induced increase in VLDL1-TG clearance was twice 
as great as the exercise-induced increase in chylomicron-like particles (Al-Shayji 
et al., 2012).  
It is not clear from the present findings how exercise increases the affinity of 
VLDL1 for LPL-mediated TG hydrolysis. We previously demonstrated that following 
exercise, VLDL1 particles were larger (higher TG/apoB ratio) and more TG-
enriched (lower CE/TG ratio) and that exercise-induced increases the fractional 
catabolic rate of VLDL1 particles were correlated with the increases in TG-
enrichment and size of the VLDL1 particle (Al-Shayji et al., 2012). As larger, more 
TG-enriched lipoprotein particles have greater affinity for LPL (Saheki et al., 1991, 
Fisher et al., 1995), we hypothesised that this compositional change was a 
potential mediator of increased affinity of VLDL1 for LPL post-exercise(Al-Shayji 
et al., 2012). In the Al-Shayji study, VLDL1 composition was only measured in the 
fasted state, and in the present study we observed changes of similar magnitude 
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in the TG/apoB ratio (39% increase with exercise in present study vs 26% increase 
in Al-Shayji et al and CE/TG ratio (26% decrease with exercise in present study vs 
29% decrease in Al-Shayji et al in fasting VLDL1 composition, although these 
compositional changes did not quite achieve statistical significance in the present 
study (Al-Shayji et al., 2012).  
 
This would be consistent with this compositional change contributing to the 
enhanced affinity for LPL-mediated clearance. However, in the postprandial state 
the VLDL1 TG/apoB ratio and CE/TG ratio were similar in the exercise and control, 
despite the affinity of VLDL1 for LPL-mediated TG hydrolysis in response to 
exercise increasing to a similar extent in the postprandial state to that observed 
in the fasted state. The similar postprandial VLDL1 CE/TG ratio observed in the 
control and exercise trials also contrasts with an earlier observation that the VLDL1 
CE/TG ratio was lower following exercise postprandially (Gill et al., 2006). This 
may indicate that the increase in VLDL1 affinity for LPL in response to exercise 
was mediated by factors other than changes in size and TG-enrichment of the 
VLDL1 particle. However, there are two other aspects worth consideration when 
interpreting these findings. First, it is important to recognise that all circulating 
VLDL1 particles are essentially remnant particles to some extent, in that they will 
have had a degree of LPL-mediated hydrolysis of their TG-core by the time the 
blood sample was taken. Post-exercise VLDL1 particles with greater affinity for 
LPL would have been exposed to proportionately greater TG hydrolysis by the time 
a blood sample was taken. Thus, relative to newly secreted VLDL1 particles, 
circulating post-exercise VLDL1 particles may have had their size and TG-
enrichment reduced to a greater extent than VLDL1 particles in the control trial. 
Thus, it is possible that following exercise, the liver produced larger, more TG-
enriched VLDL1 particles and that this contributed to their increased affinity for 
VLDL1, but this effect was not fully reflected in the composition of the measured 
circulating VLDL1 particle. However, in Al-Shayji et al, ratio of VLDL1-TG 
production to VLDL1-apoB production was similar in control and exercise trials, 
suggesting that the average size of the secreted VLDL1 particle was not influenced 
by exercise (Al-Shayji et al., 2012). However, it is also important to recognise that 
VLDL1 particles are heterogeneous, occupying a greater than three-fold range in 
size and density, and thus considering only ‘average’ lipoprotein size and 
composition in the VLDL1 range may not reveal the whole story. Interestingly, Al-
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Shayji et al reported a larger increase in the VLDL1-apoB fractional catabolic rate 
than the VLDL1-TG fractional catabolic rate with exercise (146% vs 82% increase) 
(Al-Shayji et al., 2012), which would suggest that exercise was having a 
proportionately larger effect on clearance of smaller, less TG-rich VLDL1 particles 
(which have a lower TG/apoB ratio), either via direct particle removal or by TG-
removal taking them out of the VLDL1 and into the VLDL2 density range. This 
interpretation would suggest that the observation that circulating VLDL1 particles 
post-exercise are larger and more TG-enriched reflects the fact that exercise 
disproportionately increased clearance of smaller, less TG-enriched particles at 
the lower end of the Sf 60-400 range, leaving proportionally more larger VLDL1 in 
the circulation. Accordingly, it is possible that the strong correlations between 
change in VLDL1 apoB fractional catabolic rate and change in VLDL1 TG/apoB and 
CE/TG ratio observed in that study (Al-Shayji et al., 2012) reflects greater 
clearance of smaller VLDL1 particles following exercise, which would have the net 
effect of increasing the average TG/apoB and CE/TG ratio of the remaining 
circulating lipoprotein particles across the VLDL1 density range. This 
interpretation is supported by a recent study by Harrison and colleagues who used 
nuclear magnetic resonance spectroscopy to quantify 24 different VLDL 
subfractions in the fasted state following exercise (Harrison et al., 2012). This 
report found that in response to exercise, there was a proportionally larger TG 
reduction in ‘medium VLDL’ (size range 43-55 nm, approximately corresponding 
to Sf 100-200 (Redgrave, 2004), i.e. smaller VLDL1) than in ‘large VLDL’ (size (55-
260 nm, approximately corresponding to Sf >200 (Redgrave, 2004), i.e. larger 
VLDL1), with VLDL particles over 120 nm in size being virtually unaffected by 
exercise (Harrison et al., 2012). The authors proposed that their findings were 
suggestive of independent metabolic regulation of different VLDL pools within the 
VLDL1 range (Harrison et al., 2012). This is an attractive proposition which is 
consistent with our present and earlier (Al-Shayji et al., 2012) observations on the 
effects of exercise on VLDL1 metabolism. Thus, further study is needed to both 
examine the effects of exercise on the affinity of smaller and larger VLDL1 
particles for LPL-mediated TG hydrolysis and to understand the effects of exercise 
on TG and apoB kinetics of smaller and larger VLDL1 particles.  
 
While the present findings clearly show that exercise increased the affinity of 
VLDL1 particles for clearance by LPL, this effect is unlikely to be solely responsible 
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for the observed TG lowering effect of exercise. We observed a significant 
reduction in chylomicron-TG concentration following exercise, without a 
corresponding increase in the affinity for chylomicrons for LPL-mediated 
clearance. This chylomicron-TG reduction is consistent with earlier observations 
(Gill et al., 2006, Gill and Hardman, 2000) and is likely to reflect increased LPL-
mediated chylomicron TG clearance, in line with our recent report that Intralipid-
TG fractional catabolic rate was increased by prior exercise (Al-Shayji et al., 
2012). We did not measure LPL activity in the present study, so it is unclear 
whether this is the consequence of increased LPL activity or exercise-induced 
changes in blood perfusion to LPL-rich tissues leading to increased interactions 
between chylomicron particles and LPL, or a combination of the two. It has 
previously been reported that postprandial blood flow to the leg was almost 40% 
higher on the day following 2 hours of walking (Malkova et al., 2000), so it is 
conceivable that the reduction in chylomicron-TG observed in the present study 
could have occurred without a marked increase in LPL activity, which would be 
consistent with precious studies which have generally reported that LPL activity 
is not substantially elevated in response to exercise of the nature undertaken here 
(Harrison et al., 2012, Malkova and Gill, 2006, Herd et al., 2001). It is a limitation 
to the study that we did not measure LPL activity. This information would have 
provided a more complete assessment of the relative importance of increased 
VLDL1 affinity for LPL vs increased LPL activity in mediating the overall TG-
lowering effect of exercise. However, the invasive muscle biopsies required to 
determine skeletal muscle LPL activity were not feasible, and because heparin 
injection distorts lipoprotein metabolism, it would not have been possible to 
obtain fasting and postprandial post-heparin plasma LPL activity assessments in 
parallel with other measurements made in the study. Nevertheless, it would be 
helpful if future studies investigating the effects of exercise on kinetics and 
affinity for LPL of VLDL sub-populations, could also directly measure LPL activity. 
 
A further observation was that exercise substantially reduced fasting sdLDL 
cholesterol concentrations. There is accumulating evidence that sdLDL have 
particularly high atherogenicity (Hirayama and Miida, 2012, Diffenderfer and 
Schaefer, 2014), thus, exercise-induced reductions are likely to have clinically 
relevant implications for CVD risk. Elevated concentrations of TG-rich lipoproteins 
facilitate the development of sdLDL by accelerating CETP-mediated neutral lipid 
4 Effect of Exercise on the Affinity of Lipoproteins for 
Lipoprotein Lipase 
164 
Khloud Jamil Ghafouri ® 2017  
exchange, between TG-rich lipoproteins and LDL, leading to TG-enriched LDL 
particles, which are then acted on by hepatic lipase to produce sdLDL particles 
(Hirayama and Miida, 2012, Diffenderfer and Schaefer, 2014). Thus, by lowering 
TG-rich lipoprotein concentrations, exercise is likely to have inhibited the neutral 
lipid exchange process leading to sdLDL formation.   
 
It is interesting TG-lowering effect of exercise occurs in absence of significant 
change of insulin and glucose concentrations. It was established that insulin 
resistance is an important determinant of TGR lipoproteins metabolism. However, 
in this instant TG-lowering effect may be independent of insulin sensitivity; this 
is consistent with earlier reports that TG–lowering effect is independent from 
insulin (Gill et al., 2002). 
 
In conclusion, this study’s main finding that exercise increases the affinity of 
VLDL1 for LPL-mediated TG-hydrolysis provides an important piece in the jigsaw 
of understanding the effects of exercise on the metabolism of TG-rich 
lipoproteins. These data provide clarity to the interpretation of the findings of 
many studies into the effects of exercise on postprandial lipoprotein undertaken 
over the past 15-20 years, explaining why exercise often affects VLDL1-TG 
concentrations to a greater extent than chylomicron concentrations, and why a 
TG-lowering effect of exercise is often seen without an increase in LPL activity. 
However, it is still unclear how exercise increases the affinity of VLDL1 for LPL-
mediated clearance and further study is now needed to understand the effects of 
exercise on the affinity for LPL and kinetics of sub-populations of VLDL1. 
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5 Effect of co-ingesting fat with 
carbohydrate on lipid and glucose 
response  
5.1 Introduction 
In response to meal ingestion, there are a number of perturbations to metabolism 
which are likely to impair insulin sensitivity and possibly contribute to atherosclerotic 
progression. As humans spend most of their time in the postprandial state, these 
metabolic changes have possible relevance in the development of the metabolic 
syndrome and T2D, and also increase CVD risk. There are a number of plausible 
mechanisms by which this can occur. Ingestion of fat leads to increases in 
postprandial chylomicron and VLDL concentrations. The magnitude of these changes 
is associated with the amount (Schwab et al., 2014) and type (saturated, 
monounsaturated, polyunsaturated) of fat consumed. These postprandial lipoproteins 
and their remnants may deposit into arterial walls accelerating the development of 
atheromatous plaques (Zilversmit, 1979). In addition, high concentrations of these 
triglyceride-rich lipoproteins facilitate neutral lipid exchange with HDL and LDL, 
mediated by CETP, contributing to the generation of an atherogenic lipoprotein 
phenotype (Zhong et al., 1996, Cohen et al., 1994).  
Ingestion of carbohydrate induces a rise in blood glucose concentrations which 
triggers the release of insulin from the pancreas (Scheen, 2004, Del Prato and Tiengo, 
2001, Wallum et al., 1992, Brand-Miller, 2004). There is evidence that these 
postprandial increases in glucose and insulin may have adverse effects on insulin 
sensitivity, diabetes risk and obesity (Giovannucci, 1995, Daly, 2003)  and thus, 
minimising the extent of these postprandial perturbations may be beneficial. For 
example, it has been shown that consuming foods with a low glycaemic index can 
reduce insulin demand, improve blood glucose control, and reduce blood lipid levels, 
all factors that may play important roles in the prevention or management of 
metabolic disease (Augustin et al., 2002, Jenkins et al., 1990). The magnitude of 
these postprandial changes is related to the amount of carbohydrate consumed 
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(Blaak, 2016, Wolever and Bolognesi, 1996b, Wolever and Mehling, 2003, Sheard et 
al., 2004), but the type of carohydrate ingested also plays a key role (Sheard et al., 
2004, Salmerón et al., 1997). The glycaemic index (GI) quantifies the postprandial 
glucose rise for a given food, relative to that for glucose. Foods with lower GIs lead 
to lower glucose and insulin responses (Jenkins et al., 2008). In epidemiological 
studies low GI diets are associated with reduced risk of CVD and diabetes (Barclay et 
al., 2008, Qi and Hu, 2007, Livesey et al., 2008), lower plasma TG by around 15% and 
cholesterol by 8% (Brand-Miller et al., 2003, Pelkman, 2001). There are benefits of 
using low-GI diets in the management of diabetes (Brand-Miller et al., 2003, Livesey 
et al., 2008, Rahelić et al., 2011) and interventions with low GI diets (LGI) have shown 
a reduction in fasting plasma glucose and postprandial plasma glucose and insulin in 
type-2 diabetic by around 30% (Jenkins et al., 1988). The diets are reported to reduce 
the level of HbA1c by absolute amounts varying from 3% (Calle-Pascual et al., 1987) 
to 19% (Jenkins et al., 1988, Augustin et al., 2002, Jenkins et al., 2008). Another 
study (Rizkalla et al., 2004) found that also, a low GI diet was able to improve 
glycaemic control, glucose utilization, some lipid profiles, and the capacity for 
fibrinolysis in type 2 diabetes (Rizkalla et al., 2004). In addition, a low-GI diet has 
been shown to improve the lipid profile (Thomas et al., 2007, Wolever et al., 1992). 
High GI diets, on the other hand, are associated with insulin resistance, type 2 
diabetes, dyslipidaemia and prostate, breast and colon cancer (Blaak, 2016, Pi-
Sunyer, 2002, McKeown-Eyssen, 1994, Giovannucci, 1999, Giovannucci, 1995).  
In free-living conditions, humans generally co-ingest fat and carbohydrate, so it is 
important to consider the effect consuming fat with carbohydrate on postprandial 
glucose, insulin and NEFA responses compared with ingestion of carbohydrate alone, 
as it is possible that this may slow glucose release into the circulation, thereby 
lowering the meal’s GI (Järvi et al., 1999, Wolever et al., 1999, Wolever et al., 1994, 
Moghaddam et al., 2006). Conversely, the addition of carbohydrate to fat ingestion 
will induce a larger insulin response (Moghaddam et al., 2006, Mohammed and 
Wolever, 2004), which would be expected to induce greater suppression of NEFA 
release from adipose tissue, a larger upregulation of adipose tissue LPL activity 
(Knuth et al., 2008, Knuth et al., 2007), and a greater suppression of hepatic VLDL 
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production (Schneeman et al., 1993), which might be expected to attenuate the 
postprandial TG response (Jeppesen et al., 1995). However, the effects of such 
coingestion on the concentration and composition different lipoprotein species in the 
postprandial state are not known.  
Therefore, the aim of this experimental chapter is to investigate the acute effects 
of consuming fat alone, carbohydrate alone and co-ingestion of fat and 
carbohydrate on postprandial metabolic responses, particularly on the 
concentration and composition of postprandial lipoprotein species. 
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5.2 Participants and Methods 
5.2.1 Participants  
Thirteen participants were initially recruited but three withdrew before completion of 
the experimental period for undisclosed personal reasons. Thus 10 apparently healthy 
men not taking any drugs thought to affect lipid or carbohydrate metabolism took 
part in the study. Their demographic information is given in Table 5.1 below.  
 
Table 5.1; Demographic data. 
  
Age (years) 30.0 ± 3.9 
Weight (kg) 87.4 ± 10.9 
Height (m)  182.6 ± 6.9 
BMI (kg.m-2) 26.3 ± 4.1 
Waist/ hip ratio 0.86 ± 0.07 
Percentage fat (%) 20.6 ± 6.9 
  
5.2.2 Study design  
A cross-over study design was used with participants undertaking three postprandial 
assessments: an OFTT (75 g of fat), an OGTT (75 g of Glucose) and combination of 
both (COMB) (75 g of fat and 75 g of glucose) in a randomised order with an interval 
of 7-14 days between tests. In each test, blood samples were collected in the fasted 
state and over 8 hours postprandially. Figure 5.1 shows the experimental design, 
which is described in detail below. 
 
Oral Fat Tolerance Test (OFTT)  
Participants reported to the lab in the morning after a 12-hour overnight fast. A 
cannula was inserted into an antecubital or forearm vein to acquire blood samples. 
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After a blood sample was taken in the fasted state, a high fat meal comprising 150 
ml cream, containing 75 g of fat, was ingested and further blood samples were 
collected at 30, 60, 90, 120, 240, 360 and 480 minutes after the meal. Participants 
were free to sit, read, relax, or watch TV during this time and were able to consume 
water ad libitum (see section 2.5.3). 
 
Oral Glucose Tolerance Test (OGTT) 
This trial was identical to the OFTT except participants ingested a drink containing 
75 g of glucose, instead of the fat (see section 2.5.2). 
 
OFTT and OGTT mixed meal  
In this trial the participant consumed a mixture of 75g fat and 75g glucose (see 
section 2.5.4). 
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Time (h)  
~ 12 h fasting 
 Meal (OGTT or OFTT or COMB).  Blood sample 
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360 480 
Figure 5.1. Study design. Participants reported to the lab after 12 h fasting. A base line blood sample was taken, then a meal containing either 75 g 
of fat or 75 g of glucose or combination of both was provided and serial blood samples were taken. 
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5.2.3 Plasma assays 
Serum, TG and NEFA and plasma glucose concentrations were analysed at all time 
points as previously mentioned in Appendix C. Total, HDL cholesterol and small dense 
LDL concentrations were measured in the fasted state as mentioned in Appendix C. 
LDL cholesterol was calculated in the fasted state using the Friedewald equation 
(Friedewald et al., 1972). Insulin was measured in EDTA plasma, as described in 
section 2.6.4.  
 
5.2.4 Lipoprotein separation 
Plasma and serum samples (2 ml) at 0, 1, 2, 4, 6 and 8 h were centrifuged using the 
techniques to isolate chylomicrons and lipoprotein subfractions as described in 
section 2.6.2.  
Chylomicron, VLDL1 and VLDL2 IDL and LDL fractions were assayed to determine 
concentrations and composition for TG, FC and PL using commercially available 
enzymatic and turbidimetric kits as described in Appendix C. Chylomicron fractions 
were assayed for TG concentration. Total protein was measured in all lipoprotein 
subfractions using a modified Lowry assay as described in section 2.7.  
 
5.2.5 Calculations and statistical analysis 
The rise in postprandial concentration was calculated by taking the incremental area 
under the curve (IAUC) and dividing by total time. Percentages of TG and CE were 
relative to lipoprotein total mass. TG to CE ratio was calculated as TG/CE. 
 
Statistical analysis was carried out, Statistica (version 12.0) and Microsoft Excel 
(version 14.0.6112.500). When displayed graphically SEMs were used as error bars. 
Repeated measures ANOVAs were used to calculate differences in the means for time 
average concentrations, rise in time average concentrations, time to peak, the peak 
concentration and the maximal rise in concentration of plasma glucose, insulin, NEFA, 
TG and CM TG concentration and lipoprotein composition. Statistical significance was 
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set at p<0.05 at which point a Fisher post hoc test was carried out to establish which 
groups the statistical significance lay. Cohen’s d effect size was calculated to 
measure the magnitude of the co-ingestion of fat with carbohydrate (Cohen, 2013) 
(see section 2.9.5). 
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5.3 Results  
5.3.1 Plasma measurements  
Table 2.5 and Figure 5.2 show IAUC (±SEM) for plasma glucose over 480 minutes. 
The ingestion of carbohydrate alone and/or carbohydrate with fat increased the IAUC 
plasma glucose level when compare with ingesting fat only, in particular in the first 
120 minutes. Glucose AUC and IAUC were significantly lower in OFTT compared with 
OGTT and COMB (all p<0.05). 
During the first 120 minutes observation, the consumption of fat with carbohydrate 
lowered both IAUC and AUC of the glycaemic response. Incremental glucose 
concentration in the first 2 hours was significantly higher in OGTT than in COMB by 
49% (mean (95%CI) difference: +0.55 (+0.04 to +1.06) mmol.l-1, p=0.01) and a 
moderate Cohen’s effect size of 0.76 and in the AUC OGTT glucose concentrations 
were higher in OGTT then COMB by 12% with a mean (95%CI) difference: +0.17 (+0.03 
to +0.30) mmol.l-1, p=0.03). We observed a lower glycaemic response in COMB trial 
when compared with OGTT at 30 and 60 minutes. Glucose concentrations were lower 
by 52% (p<0.01) and a moderate Cohen effect size of 0.74 at 30 minutes and by 65% 
(p< 0.01) and a large Cohen’s effect size of 2.77.  
 
Insulin response was not influenced by the addition of fat with carbohydrate 
compared to carbohydrate by itself (Table 2.5). Ingesting fat alone had a significantly 
lower effect on insulin secretion compared with the ingestion COMB test meal or 
OGTT test meal alone (all p<0.05) (Figure 5.3).  
 
The co-ingestion of fat with carbohydrate seems to have a suppressing effect on NEFA 
release. The IAUC is shown in Table 5.2 and Figure 5.4, at the first 30 minutes there 
greater reduction in NEFA concentration in the OGTT trial comparing with OFTT trial 
by 72% (p<0.01) and in comparison with the COMB trial by 58% (p<0.03). After an hour 
of ingestion, the reduction of NEFA continued to be lower in OGTT by 87% and 65% 
compared with both OFTT and COMB (all p<0.01). At 90 minutes there was significant 
different between the three trials, as NEFA concentration continued to fall in OGTT 
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by 92% and 64% from both OFTT and COMB respectively (all p<0.01) and the OFTT was 
lower by 85% compared with COMB (p<0.01). After 2 hour of food ingestion NEFA 
concentration was lower in OGTT by 77% than OFTT and by 80% versus COMB (mean 
(95%CI) difference:(-0.32 (-0.48 to -0.17)) giving a Cohen’s d effect size of 1.27 and 
(-0.23 (-0.40 to -0.17)) giving a Cohen’s d effect size of 0.86 (all p<0.01).  
 
Plasma TG concentrations for incremental postprandial states for the group are 
shown in Figure 5.5 and Tables 5.2. The co-ingestion of fat with carbohydrate did 
not have any significant effect on plasma TG concentrations. As expected OGTT trial 
was significantly different from both OFTT trial and COMB trial. The OGTT trial was 
different from OFTT trial by mean of (95%CI) difference:-0.38 (-0.54 to -0.22), and a 
large Cohen’s d effect size of 1.47; and from COMB trial (-0.39 (-0.54 to -0.24) and a 
large Cohen’s d effect size of 1.61 (all p<0.005).  
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Figure 5.2. Change in glucose response over the 480 minute observation period in the OGTT, OFTT and COMB trials. Values 
are mean ± SEM, N = 10; data were analysed using two ways ANOVA. Least significant differences post-hoc analysiss was used to 
identify where significant main effect lay. aSignificantly different from OGTT trial, bsignificantly different from OFTT trial, 
csignificantly different from COMB trial, all (p<0.001).  
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Figure 5.3. Change in insulin response over the 480 minute observation period in the OGTT, OFTT and COMB trials. Values are 
mean ± SEM, N = 10; data were analysed using two ways ANOVA. Least significant differences post-hoc analysiss was used to identify 
where significant main effect lay aSignificantly different from glucose trial, bsignificantly different from fat trial, csignificantly 
different from combination trial, all (p<0.001). 
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Figure 5.4. Change in NEFA response over the 480 minute observation period in the OGTT, OFTT and COMB trials. Values are mean ± SEM, N 
= 10; data were analysed using two ways ANOVA. Least significant differences post-hoc analysiss was used to identify where significant main effect 
lay aSignificantly different from glucose trial, bsignificantly different from fat trial, csignificantly different from combination trial, all (p<0.001).  
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Figure 5.5. Change in TG response over the 480 minute observation period in the OGTT, OFTT and COMB trials. Values are mean 
± SEM, N = 10; data were analysed using two ways ANOVA. Least significant differences post-hoc analyses was used to identify where 
significant main effect lay aSignificantly different from glucose trial, bsignificantly different from fat trial, csignificantly different 
from combination trial, all (p<0.001). 
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Table 5.2; Change in plasma values over the 480-minute postprandial observation period in the OGTT, OFTT and COMB trials. 
 
Mean Value Mean difference Effect Size 
 
OGTT OFTT COMB OGTT vs OFTT OGTT vs COMB OFTT vs COMB 
OGTT 
vs 
OFTT 
OGTT 
vs 
COMB 
OFTT 
vs 
COMB 
TG (mmol.l-1) -0.01 ± 0.05 0.37 ± 0.08 0.38 ± 0.08 -0.38 (-0.54 to -0.22) -0.39 (-0.54 to -0.24) +0.01 ( -0.13 to +0.16) 1.47** 1.61** 0.06 
NEFA (mmol.l-1) 0.02 ± 0.12 0.18 ± 0.06 0.17 ± 0.05 -0.17 (-0.36 to +0.03 -0.15 (-0.37 to +0.07) -0.02 (-0.10 to +0.07) 0.52 0.41 0.12 
Glucose (mmol.l-1) -0.10 ± 0.08 -0.35 ± 0.15 -0.19 ± 0.12 +0.26 (+0.02 to +0.49) +0.09 (-0.18 to +0.36) +0.17 (-0.22 to +0.56) 0.68** 0.21* 0.26 
First h glucose 
(mmol.l-1) 
1.11 ± 0.18 -0.29 ± 0.15 0.56 ± 0.21 +1.38 (+1.03 to +1.7) +0.54 (+0.01 to +1.05) +0.58 (+0.34 to +1.35) 2.47** 0.64* 1.04** 
Insulin (mU.l.1) 1.84 ± 2.47 -0.48 ± 0.67 2.28 ± 4.22 +2.32 (-3.36 to +8.00) -0.45 (-6.31 to +5.41) +2.76 (-5.70 to +11.2) 0.25 0.05 0.20 
First h insulin 
(mU.l-1) 
17.84 ± 5.76 2.34 ± 1.16 18.05 ± 8.69 +15.52 (+3.60 to +27.42) -0.19 (-11.06 to +10.62) +15.71 (-1.21 to +32.62) 0.81** 0.01 0.58** 
Values are the mean ± SEM, n=10; data were analysed using repeated measure ANOVA.* significant from the other group p<0.05, **p<0.005 
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5.3.2 Lipoprotein composition  
Triglyceride rich lipoprotein  
Table 5.3 shows the AUC (±SEM) values of TG concentration in chylomicron particles 
in the three trials. The pattern of TG IAUC in chylomicron was similar to TG IAUC in 
plasma (Figure 5.7). There was a significant difference between the three trials and 
the time points in each trial and the pattern of the change (all p<0.001). After food 
ingestion, within an hour the TG concentration started to rise similarly in both OFTT 
and COMB trials. The mean IAUC values of chylomicron-TG were significantly lower 
in OGTT (mean (95%CI) difference: -0.19 (-0.24 to -0.13, p<0.005)) compared with 
OFTT, giving a large Chen’s d effect size of 1.84, and in OGTT compared with COMB 
(mean (95%CI) difference: -0.13 (-0.05 to + 0.04, p<0.005)). However, there was no 
significant different between IAUC chylomicron-TG concentration in OFTT and COMB 
trials.  
 
The ingestion of carbohydrate alone and the co-ingestion of carbohydrate seem to 
increase the TG percentage in VLDL1 particles (Figure 5.7 panel A and Table 5.3). 
Whereas, if fat was ingested alone TG concentrations were significantly lower than 
OGTT and COMB trials respectively by 21% (+10.14 (0.04 to +20.33) giving a moderate 
Cohen’s effect size of 0.62 and by 21% (+10.23 (-0.63 to +21.09) giving a moderate 
Cohen’s effect size 0.58 (all p=0.03).  
The percentage of phospholipid was higher in OFTT trial when compared with OGTT 
and COMB trials. Phospholipid in OFTT trial was significantly higher by 19% from OGTT 
trial, giving a moderate Cohen’s d effect size of 0.55 (p=0.056) and 18% comparing 
OFTT with COMB trial, giving a moderate Cohen’s d effect size of 0.56 (p=0.06).  
VLDL1 particles incremental concentration seemed to increase by approximately 
double when fat alone was ingested (Figure 5.8 panel A). The co-ingestion of fat 
with carbohydrate and/ or ingestion of carbohydrate alone, reduced VLDL1 
concentrations by 45%, giving a large Cohen’s d effect size of 0.82 and 59%, giving a 
small Cohen’s d effect size of 0.42 respectively when compared with ingesting fat 
alone (Table 5.3). However, at 8 hours of meal ingestion, the concentration of VLDL1 
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in COMB trial decreased dramatically when compared with OGTT mass by 158% 
(p<0.05).  
There was no any significant difference in the percentage of FC, CE, protein and 
CE/TG ratio between the three meal types (see Table 5.3).  
 
The co-ingestion of fat with carbohydrate had a small influence on VLDL2 
composition. There was no significant different in the percentage TG, CE, FC, PL and 
protein between the three trials (see Table 5.4).  
There was a trend of reduction in VLDL2 concentration when fat alone ingested. In 
OFTT trial VLDL2 concentration was higher than OGTT trial by 67%, giving a moderate 
Cohen’s d effect size 0.43 and COMB trial by 69%, respectively.  
The CE/TG ratio was double in OFTT significantly comparing with OGTT and COMB 
and giving a small Cohen’s d effect size of 0.55 and 0.61 respectively (all p=0.05) 
(see Table 5.4 and Figure 5.8, panel B and Figure 5.10).  
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Figure 5.6. Change in chylomicron-TG response over the 480 minute observation period in the OGTT, OFTT and COMB trials. 
Values are mean ± SEM, N = 10; data were analysed using two ways ANOVA. Least significant differences post-hoc analysiss was used 
to identify where significant main effect lay aSignificantly different from glucose trial, bsignificantly different from fat trial, 
csignificantly different from combination trial, all (p<0.001). 
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Figure 5.7. Change in lipoprotein-TG response over the 480 minute observation period, panel [A] shows 
the change in VLDL1-TG and panel [B] the change in VLDL2-TG in the OGTT, OFTT and COMB trials. Values 
are mean ± SEM, n= 10; data were analysed using two ways ANOVA. Least significant differences post-hoc 
analysis was used to identify where significant main effect lay aSignificantly different from glucose trial, 
bsignificantly different from fat trial, csignificantly different from combination trial, all (p<0.05). 
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Figure 5.8. Change in lipoprotein concentration response over the 480 minute observation period, 
panel [A] shows the change in VLDL1 concentration and panels [B] the change in VLDL2 concentration in 
the OGTT, OFTT and COMB trials. Values are mean ± SEM, n= 10; data were analysed using two ways 
ANOVA. Least significant differences post-hoc analysis was used to identify where significant main effect 
lay aSignificantly different from glucose trial, bsignificantly different from fat trial, csignificantly 
different from combination trial, all (p<0.05). 
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Table 5.3; Time-averaged areas under the curve for chylomicron concentration and VLDL1 composition and concentration values over the 480-minute 
postprandial observation period in the OGTT, OFTT and COMB trials. 
 
 
Mean Value Mean difference Effect size 
OGTT OFTT COMB OGTT vs OFTT OGTT vs COMB OFTT vs COMB 
OGT
T vs 
OFTT 
OGTT 
vs 
COMB 
OFTT 
vs 
COMB 
Chylomicron TG 
(mmol.l-1) 
0.03 ± 0.01 0.22 ± 0.03 0.22 ± 0.03 -0.19 (-0.24 to -0.13) -0.19 (-0.05 to +0.04) 0.00 (+2.50 to +9.22) 2.15*
* 
2.30** 0.04 
IAUC total lipoprotein 
concentration (mg.dl-
1) 
5.94 ± 4.11 13.65 ± 4.18 6.18 ± 4.82 -7.71 (-8.29 to –1.91) -0.24 (-1.38 to +11.20) -7.47 (-8.58 to +3.58) 0.82 0.01 0.42 
Triglyceride (%) 58.56 ± 1.27 48.42 ± 4.97 58.65 ± 2.10 
 
+10.14 (+0.04 to +20.33) +0.24 ( -2.62 to +3.11) +10.23 (-0.63 to 
+21.09) 
0.62* 0.05 0.58* 
Free cholesterol (%) 
4.67 ± 0.67 5.41 ± 0.85 5.43 ± 0.28 -0.74 (-2.56 to +1.07) -0.76 (-1.77 to +0.25) +0.02 (-1.40 to +1.44) 0.25* 0.47 0.01 
Cholesteryl ester (%) 
11.11 ± 1.71 15.21 ± 4.11 10.96 ± 1.77 -4.11 (-13.03 to +4.81) +0.15 ( -1.67 to +1.96) -4.26 (-13.94 to +5.42) 0.29 0.05 0.27 
Phospholipid (%) 
15.11 ± 0.80 18.34 ± 1.78 15.43 ± 0.61 -3.23 (-6.84 to +0.38) -0.23 (-1.69 to +1.04) -2.91 (-6.16 to +0.34) 0.55 0.15 0.56* 
Protein (%) 10.55 ± 0.84 12.62 ± 2.72 9.53 ± 1.11 -2.06 (-7.22 to +3.10 +1.03 (-1.96 to +4.01) -3.09 (-7.15 to +0.98) 0.25 0.21 0.47 
CE/TG (mol:mol) 0.26 ± 0.04 0.67 ± 0.34 0.28 ± 0.06 -0.41 (-0.47 to +0.27) -0.04 (-0.02 to +0.04) +0.39 (+0.32 to+1.10) 
 
0.37 0.17 0.34 
Values for lipoprotein concentration is mean IAUC ± SEM, rest of the values are the mean ± SEM, n=10; data were analysed using repeated measure ANOVA.* 
significant from the other group p<0.05, **p<0.005. 
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Table 5.4; Time-averaged areas under the curve for VLDL2 composition and concentration values over the 480-minute postprandial observation period 
in the OGTT, OFTT and COMB trials. 
 Mean Value Mean different Effect Size 
 OGTT OFTT COMB OGTT vs. OFTT OGTT vs. COMB OFTT vs. COMB 
OGTT 
vs. 
OFTT 
OGTT 
vs. 
COMB 
OFTT 
vs. 
COMB 
IAUC total 
lipoprotein 
concentration 
(mg.dl-1) 
1.20 ± 2.55 5.03 ± 1.55 1.40 ± 3.46 -3.83 (-4.38 to +1.64) -0.20 (-0.98 to +7.55) -3.63 (-4.32 to +3.26) 0.43 0.02 0.33 
Triglyceride (%) 39.44 ± 2.80 33.24 ± 2.98 34.70 ± 3.54 +6.20 (-2.76 to +15.16) +4.74 (+0.45 to +9.04) +1.46 (-7.63 to +10.55) 0.43 0.68 0.10 
Free cholesterol 
(%) 
7.72 ± 0.87 8.40 ± 0.49 8.75 ± 0.62 -0.68 (-2.31 to +0.95) -1.03 (-2.16 to +0.09) +0.36 (-0.88 to +1.59) 0.26 0.57 0.18 
Cholesteryl ester 
(%) 
18.01 ± 1.60 17.31± 1.89 19.35 ± 2.14 +0.69 (-2.20 to +3.59) -1.34 (-5.08 to +2.39) +2.04 (-2.61 to +6.68) 0.15 0.22 0.27 
Phospholipid (%) 17.79 ± 1.63 20.45 ± 1.40 19.16 ± 1.07 -2.65 (-6.45 to +1.15) -1.37 (-3.24 to +0.50) -1.29 (-3.78 to +1.21) 0.43 0.45 0.32 
Protein (%) 17.03 ± 2.28 20.60 ± 5.93 18.04 ± 2.91 -3.57 (-15.49 to +8.35) -1.00 (-4.32 to +2.32) -2.57 (-13.02 to +7.89) 0.19 0.19 0.15 
CE/TG ratio 
(mol:mol) 
0.48 ± 0.07 1.11 ± 0.37 0.67 ± 0.11 -0.63 (-0.70 to +0.08) -0.19 (-0.21 to -0.01) +0.44 (-0.37 to +1.20) 0.55* 0.61* 0.36 
Values for lipoprotein concentration is mean IAUC ± SEM, rest of the values are the mean ± SEM, n=10; data were analysed using repeated measure ANOVA.* 
significant from the other group p<0.05, **p<0.005.  
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Cholesterol-rich lipoproteins  
Table 5.5 shows the AUC (±SEM) values of shows mean AUC (±SEM) of IDL percentage 
composition. The Carbohydrate ingestion led to enrich the particle with TG when 
compared to the two trials. However, the ratio of CE/TG did not differ significantly. 
Fat ingestion; lead the particle to have more phospholipids. There was no significant 
different in, CE, FC, protein and total lipoprotein mass (Figure 5.9, panel A and 
Figure 5.10). 
 
Table 5.6 shows mean AUC (±SEM) of LDL percentage composition. Ingesting 
carbohydrate alone increased TG concentration and reduced phospholipid 
concentration in LDL particles when compared with ingesting fat alone and/or co-
ingesting fat with carbohydrate. As shown in Table 5.6 TG concentration in OGTT 
trial was higher by 52% comparing with ingesting fat alone and/or the co-ingestion of 
both by 49% (all p=0.05).  
On the other hand, phospholipid was lower in OGTT trial by 12% and 9% comparing 
with both OFTT and COMB trials respectively, giving a moderate Cohen’s d effect size 
of 0.57 and 0.54 (p=0.3 and p=0.05) respectively. There was a trend of lower CE/TG 
ratio by 29% when carbohydrate alone was ingested comparing to ingesting fat alone, 
giving a moderate Cohen’s d effect size of 0.71. There was no significant different 
in, CE, FC, protein and total lipoprotein mass (Figure 5.9, panel B and Figure 5.10). 
The summary of lipoproteins result is shown in Figure 5.10, when carbohydrate was 
ingested alone or co-ingested with fat, both follow similar pattern on lipoprotein 
composition during 480 minutes of observation. Number of particles seem lower, 
however, they become more TG enrich.  
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Figure 5.9. Change in lipoprotein concentration response over the 480 minute observation period, 
panel [A] shows the change in IDL concentration and panel [B] shows the change in LDL concentration 
in the OGTT, OFTT and COMB trials. Values are mean ± SEM, n= 10; data were analysed using two ways 
ANOVA. Least significant differences post-hoc analysis was used to identify where significant main 
effect lay aSignificantly different from glucose trial, bsignificantly different from fat trial, csignificantly 
different from combination trial, all (p<0.05). 
[A] 
[B] 
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Table 5.5; Time-averaged areas under the curve for IDL composition and concentration values over the 480-minute postprandial observation period in 
the OGTT, OFTT and COMB trials. 
 Mean value  Mean different  Effect size 
 
OGTT OFTT COMB OGTT vs. OFTT OGTT vs. COMB OFTT vs. COMB 
OGTT 
vs. 
OFTT 
OGTT 
vs. 
COMB 
OFTT 
vs. 
COMB 
Total 
lipoprotein 
concentration 
(mg.dl-1) 
1.11 ± 2.30 1.74 ± 2.72 -2.64 ± 1.90 
-0.63 
 (-5.64 to +4.39) 
+3.75 
 (-2.53 to +10.03) 
-4.38 
 (-10.98 to +2.22) 
0.08 0.37 0.41 
Triglyceride 
(%) 
14.64 ± 2.66 10.42 ± 0.71 9.78 ± 0.97 
+4.22 
 (-0.20 to +8.63) 
+4.86  
(-0.09 to +9.81) 
-0.64 
 (-2.80 to +1.52) 
0.59* 0.61* 0.18 
Free 
cholesterol 
(%) 
13.31 ± 1.73 12.65 ± 0.67 12.31 ± 0.78 
+0.65  
(-2.51 to +3.18) 
+1.00  
(-2.53 to +4.52) 
0.34  
(-1.95 to +1.27) 
0.13 0.18 0.13 
Cholesteryl 
ester (%) 
32.13 ± 3.07 35.83 ± 2.46 36.92 ± 1.57 
-3.70 
(-9.45 to +2.05) 
-4.79  
(-11.86 to +2.27) 
+1.09  
(-5.22 to +7.40) 
0.40 0.42 0.11 
Phospholipid 
(%) 
21.81 ± 1.67 25.09 ± 0.60 22.87 ±0.69 
-3.27 
(-7.22 to +0.67) 
-1.05  
(-4.46 to +2.35) 
-2.22 
 (-3.95 to -0.49) 
0.51* 0.19 0.80* 
Protein (%) 18.15 ± 2.13 16.06 ± 1.86 18.12 ± 2.34 
+2.09 
 (-1.43 to +5.61) 
+0.04 
 (-5.53 to +5.60) 
+2.05  
(-3.48 to +7.58) 
0.37 0.00 0.23 
CE/TG ratio 
(mol:mol) 
4.21 ± 0.87 5.05 ± 0.67 5.77 ± 0.78 
-0.84 
 (-0.98 to +0.56) 
-1.56 
 (-1.78 to +0.68) 
-0.72 
(-0.90 to +1.11) 
0.37 0.43 0.24 
Values for lipoprotein concentration is mean IAUC ± SEM, rest of the values are the mean ± SEM, n=10; data were analysed using repeated measure ANOVA.* 
significant from the other group p<0.05, **p<0.005. 
Table 5.6; Time-averaged areas under the curve for LDL composition and concentration values over the 480-minute postprandial observation period 
in the OGTT, OFTT and COMB trials. 
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 Mean value  Mean different  Effect size 
 OGTT OFTT COMB OGTT vs. OFTT OGTT vs. COMB OFTT vs. COMB 
OGTT 
vs. 
OFTT 
OGTT 
vs. 
COMB 
OFTT 
vs. 
COMB 
Total 
lipoprotein 
concentration 
(mg.dl-1) 
9.73 ± 9.22 9.31 ±7.70 8.21 ± 4.44 
+0.41 
 (-26.72 to +27.55) 
+1.52  
(-20.40 to +21.05) 
-1.10  
(-19.01 to +16.80) 
0.02 0.01 0.04 
Triglyceride 
(%) 8.29 ± 2.11 4.65 ± 0.32 4.83 ± 0.37 
+3.73 
 (+0.10 to +7.36) 
+3.46  
(+0.41 to +7.32) 
+0.27 
 (-0.40 to +0.95) 
0.64* 0.55* 0.40 
Free 
cholesteryl (%) 10.64 ± 2.28 10.72 ± 0.63 11.08 ± 0.55 
-0.08 
 (-4.40 to +4.24) 
-0.44  
(-4.99 to +4.12) 
+0.35  
(-1.13 to +1.84) 
0.01 0.0.06 0.15 
Cholesterol 
ester (%) 35.74 ± 1.81 37.19 ± 1.22 37.62 ±1.39 
-1.45  
(-5.48 to +2.59) 
-1.88  
(-6.20 to +2.44) 
+0.44  
(-2.93 to +3.80) 
0.22 0.27 0.08 
Phospholipid 
(%) 19.23 ± 0.93 21.59 ± 0.69 20.99 ± 0.36 
-2.36 
 (-4.94 to +0.23) 
-1.76 
 (-3.77 to +0.26) 
-0.60 
 (-1.87 to +0.67) 
0.57* 0.54* 0.29 
Protein (%) 
26.09 ± 1.43 25.94 ± 1.77 25.47 ± 1.48 
+0.15  
(-3.22 το +3.52) 
+0.62 
 (-3,20 το 4.43) 
-0.47 
 (-3.86 to +2.93) 
0.03 0.10 0.08 
CE/TG ratio 
(mol:mol)  9.12 ± 1.56 11.81 ± 11.02 11.31 ± 1.07 
-2.69  
(-2.92 to -0.33) 
-2.19 
 (-2.49 to +0.85) 
+0.50 
 (+0.31 to +2.45) 
0.71 0.45 0.16 
Values for lipoprotein concentration is mean IAUC ± SEM, rest of the values are the mean ± SEM, n=10; data were analysed using repeated measure ANOVA.* 
significant from the other group p<0.05, **p<0.005. 
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Figure 5.10. Differences between lipoprotein compositions in the three trials, lay aSignificantly 
different from glucose trial, bsignificantly different from fat trial, csignificantly different from 
combination trial, p<0.005. Protein, phospholipid (PL) and free-cholesterol (FC) comprise the outer 
coat of the lipoprotein; triglyceride (TG) and cholesteryl-ester (CE) comprise the lipoprotein core. 
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5.4 Discussion  
The goal of this study was to address the effect of ingesting fat and carbohydrate 
separately and in combination on postprandial responses. The results of the 
experiments appear are in line with existing literature (Wilson et al., 1985, Pedersen 
et al., 1999, Knuth et al., 2008, Collier and O'Dea, 1983).  
 
Glycaemic Response  
It is well established that glucose intake increases plasma insulin (Elrick et al., 1964, 
Stumvoll et al., 2000). The finding of the current study with glucose ingestion is in 
line with this finding. Hyperglycaemia is a major contributor to endothelial damage 
providing a link between CVD and T2D (Ceriello, 2004).In contrast OFTT meal led to 
a low glycaemic and insulinemic response, in line with previously observations 
(Riccardi et al., 2004, Havel, 1957a).                                                                                                                                                                      
 
In the current study, adding equal amounts of fat and carbohydrate (75 grams each) 
reduced the glycaemic response compared to carbohydrate ingestion alone. 
However, this response will be influenced by the amounts of fat and / or 
carbohydrate consumed, for example, in studies in which 8–24 g fat was fed in mixed 
meals containing 38–104 g carbohydrate, the added fat had little effect on the 
glycaemic response (Wolever and Bolognesi, 1996a). It has been observed that an 
intake of 15 g of fat has no influence on postprandial lipaemia and lipoproteins in 
healthy adults (Dubois et al., 1998). The current data shows that the COMB meal 
significantly reduced the glucose response, compared to carbohydrate ingestion 
alone, particularly during the first hour after meal ingestion. This is as has  observed 
previously (Collier et al., 1984, Collier and O'Dea, 1983, Collier et al., 1988). The 
most likely explanation for these results is that fat slows gastric emptying (Thomas, 
1957, Gentilcore et al., 2006, Heddle et al., 1989, Phillips et al., 2015) Gastric 
emptying is an important determinant of rate of glucose appearance and blood 
glucose homeostasis in healthy and diabetic populations (Horowitz et al., 1993). This 
is mediated by gut hormones such as gastric inhibitory polypeptide and glucagon-like 
peptide-1 (GLP-1) (Rocca and Brubaker, 1995, Herrmann et al., 1995, Feltrin et al., 
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2004). The reduction of the rate of glucose absorption after the consumption of the 
mixture of carbohydrate with fat will attenuate glycaemic and insulinaemic responses 
(Gannon et al., 1988, Pi-Sunyer, 2002) and reduce the postprandial rise in some 
hormones such as incretins, and insulin (Jenkins et al., 2002, Ludwig, 2002). The 
prolonged absorption of carbohydrate seen over time will maintain suppression of the 
free fatty acids and the counter regulatory responses, resulting in slower 
carbohydrate entry into the small intestine, while at the same time achieving lower 
blood glucose concentrations (Jenkins et al., 1990, Jenkins et al., 1988, Wolever et 
al., 1988, Ludwig et al., 1999). However, COMB meal did not lower the insulin AUC 
significantly and this has been observed previously (Collier et al., 1984, Collier and 
O'Dea, 1983, Collier et al., 1988). This is might be due to the type of dietary fat in 
particular saturated fatty acid which also affects insulin sensitivity, independently of 
its effects on body weight (Jenkins et al., 1978, Mayer et al., 1993), while 
monounsaturated and polyunsaturated fatty acids improve it through modifications 
in the composition of cell membranes (Chen et al., 1988, Swinburn et al., 1991, 
Lovejoy et al., 1998, Parillo et al., 1992, Bhaswant et al., 2015). In addition, we used 
glucose as a source of carbohydrate and it is well established that type of 
carbohydrate influences insulin levels (Augustin et al., 2002, Jenkins et al., 2008). 
Although we cannot exclude the possibility that fat ingestion may alter the hepatic 
extraction of insulin, the simplest explanation would invoke the potentiation of 
insulin secretion by the co-ingestion of fat (Collier et al., 1984, Estrich et al., 1967). 
Generally, the impact of carbohydrates on blood glucose is affected by the type of 
carbohydrate, the food form, type and amount of dietary fibre (Guillon and Champ, 
2000, Eastwood and Morris, 1992, Granfeldt et al., 2008), the presence of other 
nutrients.  
 
Lipaemic response  
 
Despite the insulin response being similar in the glucose and combined trials, effects 
on NEFA suppression differed markedly. There was a substantial initial suppression of 
NEFA in the glucose trial which was markedly attenuated when glucose and fat were 
co-ingested. As it has been well established that the ingestion of carbohydrate 
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stimulates insulin release, which suppresses the release of NEFA from adipose tissue 
and stimulates fat storage (Sadur and Eckel, 1982, Coppack et al., 1990). However, 
TG concentrations did not change when OGTT meal was consumed. As carbohydrate 
has no influence on plasma TG concentrations.  
 
In the OFTT meal, there was a significant postprandial increase in TG concentrations, 
in line with previous research which has shown that fat content influences plasma TG 
concentrations (Cohen and Berger, 1990, van Tol et al., 1998). The amount of fat 
required to significantly elevate plasma TG concentration is in the order of 30–50 g. 
Some studies have been performed with increasing doses of dietary fat (Cohen et al., 
1988, Dubois et al., 1994, Murphy et al., 1995, Dubois et al., 1998). In these studies 
a very low dose (5 g) or low dose (15 g) of dietary fat does not significantly increase 
TG concentration  postprandially; moderate doses (30–50 g) dose-dependently 
increase postprandial triglyceridemia; and finally, very high doses (80 g and above) 
exaggerate postprandial triglyceridemia.  
The co-ingestion of carbohydrate with fat did not influence the postprandial plasma 
TG response in the present study. Many studies reported that the addition of 
carbohydrate to a fat meal did not influence the lipaemic response after meal 
ingestion (Cohen et al., 1988, Nicholls and Cohen, 1985, van Oostrom et al., 2004) 
but this finding is not universal. On the other hand, other studies report that the 
addition of carbohydrate to a fat meal reduces the post-prandial TG response to the 
ingested fat compared with a fat meal alone (Albrink et al., 1958, Cohen and Berger, 
1990, Westphal et al., 2002, Westphal et al., 2004). This has been linked to effect of 
carbohydrate in the delay the appearance of ingested lipid as a result of a change in 
gastric osmolarity (Cohen and Berger, 1990, Hunt, 1961, Westphal et al., 2002, Vist 
and Maughan, 1995, Jenkins et al., 1984). It has been found that the rate of gastric 
empting is reduced roughly 50% when carbohydrate is added to a fat meal (Westphal 
et al., 2002). However, our findings disagree with this result. This is might be due to 
the hepatic VLDL and chylomicron remnants accumulation due to altered lipoprotein 
secretion and/or clearance (Parks et al., 1999, Abbasi et al., 2000). As the current 
data show, chylomicron-TG concentrations were similar when fat ingested alone 
and/or when it was combined with carbohydrate. And as we mentioned above, insulin 
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response did not differ when fat was added to carbohydrate which affected LPL 
secretion and activity. Insulin has a role in the activity of adipose tissue LPL (Nilsson-
Ehle et al., 1975, Sadur and Eckel, 1982, Sadur et al., 1984). 
It is been observed that postprandial lipaemia is influenced by the amount and type 
of dietary fat present in the meal, as well as other dietary components including 
fibre, glucose, starch, and alcohol (Cohen and Berger, 1990, van Tol et al., 1998). It 
has been reported that the intake of long-chain omega(n) – 3 polyunsaturated fatty 
acids (PUFAs) (predominantly fish oil), results in lower TG levels and attenuates 
postprandial lipaemia (Tinker et al., 1999). 
Lipoproteins  
TG concentration was mostly constant over the course of the OGTT trial and this 
might be because there was no competition between chylomicron and VLDL1 particles 
to be cleared by the action of LPL (Karpe et al., 1992). This also is similar to the 
pattern of plasma TG and agrees with the findings of others (Lewis et al., 1993b, 
Lewis et al., 1993a, Vogelberg et al., 1980). 
 
In OFTT and COMB meal the response of chylomicron and VLDL TG paralleled that of 
total TG; maximum increases occurred 4 h after intake of the meals, a finding that 
was also observed by others (Karpe et al., 1995, Cohen et al., 1988). The addition of 
carbohydrate to fat did influence the composition of VLDL1 (Figure 5.10). When 
carbohydrate ingested with fat or when it was ingested alone, VLDL1 concentrations 
were lower than when fat was ingested alone, and this might be due the accumulation 
of VLDL1 particles and increase in the clearance of very rich TG-chylomicrons. 
Alternatively, it might be due to low insulin concentration and high circulating NEFA 
concentration which stimulate the production of VLDL particles (Lewis et al., 1994, 
Lewis et al., 1995). Also, it has been suggested that the increase in the influx of 
exogenous TRL into plasma will inhibit the clearance from plasma of TRL of 
endogenous origin, whereas an increase in the secretion of TRL of endogenous origin 
will inhibit the removal from plasma of newly absorbed TRL of exogenous origin 
(Schneeman et al., 1993). However, TG concentrations were higher in both trials 
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significantly when compared with fat ingestion alone. A trend of lower protein 
content in VLDL1 was observed. This would be linked to the number of particles and 
suggest that consuming carbohydrate with fat contributes to lower particle number, 
but more TG-rich particles. Lipolysis of VLDL1 has been shown to give rise to LDL 
particles in the density range that have a prolonged residence time (approx. 5 days), 
compared with LDL derived from smaller VLDL or intermediate-density lipoprotein 
precursors (which has a residence time of approx. 2 days) (Packard, 2003, Julius et 
al., 2007, Gazi et al., 2005). The newly formed LDL particles have sufficient time to 
be remodelled by the action of CETP, LDL will lose CE and gain TG. When this 
remodelling of LDL particles occurs to a significant degree, then it is postulated that 
the next exposure of the triacylglycerol-enriched LDL to HL will lead to the removal 
of enough TG to promote a shift in particle size into the small, dense range (Packard, 
2003, Julius et al., 2007, Gazi et al., 2005). This sdLDL are the most readily oxidized 
subfraction among lipoprotein classes (Tribble et al., 1994, Julius et al., 2007) which 
increase its atherogenic potential.  
 
In contrast, VLDL2 particles seem not to respond to any factors neither diet nor 
exercise as shown in this study and the study in Chapter 4. However, there was a 
trend of higher concentration of VLDL2 when fat alone was ingested, following the 
same pattern of VLDL1 particles. This mean more VLDL1 and VLDL2 were accumulated 
in the circulation when fat alone was ingested.  
 
When consuming carbohydrate alone, IDL tended to have more TG and less 
phospholipids when compared to co-ingestion or fat ingestion and this is similar to 
VLDL1 pattern during the trials.  
 
In the COMB trial IDL concentrations on the plasma were reduced, consistent with 
the lower concentrations of VLDL1 particles recorded in this trial. Also, this suggests 
a faster catabolism of VLDL1 particles due to the insulin-induced LPL activity (Nilsson-
Ehle et al., 1975, Sadur et al., 1984, Sadur and Eckel, 1982).  
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Concentration of LDL particles did not differ between the three trials. However, 
compositions differed. Ingesting carbohydrate alone increased the percentage of TG 
and lowered the percentage CE in LDL particles when compared to ingesting fat alone 
and/ or the co-ingestion of both. This might be an adverse consequence as smaller 
more cholesterol rich LDL particle sizes are statistically correlated with other risk 
factors for coronary artery disease (Rosenson et al., 2002, Lamarche et al., 2008). 
Because LDL particle size is inversely related to plasma TG concentration, it is 
important to address if whether elevations in plasma TG induced by adding 
carbohydrate to fat is associated with reductions in LDL particle size (Dreon et al., 
1994, Dreon et al., 1999). Also, its influence, the prevalence of LDL subclass pattern 
B, a categorical marker for atherogenic dyslipidemia defined by the predominance of 
sdLDL, has been linearly and positively associated with increasing concentrations of 
dietary CHOs in randomized controlled clinical trials (RCTs) (Schwingshackl and 
Hoffmann, 2013, Bueno et al., 2013, Krauss et al., 2006).  
However, one of the limitations in the study is that, it was not possible to determine 
rates of production and removal of lipoprotein particles; this would require a kinetic 
study. We didn’t measure CETP in plasma, which promotes the triacylglycerol 
enrichment of HDL with concomitant cholesteryl ester accumulation in VLDLs 
(Dullaart et al., 1989, Mann et al., 1991). We also did not measure the activity of 
LPL. Moreover, the types of ingested fatty acid have a different influence on 
lipoprotein composition. It has been shown that, the long term of ingesting specific 
fatty acids classes can affect serum total, LDL, and HDL cholesterol concentrations 
and TG concentrations (Mensink and Katan, 1992, Mensink et al., 2003). The type of 
fatty acid that ingested in the current study was principally saturated and further 
study is needed evaluate the effects of co-ingestion of different types of fatty acids 
with carbohydrate.  
 
The meal we provide contained 2.3 g of protein, which is a low amount. The existence 
of protein in diet might influence plasma lipid postprandially. High protein diets 
appear to have beneficial effects on weight loss, body composition, and certain blood 
lipids, at least in the short term (Hession et al., 2009). Satiating effects of dietary 
protein, a reduced choice of foods, and an aversion against dietary fat in the absence 
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of carbohydrates have all been attributed to better weight loss with high protein 
diets (Weickert et al., 2005). However, there is limited data on the amount of protein 
that can influence postprandial response (Lopez-Miranda et al., 2007). Previous 
studies suggest that adding fat and protein to carbohydrate reduces glycaemic 
responses nonlinearly, with the glycaemic impact reaching a plateau as more and 
more protein and fat are added (Owen and Wolever, 2003, Moghaddam et al., 2006, 
Spiller et al., 1987). It has been observed that ingesting 47 g of soya protein led to 
lower cholesterol in plasma and LDL particles and plasma TG (Anderson et al., 1995). 
Another study found that consuming 20 g of soya protein for 3 weeks rescued plasma 
remnant like (Higashi et al., 2001). Further investigation should be focused on the 
effect of ingesting protein alone or with other macronutrients on postprandial 
metabolism.  
 
The challenges that accompany scientific research in this area result in an inability 
to conclusively determine the most effective macronutrient compositions required 
for the reduction of CVD risk. The co-ingestion of both carbohydrate and fat seems 
to reduce glycaemic response, however, ingesting fat contributes to weight gain in 
the long term (Lissner and Heitmann, 1995, McMorrow et al., 2016, Hall et al., 2015, 
Purnell et al., 1999, Visscher and Seidell, 2001, Seidell, 1998, Bray and Popkin, 1998).  
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6 A pilot study to determine the effect of 
ethnicity on postprandial metabolism: a 
comparison between men of European and 
Middle-Eastern origin  
6.1 Introduction  
Cardiovascular disease is major cause of morbidity and mortality worldwide, and its 
incidence is increasing in developing countries, including those in the Middle East, 
such as Afghanistan, Turkey, Iran, Iraq, Lebanon, Gulf countries, and Palestine (Bovet 
et al., 2006). Indeed, approximately 80% of the CVD mortality worldwide occurs in 
developing countries (Sibai et al., 2010) These numbers are expected to continue to 
rise over coming years and CVD is also more likely to occur in younger ages in 
developing countries (Bovet et al., 2006). On the other hand, in the Western countries 
where the disease first had its epidemic, there is now a decline in CVD because of 
major public health efforts (Mensah et al., 2017, Mendis, 2017).  
 
The pattern of increasing disease burden in the developing countries is not only the 
case for CVD, but other risk factors and metabolic diseases. For example, in Middle 
East, overall prevalence of diabetes amongst adults aged 18-80 years is 22% in men 
and 19% in women (Shara, 2010), and over the last 3 decades obesity in some regions 
of the Middle East has tripled (Shara, 2010). The Middle East is now facing an 
epidemic of diabetes and obesity, with prevalence of type 2 diabetes amongst the 
highest in the world. 
 
Changes in lifestyle factors, including changes to eating habits to more closely 
resemble Western societies, smoking, urbanization and technological advances and 
reduced physical activity during work and leisure are likely to contribute to the 
increases in cardio-metabolic disease in the Middle East (Al‐Kandari, 2006). While 
modifiable lifestyle-related factors are likely to underpin these disease increases 
(Jamrozik et al., 2001), it is possible that the extent to which these factors influence 
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disease risk is influenced by unmodifiable risk factors such as age, sex and ethnic 
background.  
 
There is evidence of ethnic differences in postprandial responses to meal ingestion 
which could potentially contribute to the observed ethnic differences in cardio-
metabolic disease risk (Mohan et al., 1986, Raji et al., 2001). For example, young 
adults of Vietnamese, south Asian and Chinese origin displayed marked postprandial 
hyperglycaemia and hyperinsulinemia compared with age-matched Caucasian 
subjects (Dickinson et al., 2002). Furthermore, in South Asians, the glycaemic 
response was greater than in Northern Europeans and Latin Americans, although there 
were no differences in postprandial TG concentrations or in insulin sensitivity as 
assessed with the insulin tolerance test (Cruz et al., 2001a, McKeigue et al., 1991). 
Remnant-like particle cholesterol levels in Japanese subjects have consistently been 
reported to be lower than those in Caucasians (Twickler et al., 2004). Black 
populations, are more insulin resistant than white Europeans and have higher glucose 
and insulin responses to glucose ingestion (Healy et al., 2015, Ziemer et al., 2010, 
Osei et al., 1992).  
 
However, there are limited data on the metabolic responses of Middle Eastern 
populations, who are a group with high population burden of cardio-metabolic 
disease. Therefore, this experimental chapter is a pilot study to examine the 
differences in postprandial metabolic responses between Middle Eastern and 
European adults.  
 
6.2 Participants and Methods 
6.2.1 Participants  
The data of 16 men (8 Middle Eastern and 8 Europeans) were collected from the 
previous experimental Chapter 4 and 5, their characterizations are listed in Table 
6.1. All subjects were apparently healthy, normotensive, normoglycaemic (fasting 
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glucose ≤ 6 mmol.l-1), nonsmokers. None was taking any drugs known to affect lipid 
or carbohydrate metabolism. The study was conducted with the approval of 
University of Glasgow Ethics Committee, and subjects gave written informed consent 
prior to participation. 
 
6.2.2 Test meals  
Seven participants had the high fat mixed meal (HFM) meal (containing 75 g fat and 
77.4 g carbohydrate) described in section 2.5.1 and 9 participants had the COMB 
meal (containing 92.4 g fat and 86.3 g carbohydrate) described in section 2.5.4 (see 
table 6.1). Test meal was included as a co-variate in statistical analyses and shown 
not to have a significant effect on any of the postprandial responses. 
 
6.2.3  Blood sampling 
Subjects reported to the lab on the morning after fasting for at least 12h. A cannula 
was placed in an antecubital vein and, after a 10-min interval, a fasted state blood 
sample was withdrawn. A test meal, as described above in Section 6.2.2., was 
provided. Further blood samples were obtained at 30, 60, 90, 120 and 240 minutes 
after meal consumption. Subjects rested and consumed only water during this time.  
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Table 6.1; Physical characteristics 
 Meal 
AGE 
(years) 
Height 
(M) 
Body 
Mass (Kg) 
BMI 
(kg.m-2) 
Waist 
(cm) 
Hip (cm) WHR 
% body 
fat 
European 
HFM 37.00 1.91 101.90 27.93 102.00 107.00 0.95 23.31 
HFM 24.00 1.68 77.20 27.29 85.00 95.10 0.89 16.79 
HFM 34.00 1.69 75.40 26.28 94.05 99.45 0.95 26.27 
HFM 49.00 1.71 81.00 27.67 101.00 103.00 0.98 25.55 
COMB 32.00 1.85 86.35 25.07 88.81 102.10 0.87 24.74 
COMB 31.00 1.75 83.00 27.10 79.85 98.45 0.81 25.93 
COMB 25.00 1.84 83.10 24.52 95.00 102.00 0.93 15.09 
COMB 35.00 1.85 86.00 25.13 81.15 102.70 0.79 21.57 
Mean  33.38 1.79 84.24 26.37 90.86 101.23 0.90 22.41 
SD  7.80 0.09 8.11 1.32 8.52 3.55 0.07 4.30 
Middle Eastern 
HFM 55.0 1.8 89.60 28.83 101.60 103.50 0.98 33.00 
HFM 31.0 1.7 81.00 27.38 102.00 98.00 1.04 27.00 
HFM 35.0 1.8 83.00 27.10 95.50 102.00 0.94 25.93 
COMB 32.0 1.7 101.30 33.54 102.00 111.00 0.94 28.48 
COMB 35.0 2.0 90.00 22.96 74.00 98.00 0.76 10.56 
COMB 29.0 1.8 104.00 32.82 109.50 119.30 0.92 26.46 
COMB 29.0 1.9 94.00 27.47 95.50 100.00 0.96 27.00 
COMB 25.0 1.8 82.00 24.49 78.00 98.00 0.80 11.35 
Mean  33.88 1.80 90.61 28.07 94.76 103.73 0.91 23.73 
SD  9.16 0.08 8.71 3.66 12.44 7.66 0.09 8.16 
p-value (EU vs ME) 0.91 0.74 0.15 0.24 0.48 0.42 0.71 0.69 
 Values are means (SD), EU = European, ME = Middle Eastern. N= 8 European and 8 Middle eastern.  
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6.2.4 Plasma assays 
Serum, TG and NEFA and plasma glucose concentrations were analysed at all-time 
points as previously mentioned in Appendix C. Total, HDL cholesterol and sdLDL 
concentrations were measured in the fasted state as mentioned in Appendix C. LDL 
cholesterol was calculated in the fasted state using the Friedewald equation 
(Friedewald et al., 1972). Insulin was measured in EDTA plasma, as described in 
section 2.6.3, HOMA-IR was calculated as described in section 2.6.4. 
 
6.2.5 Lipoprotein separation 
Plasma samples (2 ml) at 0, 1, 2 and 4 hours were centrifuged using 
ultracentrifugation technique to isolate lipoprotein subfractions as previously 
described in section 2.6.2. VLDL1 and VLDL2 fractions were assayed to determine 
concentrations and composition for TG, free cholesterol (FC) and phospholipids, as 
mention in Appendix C Cholesterol Easter was determined as described in section. 
Chylomicron fractions were assayed for TG concentration. In the VLDL1 and VLDL2 
fractions, total protein was measured using a modified Lowry assay (see section 2.7).  
 
6.2.6 Calculations and statistical analysis 
Statistical analyses were performed using Statistica (version 10, StatSoft Inc.) and 
Minitab (version 17, Minitab Ltd). All data were tested for normality using the 
Anderson-Darling test. Where data did not approximate a normal distribution, these 
were log-transformed prior to analysis. Time-averaged postprandial concentrations, 
calculated as the trapezium rule-derived areas under concentration versus time 
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curve, divided by the duration of the postprandial observation period (240 minutes), 
were used as summary measures of the postprandial responses. Postprandial 
concentrations at individual timepoints between the two ethnic groups were 
compared by repeated measures ANOVA, with adjustment for BMI, age and test meal 
(HFM vs COMB). Post hoc Fisher tests were carried out to establish where differences 
lay. When displayed graphically SEMs were used as error bars. Unpaired T-tests were 
used to calculate differences in the area under the curve and the incremental area 
under the curve for postprandial responses. Statistical significance was set at p<0.05. 
Cohen’s d effect size was calculated by dividing the mean difference between the 
two groups by the stander deviation pool of both groups. Percentages of TG and CE 
were relative to total mass.TG to CE ratio in lipoprotein fractions was calculated as: 
TG/CE. 
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6.3 Results  
6.3.1 Fasting plasma concentration 
Table 6.2. shows fasting plasma concentrations for both groups. European had higher 
fasting TG concentration than Middle Eastern by 40% (p = 0.05), with a large Cohen’s 
d effect size for this difference of 0.96. There were no significant differences in total 
cholesterol, HDL, sdLDL, NEFA, glucose or insulin concentrations. However, although 
the differences did not achieve statistical significant fasting insulin concentrations 
and HOMA-IR were both ~4 fold higher in the Middle Eastern compared with the 
European adults, with medium Cohen’s d effect sizes of 0.71 and 0.68 respectively.  
Table 6.2; Fasting Plasma Values. 
 
European 
(n = 8) 
Middle 
Eastern 
(n = 8) 
Mean 
difference 
Effect 
size 
P-
value 
Total cholesterol (mmol.l-1) 5.13 ± 0.36 4.91 ± 0.36 +0.23 0.23 0.66 
HDL (mmol.l-1) 1.20 ± 0.09 1.35 ± 0.17 -0.15 0.39 0.46 
SdLDL (mg.dl-1) 35.56 ± 6.58 28.50 ± 5.03 +7.06 0.43 0.41 
Triglyceride (mmol.l-1) 1.32 ± 0.17 0.88 ± 0.12 +0.44 0.96 0.05 
NEFA (mmol.l-1) 0.75 ± 0.06 0.79 ± 0.08 -0.04 0.22 0.68 
Glucose (mmol.l-1) 5.00 ± 0.19 5.11 ± 0.18 -0.10 0.20 0.70 
Insulin (mU.l-1) 5.81 ± 0.76 22.16 ± 11.07 -16.36 0.71  0.16 
Log-Insulin (mU.l-1)* 1.70 ± 0.14 2.39 ± 0.44 -0.69 0.72 0.16 
HOMA-IR (units)+ 1.30 ± 0.20 5.07 ± 2.70 -3.77 0.68 0.19 
Values are means ± SEM, *log transformed values, +Homeostasis Model Assessment. . Statistical analysis 
performed using unpaired t-test. 
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6.3.2 Postprandial concentrations 
Table 6.3 shows the summary postprandial responses for the two ethnic groups. 
Europeans had higher TG AUC by 42%; this had borderline statistical significance 
(p=0.057) and a large Cohen’s d effect size. Figure 6.1 shows these responses 
graphically; TG concentrations were significantly higher in Europeans at both the 2 
and 4 hour postprandial timepoints. A similar pattern was observed when considering 
the IAUC and postprandial rises in TG concentration (i.e. adjusting for the difference 
in the fasting TG concentration). The TG IAUC was 62% higher in the Europeans, this 
difference was not statistically significant (p = 0.13), but the Cohen’s d effect size, 
at 0.77 was moderate to large. The rise in postprandial TG concentration above 
fasting was significantly higher in the Europeans than the Middle Eastern participants 
at 2 and 4 hour postprandial timepoints (see Figure 6.1). The different between the 
two groups is clear at 2 and 4 hours postprandially. At 2 and 4 hours postprandially 
TG concentrations differ between the two groups significantly, as European shows 
higher TG response by 42% and a large Cohn d effect size 0.92 (p=0.01) and 50% with 
a large Cohen d effect size of 0.94 from Middle Eastern (p=0.001) respectively. The 
same trend was observed in the incremental area under the curve at 2 and 4 hours, 
European TG was 46% higher (p=0.03) to give a medium Cohen’s d effect size 0.76 at 
2 hours postprandially and 60% higher at 4 hours postprandially (p=0.005) and an 
effect size of 0.82 (Figure 6.1 panel B).  
  
There was no significant different in AUC and IAUC for log-transformed glucose, log-
transformed insulin or NEFA (Table 6.3, Figure 6.2 panel A and B, Figure 6.3 panel 
A and B and Figure 6.4 panel A and B). However, both glucose and insulin 
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concentrations were different significantly in single time points between the two 
groups. Plasma glucose values at 60 and 90 minutes after meal ingestion were lower 
in European by 24% giving a large effect size of 0.90 (p=0.001) and 29% with a large 
effect size of 0.85 (p=0.05) respectively when compared with Middle Eastern. Also, 
incremental plasma glucose values at 60 and 90 minutes after meal ingestion were 
lower in European by 188% (p=0.005) and 27% (p=0.05) and to give a large Cohen’s d 
effect size of 0.91 and 0.94 respectively comparing with Middle Eastern (Figure 6.2 
panel B). 
Similarly insulin values were significantly lower in European compared with 
Middle Eastern, at 90 and 120 minutes was higher by 128% and 88% 
respectively compared with European (p=0.02,p=0.05) giving a Cohen’s d 
effect size of 0.94 and 0.66 respectively. IAUC was higher in Middle Eastern 
at 90 minutes by 129% compared with European (p=0.005) with a large 
Cohen’s d effect size 0.88 (see Figure 6.3 panel B).
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Table 6.3; Time-Averaged and incremental postprandial plasma Concentration. 
 
   
 
 
AUC 
 
European  
(n= 8) 
Middle eastern 
(n=8) 
Mean difference Effect size P-value 
Triglyceride (mmol.l-1) 2.07 ± 0.27 1.35 ± 0.22 +0.73  0.94 0.057 
NEFA (mmol.l-1) 0.80 ± 0.08 0.81 ± 0.08 -0.01 0.05 0.92 
Log-Glucose ( mmol.l-1)* 1.59 ± 0.04 1.71 ± 0.06 -0.12  0.83 0.10 
Log-Insulin (mU.l-1)* 2.98 ± 0.15 3.54 ± 0.42 -0.56 0.61 0.24 
IAUC 
Triglyceride (mmol.l-1) 0.76 ± 0.14 0.47 ± 0.11 +0.29  0.77 0.13 
NEFA (mmol.l-1) 0.05 ± 0.05 0.04 ± 0.07 +0.01  0.05 0.92 
Glucose (mmol.l-1) 0.06 ± 0.14 0.51 ± 0.25 -0.57 0.90 0.07 
Insulin (mU.l-1) 15.69 ± 3.84 37.83 ± 16.58 -22.14  0.64 0.21 
Values are mean time-averaged postprandial concentration ± SEM, and mean incremental rise in postprandial state ± SEM, N= 8 European and 
8 Middle eastern.*log-transformed data. Statistical analysis performed using unpaired t-test.  
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Figure 6.1. Plasma-TG concentrations during 4 h observation period in both groups; European and Middle Eastern. Panel [A] shows the mean values 
for TG concentrations; panel [B] shows the incremental time-averaged area under the curve for plasma TG, N= 8 European and 8 Middle eastern, Values are mean 
± SEM. * significant values from the other group (p< 0.005), ** (p≤0.05). Values and statistical analysis of these data is shown in Table 6.3. 
[A] Mean postprandial plasma TG 
[A] Mean postprandial plasma glucose [B] Incremental time-averaged plasma glucose  
[B] Incremental time-averaged plasma TG  
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Figure 6.2.Plasma-glucose concentrations during 4 h observation period in both groups; European and Middle Eastern. Panel [A] shows the 
mean values for glucose concentrations; panel [B] shows the incremental time-averaged area under the curve for plasma glucose. N= 8 European 
and 8 Middle eastern, Values are mean ± SEM. * significant values from the other group (p< 0.005),** (p≤0.05). Values and statistical analysis of 
these data is shown in Table 6.3. 
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[A] Mean postprandial plasma insulin [B] Incremental time-averaged plasma insulin 
Figure 6.3 . Plasma-insulin concentrations during 4 h observation period in both groups; European and Middle Eastern. Panel [A] shows the 
mean values for insulin concentrations; panel [B] shows the incremental time-averaged area under the curve for plasma insulin. N= 8 European 
and 8 Middle eastern, Values are mean ± SEM. * significant values from the other group (p< 0.005),** (p≤0.05). Values and statistical analysis of 
these data is shown in Table 6.3. 
 
 
 
6 A pilot study to determine the effect of ethnicity on postprandial metabolism: a comparison between men of European and Middle-Eastern origin  
212 
Khloud Jamil Ghafouri ® 2017  
 
 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0 60 120 180 240
N
E
F
A
 (
m
m
o
l.
l-
1
)
Time (min)
Figure 6.4. Plasma-NEFA concentrations during 4 h observation period in both groups; European and Middle Eastern. Panel [A] shows the mean 
values for NEFA concentrations; panel [B] shows the incremental time-averaged area under the curve for plasma NEFA. N= 8 European and 8 Middle 
eastern, Values are mean ± SEM. * significant values from the other group (p = 0.005). Values and statistical analysis of these data is shown in Table 
6.3.  
 
 
[B] Incremental time-averaged plasma NEFA  
 
-0.3
-0.2
-0.1
0.0
0.1
0.2
0.3
0.4
0 60 120 180 240
C
h
a
n
g
e
 i
n
 N
E
F
A
 (
m
m
o
l.
l-
1
)
Time (min)
ME
EU
[A] Mean postprandial plasma NEFA  
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6.3.3 Lipoprotein subfractions  
Fasted Lipoprotein concentrations  
Fasted VLDL1 and VLDL2 composition show in Table 6.4. VLDL1 concentrations were 
significantly higher in European by 72% when compared with Middle Eastern 
(p<0.005), giving a large Cohen’s d effect size of 0.96 for this difference (Figure 6.5 
panel A). There were no other significant differences in VLDL1 and VLDL2 percentage 
of TG, FC, EC, PL, protein or the ratio of TG/CE.  
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Table 6.4; Fasted values for VLDL1 and VLDL2 composition. 
 
 
 
European 
(n=8) 
Middle eastern 
(n=8) 
Mean 
difference 
Effect size p-value 
VLDL1 Total lipoprotein concentration (mg.dl
-1) 72.04 ± 15.80 33.55 ± 8.47 +38.49  0.96 0.05 
 Triglyceride (%) 60.03 ± 1.84 58.99 ± 2.77 +1.04  0.16 0.76 
 Free cholesteryl (%) 7.03 ± 1.17 5.51 ± 0.82 +1.52  0.53 0.31 
 Cholesterol ester (%) 9.03 ± 2.08 9.28 ± 1.55 -0.25  0.05 0.92 
 Phospholipid (%) 15.12 ± 1.07 14.47 ± 1.30 +0.56  0.20 0.71 
 Protein (%) 8.78 ± 1.29 11.73 ± 2.65 -2.95 0.50 0.33 
 CE/TG ratio (mol:mol) 0.21 ± 0.05 0.23 ± 0.06 -0.02  0.12 0.82 
 
VLDL2 
Total lipoprotein concentration (mg.dl-1) 41.20 ± 8.39 32.33 ± 9.42 +8.87  0.33 0.52 
 Triglyceride (%) 34.32 ± 3.82 33.23 ± 4.27 +1.09  0.10 0.85 
 Free cholesteryl (%) 9.66 ± 0.71 8.79 ± 0.70 +0.87 0.44 0.40 
 Cholesterol ester (%) 22.33 ± 2.18 22.45 ± 2.95 -0.12 0.02 0.97 
 Phospholipid (%) 19.99 ± 1.35 18.83 ± 1.82 +1.15 0.26 0.62 
 Protein (%) 13.70 ± 2.77 16.70 ± 3.43 -2.99 0.35 0.51 
 CE/TG ratio (mol:mol) 1.42 ± 0.36 1.45 ± 0.30 -0.02 0.03 0.96 
Values are mean ± SEM. 
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Postprandial lipoprotein concentrations  
Table 6.5 shows chylomicron, VLDL1 and VLDL2 concentration in the postprandial 
state.  
There was no significant different in the postprandial chylomicron-TG concentration 
(Table 6.5 and Figure 6.5).  
VLDL1 concentration AUC tends to be higher in Europeans when compared with Middle 
Eastern by 52% (p=0.09), giving a large effect size of 0.84. The concentration of VLDL1 
at 2 and 4 hours postprandially rose significantly among European by 58% and giving 
a large effect size of 0.93 and 42% giving a medium effect size of 0.66, (p<0.005 for 
both) respectively. (Figure 6.5 panel A). There was no significant different in VLDL1 
concentration IAUC (Figure 6.5 panel B). 
VLDL2 concentration at 2 hours postprandially was significantly higher among 
European by 43% and giving a medium effect size of 0.75 (p<0.005). (Figure 6.7, panel 
A and B). 
There were no significant differences between the two groups in the postprandial 
AUC or IAUC for both VLDL1 and VLDL2 percentage of TG, FC, EC, PL, protein or the 
ratio of TG/CE. (Table 6.5).  
 
6 A pilot study to determine the effect of ethnicity on postprandial metabolism: a comparison between men of European and Middle-Eastern origin  
216 
Khloud Jamil Ghafouri ® 2017  
Table 6.5; Time-averaged area under the curve for VLDL1 and VLDL2 composition. 
 
 
 
European 
(n=8) 
Middle eastern 
(n=8) 
Mean difference Effect size p-value 
Chlyomicron Triglyceride (mmol.l-1)* 1.17 ± 0.27 1.53 ± 0.20 +0.36 0.54 0.30 
VLDL1 Total lipoprotein concentration (mg.dl
-1) 90.42 ± 16.15 53.00 ± 13.20 +37.43  0.84 0.09 
 Triglyceride (%) 61.18 ± 1.52 60.92 ± 1.85 +0.25  0.05 0.92 
 Free cholesteryl (%) 5.74 ± 0.43 5.09 ± 0.52 +0.56  0.49 0.35 
 Cholesterol ester (%) 9.43 ± 0.91 9.60 ± 1.67 -0.17  0.04 0.93 
 Phospholipid (%) 15.42 ± 1.02 15.33 ± 1.03 +0.09  0.03 0.95 
 Protein (%) 8.23 ± 1.07 9.06 ± 1.18 -0.83  0.41 0.61 
 CE/TG ratio (mol:mol) 0.22 ± 0.03 0.27 ± 0.09 -0.05  0.31 0.55 
 
VLDL2 
Total lipoprotein concentration (mg.dl-1) 42.25 ± 7.24 28.97 ± 5.95 +13.28  0.69 0.18 
 Triglyceride (%) 37.23 ± 4.05 33.19 ± 3.41 +4.04  0.39 0.46 
 Free cholesteryl (%) 8.35 ± 0.48 8.59 ± 0.55 -0.24  0.17 0.75 
 Cholesterol ester (%) 21.05 ± 2.49 21.70 ± 2.72 -0.65  0.09 0.86 
 Phospholipid (%) 19.22 ± 1.38 18.95 ± 1.78 +0.27  0.06 0.91 
 Protein (%) 14.14 ± 2.73 17.56 ± 2.87 -3.42 0.43 0.40 
 CE/TG ratio (mol:mol) 1.41 ± 0.58 1.15 ± 0.32 +0.25 0.20 0.71 
Values are AUC mean ± SEM, CM=chylomicron. *log-transformed data.  
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Figure 6.5. Chylomicron concentrations during 4 h observation period in both groups; European and Middle Eastern. Panel [A] shows the mean 
values for chylomicron concentrations ; panel [B] shows the incremental time-averaged area under the curve for chylomicron concentrations. N= 8 
European and 8 Middle eastern, Values are mean ± SEM. * significant values from the other group (p< 0.005). Values and statistical analysis of these 
data is shown in Table 6.5. 
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Figure 6.6. VLDL1 concentrations during 4 h observation period in both groups; European and Middle Eastern. Panel [A] shows the mean 
values for VLDL1 concentrations; panel [B] shows the incremental time-averaged area under the curve for VLDL1 concentrations. N= 8 European and 8 Middle 
eastern, Values are mean ± SEM. *significant values from the other group (p< 0.005),** (p≤0.05). Values and statistical analysis of these data is shown in 
Table 6.5. 
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Figure 6.7. VLDL2 concentrations during 4 h observation period in o in both groups; European and Middle Eastern. Panel [A] shows the 
mean values for VLDL2 concentrations; panel [B] shows the incremental time-averaged area under the curve for VLDL2 concentrations. N= 8 
European and 8 Middle eastern, Values are mean ± SEM. *significant values from the other group (p< 0.005),** (p≤0.05). Values and statistical 
analysis of these data is shown in Table 6.5. 
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6.4 Discussion 
The main objective of the present study was to verify whether differences in the 
postprandial response to a fat challenge between Middle Eastern and European. 
To provide enough subjects in this exploratory analysis two test meals were 
included, COMB from Chapter 5 and the high fat meal from Chapter 4. Both 
contained approximately the same amount of fat although this was presented in 
a different format. The nature of the test meal was included as a potentially 
confounding variable in the statistical analysis. 
 
 The main findings of this study were that in matched age and BMI over weight 
European and Middle Eastern men, consuming a mixed test meal the Europeans 
had higher TG response whereas the Middle Eastern men had the higher insulin 
response. This profile of the Middle Eastern postprandial response seems to be 
broadly comparable to what has been observed when comparing Black with White 
adults (Osei and Schuster, 1994, Kodama et al., 2013). Black adults also have lower 
TG responses and higher insulin responses than White Europeans (Sumner and 
Cowie, 2008, Ford et al., 2002). This is interesting because the higher TG levels 
in plasma are usually thought to be indicative of insulin resistance (Axelsen et al., 
1999, Grundy, 1999, HÖlzl et al., 1998, Lovejoy et al., 1996, Albu et al., 1997, 
Schmidt et al., 1996). A cursory comparison of CVD risk factors in the UK shows 
striking similarities between African Caribbeans and South Asians, with an 
increased risk of glucose intolerance and diabetes, and raised fasting and post-
load insulin, indicating a greater degree of insulin resistance (Chaturvedi et al., 
1993). However, VLDL, small dense LDL, and triglyceride concentrations are 
substantially lower in African Caribbeans than in Europeans, and the latter does 
not increase to the same extent in the presence of glucose intolerance (Chaturvedi 
et al., 1994). In contrast South Asian who have an increased risks of heart disease 
compared to Europeans, probably because of increased levels of insulin resistance 
and associated factors such as inflammation and endothelial dysfunction 
(Chaturvedi, 2003). 
 
In the current study fasted TG concentrations were different and therefore, the 
postprandial response would be expected to follow the same pattern. It is well 
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established that, fasting levels of plasma TG tend to be correlated with the 
magnitude of postprandial lipaemic response (Cohn et al., 1988b). This can be 
observed in the current study, the lower fasted TG in Middle Eastern men probably 
led to a lower postprandial response. However, the chylomicron concentrations 
postprandially shows that there was no significant different between the two 
groups and the exact difference is specific to endogenous TG. It has been observed 
that lean African American women have lower TG response after ingesting high 
fat meal, comparing with lean Caucasian women this is may be partly due to 
enhanced expression, activity, and intravascular availability of LPL (Bower et al., 
2002). However, the ethnic differences in expression and function of LPL are 
attenuated with obesity (Bower et al., 2002). Friday and colleagues studied the 
postprandial response of black and white young men and they found that the black 
men have lower TG response comparing with whites and this is due to the higher 
LPL activity (Friday et al., 1999). In the Caucasian population, there is 
considerable variability in insulin resistance at given levels of body fat content. 
This variability might be because they tend to secrete a relatively large proportion 
of their VLDL as small, triglyceride-poor particles, levels of which are not 
augmented in response to loss of insulin action (Godsland et al., 2007). Another 
possible mechanism might be due to an increase of the capacity of TG clearance 
from circulation that is most likely due to a higher LPL activity and LPL mass in 
adipose tissue, which has been observed previously in Caucasian women compared 
with African American (Bower et al., 2002). This more efficient lipid-clearing 
system may help to maintain a more favourable lipid profile and lipoprotein 
subpopulation distribution. Also, it has been found that, the favourable lipid 
profile of black compared to white South African women is associated with 
polymorphisms in lipid metabolism genes, specifically the LPL and CETP genes 
(Ellman et al., 2015).  
 
Ethnic differences in postprandial glycaemia have been reported previously 
between Chinese and Europeans (Dickinson et al., 2002), Caucasians and non-
Caucasians (Wolever et al., 2009), and Europeans compared with a group of Asians 
of mixed origin (Schmidt et al., 1996). 
Despite there were no significant differences between the two groups in fasted 
and postprandial insulin and glucose concentrations, there was a trend of higher 
insulin and glucose concentrations and HOMA-IR (the Cohen’s d effect size was 
6 A pilot study to determine the effect of ethnicity on postprandial metabolism: a comparison 
between men of European and Middle-Eastern origin  
222 
Khloud Jamil Ghafouri ® 2017  
mostly medium) and this is due to the lack of power of the study. The findings 
suggest that reduced insulin sensitivity and impaired carbohydrate tolerance 
might lead to the development of some metabolic syndrome. Chronic postprandial 
hyperglycemia and/or hyperinsulinemia may therefore be the only phenotypic 
evidence of reduced insulin sensitivity for many years. Abnormalities in fat 
deposition and blood lipids characteristic of the IR syndrome may develop as a 
consequence of postprandial hyperglycaemia or hyperinsulinemia. Excessive 
glycaemia and/or insulin demand on a chronic basis may eventually affect insulin 
secretory capacity and precipitate T2D. Obesity, particularly visceral adiposity, is 
associated with insulin resistance and often assumed to be causative. The higher 
concentrations of fatty acids resulting from higher fat intake or higher visceral or 
intramuscular fat, inhibit carbohydrate oxidation and thereby produce insulin 
resistance the present study, however, there was no significant different between 
the two groups neither in the fat percentage, waist/hip ratio nor BMI. There was 
no evidence to suggest that there were differences in body fat that might explain 
our findings. BMI, waist circumference and WHR, did not differ among groups. 
However, we cannot exclude the possibility that a more precise measurement of 
body fat using dual X-ray absorptiometry or nuclear magnetic resonance may have 
shown differences among the ethnic groups. 
 
Regarding the cholesterol measurements, there was no significant different 
between the two groups in the fasting plasma total, LDL and HDL cholesterol, 
which is in agreement clinical data showing that Middle Eastern adults tend to 
have fasting plasma cholesterol level ~5.2 mmo.l-1 – comparable with values in the 
White UK population. However, the age range in those studies was different then 
the age range in the current study and there is limited data about the participant 
BMI (Al-Nozha et al., 2008, Al-Lawati et al., 2003, Zindah et al., 2008).  
 
However, the similar pattern of Middle Eastern to black ethnic group, the Middle 
Eastern seems to have higher incidence of CVD as 45% of early deaths in the Gulf 
countries are caused by CVD, whereas black have lower CVD incidence comparing 
with white ethnic groups (Manolio et al., 1995, Keil et al., 1993). This high 
incidence of CVD in the Middle Eastern population may be due to the high 
prevalence of obesity (13% for men and 24.5% for women), diabetes mellitus 
(11.3%), and smoking (48.04% among men and 13.8% among women) (International 
6 A pilot study to determine the effect of ethnicity on postprandial metabolism: a comparison 
between men of European and Middle-Eastern origin  
223 
Khloud Jamil Ghafouri ® 2017  
Obesity Task Force 2012, Khattab et al., 2012) in this region. Currently, CVD has 
emerged as one of the leading causes of death in this population (Tailakh et al., 
2014). With one of the highest rates of obesity in the world, the Gulf region is 
facing an epidemic of cardiovascular diseases. At least 50% of the population is 
below the age of 25 and the high prevalence of risk factors signal a massive 
onslaught of cardiovascular diseases in the next 10-15 years. As obesity, unhealthy 
diet, and high blood pressure have caused increases in the burden of CVD in the 
Middle East and North Africa (Zubaid et al., 2011). Cardiovascular diseases cause 
45% of early deaths in the Gulf region. Around 30% of men and 44% of women in 
Saudi Arabia are obese and one-quarter of adults have diabetes (Zubaid et al., 
2011, Alhyas et al., 2011). Although CVD and its risk factors are among the leading 
cause of death in many Middle East and East Mediterranean countries, very little 
is known about inter-ethnic differences in prevalence of risk factors, treatment 
response and survival. Ethno-cultural differences are known to be associated with 
cultural practices as well with lifestyles changes that might be related to different 
patterns of morbidity and mortality. The regions are home to various ethnic groups 
such as Arabs, Persians, Bedowins South Asian and European.  
  
The limitations of our study must be considered. The number of subjects studied 
is small and this means they may not be representative of the general population. 
Also this limited statistical power to detect significant differences between 
groups, although using Cohen’s d effect sizes helps to provide a handle on whether 
non-significant differences (due to lack of power) are likely to be physiologically 
relevant. In addition, it will be useful if we were able to measure post heparin 
LPL to detect any ethnic differences among the two groups.  
 
Despite these limitations, few studies have documented a difference in the 
glycaemic response, and this might help to explain the high prevalence of diabetes 
in the Middle East and North Africa (Whiting et al., 2011).  
 
In summary, results of the present study indicate that the more favourable 
lipoprotein profile found in over weight individuals Middle Eastern men and a trend 
of higher insulin response. Further studies are needed to explore these ethnic 
differences in more detail.
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7 General Discussion 
7.1 Summary 
CVD is a major cause of death (WHO, 2014a). Alterations in lipid metabolism 
underlie atherosclerotic cardiovascular disease (Stegemann et al., 2014). Plasma 
TG concentrations consider as an independent risk factor in fasted (Hokanson and 
Austin, 1996) and postprandial state (Stampfer et al., 1996, Karpe, 1999). 
Hypertriglyceridemia is a prevalent risk factor for CVD and increasingly important 
in the setting of current obesity and insulin resistance epidemics. Recent data add 
confidence to the conclusion that TG levels appear to provide unique information 
as a biomarker of CVD risk because of their association with atherogenic 
lipoproteins and apolipoproteins, especially apo C-III (Luo and Peng, 2016). 
Accumulating evidence suggests that non-HDL-C, which combines the cholesterol 
levels found in LDL-C and TG-rich lipoproteins are an independent risk factor for 
atherosclerosis. Very low-density lipoprotein is the most atherogenic TRL 
particles, and the measurement of VLDL-C is relatively straightforward and 
captures distinct aspects of the TRL and plasma TG (Jialal and Devaraj, 2002). A 
large cross-sectional study (Penn Diabetes Heart Study (PDHS)) found that higher 
VLDL-C levels were associated with increasing coronary artery calcification after 
adjusting for numerous traditional CV risk factors in patients with type 2 diabetes 
(Prenner et al., 2014). Elevated TRL levels are associated with increased risks of 
CVD. VLDLs are the major component and atherogenic particles of TRL in the 
circulation (Takeichi et al., 1999, Kugiyama et al., 1999). A PDHS study that 
examined VLDL-C as an alternative marker of TRL demonstrated that VLDL-C levels 
are positively associated with increased coronary artery calcification in patients 
with type 2 diabetes even after adjusting for traditional risk factors (Prenner et 
al., 2014). Also, it has been reported that higher VLDL-C levels are associated with 
an increased risk of CVD in diabetic patients (Laakso et al., 1994). Several 
mechanisms have been proposed to explain why VLDL may be causally related to 
progression of atherosclerosis and CVD. VLDL is synthesized in the liver and serves 
as a vehicle that is responsible for the redistribution of triglycerides from liver to 
the peripheral tissues. Each VLDL particle contains a single molecule of 
apolipoprotein B100 and has a hydrophobic core that consists primarily of 
triglycerides and a small amount of cholesterol esters (Niu and Evans, 2011, 
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McEneny et al., 2000). The sizes of the VLDL particles vary depending on the 
quantity of triglycerides carried in the particle. Large VLDL particles are secreted 
from patients with hypertriglyceridemia and may contain 5 to 20 times more 
cholesterol than LDL. Unlike LDL, VLDL remnants rapidly penetrate the arterial 
wall, increase endothelial inflammation and facilitate the infiltration of 
monocytes, which results in foam cell formation and atherosclerosis (Nakamura et 
al., 2005, Nakajima et al., 2006). Hepatic VLDL overproduction has been reported 
to be related to insulin resistance (Sparks et al., 2012). It has been observed that 
in patients with metabolic syndrome or type 2 diabetes, insulin-resistant states 
and the loss of insulin-mediated suppression of apoB100 secretion lead to 
increased production of large VLDL1 particles (Gill et al., 2004b, Adiels et al., 
2006). Hypersecretion of large VLDL1 particles, which contain more cholesterol, 
results in higher levels of remnant particles and small dense LDLs and lower levels 
of HDL that may contribute to the progression of vascular endothelial injury and 
atherosclerosis (Chen et al., 2012, Gianturco and Bradley, 1999).  
 To avoid the atherogenic cascade, TRL remnants must be cleared from plasma 
and metabolized by the liver before endothelial accumulation occurs. However, 
hypertriglyceridaemic states are associated with increased VLDL production and 
delayed VLDL clearance from circulation (Ooi et al., 2008, Zheng et al., 2010). In 
addition, delayed clearance of all apo-B lipoproteins, including VLDL, has been 
attributed to different mechanisms such as apo C-III–mediated inhibition of apoE 
and apoB-100 binding to hepatic receptors and proteoglycan; reduced activity of 
LPL, hepatic TG lipase; and finally, reduced apoE and apo E to C-III ratio reflecting 
reduced ability of the lipoproteins to be taken up by the liver . Similarly, CMs are 
taken up by the liver via LDL receptors or LDL receptor–related proteins and unless 
their TG core is removed they are not considered atherogenic due to their very 
large size, which slows entry into the arterial intima. It is the resulting CM 
remnants that are atherogenic, presumably because they are sufficiently small to 
pass through the endothelial cell barrier to the arterial intima (Gianturco et al., 
1998). Hepatic lipase also plays a role in remnant removal (Cooper, 1997b) and its 
deficiency is associated with reduced TRL remnant clearance. 
Lowering TRL has clearly been associated with benefit (Panel, 2002). Aside from 
lifestyle changes, further treatment with lipid-lowering drugs, such as statins, 
fibrates, nicotinic acid, or omega-3 fatty acids, may be warranted and should be 
considered to help achieve TRL targets in patients with hypertriglyceridemia. The 
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efficacies of pharmacologic interventions on TG level reduction vary depending 
on the agent used and the pre-treatment TG levels. Most cardiovascular 
diseases risks can be prevented by addressing behavioural risk factors such as 
tobacco use, unhealthy diet and obesity, physical inactivity. Table 7.1. shows the 
influence of behavioural changes on plasma TG. Treating obesity which is always 
linked to hypertriglyceridemia, could led to around 20% reductions on plasma TG, 
this reduction would be grater if individuals become physically active.  
Diet modification also lowers plasma TG by 10-15%. The quality of fatty acids 
enhances plasma TG to a greater extends (Talayero and Sacks, 2011).  
  
Table 7.1; Effects of lifestyle practices and lipid-lowering therapies on TG level reduction 
(Talayero and Sacks, 2011).   
Therapeutic intervention  % TG reduction  
Behavioural Risks  
Weight loss (5% to 10% total body weight)  20%  
Diet  10-15%  
Aerobic exercise (dependent on baseline TG levels)  
    TG level > 1.69 mmol.l-1  
    Coupled with weight loss  
15-20%  
  
20-30%  
Omega-3 PUFAs (dose dependent)  
  Per every 1-g PUFA  
   High-dose PUFA (3–4 g/d)  
  
5-10%  
25-30%  
  
In over this thesis we examined the effect of two behavioural change; diet and 
exercise and ethnicity on postprandial metabolism.   
Studies observed a reduction of TG concentration prior exercise by ~ 20-25% (Gill, 
2004, Gill et al., 2003, Malkova and Gill, 2006) and this reduction seems due to 
the increased clearance from the circulation of VLDL1 (Al-Shayji et al., 2012). 
The exact mechanism behind the increase of the clearance rate of 
VLDL1 was not clear.  
Thus, after developing a method to measure the affinity of TRL for LPL-mediated 
hydrolysis in Chapter 3, in Chapter 4 the effects exercise on the affinity of TRL 
for LPL-mediated hydrolysis was assessed in 10 overweight/obese men. The 
results indicated that 90 minutes of prior moderate exercise increased the affinity 
of VLDL1 for TG hydrolysis by lipoprotein lipase by 2.2-fold in the fasted state (p 
= 0.02) and 2.6-fold in the postprandial state (p = 0.001), but did not significantly 
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alter the affinity of chylomicrons or VLDL2, this give an insight of a possible 
mechanism by which exercise can lower TG concentrations, and helps explain the 
observation that exercise appears to have a larger effect in lowering TG 
concentrations in VLDL1 than in chylomicrons and VLDL2 (Gill et al., 2006). 
Co-ingestion of fat and carbohydrate reduced the postprandial glucose response 
significantly by 20%, but not the insulin. Also, it has been observed a substantial 
initial suppression of NEFA in the glucose trial with was markedly attenuated when 
glucose and fat were co-ingested. These changes might be due to genetic 
differences as the participants in all the studies were from different background. 
Also, we found the co-ingestions of carbohydrate with fat significantly decrease 
on VLDL1 by 13% (p = 0.05). This can explain some of the possible mechanism 
behind the long-term changes happened from the ingestion of different diet 
component.  
  
In Chapter 6 the metabolic responses to consumption of a mixed meal was 
assessed in eight white European men and eight men of Middle-Eastern origin. 
Postprandial insulin responses were higher in the Middle-Eastern men but, in 
contrast, postprandial TG concentrations were higher in the European men. Thus, 
the Middle Eastern metabolic response pattern is similar to the metabolic response 
of Black ethnic groups (Osei and Schuster, 1994). This knowledge can potentially 
help inform future strategies to mitigate metabolic disease risk in Middle Eastern 
populations by potentially considering interventions which have been effective in 
populations of Black ethnic origin and further research is needed to establish 
whether Middle Eastern groups share other metabolic risk characteristics with 
Black populations.   
  
In all studies, Cohen’s d effect sizes were used to provide additional insight into 
the likely physiological relevance of any differences observed which provides 
insights beyond whether an observation differs significantly between conditions 
(Cohen, 2013). While a P value can inform about the probability of a difference of 
the magnitude observed occurring in the absence of a true difference in the 
underlying population, it provides no information about the size of the 
effect. With a large enough study clinically trivial differences could be statistically 
significant. Conversely, for variables with large variability, it is possible to miss 
potentially clinically relevant findings, which may have been statistically 
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significant with a larger sample size, by simply considering statistical significance 
at the conventional threshold of p < 0.05. This was particularly relevant 
in Chapter 5, where some variables did not differ significantly between the two 
ethnic groups, but large effect sizes were seen.   
7.2 Limitation of the studies  
As with any scientific study there were limitations to the research undertaken in 
this thesis and it is important to acknowledge these. One of the limitations of the 
method we used to measure the affinity of TRL for LPL (Chapter 4) is the large 
amount of blood we were using which was an obstruction to take postprandial 
blood samples beyond 4 hours. It is possible that some individuals experienced 
peak TG concentrations after 4 hours, so this would have been missed in the 
experimental design. However, concentrations of TG were substantially higher at 
4 hours postprandially compared with the fasted state and chylomicron 
concentrations were high at this point. Importantly, the effects of exercise on the 
affinity of VLDL1 for LPL-mediated TG hydrolysis were similar in the fasted and 
postprandial states, so it does seem likely that this may not have been a major 
concern. The trial was time consuming; sample processing and analysis required a 
full week of laboratory work after each study day with participants. This, and 
other logistic factors, limited the scope to undertake further measurements which 
may have helped to provide an even more complete picture of the effects of 
exercise on postprandial lipoprotein metabolism. For logistic reasons including the 
large amount of blood was withdrawn it was not possible to undertake a kinetic 
study in parallel to also determine the rate of production and clearance of TRL 
species. This would have enabled correlation of the extent to which change in 
affinity of lipoprotein particles for LPL-mediated TG hydrolysis paralleled any 
differences in rates of lipoprotein clearance. It was also not possible to measure 
the post-heparin LPL activity for two main reasons. The first was the need for 
clinical cover during heparin injections which was not available for these studies. 
The second was that injection of heparin disturbs lipoprotein metabolism, thus to 
obtain a picture of the effects of exercise on LPL activity in the fasted as well as 
postprandial states, it would have been necessary for each participant to 
undertake the overall protocol twice – once with fasting measurements of LPL 
activity made in the presence and absence to exercise and a second time with LPL 
activity measurements made in the postprandial state. It was felt that this would 
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have induced too much burden of participants who were already undertaking a 
challenging research protocol. Again, this limited the potential to understand the 
extent to which any difference in TG clearance may have been mediated by 
altered lipoprotein affinity for LPL vs an increase in LPL activity. We also did not 
evaluate the effects of exercise on meals with different compositions of fatty 
acids which could conceivably influence the affinity of chylomicrons for LPL-
mediated TG hydrolysis.  
For the experiment in Chapter 5, the aim was to determine in principle the effects 
of fat and carbohydrate consumed separately or together on postprandial 
metabolism. To maximise the potential effects the meals used were extreme ones, 
with a very large fat intake (75g) and the carbohydrate consumed being all 
glucose. Thus does not fully reflect the actual meals that are consumed in the 
daily life. Thus the postprandial responses to meal ingestion in real life setting are 
likely to be less pronounced than the ones observed here. In addition, only one 
composition of fatty acids (high in SFA) was considered, and responses to different 
fatty acid compositions may be different. In terms of sample analysis, we didn’t 
measure apoB concentrations in lipoprotein particles and total, HDL and sdLDL in 
postprandial state.  
A key limitation in the study in Chapter 6 was that the small sample size may have 
limited our ability to detect more robust associations between ethnicity and 
differences in postprandial response. Larger studies are needed to confirm the 
findings that were observed. In addition, we did not ask the participant to follow 
unified controlled diet during the three days prior the trial, so differences 
between the two ethnic groups in habitual diet may have influenced the findings. 
However, there is no simple solution here as providing all participants with the 
same preceding diet may reflect a dietary intervention if this diet differs 
substantially from what participants usually eat. Some might argue the differences 
between the two groups in the baseline measurements lead to the different 
postprandial responses between the two groups. However, any difference in 
fasting measure would also reflect an ethnic difference and attempting to control 
for this may not be helpful. Participants were matched for age and BMI, thus also 
attempting to match for baseline metabolic characteristics may result in 
participants who are atypical for their given ethnicity. This has been shown in 
many studies comparing ethnic groups, measuring factors such as mineral ion 
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handling (Gutiérrez et al., 2010), glycaemic response (Venn et al., 2010, Likhari 
and Gama, 2009) and lipaemic response (Punyadeera et al., 2001, Sharrett et al., 
2001). For the postprandial response one of the factors might led to different 
response between the two groups is that two different meals consumed (however, 
there was no significant statistical differences between the different meals for 
any of the responses measured).  
For all studies, we hoped to measure many different metabolites using a nuclear 
magnetic resonance (NMR) platform – a novel technology which enables 
simultaneous detections of over 200 metabolites within a single small amount of 
blood (Ala-Korpela et al., 2012). This technique would have yielded further 
insights into the effects of exercise, dietary intake and ethnicity on postprandial 
responses, but unfortunately, these methods were not up and running in Glasgow 
within the timeframe needed for inclusion in this thesis.  
7.3 Future experiments  
Taken together, these studies provide new insights in the role of dietary intake, 
exercise and ethnicity on postprandial responses. This will increase our 
understanding in the changes that occur in the postprandial state. Going forward 
there are a number of factors we can consider with respect to study of exercise 
and lipoprotein metabolism; one factor that can be taken into consideration is 
evaluating the competition of the affinity between VLDL1 and chylomicron by 
incubating both particles in vivo assay. It is well established that chylomicron 
affinity for LPL-mediated hydrolysis is greater than VLDL1 affinity, which is in turn 
greater than VLDL2 affinity (Fisher et al., 1995). This can done by radiolabelling 
VLDL1 particles taken from exercise and non-exercised conditions co-incubating 
with chylomicrons and assessing their affinity for LPL-mediated TG hydrolysis 
under this competitive situation which more closely reflects in vivo physiology.  
Also, it would be helpful to perform a kinetic study in which VLDL is subdivided 
into more than the two standard subfractions to provide a clearer insight into how 
exercise may be influencing affinity of VLDL1 for clearance – for example by 
altering the size distribution of particles within the VLDL1 range. Although an 
increase of LPL activity does not always accompany the exercise-induced 
reductions in postprandial TG (Malkova et al., 1999, Herd et al., 2001, Miyashita 
and Tokuyama, 2008), past literature did report such changes in some cases while 
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not in other cases (Herd et al., 2001), it would be helpful to measure lipoprotein 
lipase activity in this same study to reach to a final conclusion. Also, investigating 
the lipaemic response to differing types of exercise in individuals who have or are 
at risk for developing metabolic disease, including female participants and 
individuals who are under the age of 18 years or over the age of 40 years, will 
broaden the understanding of exercise and the postprandial lipaemic response. 
 
It would be helpful to examine the effects of ingesting different ratios of fat and 
carbohyrate, and different qualities of fat and carbohyrate, with respect to fatty 
acid composition and glycaemic index on posptrandial metaboic responses. Here 
examining NMR metabolomic responses will provide a step-change in the ability to 
characterise the metabolic responses to fat and carbohydrate ingestion and the 
time-based nature of postprandial interactions between metabolites. Future 
research should aim to gain further understanding of exercise-nutrition 
interactions, such as peri-exercise carbohydrate availability which may help to 
refine interventions and future public health guidelines.  
 
Future research should focus on large enough samples to be able to evaluate 
genetic–lifestyle effects (Crook and Taylor, 2003), although this may be difficult 
to do with large enough samples, given the labour-intensive nature of these 
investigations.  
Comparison studies similar ethnic groups in different environments provide 
powerful epidemiological tools and thus further study could include studying 
individuals of Middle Eastern descent living in the Middle East and in the UK.  
More detailed measurements of lipoprotein metabolism as descirbed above (i.e. 
kinetic studies, LPL measurement, NMR metabolomic measuresments) will help 
provide further insights into differences between the Middle Eastern and European 
men, and of course, it is important to replicate these studies in women. Moreover, 
it will be interesting to determine the effect of exercise and dietary interventions 
on metabolic responses among this population. Giving what has been observed on 
experimental Chapter 6, it would be great to match the participants for their 
fasteing TG level and investgate the influnce of the ingestion of high fat meal on 
postprandial TG responses and TG-rich lipoprotein metabolism. 
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7.4 Conclusion 
In conclusion, this thesis has provided novel insights into understanding 
to lipid and carbohydrate metabolism in response to different factors. 
The first study showed that the affinity of VLDL1 increased to LPL 
enzyme post-exercise, which may explain, at least in part, the 
mechanism by which exercise reduces plasma TG. In addition fasting and 
postprandial sdLDL concentrating was significantly lowered post-
exercise. The second study aimed to investigate the metabolic responses 
to three different meal compositions (fat only, carbohydrate only and 
combination of equal amount of both). Although, the plasma TG 
concentrations were unexpectedly similar in fat and combination meal, 
the glycaemic response was significantly lower when fat and 
carbohydrate were ingested together. Finally the third study was a pilot 
study which investigated the ethnic differences between recruited 
Middle Eastern and recruited European in their metabolic response to a 
mixed meal. This study revealed potential differences in TG and glucose 
metabolism between the two ethnic groups, where fasting and 
postprandial TG were significantly higher European (almost double) than 
that of Middle Eastern. Although, there was no significant different in 
fasting glucose concentrations between the two ethnic groups, the 
postprandial response tented to be slightly higher in the Middle Eastern 
group. Interestingly, the insulin concentration was 3 and 4 times higher 
in fasted and postprandial states in Middle Eastern compared to 
European, although this it did not reach statistical significance, likely 
due to the relatively small sample size. Thus, taken together, the results 
of this thesis add to the basic science understanding of the effect of 
exercise, dietary intake and ethnicity on postprandial metabolism.
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9 Appendices  
Appendix A; Heath Screen Questionnaire 
–Chapter 4, 5 & 6 
 
HEALTH SCREEN FOR STUDY VOLUNTEERS 
 
Name: 
________________________________________________________________ 
 
It is important that volunteers participating in research studies are currently in 
good health and have had no significant medical problems in the past. This is to 
ensure (i) their own continuing well-being and (ii) to avoid the possibility of 
individual health issues confounding study outcomes. 
 
Please complete this brief questionnaire to confirm fitness to participate: 
 
1. At present, do you have any health problem for which you are: 
(a) on medication, prescribed or otherwise  yes [ ] no [ ] 
(b) attending your general practitioner   yes [ ] no [ ] 
(c) on a hospital waiting list    yes [ ] no [ ] 
2. In the past two years, have you had any illness which required you to: 
(a) consult your GP      yes [ ] no [ ] 
(b) attend a hospital outpatient department  yes [ ] no [ ] 
(c) be admitted to hospital     yes [ ] no [ ] 
3. Have you ever had any of the following: 
(a) Convulsions/epilepsy      yes [ ] no [ ] 
(b) Asthma       yes [ ] no [ ] 
(c) Diabetes       yes [ ] no [ ] 
(d) A blood disorder       yes [ ] no [ ] 
(e) Digestive problems     yes [ ] no [ ] 
(f) Disturbance of balance/co-ordination  yes [ ] no [ ] 
(g) Numbness in hands or feet    yes [ ] no [ ] 
(h) Disturbance of vision     yes [ ] no [ ] 
(i) Thyroid problems     yes [ ] no [ ] 
(j) Kidney or liver problems    yes [ ] no [ ] 
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(k) Chest pain or heart problems    yes [ ] no [ ] 
(l) Any other health problems    yes [ ] no [ ] 
4. Have any of your family (parents, grandparents, brothers, sisters, children, 
aunts, uncles, cousins) ever had any of the following: (if yes please give details 
including age of first diagnosis) 
(a) Any heart problems     yes [ ] no [ ] 
(b) Diabetes      yes [ ] no [ ] 
(c) Stroke      yes [ ] no [ ] 
(d) Any other family illnesses   yes [ ] no [ ] 
 
5. Do you currently smoke     yes [ ] no [ ] 
 Have you ever smoked    yes [ ] no [ ] 
  If so, for how long did you smoke and when did you stop?  
6. How many units of alcohol do you typically drink in a week? …………………. 
7. Have you taken part in a research study in the last 3 months?  yes [ ]
 no [ ] 
 
If YES to any question, please describe briefly if you wish (e.g. to confirm 
whether problem was short-lived, insignificant or well controlled.) (Use a 
separate sheet if necessary) 
…………………………………………………………………………………………………………………………………
…………………………………………………………………………………………..…………………………………… 
Blood pressure measured at screening…………………..mm Hg  
Blood Glucose measured at screening…………………..mmol.l-1  
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Appendix B1; Subjects Information Sheet 
and consent Form –Chapter 4 
 
 
 
VOLUNTEER INFORMATION SHEET 
 
Title: A Pilot Study to Determine the Effect of Exercise on the Affinity of 
Lipoprotein for lipoprotein Lipase 
Lay title: Effect of Exercise on Fats in the Blood 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss 
it with others if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish to take 
part. 
 
Thank you for reading this. 
What is the purpose of the study? 
Heart disease is the leading cause of death in Scotland. A high level of fat in the blood is an important risk factor. We know 
exercise reduces the level of fat in the blood, but we don’t know fully understand how it does this. Recent research from 
our lab suggested that mild exercise changes the nature of fat particles in the blood stream so that they are more easily 
cleared away. This study will help to increase understanding of how this happens. This is important as exercise could be 
used as a treatment option, rather than drugs, to prevent and treat disturbances in blood fat metabolism. 
 
Why have I been chosen? 
You have been chosen because you are a healthy man aged between 18-60 years, 
and you are heavier than the ideal weight for your height.  
 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide, you will be 
given this information sheet to keep and be asked to sign a consent form. If you 
do this you are still free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect 
the standard of care you receive. 
 
What will happen to me if I take part? 
In the first instance you will be asked to attend for a screening visit in which we will: 
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 discuss with you and complete confidential questionnaires regarding your 
health, family history and physical activity level 
 measure your blood pressure 
 take your height, weight and waist measurements 
 take a small blood samples to check the fat and sugar levels in your blood.  
 provide an opportunity for you to ask questions 
 
These preliminary procedures will enable us to determine whether you fall into 
the group of people we wish to study and will also ensure that it is perfectly safe 
for you to take part.  
 
Experimental procedures 
 
A. Preliminary Exercise Test 
At the beginning of the study, an exercise test will be undertaken. This will involve 
walking on a motorised treadmill. If you are not used to walking on a treadmill, 
we will familiarise you with this before any ‘real’ sessions are performed. The test 
is designed to estimate your body’s ability to use oxygen and enables us to find 
the correct speed and gradient for you to walk at during your treadmill walks. This 
will not require a maximal effort and the test will last for about 20 minutes. Heart 
rate will be monitored and recorded throughout using a heart rate monitor and 
expired air will be collected at intervals using a mouthpiece and respiratory valve. 
For safety reasons, the test will be stopped if your heart rate exceeds 85% of your 
predicted maximum. 
 
B. Body Composition  
The amount and distribution of your body fat will be determined by measuring body 
girths and by using callipers to measure skin fold thickness at four different sites (a 
sophisticated version of "pinch an inch"). Your height, weight and waist and hip 
circumferences will also be recorded. You will need to wear only underclothing for 
these measurements which will be made in private by an experienced researcher. 
These measurements only take a few minutes and can be made on the same day as 
other tests. 
 
C. Main Trials 
We will ask you to undertake two trials in random order. The first trial is a control 
with no exercise and the other is by performing a single exercise session. On the 
day prior the test, a controlled exercise session of 90-minute walk will be 
undertaken (Exercise test). Other than this, conditions (such as alcohol 
consumption, food eaten, etc) in the days leading up to each trial will be EXACTLY 
the same. On day 2 you will report to the lab after ~12 h fasting, a cannula will 
be inserted into an antecubital or forearm vein. No more than 120 ml 
(approximately 8 tablespoons) of blood will be taken in total during the course of 
this trial (less than quarter the volume of blood given in a blood donation) and a 
fatty meal will be provided as an oral fat tolerance test (OFTT). (Please refer to 
what do I have to do section). 
 
Control Trial (con): on day one you will be asked to stay at home without doing 
any exercise. On day 2 you will come to the Clinical Investigation Suite (or 
whatever it’s called) after approximately 12hours fasting overnight. After giving 
a blood sample we will provide you with a creamy milkshake and buttered 
croissant, we will have 4 more blood samples at 30 min, 0hr, 2hr and 4hr. You will 
9 Appendices  
 
321 
Khloud Jamil Ghafouri ® 2017  
remain fasting but we will provide you with plenty of water or low you are free to 
sit, read, relax, or watch TV during the entire observation. 
Exercise trial: 
This trial will be identical to the control trial except on the Day 1 you will visit 
the exercise laboratory in the evening and complete a treadmill walk at brisk force 
representing half of your maximum capacity.  
  
What do I have to do? 
We also ask you to maintain your usual lifestyle (i.e. don’t change your diet or 
exercise habits) for the duration of this study. However, before each trial, we ask 
you to do the following: 
1. For 3 days before each trial, refrain from planned or strenuous exercise, 
other than for personal transportation and the 90-minute treadmill walk in our 
laboratory. 
2. Weigh and record everything you eat and drink for 2 days before each test. 
We will provide you with weighing scales and diet sheets to do this.  
3. Refrain from alcohol consumption on the day before each test. 
4. For the 2 days leading up to the second test, we will ask you to eat the 
same diet as you did on the two days leading up to the first test. Therefore, we 
would advise you to eat meals that you will be able to easily repeat during the 
days preceding both tests.  
5. FASTING 
 
What are the possible disadvantages and risks of taking part? 
 Exercise testing will not be at a maximal level but the possibility exists that, 
very occasionally, certain changes may occur during or shortly after the tests. 
They include abnormal blood pressure, fainting or a change in the normal rhythm 
of the heartbeat. Reassure them that they will be looked after 
 Blood sampling via the cannula may cause minor bruising or an inflammation of 
the vein. Good practice, however, minimises this risk. Some people may feel faint 
when they give blood. 
 
What are the possible benefits of taking part? 
There may be no immediate benefits to you personally,but as a result of being 
involved in this study you will receive health and fitness information about 
yourself including fitness tests, dietary assessment, body fat measurement and 
your cholesterol and blood sugar levels. This study will help us to determine how 
exercise can improve risk factors for heart disease and diabetes. The findings will 
be published in scientific journals so that understanding of the way in which 
exercise decreases the risk of heart disease and diabetes can be increased. This 
information may help make up better exercise guidelines, particularly for people 
who are overweight or obese.  
 
We will provide you with feedback about the main study findings and also about 
your own results and would be delighted to explain results and discuss the 
implications with you. 
 
What if something goes wrong? 
The chances of something going wrong are extremely small. We have recently 
conducted a similar project and there were no problems. All of the procedures 
involved in this study are low risk and our screening tests are designed to ensure 
that you will only participate if it is safe for you to do so. In the unlikely event 
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that you are harmed due to someone's negligence, then you may have grounds for 
a legal action but you may have to pay for it.  
Ressurance again re experienced researchers 
 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will 
be kept strictly confidential. Any information about you which leaves the 
University or hospital will have your name and address removed so that you cannot 
be recognised from it. In addition, your records, samples and results will be 
identified by a number and not your name. where will it be stored? 
 
What will happen to the results of the research study? 
The results from this study will be presented at scientific meetings and published 
in scientific journals. A copy of the published results will be sent to you upon 
request. You will be informed which part of the study you were in, as this 
information will be confidential and no one else will know your name and which 
part you participated in. thesis? 
 
What will happen to my samples after the study has finished? 
The blood samples that you provide for this study may be useful for future research 
into the prevention and treatment of diabetes and heart disease; this may involve 
investigating new biochemical markers that are not yet identified. Samples will 
be analysed anonymously and will require a new ethics application before they 
would be used for future research. If you do not wish your samples to be used for 
future research, please indicate this on the consent form. 
Who has reviewed the study? 
College of Medial veterinary and Life Science (MVLS), ethics committee.  
 
 
Contact for Further Information 
Any questions about the procedures used in this study are encouraged. If you have 
any doubts or questions, please ask for further explanations by contacting either: 
 
Khloud Ghafouri   E-mail: k.ghafouri.1@research.gla.ac.uk   
Tel: 07868351398 
Dr Jason Gill 
Tel: 0141 3302916    E-mail:Jason.Gill@glasgow.ac.uk 
 
You will be given a copy of this information sheet and a signed consent form 
to keep for your records. 
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 Volunteer Identification Number for this trial: ___________ 
 
CONSENT FORM 
 
Title of Project: A Pilot Study to Determine the Effect of Exercise on the 
Affinity of Lipoprotein for lipoprotein Lipase 
 
Lay title: Effect of Exercise on Fats in the Blood 
 
Name of Researcher: ____________________________________________ 
 
Please initial box 
 
1. I confirm that I have read and understand the 
information sheet dated ……….for the above study and have 
had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that  
I am free to withdraw at any time, without giving any reason, 
without my medical care or legal rights being affected. 
 
3. I agree to take part in the above study. 
 
4. I agree for my samples to be used for future research into the 
prevention and treatment of diabetes and heart disease. This may 
involve analysis of new biochemical markers not yet identified. 
 
 
      
           
Name of Subject    Date   Signature 
 
    
Name of Person taking consent  Date   Signature 
(if different from researcher) 
 
   
Researcher     Date   Signature 
 
 
Copy for subject 
Copy for researcher 
 
 
Yes  
  
 No 
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Appendix B2; Subjects Information Sheet 
and consent Form –Chapter 4 
 
 
 
VOLUNTEER INFORMATION SHEET 
 
Title: A pilot study to determine metabolomic responses to fat and 
carbohydrate ingestion 
Lay title: Metabolic responses to consuming fat and sugar 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss 
it with others if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish to take 
part. 
 
Thank you for reading this. 
What is the purpose of the study? 
Heart disease and diabetes are leading causes of death and ill health in Scotland. High levels of fat and sugar in the blood, 
particularly after we eat food, are important risk factors for these conditions. Many different factors in the blood change 
when we eat, but until recently it was difficult to measure all of them. With new technology it has become possible to 
measure dozens of different factors in the blood related to fat and sugar metabolism in a single blood sample. Measuring 
how all of these factors change after eating different types of meals help our understanding of how fat and sugar 
consumption can influence risk for heart disease and diabetes. 
 
Why have I been chosen? 
You have been chosen because you are a healthy adult aged between 18-60 years.  
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to 
participate, you will be given this information sheet to keep and be asked to sign 
a consent form. If you do this you are still free to withdraw at any time and without 
giving a reason. A decision to withdraw at any time, or a decision not to take part, 
will not affect the standard of care you receive. 
What will happen to me if I take part? 
In the first instance you will be asked to attend for a screening visit in which we will: 
 discuss with you and complete confidential questionnaires regarding your 
health, family history and physical activity level 
 measure your blood pressure 
 take your height, weight and waist measurements 
 take a small blood samples to check the sugar level in your blood.  
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 provide an opportunity for you to ask questions 
 
These preliminary procedures will enable us to determine whether you fall into 
the group of people we wish to study and will also ensure that it is perfectly safe 
for you to take part.  
 
Experimental procedures 
We will ask you to undertake three experimental trials in random order, separated 
by an interval of 1-3 weeks, as described below. 
 
Glucose test: We will ask you to come to the University after an overnight fast 
(i.e. having eaten nothing for 12 hours) and spend about 9 hours with us in our 
metabolic investigation suite. We will give you a sugary drink containing 75 g (15 
teaspoons) of glucose and will take small blood samples before the meal and at 
intervals for 8 hours afterwards to determine how your body is handling the food. 
Taking blood will be no more painful than a simple blood test as samples will be 
obtained from a tiny plastic tube called a ‘cannula’ placed in a forearm vein. A 
total of 140 ml (about 9 tablespoons, or less than a third of the amount taken 
when you donate a “pint” of blood) will be taken over the course of the day. 
During your time with us, you will be able to rest comfortably in our metabolic 
investigation suite, watching TV or videos, reading or working. At the end of the 
experiment we will give you a meal to eat before you go home. On the morning of 
the next day we will ask you to come back to the lab after an overnight fast for 
one further blood sample.  
 
Fat test: This will be identical to the glucose trial except we will give you a creamy 
milkshake to drink that contains 75 g of fat.  
 
Combined fat and glucose test: This trial will be identical to the previous trials 
except we will give you both drinks together.  
  
  
What do I have to do? 
Other than the specific tasks described above, we ask you to maintain your usual 
lifestyle (i.e. don’t change your diet or exercise habits) for the duration of this 
study. We will ask you to weigh and record everything you eat and drink for two 
days before your first main trial, and not to drink alcohol or exercise on these 
days, and to repeat this diet before your second and third main trials. We will 
provide you with weighing scales and diet sheets to do this.  
 
What are the possible disadvantages and risks of taking part? 
 Blood sampling via the cannula may cause minor bruising or an inflammation of 
the vein. Good practice, however, minimises this risk. Some people may feel faint 
when they give blood. 
 There is a small possibility that taking part in this study will reveal a health 
problem that you already have such as high cholesterol or high blood pressure. If 
such a problem is revealed, we will ask your permission to inform your GP to 
ensure that you receive appropriate treatment. 
 
 
 
 
What are the possible benefits of taking part? 
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There may be no immediate benefits to you personally, but as a result of being 
involved in this study you will receive health information about yourself including 
dietary assessment and your cholesterol and blood sugar levels. This study will 
help us to determine how fat and sugar intake influences risk factors for heart 
disease. The findings will be published in scientific journals so that understanding 
of the way in which diet influences the risk of heart disease and diabetes can be 
increased.  
 
We will provide you with feedback about the main study findings and also about 
your own results and would be delighted to explain results and discuss the 
implications with you. 
 
What if something goes wrong? 
The chances of something going wrong are extremely small. We have conducted 
several similar projects over the past 10-15 years, with many hundreds of 
participants, and have never had any problems. All of the procedures involved in 
this study are low risk and our screening tests are designed to ensure that you will 
only participate if it is safe for you to do so. In the unlikely event that you are 
harmed due to someone's negligence, then you may have grounds for a legal action 
but you may have to pay for it.  
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will 
be kept strictly confidential. Any information about you which leaves the 
University or hospital will have your name and address removed so that you cannot 
be recognised from it. In addition, your records, samples and results will be 
identified by a number and not your name.  
 
What will happen to the results of the research study? 
The results from this study will be presented at scientific meetings and published 
in scientific journals. The results will also form part of Miss Khloud Ghafouri’s PhD 
thesis. A copy of the published results will be sent to you upon request. You will 
not be identifiable in any of the data presented or published from this study. 
 
What will happen to my samples after the study has finished? 
The blood samples that you provide for this study may be useful for future research 
into the prevention and treatment of diabetes and heart disease; this may involve 
investigating new biochemical markers that are not yet identified. Samples will 
be analysed anonymously and will require a new ethics application before they 
would be used for future research. If you do not wish your samples to be used for 
future research, please indicate this on the consent form. 
Who has reviewed the study? 
This study has been reviewed and approved by the College of Medial Veterinary 
and Life Sciences Ethics Committee at the University of Glasgow.  
 
Contact for Further Information 
Any questions about the procedures used in this study are encouraged. If you have 
any doubts or questions, please ask for further explanations by contacting either: 
 
Khloud Ghafouri   E-mail: k.ghafouri.1@research.gla.ac.uk   
Tel: 0141 2329494 (office) or 07868351398 (mobile) 
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Dr Jason Gill 
Tel: 0141 3302916    E-mail:jason.gill@glasgow.ac.uk 
 
You will be given a copy of this information sheet and a signed consent form 
to keep for your records. 
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 Volunteer Identification Number for this trial: ___________ 
 
CONSENT FORM 
 
Title: A pilot study to determine metabolomic responses to fat and 
carbohydrate ingestion 
Lay title: Metabolic responses to consuming fat and sugar 
 
 
Name of Researcher: ____________________________________________ 
 
Please initial box 
 
1. I confirm that I have read and understand the 
information sheet dated ………. 
 for the above study and have had the opportunity to ask 
questions. 
 
5. I understand that my participation is voluntary and that  
I am free to withdraw at any time, without giving any reason, 
without my medical care or legal rights being affected. 
 
6. I agree to take part in the above study. 
 
 
7. I agree for my samples to be used for future research into the 
prevention and treatment of diabetes and heart disease. This may 
involve analysis of new biochemical markers not yet identified. 
 
 
      
           
Name of Subject    Date   Signature 
 
    
Name of Person taking consent  Date   Signature 
(if different from researcher) 
 
   
Researcher     Date   Signature 
 
Copy for subject 
Copy for researcher 
 
 
Yes  
  
 No 
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Appendix C; Blood and lipoprotein 
subfraction analysis  
Spectrophotometric Assays 
Plasma analyses were carried out using commercially available kits. Plasma 
glucose (Randox Laboratories Ltd, UK) and total and HDL cholesterol (Roche 
Diagnostics, UK,) were analysed in the fasted state. LDL cholesterol was 
calculated in the fasted state using the Friedewald equation (Friedewald et al., 
1972). TG (Randox Laboratories, Crumlin, UK), NEFA (Wako Chemicals, GmbH, UK, 
LTD). 
Samples were analysed in duplicate on an automated spectrophotometric IL600 
Analyser (Instrumentation Laboratories, USA). The IL600 is an automated, random 
access clinical chemistry analyser which uses analytical technique photometry for 
the in vitro quantitation of analyses found in physiological fluids, such as serum, 
plasma, urine or cerebrospinal fluid.  
All the samples were analysed in McGregor Building, University of Glasgow by 
Mrs. Josephine Cooney.  
 
Method and materials  
The following materials and equipment were used in all testes.  
Equipment 
 IL600 Analyser (Instrumentation Laboratories, USA). 
 2 ml Free standing Apex tubes (Alpha Laboratories).  
 Hitachi sample cups (Sarstedt Ltd). 
 
Samples 
 500 µl Plasma and serum samples were stored at 4 ºC fridge and/or frozen 
at -80 ºC.  
 
Quality Control 
 Each test QC were prepared and stored as 350 µl aliquots in Apex tubes at 
-80°C. 
 
Procedure  
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The following steps were applied in each test: 
 QC and standers for each test were prepared according to the insert inside 
each kit and stored as recommended.  
 Reagents were prepared freshly before each test.  
 QC, stander and samples were defrosted (or removed from the fridge) for 45 
minutes, then mixed genteelly.  
 The IL600 analyser was calibrated before each test was started.  
 Samples and reagent were loaded into the sample tray as per worksheet. A 
minimum sample volume of 200 µl is required and the test was started by sending 
an order via computer system.  
 The samples and QC were incubated in for 5 minutes at 37 ºC and the 
absorbance were read at the required wave length.  
 The values of the samples and QC were determined by the analyser using a 
regression equation from analysis if the standers.  
 QC values were checked against acceptable ranges in the kit inserts in the 
stock book or by using the QC package on Modulab. If QCs were out of acceptable 
range, the IL600 was recalibrated and the samples were retested, if the QC was 
still out, a norther sample aliquot was used and the reagents were checked for 
contamination. 
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Determination of plasma glucose 
concentration  
Plasma glucose concentrations were determined in by enzymatic method using 
commercially available kits (Glucose hexokinase, Randox Laboratories, Crumlin, 
UK). Samples were analysed in IL600 as mentioned above. 
Principle  
The enzymatic hexokinase (HK) catalyses the reaction between glucose and 
adenosine triphosphate (ATP) to form glucose-6phosphate and adenosine 
diphosphate (ADP). In the presence of NAD, the enzyme glucose-6-phosphate 
dehydrogenase (G6PDH), oxidizes glucose-6-phosphate to 6-phosphogluconate. 
The increase in NADH concentration is directly proportional to the glucose 
concentration and can be measured photometrically using the IL600 analyser at 
340 nm. The equation is shown below: 
Glucose + ATP             glucose-6-phosphate + ADP   
 
Glucose-6-phosphate+ NADP+             gluconate-6-phosphate + NADPH + H+  
The CV for the assay was 2.0%.  
 
Reagents 
 Glucose Kit. (Randox Laboratories, Northern Ireland). 
 R1- Buffer/Coenzymes (contents ready for use). 
 R2 –made by mixing Reagent 2 diluent to one bottle of R2 enzymes rinsing 
the contents several times with the diluent.  
 
Standards 
 Randox Calibration Serum Level 2 was reconstituted in 3 ml of distilled 
water at room temperature with gentle mixing. 
 
Quality Control 
Human Assay Control (HC2 and HC3 Catalogue No. HS2611, Randox, Crumlin, UK), 
were prepared by mixing each control into 5 ml of distilled or deionised water.  
HK 
G-6-PDH 
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Determination of plasma and lipoprotein 
triglyceride  
Plasma and lipoprotein TG concentrations were determined by an enzymatic 
method using commercially available kits (GPO-PAP, Randox Laboratories, 
Crumlin, UK). Samples were analysed in IL600 as mentioned above. 
 
Principle  
The method based on lipase hydrolysis of TG to glycerol followed by oxidation to 
dihydroxyacetone phosphate and hydrogen peroxide. The hydrogen peroxide 
produced then reacts with 4-aminophenazone and 4-chlorophenol under the 
catalytic action of peroxidase to form a red dyestuff which was measured 
spectrophotometrically using the IL600 analyser at 550 nm. The equation is shown 
below: 
Triglycerides + H2O              glycerol + fatty acids  
Glycerol + ATP                    glycerol-3-phosphate + ADP  
glycerol-3-phosphate + Ο2                 DHAP+ H2O2 
H2O2 + 4 aminophenazone + p-chlorophenol          Quinoneime + 4 H2O + HCl  
(GK: Glycerol kinase; GPO: Glycerol phosphate oxidase; POD: Peroxidase; DHAP: 
dihydroxyacetote phosphate). The CV for the assay was 3.8%. 
 
Reagents 
 Triglyceride Reagent (Randox laboratories Reagent Kit Cat No TR210ridge) 
was made by dissolving R1b on 15 ml of R1a. 
 Sodium Chloride (NaCl)Cat No: S9888 Sigma. 
Standards 
 0.9% NaCl (used as Saline Blank). 
 Ready to use calibrator 
  
Quality Control 
Two controls were included in the kit. Normal lipid control (LPD1) and abnormal 
Lipid control (LPD3)(Catalogue No LE 2661 and No LE 2663, Randox Laboratories, 
Crumlin, UK. Each control has been reconstituted in 3 ml distilled or deionised 
water.  
Lipase 
GK 
GPO 
POD 
9 Appendices  
 
333 
Khloud Jamil Ghafouri ® 2017  
Determination of plasma glycerol  
Determinations for Glycerol were performed using commercially kits (Randox 
Laboratories, Crumlin, UK). Samples were analysed in IL600 as mentioned above. 
 
Principle  
A direct spectrophotometric procedure for the measurement of glycerol utilising 
a quinoneimine chromogen system in the presence of glycerol kinase, peroxide 
and glycerol phosphate oxidase. The equation is shown below:  
 
Glycerol + ATP      Glycerol-3-phosphate + ADP 
Glycerol-3-phosphate + O2   DAP + H2O2  
H2O2 + DCHSB + 4 aminophenazone       ACSB 
 
(GK: Glycerol kinase; GPO: Glycerol phosphate oxidase; DCHBS: 3.5-dichloro-2-
hydroxybenzene sµlphonic acid; ACSB: n-(4-antipyryl_-3-chloro-5-sµlponate-p-
benzoquinoneimine). The CV for the assay was 1.9%. 
 
Reagents 
Randox glycerol Colorimetric Assay (cat no GY105, Randox Laboratories, Crumlin, 
UK). 
Reagent 1-Buffer as supplied 
Reagent 2-4-aminophenazone color reagent lyophylised. 
Glycerol reagent prepared by adding 15 ml of reagent 1 to one bottle of reagent 
2, then mixed gently and use for analysis.  
 
Standards 
100 µmol.l-1 standard supplied ready to use. 
 
Quality Control 
Randox glycerol (Control cat no GY1369, Randox Laboratories, Crumlin, UK). 
 
 
  
GK 
GPO 
Peroxidase 
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Determination of plasma hydroxybutrate 
Analysis  
Determinations for hydroxybutrate were performed using commercially available 
(Wako Chemicals, GmbH, UK, LTD). Samples were analysed in IL600 as mentioned 
above. 
 
Principle  
The principle of this test is based upon the enzymatic conversion of β-
hydroxybutyrate dehydrogenase to acetoacetate by the action of D-3-
hydroxybutyrate dehydrogenase, and concomitantly the co-factor nicotineamide 
adenine dinucleotide (NAD+) is converted to its reduced form β-nicotinamide 
adenine dinucleotide (NADH). In the presence of diaphorase, NADH reacts with 
the colorimetric detector WST-1 to produce a formazan dye with a maximum 
absorbance at 505 nm. The equation is shown below: 
D-3-hydroxybutyrate + NAD    Acetoacetate + NADH + H+ 
 
NADH + INT (oxidized)      NAD + INT (reduced) colour. 
(INT: (2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium chloride)); 
NAD: nicotineamide adenine dinucleotide; NADH: β-nicotinamide adenine 
dinucleotide). 
 
Reagents 
R1 containing β-hydroxybutyrate dehydrogenase and diaphorase enzymes.  
R2 containing NAD, INT and oxalate.  
Reagent prepared by mixing 10 ml of reagent 1 with 1.5 ml of reagent 2.  
 
Standards 
Standard containing 1mM sodium D-3-hydroxybutyrate was provided in the kit.  
 
Quality Control 
Randox glycerol (Control cat no GY1369, Randox Laboratories, Crumlin, UK). 
 
  
D-3-hydroxybutyrate 
dehydrogenase 
Diaphorase 
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Determination of plasma NEFA Analysis  
Determinations for NEFA were performed using commercially available (Wako 
Chemicals, GmbH, UK, LTD). Samples were analysed in IL600 as mentioned above. 
 
Principle  
This method relies upon the acylation of coenzyme A (CoA) by the fatty acids in 
the presence of added acyl-CoA synthetase (ACS). The acyl-CoA thus produced is 
by added acyl-CoA oxidase (ACOD)with generation of hydrogen peroxide. 
Hydrogen peroxide, in the presence of peroxidase(POD) permits the oxidative 
condensation of 3-methyl-N-ethyl-N (B-hydroxyethyl)-aniline (MEHA) with 4-
aminoantipyrine to form a purple colour adduct which can be measured 
spectrophotometrically at 550 nm.  The equation is shown below: 
 
RCOOH (NEFA) + ATP + CoA             Acyl-CoA + AMP + Ppi  
 
Acyl-CoA + O2             2,3-trans-Enoyl-CoA + H2O2  
2 H2O2 + 4-Aminoantipyrine + MEHA              blue purple pigment + 3 H2O  
(ACS: acyl-CoA synthetase; ACOD: acyl-CoA oxidase; MEHA: 3-methyl-N-ethyl-N-β-
hydoxyethyl-aniline). The CV for the assay was 5.2%.  
 
 
Reagents 
Two colour reagents (R1A and R2A) were supplied in powder form with the kit. For 
analysis performed, the reagent R1A was reconstituted in 50 solvent R1. Colour 
reagent R2A, reconstitute with 20ml of solvent. Standard Solution is(1.0 mEq.L-1) 
 
Standards 
Standard supplied with kit.  
 
Quality Control 
Human Assay Control (HC2 andd HC3 Catalogue No. HS2611, Randox, Crumlin, UK), 
were reconstituted by mixing each control into 5 ml of distilled or deionised water.  
Determination of plasma and lipoprotein total 
cholesterol 
ACS 
ACOD 
Peroxidase 
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Total plasma cholesterol was determined using commercially available kits 
(Randox Laboratories, Crumlin, UK). Samples were analysed in IL600 as mentioned 
above. 
 
Principle  
The principle based on the generation of hydrogen peroxide from the substrate by 
the action of cholesterol esterase, after the hydrolysis of EC, which is coupled 
through peroxidase to produce a chromogen, detected by its absorbance at 500 
nm. The equation is shown below:  
 
Cholesterol esters + H2O                        cholesterol + RCOOH  
 
Cholesterol + O2                          cholesterol-3-one + H2O2  
 
2 H2O2 + phenol + 4-aminophenazone             Quinoneime + 4 H2O    
The CV for the assay was 2.9%. 
 
Reagents 
 Cholesterol Reagent (Reagent Kit Cat No CH200, Randox Laboratories, 
Crumlin, UK ), used as supplied.  
 Sodium Chloride (NaCl)Cat No: S9888 Sigma 
 
Standards 
 0.9% NaCl (used as Standard Blank). 
 Calibrator (CFAS, Cat. No.10759350, Roche).  
 The calibrator was reconstituted in 3 ml of distilled water at room 
temperature with gentle mixing.  
 
Quality Control 
Two controls were included in the kit. Normal lipid control (LPD1) and abnormal 
Lipid control (LPD3)(Catalogue No LE 2661 and No LE 2663, Randox Laboratories, 
Crumlin, UK. Each control has been reconstituted in 3 ml distilled or deionised 
water.  
Determination of plasma and lipoprotein free 
cholesterol  
Cholesterol esterase  
Cholesterol oxidase  
Peroxidase 
9 Appendices  
 
337 
Khloud Jamil Ghafouri ® 2017  
Plasma and lipoprotein free cholesterol concentrations were determined by an 
enzymatic method using commercially available kits (Diagnostic Systems GmbH, 
Germany). Samples were analysed in IL600 as mentioned above. 
 
Principle  
Free cholesterol in the serum is oxidised by cholesterol oxidase to cholestenone 
and produces simultaneously hydrogen peroxide. The hydrogen peroxide formed 
causes phenol and 4-aminoantipyrine to undergo quantitatively an oxidative 
condensation in the presence of peroxidase, to produce a red colour. The amount 
of free cholesterol in the test sample is determined by measurement of the 
absorbance of the red colour at 510 nm. The equation is shown below:  
 
Cholesterol esters + O2                      cholesterol-3-one + H2O  
 
2 H2O2 + phenol + 4-aminophenazone             Quinoneime + 4 H2O    
The CV for the assay was 2.2%. 
 
Reagents 
 
 Wako Free Cholesterol C (code No. 274-47106, wako chemicals, GmbH, UK, 
LTD). 
 Buffer solution, use as supplied 
 Colour reagent, reconstituted in 75 ml of buffer solution. 
 
 
Standards 
 Standard Solution (supplied with kit) 
 Diluent for standard solution. 
 
 
Quality Control 
 
Two controls were used. Normal control serum 1 and abnormal control serum 2 
(Catalogue No. 410-00101 and No 416-00201, wako chemicals, GmbH, UK, LTD). 
Both controls had been reconstituted Wako 1 and Wako 2 in 5 ml distilled or 
deionised water.  
 
 
Calculation of esterified cholesterol 
CHO  
Peroxidase 
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CE concentration was calculated by multiplying the difference in mass (mg.dl-1) 
of TC and FC by 1.68 and converted to mmol.l-1 by dividing with 38.7. 
 
Determination of plasma HDL cholesterol  
Determinations for plasma HDL cholesterol were performed using commercially 
available enzymatic kits (Roche Diagnostics, Mannheim, Germany). Samples were 
analysed in IL600 as mentioned above. 
 
Principle  
 
The cholesterol concentration of HDL-cholesterol is determined enzymatically by 
cholesterol esterase and cholesterol oxidase coupled with polyethylene glycol 
(PEG) to the amino groups. In the presence of magnesium sulphate, dextran 
sulphate selectively forms water-soluble complexes with LDL,VLDL and 
chylomicrons which are resistant to PEG- modified enzymes. Cholesterol esters 
are broken down quantitatively into free cholesterol and fatty acids by cholesterol 
esterase, in the presence of oxygen, cholesterol is oxidised by cholesterol oxidase 
to cholesterone and hydrogen peroxide. The hydrogen peroxide generated reacts 
with 4-amino-antipyrine and N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline to 
form a purple-blue dye. The colour intensity of the dye is directly proportional to 
the cholesterol concentration and is measured photometrically at 600 nm. The 
equation is shown below:  
 
 
HDL cholesterol + H2O                         HDL-cholesterol + RCOOH 
  
HDL-cholesterol + O2                          ∆4-cholestenone + H2O2  
 
2 H2O2 + 4-aminoantipyrine + HSDA                        Purple- blue pigmentation + 5 
H2O 
(HSDA: Sodium N-(2-hydroxy-3-sµlfopropyl)-3,5-dimethoxyaniline). The CV for the 
assay was 2.8%.  
 
Reagents 
PEG-cholesterol esterase  
PEG-cholesterol oxidase  
Peroxidase  
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 HDL-C Reagent 3rd generation (Cat No 04713214, Roche Diagnostics, 
Mannheim, Germany) 
 Sodium Chloride (NaCl). 
 
Standards 
 0.9% NaCl (used as Standard Blank).  
  Roche CFAS Lipids calibrator (Cat. No.12172623, Roche Diagnostics, 
Mannheim, Germany) was reconstituted in 1 ml distilled water.  
 
Quality Control 
Two controls were included in the kit. Normal lipid control (LPD1) and abnormal 
Lipid control (LPD2)(Catalogue No LE 2661 and No LE 2663, Randox Laboratories, 
Crumlin, UK. Each control has been reconstituted in 3 ml distilled or deionised 
water.  
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Determination of plasma small dense LDL  
Determinations for plasma sdLDL cholesterol were performed using commercially 
available enzymatic and turbidimetric kits (Denka Seiken, Japan). Samples were 
analysed in ILab600 as mentioned above. 
 
Principle  
The principle of cholesterol determination is based on the following 2 steps of 
colorimetric reaction: of two steps; the first step removes non-sdLDL lipoproteins 
(chylomicrons, VLDL, IDL,L LDL and HDL) using a surfactant and sphingomyelinase 
in Reagent 1, where the released cholesterol is then degraded by standard 
enzymatic reactions; in the second step, another specific surfactant releases 
cholesterol only from the sdLDL particles and the catalase in Reagent 1 is inhibited 
by sodiumazide while the hydrogen peroxide produced from the reaction of 
cholesterol esterase and cholesterol oxidase results in a purple red colour with 
the coupler in the presence of peroxidase. The colour intensity of the dye is 
directly proportional to the cholesterol concentration and is measured 
photometrically at 550 nm. The equation is shown below:  
  
First Step  
Chylomicrons, VLDL, IDL. L LDL and HDL              Cholestenone + Fatty acid + H2O2 
2 H2O2    2 H2O +O2 
 
Second Step 
 
sdLDL-C      Cholestenone + Fatty acid + H2O2 
 
2 H2O2 + 4-aminoantipyrine + TOOS              Purple-blue colour + 4H2O 
(TOOS: N-Ethyl-n-(2-hydroxy-3-sµlfopropyl)-3-methylaniline). The CV for the assay 
was 2.8%. 
 
 
 
  
CHE & O    
Catalase 
CHE & CO    
Peroxidase     
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Determination of lipoprotein phospholipid  
Determinations of phospholipid concentrations in lipoprotein subfractions were 
performed using spectrophotometric test for using available enzymatic and 
turbidimetric kits (Roche Diagnostics, UK). Samples were analysed in IL600 as 
mentioned above. 
 
Principle 
Phospholipids in serum are hydrolysed to free choline by phospholipase D. The 
liberated choline is subsequently oxidised with simultaneous production of 
hydrogen peroxide. The hydrogen peroxide, which is produced quantitatively, 
oxidatively couples 4- aminoantipyrine and phenol to yield a chromogen with a 
maximum absorbance at 570 nm. The equation is shown below:  
 
Phospholipids (Lecithin Sphingomyelin Lysolecithin ) +H2O            Choline + 
Phosphatidic acid N-acylsphingosyl phos Lysophosphatidic acid 
 
 
 
 
Reagents 
 
 Phospholipid available Kit (Cat No. MRP2 691844, Roche Diagnostics, UK).  
 Bottle 1 - Buffer 
 Bottle 2 - Enzyme reagent 
Working reagent solution was prepared by dissolving contents of one bottle 2 in 
40 ml buffer from bottle 1.  
 
Standards 
 Bottle 3  - Choline Chloride Standard Solution 300mg/dl, supplied ready 
to use. 
 Use 0.9% NaCl as Standard Blank 
 
Quality Control 
Diluted Quality control 1:5 using 0.9% Saline (cat no 5 9020 99 10 065, Diagnostic 
Systems GmbH, Germany).  
Phospholipase D 
       Peroxidase           
H2O + 4-aminoantipyrine + DAOS                  blue pigmentation + Η2Ο 
              Choline oxidase  
 Choline + 2 O2                           Betaine + 2 H2Ο 
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Determination of lipoprotein ApoE 
Determinations of ApoE concentrations in lipoprotein subfractions were 
determined by turbidometric immunoassay using commercially available 
turbidimetric kits (Randox Laboratories, Crumlin, UK). Samples were analysed in 
IL600 as mentioned above. 
 
Principle  
Through specific antibody binding to Apolipoprotein E in plasma, insoluble 
aggregates are formed which cause an increase in turbidity. The level of turbidity 
was measured at 340 nm. The CV for the assay was 3.3%.  
 
Reagents 
 
 Apolipoprotein E Diagnostic Kit – Randox Apo E (Cat No LP 3864, Randox 
Laboratories, Crumlin, UK), used as supplied. 
 
Standards 
 
 Apolipoprotein calibrator (Cat No 3023, Randox Laboratories, Crumlin, UK). 
 
Quality Control 
Two controls were included in the kit. Normal lipid control (LPD1) and abnormal 
Lipid control (LPD3)(Catalogue No LE 2661 and No LE 2663, Randox Laboratories, 
Crumlin, UK. Each control has been reconstituted in 3 ml distilled or deionised 
water.  
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Determination of ApolipoproteinB Analysis  
This is a turbidometric immunoassay using commercially available kits (Randox 
Laboratories, Crumlin, UK). Through specific antibody binding to Apolipoprotein B 
in plasma, insoluble aggregates are formed which cause an increase in turbidity. 
The level of turbidity is measured using an IL600 analyser nm and is proportional 
to the amount of Apo B (mg.dl-1) present. 
 
Principle  
This method is based on the reaction of a sample containing human apolipprotein-
B (apoB) and specific antibodies to form an insoluble complex which can be 
measured turbidimetrically at 340 nm in an autoanalyser (ILabTM 600, Clinical 
Chemistry System, Instrumentation Laboratory, USA) . The method in Vascular 
Biochemistry Lab has been optimised for apoB measurements in lipoprotein 
fractions by increasing the volume of sample used in the assay from 3 μl to 12 μl 
(results were then multiplied by a factor of 0.25). The supplied quality control 
was also diluted to account for the lower concentrations of apoB. The CV of apoB 
in plasma was 3.8 and 2.5% and 3.2% in VLDL1 and VLDL2 respectively.  
 
Reagents 
Apolipoprotein B Diagnostic Kit – Randox Apo B (Cat No LP 3839 ), distributed by 
Randox Laboratories ( Fridge 1 beside analyser). Use as supplied. 
 
Standards 
Calibration is not necessary as it is linked to the standard curve on SOP/LIPRES/159 
(Apo B) partnered 10 coefficient 0.25 
 
Quality Control 
Two controls were included in the kit. Normal lipid control (LPD1) and abnormal 
Lipid control (LPD2)(Catalogue No LE 2661 and No LE 2663, Randox Laboratories, 
Crumlin, UK. Each control has been reconstituted in 3 ml distilled or deionised 
water.  
LPDA made by diluting LPD1 1:5 with deionised water 
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Determination of Apolipoprotein C-II Analysis  
This is a turbidometric immunoassay using commercially available kits (Randox 
Laboratories, Crumlin, UK). Through specific antibody binding to Apolipoprotein 
CII in the sample , insoluble aggregates are formed which cause an increase in 
turbidity. The level of turbidity is measured using an IL600 analyser and is 
proportional to the amount of Apo CII (mg.dl-1) present. 
 
Principle  
This method is based on the reaction of a sample containing human ApoC-II and 
specific antiserum to form an insoluble complex which can be measured 
turbidimetrically at 340 nm. The CV for the assay was 3.3%  
 
Reagents 
Apolipoprotein C11 Diagnostic Kit – Randox Apo C11 (Cat No LP 3866), distributed 
by (Randox Laboratories. (Fridge 1 beside analyser). Used as supplied  
 
Standard 
Calibration is not necessary as it is linked to the standard curve on SOP/LIPRES/160 
(Apo C2)) 
 Partnered 6 coefficient 0.25 
 
Quality Control 
Two controls were included in the kit. Normal lipid control (LPD1) and abnormal 
Lipid control (LPD2)(Catalogue No LE 2661 and No LE 2663, Randox Laboratories, 
Crumlin, UK. Each control has been reconstituted in 3 ml distilled or deionised 
water.  
LPDA made by diluting LPD1 1:5 with deionosed water 
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Determination of Apolipoprotein C-III Analysis  
This is a turbidometric immunoassay. Through specific antibody binding to 
Apolipoprotein CIII in plasma, insoluble aggregates are formed which cause an 
increase in turbidity. The level of turbidity is measured using an ILab600 analyser 
and is proportional to the amount of Apo CIII (mg.dl-1) present. 
 
Principle 
This method is based on the reaction of a sample containing human ApoC-II and 
specific antiserum to form an insoluble complex which can be measured 
turbidimetrically at 340 nm. The CV for the assay was 3.3%  
 
Reagents 
 
Apolipoprotein CIII Diagnostic Kit – Randox Apo CIII (Cat No LP 3865), distributed 
by Randox Laboratories. 
Use as supplied. 
 
Standards 
 
 Apolipoprotein calibrator (Randox LP Cat No 3023), distributed by Randox 
Laboratories ( Fridge 1 beside analyser). Calibrator values are lot specific. 
 
To prepare std curve reconstitute one vial of calibrator with 1ml of distilled 
water at room   temperature with gentle mixing, - Apo Cal . 
 
Quality Control 
 
Two controls were included in the kit. Normal lipid control (LPD1) and abnormal 
Lipid control (LPD2)(Catalogue No LE 2661 and No LE 2663, Randox Laboratories, 
Crumlin, UK. Each control has been reconstituted in 3 ml distilled or deionised 
water.  
  
9 Appendices  
 
346 
Khloud Jamil Ghafouri ® 2017  
Appendix D; participants Feedback Sheet  
 
 
 
 
 
Title: The effects of exercise on lipoprotein 
affinity for lipoprotein lipase 
 
Lay title: The effects of exercise on fats in the 
blood 
 
 
RESULTS FEEDBACK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Miss Khloud Ghafouri, MSc 
PhD Researcher 
Tel: 0141 2329494 
E-mail: k.ghafouri.1@research.gla.ac.uk 
 
 
Name:  
DOB:   
Address:   
 
 
 
Study Start Date:  
Study End Date:  
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Body Composition Measurements 
 
 
1. Height and Weight  
Height and body mass are widely used to measure body fatness. An index called the 
‘Body mass index’ or ‘BMI’ can be used to determine whether somebody is the 
correct weight for his or her height. Usually, a BMI value of 20 to 25 is normal, 25 
to 30 is overweight, and 30+ is classed as obese. (BMI is calculated by dividing body 
mass in kg by height in metres squared, i.e. kg/m2). However, this index is of limited 
value, as it does not take into account an individual’s build and does not distinguish 
between fat and muscle mass. (In fact a number of athletes would be classed as 
overweight by this index, due to their large muscle mass.)  
Your height xx cm xx ft xx inch 
Your weight: xx kg  (xx stn xx lbs) 
Your body mass index (BMI): xx kg/m2 
 
The following graph shows the ideal body mass based on BMI and optimized for 
men. According to your height, your body mass should be between about xx-xx 
stones. 
 
 
 
 
 
 
 
2. Skinfolds 
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When deciding how fat somebody is, it is more useful to consider body fat levels 
rather than weight. A body fat estimation was calculated from measurements of the 
fat layer under the skin at four sites (biceps (front of the arm), triceps (back of the 
arm), subscapular (under the shoulder blade) and suprailiac (above the hip)). This 
was expressed as a percentage of total body mass (e.g. an 80kg man with 25% body 
fat would be carrying 20kg of fat). High percentages of body fat are linked with a 
number of diseases including heart disease and diabetes. For an adult male, body 
fat should ideally be between about 15-25%. 
Your Biceps: xx  mm  
Your Triceps:  xx mm 
Your Subscapular:  xx mm 
Your Suprailiac:   xx mm 
Your Percentage Body Fat (%BF):  xx % 
 
 
3. Waist Circumference  
The waist circumference is perhaps of greater importance than BMI or % body fat 
in determining risk of metabolic disorders such as diabetes and heart disease. This 
is because abdominal fat is thought to be in a position anatomically (i.e. near to the 
liver and other internal organs) where it could potentially cause a lot of harm. A 
waist measurement of greater than 100 cm (39.5 in) may increase the risk of certain 
metabolic complications. 
Your Waist Circumference (WC): xx cm  (xx inch) 
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Health Screening Results 
 
(A copy of your blood results has been sent to your GP.) 
 
1. Blood Pressure 
Your Blood Pressure:  xx mm Hg 
A blood pressure of xx mm Hg is considered (low, normal or high). The systolic 
pressure (xx mm Hg) indicates how hard the heart is working and the force that is 
blood exerts when blood is pumped from the heart. The diastolic pressure (xx mm 
Hg) tells us what resistance there is to blood flow and therefore how easily blood 
flows through the blood vessels. 
 
 
2. Fasting Glucose  
Fasting glucose level is used to determine whether you have diabetes or not. The 
normal range of fasting glucose is 3.5-5.5 mmol/l and a value of greater than 7 
mmol/l suggests diabetes.  
 
Your Fasting Glucose:  xx  mmol/l  (which is low, normal or 
high) 
 
 
3. Blood Lipid Measurements 
Lipids, or fats, are normal constituents of the ‘watery’ part of the blood, known as 
plasma. They are present in a number of forms, but in this study we are most 
interested in cholesterol and triglycerides. 
  
Cholesterol is a fundamental component of all the cells in our bodies and is 
essential for the normal functioning of the body. Part of the cholesterol in plasma 
comes from the liver, where it is made, the remainder being absorbed from the diet. 
Ideally, the level of cholesterol in the plasma should not exceed 5.0 mmol/l. 
 
Your Cholesterol:  xx mmol/l  (which is low, normal or 
high) 
  
High-density lipoprotein cholesterol or HDL cholesterol is commonly 
referred to as ‘good cholesterol’. These particles are responsible for transporting 
excess cholesterol away from the cells to the liver where it can be disposed of safely. 
High levels of HDL cholesterol are associated with a reduced risk of heart disease. 
It is desirable for your HDL concentration to be above 1.0 mmol/l. 
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 Your HDL Cholesterol: xx  mmol/l  (which is low, normal or 
high) 
 
 
 
Low-density lipoprotein cholesterol or LDL cholesterol, on the other hand, 
is commonly referred to as ‘bad cholesterol’. These particles are responsible for 
transporting cholesterol from the liver to all cells of the body. This is essential as 
cholesterol is an integral component of every cell. However, high levels of LDL 
cholesterol will result in the deposition of cholesterol inside the arteries which is 
associated with an increased risk of heart disease. It is desirable for your LDL 
cholesterol to be below 3.0 mmol/l. 
 
 Your LDL Cholesterol: xx mmol/l  (which is low, normal or 
high) 
 
Cholesterol-to-HDL (Chol/HDL) ratio is the ratio of ‘bad’ to ‘good’ cholesterol. 
Ideally, it should be less than 5.0.  
 
 Your Chol/HDL ratio: xx   
 
Triglyceride (TG) is an important source of energy and like cholesterol is both 
made by the liver and absorbed from the diet. Concentrations of TG in plasma rise 
after eating a fatty meal, but after an overnight fast it is desirable for concentrations 
to be below 2.3 mmol/l. 
 
 Your Triglycerides: xx  mmol/l  (which is low, normal or high) 
 
Many people living in Western societies have elevated levels of cholesterol and TG. 
Comparisons of the incidence of coronary heart disease in different societies 
indicate that high levels of lipids are associated with increased risk of heart disease. 
However, it is important to realise that an elevated blood lipid concentration is only 
one of several well-documented risk factors for coronary heart disease, others 
include family history, high blood pressure, diabetes, obesity and smoking. In most 
circumstances it is only when a person exhibits several of these risk factors that there 
is a major cause for concern. 
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Fitness Analysis 
 
 
1. Predicted Maximum Heart Rate (HRmax) 
This is the maximum number of beats that your heart can produce in a minute (beat 
per minute or BPM). It is calculated using the equation of (220 – your age). Common 
use for this value is for developing fitness programs and prescribing exercise 
intensities.  
 
Your Predicted Maximum Heart Rate (HRmax):  xx  BPM 
 
 
2. Predicted Maximal Oxygen Uptake (VO2max) 
Your maximal oxygen uptake or VO2max is a measure of your body’s ability to use 
oxygen and is one measure of endurance fitness. The point at which you perform 
exercise at increasing intensity without consuming more oxygen is considered your 
VO2max and is the point at which exercise can no longer normally be sustained. The 
major determinant of VO2 max is genetics, or how well you chose your parents. 
Another big factor is how heavy you are, as the value is expressed per kg body mass 
(your VO2max will increase if you lose weight). Perhaps a better measure of 
endurance fitness is the ability to sustain a reasonable percentage of VO2max for a 
prolonged period. This, quite clearly, is something that you can manage well!  
Your Maximal Oxygen Uptake (VO2max):   xx ml O2/kg/min 
 
The fitness classifications for your age group and gender are shown below: 
 
Fitness 
category 
VO2max (ml 
O2/kg/min) 
Excellent 44+ 
Good 35-43 
Average 29-34 
Below average 23-28 
Poor <23 
 
 
3. Energy Expenditure  
The body requires energy for every physical activity which is dependent on the 
duration and type of activity and the body’s age and gender. Energy is measured in 
calories (cal) and is obtained from the body stores or the food we eat, namely 
carbohydrates, fat and protein. The longer and harder the exercise is, the more 
calories you burn in order to sustain it. In order to lose 1 pound of fat, you need to 
burn 3500 kcal (7700 kcal for 1 kg). For the 90-minute brisk walking session you 
performed: 
Your Energy Expenditure:  xx kcal 
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4. Exercise Recommendations 
We asked you in this study to walk for 90 minutes at about 50% of your VO2max to 
maximise the potential effects of exercise on your body’s fat metabolism. This would 
allow us to see the effects of exercise on fat metabolism more clearly. In practice, 
you don’t have to perform such long exercise sessions to get a beneficial effect. We 
would recommend that you perform a total of 30 minutes of moderate intensity 
exercise (e.g. walking, gardening, golf, tennis, cycling, swimming etc.) on most, 
preferably all days of the week. This 30 minutes does not need to be continuous - 
you could split it up into a number of shorter exercise periods (each of at least 10 
minutes). In addition, everyday activities such as walking to the shops can all count 
towards your daily exercise. This amount of exercise is the ideal, but taking any 
exercise at all will be beneficial. We recommend you to exercise at an exercise 
intensity of 50-70% of your VO2max. For you, this would be at a heart rate 
range of xx BPM. 
 
 
 
 
 
 
 
 
 Thank you for your time and participation 
 
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Appendix E; Statistician Report about 
statistical test used in Chapter 4 
 
  
